0001428336-20-000019.txt : 20200604 0001428336-20-000019.hdr.sgml : 20200604 20200604160450 ACCESSION NUMBER: 0001428336-20-000019 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20200430 FILED AS OF DATE: 20200604 DATE AS OF CHANGE: 20200604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 20942971 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 10-Q 1 hqy-20200430.htm 10-Q hqy-20200430
00014283361/312021Q1FALSEP5YP5YP4YP4Y0.66670.33330.33330.33330.66670.666700014283362020-02-012020-04-30xbrli:shares00014283362020-05-28iso4217:USD00014283362020-04-3000014283362020-01-31iso4217:USDxbrli:shares0001428336us-gaap:ServiceMember2020-02-012020-04-300001428336us-gaap:ServiceMember2019-02-012019-04-300001428336us-gaap:FinancialServiceOtherMember2020-02-012020-04-300001428336us-gaap:FinancialServiceOtherMember2019-02-012019-04-300001428336us-gaap:CreditAndDebitCardMember2020-02-012020-04-300001428336us-gaap:CreditAndDebitCardMember2019-02-012019-04-3000014283362019-02-012019-04-3000014283362019-01-310001428336us-gaap:CommonStockMember2020-01-310001428336us-gaap:CommonStockMember2019-01-310001428336us-gaap:CommonStockMember2020-04-300001428336us-gaap:CommonStockMember2019-04-300001428336us-gaap:AdditionalPaidInCapitalMember2020-01-310001428336us-gaap:AdditionalPaidInCapitalMember2019-01-310001428336us-gaap:AdditionalPaidInCapitalMember2020-02-012020-04-300001428336us-gaap:AdditionalPaidInCapitalMember2019-02-012019-04-300001428336us-gaap:AdditionalPaidInCapitalMember2020-04-300001428336us-gaap:AdditionalPaidInCapitalMember2019-04-300001428336us-gaap:RetainedEarningsMember2020-01-310001428336us-gaap:RetainedEarningsMember2019-01-310001428336us-gaap:RetainedEarningsMember2020-02-012020-04-300001428336us-gaap:RetainedEarningsMember2019-02-012019-04-300001428336us-gaap:RetainedEarningsMember2020-04-300001428336us-gaap:RetainedEarningsMember2019-04-3000014283362019-04-300001428336us-gaap:ComputerSoftwareIntangibleAssetMember2020-02-012020-04-300001428336us-gaap:ComputerSoftwareIntangibleAssetMember2019-02-012019-04-300001428336hqy:WageWorksIncMember2019-08-300001428336hqy:WageWorksIncMember2019-08-302019-08-300001428336hqy:TermLoanFacilityMemberus-gaap:LineOfCreditMemberhqy:WageWorksIncMember2019-08-302019-08-300001428336hqy:WageWorksIncMember2019-08-302020-04-300001428336hqy:WageWorksIncMember2020-04-300001428336us-gaap:LeaseholdImprovementsMember2020-04-300001428336us-gaap:LeaseholdImprovementsMember2020-01-310001428336us-gaap:FurnitureAndFixturesMember2020-04-300001428336us-gaap:FurnitureAndFixturesMember2020-01-310001428336us-gaap:ComputerEquipmentMember2020-04-300001428336us-gaap:ComputerEquipmentMember2020-01-310001428336srt:MinimumMember2020-02-012020-04-300001428336srt:MaximumMember2020-02-012020-04-300001428336srt:MinimumMember2020-04-300001428336srt:MaximumMember2020-04-30xbrli:pure0001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-04-300001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2020-04-300001428336hqy:AcquiredHSAIntangibleAssetsMember2020-01-310001428336us-gaap:CustomerRelationshipsMember2020-04-300001428336us-gaap:CustomerRelationshipsMember2020-01-310001428336us-gaap:DevelopedTechnologyRightsMember2020-04-300001428336us-gaap:DevelopedTechnologyRightsMember2020-01-310001428336us-gaap:TradeNamesMember2020-04-300001428336us-gaap:TradeNamesMember2020-01-310001428336us-gaap:InProcessResearchAndDevelopmentMember2020-04-300001428336us-gaap:InProcessResearchAndDevelopmentMember2020-01-31hqy:lawsuit00014283362018-09-062018-09-0600014283362018-06-222018-06-220001428336us-gaap:OtherAssetsMember2020-04-300001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberus-gaap:SecuredDebtMember2019-08-302019-08-300001428336hqy:TermLoanFacilityMemberhqy:CreditAgreementMemberus-gaap:SecuredDebtMember2019-08-300001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-08-302019-08-300001428336us-gaap:LineOfCreditMemberhqy:CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-08-300001428336us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2020-02-012020-04-300001428336srt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-02-012020-04-300001428336srt:MinimumMemberus-gaap:BaseRateMember2020-02-012020-04-300001428336srt:MaximumMemberus-gaap:BaseRateMember2020-02-012020-04-300001428336srt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2020-02-012020-04-300001428336srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2020-02-012020-04-30utr:Rate0001428336hqy:DebtCovenantPeriodOneMember2020-04-300001428336hqy:DebtCovenantPeriodTwoMember2020-04-300001428336hqy:DebtCovenantPeriodThreeMember2020-04-300001428336hqy:DebtCovenantPeriodFourMember2020-04-300001428336us-gaap:CostOfSalesMember2020-02-012020-04-300001428336us-gaap:CostOfSalesMember2019-02-012019-04-300001428336hqy:SalesandMarketingMember2020-02-012020-04-300001428336hqy:SalesandMarketingMember2019-02-012019-04-300001428336hqy:TechnologyandDevelopmentMember2020-02-012020-04-300001428336hqy:TechnologyandDevelopmentMember2019-02-012019-04-300001428336us-gaap:GeneralAndAdministrativeExpenseMember2020-02-012020-04-300001428336us-gaap:GeneralAndAdministrativeExpenseMember2019-02-012019-04-300001428336us-gaap:EmployeeStockOptionMember2020-02-012020-04-300001428336us-gaap:EmployeeStockOptionMember2019-02-012019-04-300001428336us-gaap:PerformanceSharesMember2020-02-012020-04-300001428336us-gaap:PerformanceSharesMember2019-02-012019-04-300001428336us-gaap:RestrictedStockUnitsRSUMember2020-02-012020-04-300001428336us-gaap:RestrictedStockUnitsRSUMember2019-02-012019-04-300001428336hqy:PerformanceRestrictedStockUnitsMember2020-02-012020-04-300001428336hqy:PerformanceRestrictedStockUnitsMember2019-02-012019-04-300001428336us-gaap:RestrictedStockMember2020-02-012020-04-300001428336us-gaap:RestrictedStockMember2019-02-012019-04-300001428336hqy:PerformanceRestrictedStockAwardsMember2020-02-012020-04-300001428336hqy:PerformanceRestrictedStockAwardsMember2019-02-012019-04-300001428336hqy:IncentivePlanMember2020-04-300001428336hqy:WageWorksIncMemberus-gaap:RestrictedStockUnitsRSUMember2020-02-012020-04-300001428336hqy:WageWorksIncentivePlanMember2020-04-300001428336srt:MinimumMember2019-02-012019-04-300001428336srt:MaximumMember2019-02-012019-04-3000014283362019-02-012020-01-310001428336us-gaap:EmployeeStockOptionMember2020-04-300001428336hqy:PerformanceRestrictedStockUnitsMember2017-03-012017-03-310001428336srt:MinimumMemberhqy:PerformanceRestrictedStockUnitsMember2017-03-012017-03-310001428336srt:MaximumMemberhqy:PerformanceRestrictedStockUnitsMember2017-03-012017-03-310001428336hqy:PerformanceRestrictedStockAwardsMember2018-03-012018-03-310001428336srt:MaximumMemberhqy:PerformanceRestrictedStockAwardsMember2018-03-012018-03-31hqy:numberOfMember0001428336srt:MinimumMemberhqy:PerformanceRestrictedStockAwardsMember2018-03-012018-03-310001428336hqy:PerformanceRestrictedStockUnitsMember2019-03-012019-03-310001428336srt:MinimumMemberhqy:PerformanceRestrictedStockAwardsMember2019-03-012019-03-310001428336srt:MaximumMemberhqy:PerformanceRestrictedStockAwardsMember2019-03-012019-03-310001428336hqy:PerformanceRestrictedStockUnitsMember2020-04-300001428336srt:MinimumMemberhqy:PerformanceRestrictedStockAwardsMember2020-02-012020-04-300001428336srt:MaximumMemberhqy:PerformanceRestrictedStockAwardsMember2020-02-012020-04-300001428336us-gaap:RestrictedStockUnitsRSUMember2020-01-310001428336us-gaap:RestrictedStockMember2020-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2020-04-300001428336us-gaap:RestrictedStockMember2020-04-300001428336us-gaap:RestrictedStockUnitsRSUMember2019-04-30



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-36568
HEALTHEQUITY, INC.
(Exact name of registrant as specified in its charter)
Delaware52-2383166
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(Address of principal executive offices) (Zip code)

(801) 727-1000
(Registrant's telephone Number, including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
 Emerging growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 28, 2020, there were 71,399,355 shares of the registrant's common stock outstanding.



HealthEquity, Inc. and subsidiaries
Form 10-Q quarterly report

Table of contents
Page
Part I. FINANCIAL INFORMATION
Item 1.
Item 2.
Item 3.
Item 4.
Part II. OTHER INFORMATION
Item 1.
Item 1A.
Item 6.


-2-


Part I. Financial information
Item 1. Financial statements

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in thousands, except par value)April 30, 2020January 31, 2020
(unaudited)
Assets
Current assets
Cash and cash equivalents$171,093  $191,726  
Accounts receivable, net of allowance for doubtful accounts of $1,681 and $1,216 as of April 30, 2020 and January 31, 2020, respectively
69,789  70,863  
Other current assets42,901  34,711  
Total current assets283,783  297,300  
Property and equipment, net35,821  33,486  
Operating lease right-of-use assets97,554  83,178  
Intangible assets, net777,483  783,279  
Goodwill1,332,631  1,332,631  
Deferred tax asset38  18  
Other assets35,169  35,089  
Total assets$2,562,479  $2,564,981  
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$7,338  $3,980  
Accrued compensation27,197  50,121  
Accrued liabilities39,985  46,372  
Current portion of long-term debt46,875  39,063  
Operating lease liabilities13,210  12,401  
Total current liabilities134,605  151,937  
Long-term liabilities
Long-term debt, net of issuance costs1,167,192  1,181,615  
Operating lease liabilities, non-current81,982  68,017  
Other long-term liabilities3,783  2,625  
Deferred tax liability134,267  130,492  
Total long-term liabilities1,387,224  1,382,749  
Total liabilities1,521,829  1,534,686  
Commitments and contingencies (see Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively
    
Common stock, $0.0001 par value, 900,000 shares authorized, 71,398 and 71,051 shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively
7  7  
Additional paid-in capital827,303  818,774  
Accumulated earnings213,340  211,514  
Total stockholders’ equity1,040,650  1,030,295  
Total liabilities and stockholders’ equity$2,562,479  $2,564,981  
See accompanying notes to condensed consolidated financial statements.

-3-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and
comprehensive income (unaudited)
Three months ended April 30,
(in thousands, except per share data)20202019
Revenue
Service revenue$111,271  $26,808  
Custodial revenue46,899  41,952  
Interchange revenue31,841  18,292  
Total revenue190,011  87,052  
Cost of revenue
Service costs71,013  20,649  
Custodial costs5,045  4,123  
Interchange costs5,879  4,527  
Total cost of revenue81,937  29,299  
Gross profit108,074  57,753  
Operating expenses
Sales and marketing11,455  8,970  
Technology and development31,078  10,905  
General and administrative18,998  8,709  
Amortization of acquired intangible assets18,702  1,491  
Merger integration12,770    
Total operating expenses93,003  30,075  
Income from operations15,071  27,678  
Other income (expense)
Interest expense(12,263) (63) 
Other income (expense), net(764) 23,663  
Total other income (expense)(13,027) 23,600  
Income before income taxes2,044  51,278  
Income tax provision218  9,456  
Net income and comprehensive income$1,826  $41,822  
Net income per share:
Basic$0.03  $0.67  
Diluted$0.03  $0.65  
Weighted-average number of shares used in computing net income per share:
Basic70,980  62,326  
Diluted72,292  63,901  
See accompanying notes to condensed consolidated financial statements.
-4-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of stockholders’ equity (unaudited)
Three months ended April 30,
(in thousands)20202019
Total stockholders' equity, beginning balance$1,030,295  $477,079  
Common stock:
Beginning balance7  6  
Issuance of common stock upon exercise of stock options, and for restricted stock—  —  
Ending balance7  6  
Additional paid-in capital:
Beginning balance818,774  305,223  
Issuance of common stock upon exercise of stock options, and for restricted stock1,133  4,370  
Stock-based compensation7,396  6,028  
Ending balance827,303  315,621  
Accumulated earnings
Beginning balance211,514  171,850  
Net income1,826  41,822  
Ending balance213,340  213,672  
Total stockholders' equity, ending balance$1,040,650  $529,299  
See accompanying notes to condensed consolidated financial statements.

-5-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
Three months ended April 30,
(in thousands)20202019
Cash flows from operating activities:
Net income$1,826  $41,822  
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization27,507  4,773  
Stock-based compensation7,396  6,028  
Amortization of debt issuance costs1,201  15  
Gains on marketable equity securities  (23,511) 
Other non-cash items1,494  12  
Deferred taxes3,786  7,542  
Changes in operating assets and liabilities:
Accounts receivable552  (1,354) 
Other assets(8,360) (1,694) 
Operating lease right-of-use assets3,104  635  
Accounts payable3,632  (1,577) 
Accrued compensation(22,924) (8,480) 
Accrued liabilities and other current liabilities(2,270) 1,769  
Operating lease liabilities, non-current(3,045) (627) 
Other long-term liabilities1,127  (17) 
Net cash provided by operating activities15,026  25,336  
Cash flows from investing activities:
Purchases of marketable securities  (53,845) 
Purchases of property and equipment(7,511) (1,126) 
Purchases of software and capitalized software development costs(11,775) (5,497) 
Acquisition of intangible member assets(6,008) (1,262) 
Net cash used in investing activities(25,294) (61,730) 
Cash flows from financing activities:
Principal payments on long-term debt(7,812)   
Settlement of client-held funds obligation(3,776)   
Proceeds from exercise of common stock options1,223  4,229  
Net cash provided by (used in) financing activities(10,365) 4,229  
Decrease in cash and cash equivalents(20,633) (32,165) 
Beginning cash and cash equivalents191,726  361,475  
Ending cash and cash equivalents$171,093  $329,310  
Supplemental cash flow data:
Interest expense paid in cash$10,749  $50  
Income taxes paid in cash, net of refunds received733  (51) 
Supplemental disclosures of non-cash investing and financing activities:
Exercise of common stock options receivable  141  
Purchases of property and equipment included in accounts payable or accrued liabilities at period end968  21  
Purchases of software and capitalized software development costs included in accounts payable or accrued liabilities at period end1,537  158  
See accompanying notes to condensed consolidated financial statements.
-6-

Table of Contents

HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements
Note 1. Summary of business and significant accounting policies
Business
HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. HealthEquity, Inc. is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity, Inc., and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation
The accompanying condensed consolidated financial statements as of April 30, 2020 and for the three months ended April 30, 2020 and 2019 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2020. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2020.
Recently adopted accounting pronouncements
In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020 using the modified retrospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
-7-

Table of Contents


Note 2. Net income per share
The following table sets forth the computation of basic and diluted net income per share:
Three months ended April 30,
(in thousands, except per share data)20202019
Numerator (basic and diluted):
Net income $1,826  $41,822  
Denominator (basic):
Weighted-average common shares outstanding70,980  62,326  
Denominator (diluted):
Weighted-average common shares outstanding70,980  62,326  
Weighted-average dilutive effect of stock options and restricted stock units1,312  1,575  
Diluted weighted-average common shares outstanding72,292  63,901  
Net income per share:
Basic $0.03  $0.67  
Diluted$0.03  $0.65  

For the three months ended April 30, 2020 and 2019, approximately 0.5 million and 0.2 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
Note 3. Business combination
Acquisition of WageWorks
On August 30, 2019, the Company closed the acquisition (the "Acquisition") of WageWorks, Inc. ("WageWorks") for $51.35 per share in cash, or approximately $2.0 billion to WageWorks stockholders. The Company financed the transaction through a combination of $816.9 million cash on hand plus net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.5 million, under a term loan facility (see Note 8—Indebtedness).
The Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the Acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to potential adjustment during the measurement period (up to one year from the Acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
The following table summarizes the Company's current allocation of the consideration paid in the Acquisition:
(in millions)Initial AllocationAdjustmentsUpdated Allocation
Cash and cash equivalents$406.8  $(14.5) $392.3  
Other current assets56.5  1.0  57.5  
Property, plant, and equipment26.6  —  26.6  
Operating lease right-of-use assets42.5  —  42.5  
Intangible assets715.3  —  715.3  
Goodwill1,330.5  (2.5) 1,328.0  
Other assets5.9  —  5.9  
Client-held funds obligation(237.5) 17.8  (219.7) 
Other current liabilities(69.1) (2.9) (72.0) 
Other long-term liabilities(26.7) —  (26.7) 
Deferred tax liability(128.7) 1.1  (127.6) 
Total consideration paid$2,122.1  $  $2,122.1  
-8-

Table of Contents

Adjustments to the initial allocation are based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters.
Note 4. Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income components consist of the following:
Property and equipment
Property and equipment consisted of the following as of April 30, 2020 and January 31, 2020:
(in thousands)April 30, 2020January 31, 2020
Leasehold improvements$22,084  $19,240  
Furniture and fixtures9,097  7,929  
Computer equipment24,123  22,074  
Property and equipment, gross55,304  49,243  
Accumulated depreciation(19,483) (15,757) 
Property and equipment, net$35,821  $33,486  
Depreciation expense for the three months ended April 30, 2020 and 2019 was $3.9 million and $0.9 million, respectively.
Contract balances
The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. The Company's deferred revenue increased from $3.7 million as of January 31, 2020 to $4.1 million as of April 30, 2020. The balances are related to cash received in advance for an interchange revenue arrangement, other up-front fees and other commuter deferred revenue, and are generally recognized within twelve months, with the exception of the interchange arrangement, which is recognized over a term of approximately ten years. Revenue recognized during the three months ended April 30, 2020 that was included in the beginning balance of deferred revenue was $0.2 million. The Company expects to satisfy its remaining obligations for these arrangements.
Other income (expense), net
Other income (expense), net, consisted of the following:
Three months ended April 30,
(in thousands)20202019
Interest income$600  $1,343  
Gain on equity securities  23,511  
Acquisition costs(94) (1,184) 
Other expense(1,270) (7) 
Total other income (expense), net$(764) $23,663  

Note 5. Leases
The Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of less than 1 year to approximately 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.


-9-

Amortization and interest expense related to finance leases were not material during the three months ended April 30, 2020 and 2019.
The components of operating lease costs are as follows:
Three months ended April 30,
(in thousands, except for term and percentages)20202019
Operating lease expense$4,308  1,074  
Sublease income(450)   
Net operating lease cost$3,858  $1,074  
Weighted average lease term and discount rate are as follows:
As of April 30, 2020
Weighted average remaining lease term9.47 years
Weighted average discount rate4.35 %
Maturities of operating lease liabilities as of April 30, 2020 were as follows:
Fiscal year ending January 31, (in thousands)Operating leases
Remaining 2021$9,177  
202214,517  
202312,348  
202410,318  
202510,279  
Thereafter60,429  
Total lease payments117,068  
Less imputed interest(21,876) 
Present value of lease liabilities$95,192  
Current$13,210  
Non-current81,982  
Total lease liabilities$95,192  
As of April 30, 2020, the Company had an additional operating lease for office space that had not yet commenced with aggregate undiscounted lease payments of $63.1 million. This operating lease will commence in fiscal year 2021 with a lease term of approximately 11 years.
Supplemental cash flow information related to the Company's operating leases was as follows:
Three months ended April 30,
(in thousands, except for term and percentages)20202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3,297  $977  
ROU assets obtained in exchange for new operating lease obligations$17,480  $199  





-10-

Table of Contents
Note 6. Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of April 30, 2020 and January 31, 2020:
(in thousands)April 30, 2020January 31, 2020
Amortizable intangible assets:
Software and software development costs$89,949  $76,221  
Acquired HSA portfolios98,778  92,770  
Acquired customer relationships601,381  601,381  
Acquired developed technology96,925  96,925  
Acquired trade names12,300  12,300  
Amortizable intangible assets, gross899,333  879,597  
Accumulated amortization(122,442) (98,851) 
Total amortizable intangible assets, net776,891  780,746  
Acquired in process software development costs592  2,533  
Total intangible assets, net$777,483  $783,279  
During the three months ended April 30, 2020 and 2019, the Company expensed a total of $10.3 million and $3.9 million, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software.
Amortization expense for the three months ended April 30, 2020 and 2019 was $23.6 million and $3.9 million, respectively.
Goodwill
There were no changes to the goodwill carrying value during the three months ended April 30, 2020 and 2019.
Note 7. Commitments and contingencies
Commitments
In addition to the indebtedness described in Note 8 below, the Company’s principal commitments consist of operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments. These commitments as of January 31, 2020 are disclosed in the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the fiscal year ended January 31, 2020, and did not change materially during the three months ended April 30, 2020.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
WageWorks is pursuing affirmative claims against the Office of Personnel Management ("OPM") to obtain payment for services provided by WageWorks between March 1, 2016 and August 31, 2016 pursuant to its contract with OPM. In connection with WageWorks' claims against OPM, OPM has also claimed that an erroneous statement in a certificate signed by a former executive officer constituted a violation of the False Claims Act and moved to dismiss part of WageWorks' claim against OPM as a result. As with all legal proceedings, no assurance can be provided as to the outcome of these matters or if WageWorks or OPM will be successful.
On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs
-11-

Table of Contents

asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks, its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleges claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering.
On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages and fees and costs.
Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint.
WageWorks voluntarily contacted the San Francisco office of the SEC Division of Enforcement regarding the restatement of WageWorks' financial statements and related independent investigation. WageWorks is providing information and documents to the SEC and continues to cooperate with the SEC’s investigation into these matters. The U.S. Attorney’s Office for the Northern District of California also opened an investigation. WageWorks has provided documents and information to the U.S. Attorney’s Office and continues to cooperate with any inquiries by the U.S. Attorney’s Office regarding the matter.
Beginning on July 30, 2019, putative class action suits were filed in the U.S. District Court Courts for the Southern District of New York, the District of Delaware, and the Northern District of California asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks and the former members of its board of directors. The complaints generally allege disclosure violations in the proxy statement issued by WageWorks in connection with the stockholder vote on the proposed merger with the Company. After WageWorks issued certain supplemental disclosures, these actions were voluntarily dismissed, but WageWorks may still be required to pay attorneys fees to the plaintiffs' lawyers.
WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense of its former directors and officers in the legal proceedings described above.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. While it is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, the Company believes, based on current knowledge, that such litigation, proceedings and claims will not have a material impact on the Company’s financial position, results of operations and cash flows for the period.
The Company maintains liability insurance coverage that is intended to cover the legal matters described above; however, it is possible that claims may be denied by our insurance carriers or could exceed the amount of our applicable insurance coverage, we may be required by our insurance carriers to contribute to the payment of claims, and our insurance coverage may not continue to be available to us on acceptable terms or in sufficient amounts.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.



-12-

Note 8. Indebtedness
As of April 30, 2020, long-term debt consisted of the following:
(in millions)April 30, 2020
Term loan facility$1,234.4  
Less: unamortized loan issuance costs (1)20.3  
Long-term debt, net of issuance costs$1,214.1  
(1) In addition to the $20.3 million of unamortized issuance costs related to the term loan facility, $6.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the April 30, 2020 condensed consolidated balance sheet.
In connection with the closing of the Acquisition, on August 30, 2019, the Company entered into a credit facility (the "Credit Agreement”) that provided for:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion, the proceeds of which were used to finance the Acquisition, to refinance substantially all outstanding indebtedness of HealthEquity and WageWorks and to pay related fees and expenses; and
(ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of April 30, 2020.
Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of April 30, 2020, the stated interest rate was 2.15% and the effective interest rate was 2.59%. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The loans made under the Term Loan Facility are required to be repaid as described in the following table:
Fiscal year ending January 31, (in millions)Principal payments
Remaining 2021$31.3  
202262.5  
202370.3  
2024101.6  
2025968.7  
Total principal payments$1,234.4  
The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.25 to 1.00, which steps down to (x) 5.00 to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) 4.50 to 1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of April 30, 2020, and for the period then ended.
The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of HealthEquity and the guarantors, in each case, subject to certain customary exceptions.
-13-

Table of Contents
Note 9. Income taxes
The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three months ended April 30, 2020, the Company recorded income tax expense of $0.2 million. This resulted in an effective income tax expense rate of 10.7% for the three months ended April 30, 2020, compared with an effective income tax expense rate of 18.4% for the three months ended April 30, 2019. For the three months ended April 30, 2020 and 2019, the net impact of discrete tax items caused a 16.8 and 4.5 percentage point benefit, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes relative to pre-tax book income. Due to significantly lower pre-tax book income during the three months ended April 30, 2020, such excess tax benefit had a greater impact on the effective income tax rate.
As of April 30, 2020 and January 31, 2020, the Company’s total gross unrecognized tax benefit was $9.6 million and $9.4 million, respectively. As of April 30, 2020 and January 31, 2020, a net unrecognized tax benefit of $0.5 million was recorded in the condensed consolidated balance sheets. If recognized, $8.8 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of April 30, 2020.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2000.
Note 10. Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:
Three months ended April 30,
(in thousands)20202019
Cost of revenue$1,463  $860  
Sales and marketing958  1,007  
Technology and development2,917  1,499  
General and administrative2,058  2,662  
Total stock-based compensation expense$7,396  $6,028  
The following table shows stock-based compensation by award type:
Three months ended April 30,
(in thousands)20202019
Stock options$1,449  $1,783  
Performance stock options    
Restricted stock units6,509  2,926  
Performance restricted stock units(1,979) 651  
Restricted stock awards872  163  
Performance restricted stock awards545  505  
Total stock-based compensation expense$7,396  $6,028  
Stock award plans
Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of April 30, 2020, 6.5 million shares were available for grant under the Incentive Plan.
-14-

WageWorks Incentive Plan. At the closing of the Acquisition, and in accordance with the merger agreement related to the Acquisition, certain RSUs with respect to WageWorks common stock, granted under WageWorks, Inc. 2010 Equity Incentive Plan (the "WageWorks Incentive Plan"), were replaced by the Company and converted into RSUs with respect to 523,318 shares of common stock of the Company. No additional shares were issued under the WageWorks Incentive Plan, and the period during which the remaining 5,255,027 shares were available to be utilized expired on May 26, 2020.
Stock options
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.
Valuation assumptions. The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.
Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.
The weighted-average fair value of options granted during the three months ended April 30, 2020 and 2019 was $23.68 and $25.97 per share, respectively. The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented are as follows:
Three months ended April 30,
20202019
Expected dividend yield%%
Expected stock price volatility37.97%
35.98% - 36.53%
Risk-free interest rate1.39%
2.21% - 2.43%
Expected life of options5.18 years
4.95 - 5.09 years
The Company estimates the expected life of an option using historical option exercise and termination data. Expected volatility is determined using the weighted average volatility of the Company's historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term of the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations.
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20202,040  
$0.10 - 82.39
$30.35  5.90$74,009  
Granted16  $66.06  $66.06  
Exercised(51) 
$0.10 - 44.53
$22.07  
Forfeited(4) 
$25.45 - 44.53
$32.61  
Outstanding as of April 30, 20202,001  
$0.10 - 82.39
$30.85  5.72$54,009  
Vested and expected to vest as of April 30, 20202,001  $30.85  5.72$54,009  
Exercisable as of April 30, 20201,632  $25.71  5.29$50,730  
-15-

The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options. The total intrinsic value of options exercised during the three months ended April 30, 2020 and 2019 was $2.1 million and $9.2 million, respectively.
As of April 30, 2020, the weighted-average vesting period of non-vested options expected to vest was approximately 1.3 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately $6.1 million.
Restricted stock units and restricted stock awards
The Company grants RSUs and RSAs to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate. The weighted-average fair value of RSUs granted during the three months ended April 30, 2020 and 2019 was $56.27 and $73.02 per share, respectively.
Performance restricted stock units and awards. In March 2017, the Company awarded 146,964 performance-based RSUs ("PRSUs"). The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred during the three months ended April 30, 2020 following approval by the Compensation Committee of the board of directors, based on the level of achievement of the performance goal as measured on January 31, 2020. The performance conditions allowed for a range of vesting from 0% to 150%. The PRSUs vested at 118.1%.
In March 2018, the Company awarded 227,760 performance-based RSAs ("PRSAs"). The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. The underlying shares were issued at 200% of the target level of achievement at the grant date. During the three months ended April 30, 2020, the Compensation Committee modified the awards by deeming the performance condition related to two-thirds of the awards to be achieved at 100% and creating a new performance condition related to the remaining one-third of the awards to reflect the state of the Company after the Acquisition of WageWorks. The new performance condition is based on the achievement of certain financial criteria measured on January 31, 2021. The modification affected 10 team members and did not result in an adjustment to stock-based compensation expense. The PRSAs cliff vest upon approval by the Compensation Committee. The modified performance condition for the one-third tranche allows for a range of vesting from 0% to 200% based on the level of achievement of the performance condition, and the Company believes it is probable that the PRSAs will vest at least in part. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance.
In March 2019, the Company awarded 129,963 PRSUs. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. During the three months ended April 30, 2020, the Compensation Committee modified the awards by deeming the performance condition related to one-third of the awards to be achieved at 100% and creating new performance conditions related to the remaining two-thirds of the awards to reflect the state of the Company after the Acquisition of WageWorks. The new performance conditions are based on the achievement of certain financial criteria measured on January 31, 2021 and 2022. The modification affected 12 team members and will result in incremental stock-based compensation expense of $6.6 million, which will be recognized over the remaining service period, adjusted for the level of achievement of the performance conditions and any forfeitures. Prior to the modification, the Company did not believe the PRSUs were likely to vest, and as a result, $2.9 million of previously recorded stock-based compensation expense was reversed during the three months ended April 30, 2020. The PRSUs cliff vest upon approval by the Compensation Committee. The modified performance conditions for the two-thirds tranche allow for a range of vesting from 0% to 200% based on the level of achievement of the new performance conditions, and the Company believes it is probable that the PRSUs will vest at least in part.
During the three months ended April 30, 2020, the Company awarded 257,680 PRSUs subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2023. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was approximately $19.0 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee.

-16-

A summary of the RSU and RSA activity is as follows:
RSUs and PRSUsRSAs and PRSAs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
Outstanding as of January 31, 20201,380  $63.33  235  $61.91  
Granted1,085  56.27  14  74.81  
Vested(296) 51.38  (10) 62.80  
Forfeited(167) 71.72  (14) 63.31  
Outstanding as of April 30, 20202,002  $60.57  225  $62.58  
For the three months ended April 30, 2020 and 2019, the aggregate intrinsic value of RSUs and RSAs vested was $16.4 million and $7.7 million, respectively.
Total unrecorded stock-based compensation expense as of April 30, 2020 associated with RSUs and PRSUs was $109.1 million, which is expected to be recognized over a weighted-average period of 3.1 years. Total unrecorded stock-based compensation expense as of April 30, 2020 associated with RSAs and PRSAs was $2.4 million, which is expected to be recognized over a weighted-average period of 0.9 years.
Note 11. Fair value
Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of April 30, 2020 due to the short-term nature of these instruments. 
Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.
-17-

Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning the impact of the ongoing COVID-19 pandemic on the Company, the anticipated synergies and other benefits of the acquisition of WageWorks, health savings accounts and other tax-advantaged consumer-directed benefits, tax and other regulatory changes, market opportunity, our future financial and operating results, investment and acquisition strategy, sales and marketing strategy, management’s plans, beliefs and objectives for future operations, technology and development, economic and industry trends or trend analysis, expectations about seasonality, opportunity for portfolio purchases and other acquisitions, operating expenses, anticipated income tax rates, capital expenditures, cash flows and liquidity. These statements are based on the beliefs and assumptions of our management based on information currently available to us. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2020, this Quarterly Report on Form 10-Q, and in our other reports filed with the SEC. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such events.

Overview
We are a leader and an innovator in providing technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions. Consumers and employers use our platforms to manage tax-advantaged health savings accounts ("HSAs") and other consumer-directed benefits ("CDBs") offered by employers, flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit information, access remote and telemedicine benefits, earn wellness incentives, and receive investment advice to grow their tax-advantaged healthcare savings.
The core of our offerings is the HSA, a financial account through which consumers spend and save long-term for healthcare expenses on a tax-advantaged basis. As of April 30, 2020, we administered 5.4 million HSAs, with balances totaling $11.5 billion, which we call HSA Assets. Also, as of April 30, 2020, we administered 7.3 million complementary CDBs. We refer to the aggregate number of HSAs and other CDBs on our platforms as Total Accounts, of which we had 12.7 million as of April 30, 2020.
We reach consumers primarily through relationships with their employers, which we call Clients. We reach Clients primarily through a sales force that calls on Clients directly, relationships with benefits brokers and advisors, and integrated partnerships with a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan recordkeepers, which we call Network Partners.
We have grown our share of the growing HSA market from 4% in calendar year 2010 to 16% in 2019, including by 3% as a result of the acquisition (the "Acquisition") of WageWorks, Inc. ("WageWorks") on August 30, 2019. According to Devenir, today we are the largest HSA provider by accounts and second largest by assets. In addition, we believe we are the largest provider of other CDBs. We seek to differentiate ourselves through our proprietary technology, product breadth, ecosystem connectivity, and service-driven culture. Our proprietary technology is designed to help consumers optimize the value of their HSAs and other CDBs, as they gain confidence and skill in their management of financial responsibility for lifetime healthcare.
-18-

Our ability to engage consumers is enhanced by our platforms’ capacity to securely share data in both directions with others in the health, benefits, and retirement ecosystems, which we call Ecosystem Partners. Our commuter benefits offering also leverages connectivity to an ecosystem of mass transit, ride hailing, and parking providers. These strengths reflect our “DEEP Purple” culture of remarkable service to customers and teammates, achieved by driving excellence, ethics, and process into everything we do.
We earn revenue primarily from three sources: service, custodial, and interchange. We earn service revenue mainly from fees paid by Clients on a recurring per-account per-month basis. We earn custodial revenue mainly from HSA Assets held at our members’ direction in federally insured cash deposits, insurance contracts or mutual funds, and from investment of Client-held funds. We earn interchange revenue mainly from fees paid by merchants on payments that our members make using our physical payment cards and virtual platforms. See “Key components of our results of operations” for additional information on our sources of revenue, including regarding the adverse impacts caused by the ongoing COVID-19 pandemic.
Acquisition of WageWorks
On August 30, 2019, we completed the Acquisition of WageWorks and paid approximately $2.0 billion in cash to WageWorks stockholders, financed through net borrowings of approximately $1.22 billion under a new term loan facility and approximately $816.9 million of cash on hand.
We expect the Acquisition to enable us to increase the number of our employer sales opportunities, the conversion of these opportunities to Clients, and the value of Clients in generating members, HSA Assets and complementary CDBs. WageWorks’ historic strength of selling to employers directly and through health benefits brokers and advisors complements our distribution through health plans, benefit administrators and retirement record-keeping partners. With WageWorks’ CDB capabilities, we are working to provide employers with a single partner for both HSAs and other CDBs, which is preferred by the vast majority of employers according to research conducted for us by Aite Group. For Clients that partner with us in this way, we believe we can produce more value by encouraging both CDB participants to contribute to HSAs and HSA-only members to take advantage of tax savings by increasing their account balances in other CDBs. Accordingly, we believe that there are significant opportunities to expand the scope of services that we provide to our Clients.
The Acquisition has significantly increased the number of our Total Accounts, HSA Assets, Client-held funds, Adjusted EBITDA, total revenue, total cost of revenue, operating expenses, and other financial results. These increases are reflected in the period-over-period results described in this report.
Key factors affecting our performance
We believe that our future performance will be driven by a number of factors, including those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See also "Results of Operations - Revenue" for information relating to the ongoing COVID-19 pandemic and also the section entitled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2020, this Quarterly Report on Form 10-Q and our other reports filed with the SEC.
WageWorks integration
On August 30, 2019, we completed the Acquisition of WageWorks. We are now pursuing a multi-year integration effort that we expect will produce long-term cost savings and revenue synergies. We have identified near-term opportunities, estimated to be approximately $50 million in annualized ongoing net synergies, which we expect to achieve by the end of the second quarter of fiscal 2021. Furthermore, we anticipate generating additional revenue synergies over the longer-term as our combined distribution channels and existing client base take advantage of the broader platform and service offerings and as we continue to drive member engagement. We estimate non-recurring costs to achieve these synergies of approximately $80 million to $100 million realized within 24 to 36 months of the closing of the Acquisition, resulting from investment in technology platforms, back-office systems and platform integration, as well as rationalization of cost of operations. As of April 30, 2020, we had incurred a total of approximately $45 million of non-recurring merger integration costs related to the Acquisition of WageWorks.
Structural change in U.S. health insurance
We derive revenue primarily from healthcare-related saving and spending by consumers in the U.S., which are driven by changes in the broader healthcare industry, including the structure of health insurance. The average premium for employer-sponsored health insurance has risen by 22% since 2014 and 54% since 2009, resulting in increased participation in HSA-qualified health plans and HSAs and increased consumer cost-sharing in health insurance more generally. We believe that continued growth in healthcare costs and related factors will spur
-19-

continued growth in HSA-qualified health plans and HSAs and may encourage policy changes making HSAs or similar vehicles available to new populations such as individuals in Medicare. However, the timing and impact of these and other developments in U.S. healthcare are uncertain. Moreover, changes in healthcare policy, such as proposed "Medicare for all" plans, could materially and adversely affect our business in ways that are difficult to predict.
Trends in U.S. tax law
Tax law has a profound impact on our business. Our offerings to members, Clients, and Network Partners consist primarily of services enabled, mandated, or advantaged by provisions of U.S. tax law and regulations. We believe that the present direction of U.S. tax policy is favorable to our business, as evidenced for example by recent regulatory action and bipartisan policy proposals to expand the availability of HSAs. However, changes in tax policy are speculative, and may affect our business in ways that are difficult to predict.
Our client base
Our business model is based on a B2B2C distribution strategy, meaning that we attract Clients and Network Partners to reach consumers to increase the number of our members with HSA accounts and complementary CDBs. We believe that there are significant opportunities to expand the scope of services that we provide to our current Clients.
Broad distribution footprint
We believe we have a diverse distribution footprint to attract new Clients and Network Partners. Our sales force calls on enterprise and regional employers in industries across the U.S., as well as potential Network Partners from among health plans, benefits administrators, and retirement plan record keepers.
Product breadth
We are the largest custodian and administrator of HSAs (by number of accounts), as well as a market-share leader in each of the major categories of complementary CDBs, including FSAs and HRAs, COBRA and commuter benefits administration. Our Clients and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs. With our newly acquired CDB capabilities, we can provide employers with a single partner for both HSAs and complementary CDBs, which is preferred by the vast majority of employers, according to research conducted for us by Aite Group. We believe that the combination of HSA and complementary CDB offerings significantly strengthens our value proposition to employers, health benefits brokers and consultants, and Network Partners as a leading single-source provider.
Our proprietary technology platforms
We believe that innovations incorporated in our technology that enable consumers to make healthcare saving and spending decisions and maximize the value of their tax-advantaged benefits differentiate us from our competitors and drive our growth. We plan to build on these innovations by combining our HSA platform with WageWorks' complementary CDB offerings, giving us a full suite of CDB products, and adding to our solutions set and leadership position within the HSA sector. We intend to continue to invest in our technology development to enhance our platforms' capabilities and infrastructure, while maintaining a focus on data security and the privacy of our customers' data. For example, we are making significant investments in our platforms' architecture and related platform infrastructure to improve our transaction processing capabilities and support continued account and transaction growth, as well as in data-driven personalized engagement to help our members spend less, save more, and build wealth for retirement.
Our “DEEP Purple” service culture
The successful healthcare consumer needs education and guidance delivered by people as well as technology. We believe that our "DEEP Purple" culture, which we define as Driving Excellence, Ethics, and Process while providing remarkable service, is a significant factor in our ability to attract and retain customers and to address nimbly, opportunities in the rapidly changing healthcare sector. We make significant efforts to promote and foster DEEP Purple within our workforce. We invest in and intend to continue to invest in human capital through technology-enabled training, career development, and advancement opportunities.
Interest rates
As a non-bank custodian, we contract with federally insured banks, credit unions, and insurance company partners, which we collectively call our Depository Partners, to hold custodial cash assets on behalf of our members. We earn a material portion of our total revenue from interest paid to us by these partners. The lengths of our agreements with Depository Partners generally range from three to five years and may have fixed or variable
-20-

interest rate terms. The terms of new and renewing agreements may be impacted by the then-prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members. We believe that diversification of Depository Partners, varied contract terms and other factors reduce our exposure to short-term fluctuations in prevailing interest rates and mitigate the short-term impact of sustained increases or declines in prevailing interest rates on our custodial revenue. Over longer periods, sustained shifts in prevailing interest rates affect the amount of custodial revenue we can realize on custodial assets and the interest retained by our members.
We expect our custodial revenue to be adversely affected by the interest rate cuts by the Federal Reserve associated with the ongoing COVID-19 pandemic and other market conditions that have caused interest rates to decline significantly and, as a result, funds that we place with our Depository Partners in this environment will receive lower interest rates than we originally expected.
Interest on our long-term debt changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Our competition and industry
Our direct competitors are HSA custodians and other CDB providers. Many of these are state or federally chartered banks and other financial institutions for which we believe technology-based healthcare services are not a core business. Certain of our direct competitors have chosen to exit the market despite increased demand for these services. This has created, and we believe will continue to create, opportunities for us to leverage our technology platforms and capabilities to increase our market share. However, some of our direct competitors (including well-known mutual fund companies such as Fidelity Investments and healthcare service companies such as United Health Group's Optum) are in a position, should they choose, to devote more resources to the development, sale, and support of their products and services than we have at our disposal. In addition, numerous indirect competitors, including benefits administration technology and service providers, partner with banks and other HSA custodians to compete with us. Our Network Partners may also choose to offer competitive services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
As a result of the outbreak of the COVID-19 virus, we have seen some impact on sales opportunities, with some opportunities delayed or now being held virtually. As an increasing number of companies go out of business, the number of our clients and potential clients would be adversely affected. Increased unemployment may mean that fewer of our members contribute to HSAs, FSAs or other CDBs. We have seen a significant decline in the use of commuter benefits due to many of our members working from home during the outbreak or other impacts from the outbreak, which has negatively impacted both our interchange revenue and service revenue. We have also seen a decline in interchange revenue across all other products. The extent to which the COVID-19 virus will negatively impact our business is highly uncertain and cannot be accurately predicted.
Regulatory environment
Federal law and regulations, including the Affordable Care Act, the Internal Revenue Code, the Employee Retirement Income Security Act and Department of Labor regulations, and public health regulations that govern the provision of health insurance and provide the tax advantages associated with our products, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as the Health Insurance Portability and Accountability Act, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, or the Advisers Act, the USA PATRIOT Act, anti-money laundering laws, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. For example, our subsidiary HealthEquity Trust Company is regulated by the Wyoming Division of Banking, and several states are considering, or have already passed, new privacy regulations that can affect our business. Various states also have laws and regulations that impose additional restrictions on our collection, storage, and use of personally identifiable information. Privacy regulation in particular has become a priority issue in many states, including California, which in 2018 enacted the California Consumer Privacy Act broadly regulating California residents’ personal information and providing California residents with various rights to access and control their data. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.


-21-

Our acquisition strategy
In addition to the WageWorks acquisition, we have a successful history of acquiring HSA portfolios from competitors who have chosen to exit the industry and complementary assets and businesses that strengthen our platform. We seek to continue this growth strategy and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate, and integrate acquired HSA portfolios. We intend to continue to thoughtfully pursue acquisitions of complementary assets and businesses that we believe will strengthen our platform.
Key financial and operating metrics
Our management regularly reviews a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
Total Accounts
The following table sets forth our HSAs, CDBs, and Total Accounts as of and for the periods indicated:
(in thousands, except percentages)April 30, 2020April 30, 2019% ChangeJanuary 31, 2020
HSAs5,380  4,054  33 %5,344  
New HSAs from Sales - Quarter-to-date104  89  17 %379  
New HSAs from Sales - Year-to-date104  89  17 %724  
New HSAs from Acquisitions - Year-to-date—  —  n/a  757  
HSAs with investments245  177  38 %220  
CDBs7,338  670  995 %7,437  
Total Accounts12,718  4,724  169 %12,781  
Average Total Accounts - Quarter-to-date12,784  4,681  173 %12,603  
Average Total Accounts - Year-to-date12,784  4,681  173 %8,013  
The number of our HSAs and CDBs are key metrics because our revenue is driven by the amount we earn from them. The number of our HSAs increased by approximately 1.3 million, or 33%, from April 30, 2019 to April 30, 2020, primarily driven by the HSAs acquired through the Acquisition of WageWorks and other HSA portfolio acquisitions, which contributed approximately 757,000 HSAs. The remainder of the increase was due to further penetration into existing Network Partners and the addition of new Network Partners. The number of our CDBs increased by approximately 6.7 million from April 30, 2019 to April 30, 2020, driven by the CDBs acquired through the Acquisition of WageWorks.
HSAs are individually owned portable healthcare accounts. As HSA members transition between employers or health plans, they may no longer be enrolled in an HDHP that qualifies them to continue to make contributions to their HSA.
HSA Assets
The following table sets forth our HSA Assets as of and for the periods indicated:
(in millions, except percentages)April 30, 2020April 30, 2019% ChangeJanuary 31, 2020
HSA cash with yield (1)$8,338  $6,404  30 %$8,301  
HSA cash without yield (2)386  —  n/a  383  
Total HSA cash8,724  6,404  36 %8,684  
HSA investments with yield (1)2,483  1,917  30 %2,495  
HSA investments without yield (2)297  —  n/a  362  
Total HSA investments2,780  1,917  45 %2,857  
Total HSA Assets11,504  8,321  38 %11,541  
Average daily HSA cash with yield - Year-to-date8,283  6,407  29 %6,937  
Average daily HSA cash with yield - Quarter-to-date$8,283  $6,407  29 %$7,791  
(1) HSA Assets that generate custodial revenue.
(2) HSA Assets that do not generate custodial revenue.
-22-

Our HSA Assets, which are our HSA members' assets for which we are the custodian or administrator, or from which we generate custodial revenue, consist of the following components: (i) cash deposits, which are deposits with our Depository Partners or other custodians, (ii) custodial cash deposits invested in annuity contracts with our insurance company partners, and (iii) investments in mutual funds through our custodial investment fund partners. We are working to transition HSA cash without yield to HSA cash with yield in fiscal 2021. Measuring our HSA Assets is important because our custodial revenue is directly affected by average daily custodial balances for HSA Assets that are revenue generating.
Our total HSA Assets increased by $3.2 billion, or 38%, from April 30, 2019 to April 30, 2020, including $1.7 billion of HSA Assets acquired through the Acquisition of WageWorks and other HSA portfolio acquisitions and $1.5 billion from existing HSA members and new HSA members.
Our HSA investment assets increased by $0.9 billion, or 45%, from April 30, 2019 to April 30, 2020, reflecting the Acquisition of WageWorks and our strategy of helping our HSA members build wealth and invest for retirement.
Client-held funds
(in millions, except percentages)April 30, 2020April 30, 2019% ChangeJanuary 31, 2020
Client-held funds (1)$894  $—  n/a  $779  
Average daily Client-held funds - Year-to-date (1)831  —  n/a  382  
Average daily Client-held funds - Quarter-to-date (1)831  —  n/a  727  
(1) Client-held funds that generate custodial revenue. The Company did not hold material Client-held funds prior to the Acquisition.
Our Client-held funds are interest-earning deposits from which we generate custodial revenue. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of CDBs. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration.
Our total Client-held funds increased by $894 million from April 30, 2019 to April 30, 2020, due to the Acquisition of WageWorks.
Adjusted EBITDA
We define Adjusted EBITDA, which is a non-GAAP financial metric, as adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on marketable equity securities, and certain other non-operating items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses, and serves as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income, the most comparable GAAP financial measure, to Adjusted EBITDA for the periods indicated:
Three months ended April 30,
(in thousands)20202019
Net income$1,826  $41,822  
Interest income(600) (1,343) 
Interest expense12,263  63  
Income tax provision218  9,456  
Depreciation and amortization8,805  3,282  
Amortization of acquired intangible assets18,702  1,491  
Stock-based compensation expense7,396  6,028  
Merger integration expenses12,770  —  
Acquisition costs94  1,184  
Gain on marketable equity securities—  (23,511) 
Other (1)1,534  451  
Adjusted EBITDA$63,008  $38,923  
(1)For the three months ended April 30, 2020, Other consisted of amortization of incremental costs to obtain a contract of $0.3 million and other costs of $1.3 million. For the three months ended April 30, 2019, Other consisted of amortization of incremental costs to obtain a contract of $0.5 million.
-23-

The following table further sets forth our Adjusted EBITDA as a percentage of revenue:
Three months ended April 30,
(in thousands, except percentages)20202019$ Change% Change
Adjusted EBITDA$63,008  $38,923  $24,085  62 %
As a percentage of revenue33 %45 %
Our Adjusted EBITDA increased by $24.1 million, or 62%, from $38.9 million for the three months ended April 30, 2019 to $63.0 million for the three months ended April 30, 2020. The increase in Adjusted EBITDA was driven by the overall growth of our business and by the Acquisition.
Our use of Adjusted EBITDA has limitations as an analytical tool, and it should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
Key components of our results of operations
Acquisition of WageWorks
As the Acquisition closed on August 30, 2019, WageWorks' results of operations are included in our consolidated results of operations for the three months ended April 30, 2020, but are not included in our consolidated results of operations for the three months ended April 30, 2019. In addition, the results of operations attributable to WageWorks may not be directly comparable to WageWorks' results of operations reported by WageWorks prior to the Acquisition.
Revenue
We generate revenue from three primary sources: service revenue, custodial revenue, and interchange revenue.
Service revenue.    We earn service revenue from the fees we charge our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. With respect to our Network Partners and Clients, our fees are generally based on a fixed tiered structure for the duration of the relevant service agreement and are paid to us on a monthly basis. We recognize revenue on a monthly basis as services are rendered to our members and Clients. As a result of the WageWorks Acquisition, service revenue now comprises a majority of our revenue.
Custodial revenue.    We earn custodial revenue primarily from our HSA Assets deposited with our Depository Partners and with our insurance company partners, Client-held funds deposited with our Depository Partners, and recordkeeping fees we earn in respect of mutual funds in which our members invest. We deposit HSA cash with our Depository Partners pursuant to contracts that (i) generally have terms ranging from three to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances deposited with the relevant Depository Partner, and (iii) have minimum and maximum required deposit balances. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. We earn custodial revenue on HSA Assets and Client-held funds that is based on the interest rates offered to us by these Depository Partners. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA Assets in mutual funds through our custodial investment partner. We earn a recordkeeping fee, calculated as a percentage of custodial investments. We are working to transition HSA cash without yield to HSA cash with yield in fiscal 2021.
Interchange revenue.    We earn interchange revenue each time one of our members uses one of our payment cards to make a purchase. This revenue is collected each time a member “swipes” our payment card to pay expenses. We recognize interchange revenue monthly based on reports received from third parties, namely, the card-issuing banks and card processors.
Cost of revenue
Cost of revenue includes costs related to servicing accounts, managing Client and Network Partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations (such as office rent, supplies, and other overhead expenses), new member and participant supplies, and other operating costs related to servicing our members. Other components of cost of revenue include interest retained by members on HSA cash and interchange costs incurred in connection with processing card transactions for our members.
Service costs.    Service costs include the servicing costs described above. Additionally, for new accounts, we incur on-boarding costs associated with the new accounts, such as new member welcome kits, the cost associated with issuance of new payment cards, and costs of marketing materials that we produce for our Network Partners.
-24-

Custodial costs.    Custodial costs are comprised of interest retained by our HSA members, in respect of HSA cash with yield, and fees we pay to banking consultants whom we use to help secure agreements with our Depository Partners. Interest retained by HSA members is calculated on a tiered basis. The interest rates retained by HSA members can change based on a formula or upon required notice.
Interchange costs.    Interchange costs are comprised of costs we incur in connection with processing payment transactions initiated by our members. Due to the substantiation requirement on FSA/HRA-linked payment card transactions, payment card costs are higher for FSA/HRA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the transaction.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including interest rates, the amount we charge our Network Partners, Clients, and members, the mix of our sources of revenue, how many services we deliver per account, and payment processing costs per account.
Operating expenses
Sales and marketing.    Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense allocations.
Technology and development.    Technology and development expenses include personnel and related expenses for software development and delivery, information technology, data management, product, and security. Technology and development expenses also include software engineering services, the costs of operating our on-demand technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
General and administrative.    General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, internal audit, corporate development, compliance, and people departments. They also include depreciation, amortization, stock-based compensation, and common expense allocations.
Amortization of acquired intangible assets.    Amortization of acquired intangible assets results primarily from intangible assets acquired in connection with business combinations. The assets include acquired customer relationships, acquired developed technology, and acquired trade names and trademarks, which we amortize over the assets' estimated useful lives, estimated to be 10-15 years, 2-5 years, and 3 years, respectively. We also acquired intangible HSA portfolios from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We evaluate our acquired intangible assets for impairment annually, or at a triggering event.
Merger integration.    Merger integration expenses include personnel and related expenses, including severance, professional fees, and technology-related expenses directly related to the integration activities to merge operations as a result of the Acquisition.
Interest expense
Interest expense consists of accrued interest expense and amortization of deferred financing costs associated with our credit agreement. Interest on our long-term debt changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Other expense, net
Other expense, net, primarily consists of acquisition costs, gains and losses on marketable equity securities, and non-income-based taxes, less interest income earned on corporate cash.
Income tax provision
We are subject to federal and state income taxes in the United States based on a calendar tax year-end through December 31, 2019; however, beginning January 31, 2020, the Company will report for federal and state income tax purposes using a January 31 year-end, consistent with the financial reporting fiscal year. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
-25-

carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. As of April 30, 2020, we have recorded an overall net deferred tax liability with the exception of an insignificant amount of federal capital losses recorded as a net deferred tax asset on our condensed consolidated balance sheet.
Comparison of the three months ended April 30, 2020 and 2019
Impact of Acquisition
The comparability of our operating results is impacted by our Acquisition of WageWorks on August 30, 2019. Revenue and expense attributable to us or WageWorks generally may not be separately identifiable due to the integration of WageWorks into our existing operations.
Revenue
The following table sets forth our revenue for the periods indicated:
Three months ended April 30,
(in thousands, except percentages)20202019$ Change% Change
Service revenue$111,271  $26,808  $84,463  315 %
Custodial revenue46,899  41,952  4,947  12 %
Interchange revenue31,841  18,292  13,549  74 %
Total revenue$190,011  $87,052  $102,959  118 %
Service revenue. The $84.5 million, or 315%, increase in service revenue from the three months ended April 30, 2019 to the three months ended April 30, 2020 was primarily due to the inclusion of service revenue associated with the CDBs added through the Acquisition, partially offset by the negative impact of the COVID-19 pandemic on service revenues related to commuter benefits and other CDBs.
The number of our HSAs increased by approximately 1.3 million, or 33%, from April 30, 2019 to April 30, 2020, primarily due to acquiring approximately 757,000 HSAs through the Acquisition of WageWorks and other portfolio acquisitions. The remainder of the increase was due to further penetration into existing Network Partners and the addition of new Network Partners.
Service revenue as a percentage of our total revenue increased primarily due the service revenue contributed by CDBs added through the Acquisition of WageWorks.
Custodial revenue. The $4.9 million, or 12%, increase in custodial revenue from the three months ended April 30, 2019 to the three months ended April 30, 2020 was primarily due to an increase in the year-over-year average daily balance of HSA cash with yield of $1.9 billion, or 29%. The increase was partially offset by a decrease in yield from 2.53% for the three months ended April 30, 2019 to 2.12% for the three months ended April 30, 2020, which was due in part to the interest rate cuts made by the Federal Reserve in response to the COVID-19 pandemic and due to the lower yield on HSA cash with yield added through the Acquisition.
Custodial revenue as a percentage of our total revenue decreased primarily due to the inclusion of WageWorks' financial results following the Acquisition, which included relatively less custodial revenue.
Over the course of fiscal 2021, we intend to move the majority of HSA cash without yield to HSA cash with yield. This cash will be placed with our Depository Partners at prevailing interest rates, which we expect will generate additional custodial revenue.
Interchange revenue. The $13.5 million, or 74%, increase in interchange revenue from the three months ended April 30, 2019 to the three months ended April 30, 2020 was primarily due to the inclusion of interchange revenue associated with the CDBs added through the Acquisition, partially offset by a decrease in spend per CDB, primarily with respect to FSA and commuter benefit accounts, as well as lower healthcare spending, during the three months ended April 30, 2020 due to decreased card spend partially attributable to the restrictions imposed by local governments around the country in connection with the COVID-19 pandemic.
-26-

Total revenue. Total revenue increased by $103.0 million, or 118%, from the three months ended April 30, 2019 to the three months ended April 30, 2020, due to the impact of the WageWorks acquisition and related realized net revenue synergies.
Impact of COVID-19. We expect our business to continue to be adversely affected by the recent outbreak of the COVID-19 virus, including as a result of the associated interest rate cuts by the Federal Reserve and other market conditions that have caused interest rates to decline significantly and, as a result, funds that we place with our depository partners in this environment will receive lower interest rates than we originally expected. Sales opportunities have also been impacted, with some opportunities delayed or now being held virtually. As an increasing number of companies go out of business, the number of our clients and potential clients would be adversely affected. Increased unemployment may mean that fewer of our members contribute to HSAs, FSAs or other CDBs. We may be unable to meet our service level commitments to our clients as a result of disruptions to our work force and disruptions to third part contracts that we rely on to provide our services. Our financial results related to certain of our products may be adversely affected, such as commuter benefits, due to many of our members working from home during the outbreak or other impacts from the outbreak. Clients may be unable to pay fees required under contracts and exercise "force majeure" or similar defenses, which would negatively impact our financial results. The extent to which the COVID-19 virus will negatively impact our business remains highly uncertain and as a result may have a material adverse impact on our business and financial results.
Cost of revenue
The following table sets forth our cost of revenue for the periods indicated:
Three months ended April 30,
(in thousands, except percentages)20202019$ Change% Change
Service costs$71,013  $20,649  $50,364  244 %
Custodial costs5,045  4,123  922  22 %
Interchange costs5,879  4,527  1,352  30 %
Total cost of revenue$81,937  $29,299  $52,638  180 %
Service costs. The $50.4 million, or 244%, increase in service costs from the three months ended April 30, 2019 to the three months ended April 30, 2020 was primarily due to the Acquisition and the resulting higher volume of accounts being serviced, including additional hiring of personnel to implement and support our new Network Partners and HSAs, increases in stock-based compensation expense, and increases in other expenses.
Custodial costs. The $0.9 million, or 22%, increase in custodial costs from the three months ended April 30, 2019 to the three months ended April 30, 2020 was due to an increase in the average daily balance of HSA cash with yield, which increased from $6.4 billion for the three months ended April 30, 2019 to $8.3 billion for the three months ended April 30, 2020. The increase was partially offset by a lower average interest rate paid on HSA assets with yield, which decreased from 0.23% for the three months ended April 30, 2019 to 0.21% for the three months ended April 30, 2020.
Interchange costs. The $1.4 million, or 30%, increase in interchange costs for the three months ended April 30, 2019 compared to the three months ended April 30, 2020 was due to an overall increase in average Total Accounts, which increased primarily due to accounts added through the Acquisition of WageWorks, partially offset by decreased card spend per average account.
Total cost of revenue. As we continue to add Total Accounts, we expect that our cost of revenue will increase in dollar amount to support our Network Partners, Clients, and members. Cost of revenue will continue to be affected by a number of different factors, including our ability to scale our service delivery, Network Partner implementation and account management functions.
-27-

Operating expenses
The following table sets forth our operating expenses for the periods indicated:
Three months ended April 30,
(in thousands, except percentages)20202019$ Change% Change
Sales and marketing$11,455  $8,970  $2,485  28 %
Technology and development31,078  10,905  20,173  185 %
General and administrative18,998  8,709  10,289  118 %
Amortization of acquired intangible assets18,702  1,491  17,211  1,154 %
Merger integration12,770  —  12,770  n/a  
Total operating expenses$93,003  $30,075  $62,928  209 %
Sales and marketing. The $2.5 million, or 28%, increase in sales and marketing expense from the three months ended April 30, 2019 to the three months ended April 30, 2020 was primarily due to increased staffing, increases in other expenses, and higher stock-based compensation expense resulting from the Acquisition.
We expect our sales and marketing expenses to increase for the foreseeable future as we continue to increase the size of our sales and marketing organization and expand into new markets. On an annual basis, we expect our sales and marketing expenses to remain steady as a percentage of our total revenue. However, our sales and marketing expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our sales and marketing expenses.
Technology and development. The $20.2 million, or 185%, increase in technology and development expense from the three months ended April 30, 2019 to the three months ended April 30, 2020 was primarily due to increased personnel-related expense, increases in professional fees, increased stock-based compensation expense, increases in amortization and depreciation, and other increases resulting from the Acquisition, which were partially offset by increases in capitalized development.
We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development and security of our proprietary platforms. On an annual basis, we expect our technology and development expenses to increase as a percentage of our total revenue pursuant to our growth initiatives. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses.
General and administrative. The $10.3 million, or 118%, increase in general and administrative expense from the three months ended April 30, 2019 to the three months ended April 30, 2020 was primarily due to increased personnel-related expense, increases in professional fees, and increased stock-based compensation expense resulting from the Acquisition.
We expect our general and administrative expenses to increase for the foreseeable future due to the additional demands on our legal, compliance, accounting, and insurance functions that we incur as we continue to grow our business, as well as other costs associated with being a public company. On an annual basis, we expect our general and administrative expenses to remain steady as a percentage of our total revenue over the near term pursuant to our growth initiatives. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.
Amortization of acquired intangible assets. The $17.2 million increase in amortization of acquired intangible assets from the three months ended April 30, 2019 to the three months ended April 30, 2020 was due to identified intangible assets acquired through the Acquisition of WageWorks.
Merger integration. The $12.8 million in merger integration expense for the three months ended April 30, 2020 was due to personnel and related expenses, including expenses incurred in conjunction with the migration of accounts, severance, professional fees, technology-related, and facilities expenses directly related to the Acquisition of WageWorks. We expect integration expenses totaling $80 million to $100 million in the aggregate to continue for 24 to 36 months following the closing of the Acquisition, which closed on August 30, 2019. As of April 30, 2020, we had incurred a total of approximately $45 million of non-recurring merger integration costs related to the Acquisition of WageWorks.
-28-

Interest expense
The $12.3 million in interest expense for the three months ended April 30, 2020 consists primarily of interest accrued under our term loan facility and amortization of financing costs. We expect interest expense to decrease as a result of interest rate cuts made by the Federal Reserve in response to the COVID-19 pandemic and principal repayments required pursuant to our credit agreement.
Other income (expense), net
The $24.4 million change in other income (expense), net, from income of $23.7 million during the three months ended April 30, 2019 to expense of $0.8 million during the three months ended April 30, 2020 was primarily due to a $23.5 million gain in connection with our equity investment in WageWorks during the three months ended April 30, 2019. The remainder of the change was due to a decrease in interest income of $0.7 million, a decrease in acquisition costs of $1.1 million, and an increase in other expense of $1.3 million.
Income tax provision
Income tax provision for the three months ended April 30, 2020 was $0.2 million as compared to $9.5 million for the three months ended April 30, 2019. The decrease in the tax provision for the three months ended April 30, 2020 compared to the three months ended April 30, 2019 of $9.3 million was primarily due to a significant decrease in pre-tax book income netted with a decrease of excess tax benefits on stock-based compensation expense recognized in the provision for income taxes.
Our effective income tax rate for the three months ended April 30, 2020 was a provision of 10.7%, compared to a provision of 18.4% for the three months ended April 30, 2019. The 7.7 percentage point decrease for the three months ended April 30, 2020 compared to the three months ended April 30, 2019 was primarily due to the impact of excess tax benefits on stock-based compensation expense recognized in the provision for income taxes relative to pre-tax book income.
Seasonality
Seasonal concentration of our growth combined with our recurring revenue model create seasonal variation in our results of operations. Revenue results are seasonally impacted due to ancillary service fees, timing of HSA contributions, and timing of card spend. Cost of Revenue is seasonally impacted as a significant number of new and existing Network Partners bring us new HSAs and CDBs beginning in January of each year concurrent with the start of many employers’ benefit plan years. Before we realize any revenue from these new accounts, we incur costs related to implementing and supporting our new Network Partners and new accounts. These costs of services relate to activating accounts and hiring additional staff, including seasonal help to support our member support center. These expenses begin to ramp up during our third fiscal quarter with the majority of expenses incurred in our fourth fiscal quarter.
Liquidity and capital resources
Cash and cash equivalents overview
Our principal source of liquidity is our current cash and cash equivalents balances, collections from our service, custodial, and interchange revenue activities, and availability under our revolving credit facility described below. We rely on cash provided by operating activities to meet our short-term liquidity requirements, which primarily relate to the payment of corporate payroll and other operating costs, payments under our term loan facility, and capital expenditures.
As of April 30, 2020 and January 31, 2020, cash and cash equivalents were $171.1 million and $191.7 million, respectively.
Capital resources
We have a “shelf” registration statement on Form S-3 on file with the SEC. This shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings. Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, including, but not limited to, working capital, sales and marketing activities, general and administrative matters and capital expenditures, and if opportunities arise, for the acquisition of, or investment in, assets, technologies, solutions or businesses that complement our business. Pending such uses, we may invest the net proceeds in interest-bearing securities. In addition, we may conduct concurrent or other financings at any time.
-29-

Our credit agreement includes a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350.0 million, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments. For a description of the terms of the credit agreement, refer to Note 8—Indebtedness. We were in compliance with all covenants under the credit agreement as of April 30, 2020.
Use of cash
Capital expenditures for the three months ended April 30, 2020 and 2019 were $19.3 million and $6.6 million, respectively. We expect to continue our current level of increased capital expenditures for the remainder of the fiscal year ending January 31, 2021 as we continue to devote a significant amount of our capital expenditures to improving the architecture and functionality of our proprietary systems. Costs to improve the architecture of our proprietary systems include computer hardware, personnel and related costs for software engineering and outsourced software engineering services.
We believe our existing cash, cash equivalents, and revolving credit facility will be sufficient to meet our operating and capital expenditure requirements for at least the next 12 months. To the extent these current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to raise additional funds through public or private equity or debt financing. In the event that additional financing is required, we may not be able to raise it on favorable terms, if at all.
The following table shows our cash flows from operating activities, investing activities, and financing activities for the stated periods:
Three months ended April 30,
(in thousands)20202019
Net cash provided by operating activities$15,026  $25,336  
Net cash used in investing activities(25,294) (61,730) 
Net cash provided by (used in) financing activities(10,365) 4,229  
Decrease in cash and cash equivalents(20,633) (32,165) 
Beginning cash and cash equivalents191,726  361,475  
Ending cash and cash equivalents$171,093  $329,310  
Cash flows from operating activities. Net cash provided by operating activities during the three months ended April 30, 2020 resulted from net income of $1.8 million, plus depreciation and amortization expense of $27.5 million, stock-based compensation expense of $7.4 million, and amortization of debt issuance costs of $1.2 million, partially offset by non-cash items and working capital changes totaling $22.9 million.
Net cash provided by operating activities during the three months ended April 30, 2019 resulted from net income of $41.8 million, plus depreciation and amortization expense of $4.8 million, stock-based compensation expense of $6.0 million, and gains on marketable equity securities of $23.5 million, partially offset by non-cash items and working capital changes totaling $3.8 million.
Cash flows from investing activities. Net cash used in investing activities for the three months ended April 30, 2020 resulted from $7.5 million in purchases of property and equipment, $11.8 million in software and capitalized software development, and $6.0 million in acquisitions of intangible member assets.
Cash flows used in investing activities during the three months ended April 30, 2019 was primarily the result of purchases of marketable equity securities of $53.8 million. In addition, we invested $5.5 million in software and capitalized software development, $1.1 million in purchases of property and equipment, and $1.3 million in acquisitions of intangible member assets.
Cash flows from financing activities. Cash flow used in financing activities during the three months ended April 30, 2020 resulted from $7.8 million of principal payments on our long-term debt and $3.8 million used in the settlement of client-held funds obligation, partially offset by $1.2 million of proceeds associated with the exercise of stock options.
Cash flows provided by financing activities during the three months ended April 30, 2019 resulted from proceeds associated with the exercise of stock options of $4.2 million.
-30-

Contractual obligations
There were no material changes during the three months ended April 30, 2020, outside of the ordinary course of business, in our contractual obligations from those disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2020.
Off-balance sheet arrangements
As of April 30, 2020, other than outstanding letters of credit issued under our revolving credit facility, we did not have any off-balance sheet arrangements. The majority of the standby letters of credit expire within one year. However, in the ordinary course of business, we will continue to renew or modify the terms of the letters of credit to support business requirements. The letters of credit are contingent liabilities, supported by our revolving credit facility, and are not reflected on our condensed consolidated balance sheets.
Critical accounting policies and significant management estimates
Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.
Our significant accounting policies are more fully described in Note 1 of the accompanying unaudited condensed consolidated financial statements and in Note 1 to our audited consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended January 31, 2020. There have been no significant or material changes in our critical accounting policies during the three months ended April 30, 2020, as compared to those disclosed in “Management’s discussion and analysis of financial condition and results of operations – Critical accounting policies and significant management estimates” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2020.
Recent accounting pronouncements
See Note 1. Summary of business and significant accounting policies within the interim financial statements included in this Form 10-Q for further discussion.
Item 3. Qualitative and quantitative disclosures about market risk
Market risk
Concentration of market risk. We derive a substantial portion of our revenue from providing services to tax-advantaged healthcare account holders. A significant downturn in this market or changes in state and/or federal laws impacting the preferential tax treatment of healthcare accounts such as HSAs could have a material adverse effect on our results of operations. During the three months ended April 30, 2020 and 2019, no one customer accounted for greater than 10% of our total revenue. We monitor market and regulatory changes regularly and make adjustments to our business if necessary.
Inflation. Inflationary factors may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain current levels of expenses as a percentage of revenue if our revenue does not correspondingly increase with inflation.
Concentration of credit risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents. We maintain our cash and cash equivalents in bank and other depository accounts, which frequently may exceed federally insured limits. Our cash and cash equivalents as of April 30, 2020 were $171.1 million, of which $2.3 million was covered by federal depository insurance. We have not experienced any material losses in such accounts and believe we are not exposed to any significant credit risk with respect to our cash and cash equivalents. Our accounts receivable balance as of April 30, 2020 was $69.8 million. We have not experienced any significant write-offs to our accounts receivable and believe that we are not exposed to significant credit risk with respect to our accounts receivable; however, the extent to which the ongoing COVID-19 pandemic will negatively
-31-

impact our credit risk is highly uncertain and cannot be accurately predicted. We continue to monitor our credit risk and place our cash and cash equivalents with reputable financial institutions.
Interest rate risk
HSA Assets and Client-held funds. Our HSA Assets consists of custodial HSA funds we hold in custody on behalf of our members. As of April 30, 2020, we had HSA Assets of approximately $11.5 billion. As a non-bank custodian, we contract with our Depository Partners and insurance company partners to hold custodial cash assets on behalf of our members, and we earn a significant portion of our total revenue from interest paid to us by these partners. The contract terms generally range from three to five years and have either fixed or variable interest rates. As our HSA Assets increase and existing contracts expire, we seek to enter into new contracts with Depository Partners, the terms of which are impacted by the then-prevailing interest rate environment. The diversification of deposits among Depository Partners and varied contract terms substantially reduces our exposure to short-term fluctuations in prevailing interest rates and mitigates the short-term impact of a sustained increase or decline in prevailing interest rates on our custodial revenue. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the interest rate yield, or yield, available to us and thus the amount of the custodial revenue we can realize. Conversely, a sustained increase in prevailing interest rates can increase our yield. An increase in our yield would increase our custodial revenue as a percentage of total revenue. In addition, if our yield increases, we expect the spread to also increase between the interest offered to us by our Depository Partners and the interest retained by our members, thus increasing our profitability. However, we may be required to increase the interest retained by our members in a rising prevailing interest rate environment. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control, such as the interest rate cuts by the Federal Reserve associated with the ongoing COVID-19 pandemic.
Our Client-held funds are interest earning deposits from which we generate custodial revenue. As of April 30, 2020, we had Client-held funds of approximately $894.0 million. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of our other CDBs. These deposits are held with Depository Partners. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the yield, available to us and thus the amount of the custodial revenue we can realize from Client-held funds. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Cash and cash equivalents. We consider all highly liquid investments purchased with an original maturity of three months or less to be unrestricted cash equivalents. Our unrestricted cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market account that is unrestricted as to withdrawal or use. As of April 30, 2020, we had unrestricted cash and cash equivalents of $171.1 million. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our cash and cash equivalents as a result of changes in interest rates.
Credit agreement. As of April 30, 2020, we had $1.23 billion outstanding under our term loan facility and no amounts drawn under our revolving credit facility.  Our overall interest rate sensitivity under these credit facilities is primarily influenced by any amounts borrowed and the prevailing interest rates on these instruments.  The interest rate on our term loan credit facility and revolving credit facility is variable and was 2.15 percent at April 30, 2020.  Accordingly, we may incur additional expense if interest rates increase in future periods.  For example, a one percent increase in the interest rate on the amount outstanding under our credit facilities at April 30, 2020 would result in approximately $12.4 million of additional interest expense over the next 12 months. 

Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of April 30, 2020, the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated
-32-

and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, and subject to the below exclusion, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of April 30, 2020, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.
In accordance with interpretive guidance issued by SEC staff, companies are allowed to exclude acquired businesses from the assessment of internal control over financial reporting during the first year after completion of an acquisition and from the assessment of disclosure controls and procedures to the extent subsumed in such internal control over financial reporting (the “Internal Controls Guidance”). In accordance with the Internal Controls Guidance, as the Company acquired WageWorks on August 30, 2019, management's evaluation and conclusion as to the effectiveness of the Company's disclosure controls and procedures as of April 30, 2020 excluded the portion of disclosure controls and procedures that are subsumed by internal control over financial reporting of WageWorks. WageWorks’ assets represented approximately 10% of the Company’s consolidated total assets, excluding the effects of purchase accounting, and its revenues represented approximately 51% of the Company's consolidated total revenues, each as of and for the quarter ended April 30, 2020.
Material Weaknesses in Internal Control over Financial Reporting
Management determined the following material weaknesses existed as of April 30, 2020, all of which were disclosed previously by WageWorks in Item 9A of its Annual Report on Form 10-K for the year ended December 31, 2018.
Control Environment, Risk Assessment, Control Activities, Information and Communication, and Monitoring Activities
There was an inadequate open flow, transparency, communication and dissemination of relevant and pertinent information from former WageWorks senior management concerning a complex transaction with the federal government that contributed to an ineffective control environment driven by the tone at the top. WageWorks management’s failure to timely communicate all pertinent information resulted in an environment which led to errors in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
It was noted that WageWorks did not maintain effective internal control over financial reporting related to the following areas: control environment, risk assessment, control activities information and communication, and monitoring activities:
WageWorks did not have processes and controls to ensure there were adequate mechanisms and oversight to ensure accountability for the performance of internal control over financial reporting responsibilities and to ensure corrective actions were appropriately prioritized and implemented in a timely manner.
WageWorks did not effectively execute a strategy to attract, develop and retain a sufficient complement of qualified resources with an appropriate level of knowledge, experience, and training in certain areas important to financial reporting.
There was not an adequate assessment of changes in risks by management that could significantly impact internal control over financial reporting or an adequate determination and prioritization of how those risks should be managed.
WageWorks did not have adequate management oversight of accounting and financial reporting activities in implementing certain accounting practices to conform to its policies and GAAP.
WageWorks did not have adequate management oversight around completeness and accuracy of data material to financial reporting.
There was a lack of robust, established and documented accounting policies and insufficiently detailed procedures to put these policies into effective action.
WageWorks was not focused on a commitment to competency as it relates to creating priorities, allocating adequate resources and establishing cross functional procedures around managing complex contracts and non-routine transactions as well as managing change and attracting, developing and retaining qualified resources.
-33-

These deficiencies in WageWorks' internal control over financial reporting contributed to the following identified material weaknesses:
A. Accounting Close and Financial Reporting
WageWorks had inadequate or ineffective senior accounting leadership and corresponding process level and monitoring controls in the area of accounting close and financial reporting specifically, but not exclusively, around the review of account reconciliations, account estimates and related cut-off, and monitoring of the accounting close cycle and some areas of related sub-processes such as equity. WageWorks also did not have effective business processes and controls to conduct an effective review of manual data feeds into journal entries for platforms which were not integrated with the main enterprise resource planning system.
WageWorks did not have robust, established and documented accounting policies that were implemented effectively, which led to adjustments in areas such as, but not exclusive to, impairment of internally developed software (IDS) and unclaimed liability. As a result of these adjustments, the accounts related to amortization of IDS, fixed assets, and operating expenses as they relate to interest and penalties were impacted.
WageWorks also did not have a robust process around managing change and corresponding assessment and implementation of accounting policies. Furthermore, it also resulted in the delayed assessment and design of controls for the timely implementation of controls around Accounting Standard 606 (ASC 606) for Revenue Recognition, which was effective January 2018. These gaps resulted in several adjustments in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
B. Contract to Cash Process
WageWorks did not have effective controls around the contract-to-cash life cycle. The root cause of these gaps were due to inadequate or ineffective process level controls around billing set-up during customer implementation, managing change to existing customer billing terms and conditions, timely termination of customers, implementing complex and/or non-standard billing arrangements which require manual intervention or manual controls for billing to customers, processing timely adjustments, lack of robust, established and documented policies to assess collectability and reserve for revenue, bad debts and accounts receivable, and availability of customer contracts.
These gaps resulted in several adjustments in revenue, accounts receivable, and accounts receivable reserves in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
C. Risk Assessment and Management of Change
WageWorks did not maintain an effective risk assessment and monitoring process to manage the expansion of its business. Hence, there were inadequate and ineffective business and financial reporting control activities associated with change and growth in the business. Among other areas, the assessment of the control environment and the design of manual controls around financial system implementations was not performed adequately.
As a result, WageWorks did not properly estimate, reserve and record certain transactions that resulted in errors in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
D. Review of New, Unusual or Significant Transactions and Contracts
WageWorks did not have adequate risk assessment controls to continuously formally assess the financial reporting risks associated with executing new, significant or unusual transactions, contracts or business initiatives. As a result, WageWorks did not adequately identify and analyze changes in the business and hence implement effective process level controls and monitoring controls that were responsive to these changes and aligned with financial reporting objectives. This failure to identify and analyze changes occurred in connection with the integration of acquisitions and the monitoring and recording of certain revenues associated with a complex government contract. As a result, WageWorks did not properly account for certain transactions including revenue and customer obligation accounts, which resulted in errors in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
E. Manual Reconciliations of High-Volume Standard Transactions
WageWorks did not have effective business processes and controls as well as resources with adequate training and support to conduct an effective review of manual reconciliations including the complex data feeds into the reconciliations of high-volume standard transactions. This resulted in several errors mainly to balance sheet classifications around accounts receivable, customer obligations and other related accounts as of December 31, 2018.

-34-

F. Information Technology General Controls (ITGC)
WageWorks did not have effective controls related to information technology general controls (ITGCs) in the areas of logical access and change-management over certain information technology (IT) systems that supported its financial reporting processes. WageWorks’ business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted. WageWorks believed that these control deficiencies were a result of IT control processes having an inadequate risk-assessment process to identify and assess changes in business environment which would impact IT environments related to internal control over financial reporting. Hence, the control design, implementation, and documentation were not enhanced to adapt to the changing business environment. There was also insufficient training of IT personnel on how to design and implement ITGCs.
These material weaknesses and other deficiencies could result in a misstatement of the aforementioned account balances or disclosures that would result in a material misstatement to the annual or interim condensed consolidated financial statements that would not be prevented or detected.
Remediation Efforts
The Company continues to assess the impact of the Acquisition on its internal control over financial reporting. As part of this assessment, the Company has continued working with an external specialist, has completed a detailed review of all noted controls deficiencies, and is developing a plan to address the underlying control deficiencies associated with the disclosed material weaknesses. The Company has also hired new leadership for its internal audit function.
Further, the Company has begun to design and implement new control activities and enhance existing control activities related to ITGCs. The Company intends to begin testing these control activities once they have been fully implemented.
Changes in Internal Control Over Financial Reporting
Other than the remediation efforts described above, there were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended April 30, 2020 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
-35-


Part II—Other Information
Item 1. Legal Proceedings
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Our wholly owned subsidiary, WageWorks, is party to certain pending material litigation and other legal proceedings. Except for such matters, as of the date of this Quarterly Report on Form 10-Q, we were not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations, cash flows or financial position. For a description of these legal proceedings, see Note 7—Commitments and contingencies of the Notes to condensed consolidated financial statements.
Item 1A. Risk factors
The risks described in “Risk factors” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2020 could materially and adversely affect our business, financial condition and results of operations. Except as described below, there have been no material changes in such risks. These risk factors do not identify all risks that we face, and our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations.
The ongoing COVID-19 pandemic has materially impacted our business and may continue to materially impact our business.
Our business has been, and may continue to be, materially and adversely affected by the current outbreak of the COVID-19 virus. The Federal Reserve’s interest rate cut in response to the economic impact of the COVID-19 pandemic and other interest rate market conditions have caused interest rates to decline significantly. As a result, the funds that we place with our depository partners in this environment have been, and are likely to continue to be, placed at, lower interest rates than we originally expected. In addition, stock market declines have negatively impacted HSA investment assets and the related fees we earn from HSA investment assets, and any future declines will also have a negative impact.

Our financial results related to certain of our products have also been adversely affected. For example, we have seen a significant decline in the use of commuter benefits and our members' spend on healthcare, which has negatively impacted both our interchange revenue and service revenue. We have also seen a decline in interchange revenue across all other products. Going forward, some clients may be unable to pay fees required under contracts and exercise "force majeure" or similar defenses, which would negatively impact our financial results.

In addition, as an increasing number of companies go out of business, the number of our clients and potential clients would be adversely affected. Increased unemployment may mean that fewer of our members contribute to HSAs, FSAs or other CDBs. Regulatory changes related to our products, such as COBRA, have created uncertainty and additional workload on our team members, which could reduce our operational efficiency and result in additional costs. In the event our financial results continue to be severely impacted or the impact worsens, it may make it more difficult for us to comply with the financial covenants in our credit agreement, which could result in a breach of the financial covenants and the acceleration of our outstanding debt by our lenders.

As a result of the ongoing pandemic, substantially all of our team members are working from home. Sales opportunities have been impacted by the lack of travel and in-person meetings, with some opportunities delayed or now being held virtually. We may be unable to meet our service level commitments to our clients as a result of disruptions to our work force and disruptions to third-party contractors that we rely on to provide our services. Our team members may be less efficient at home, and it may take additional time for us to pursue significant business initiatives. The risk of cybersecurity breaches and incidents, and the potential impact of these on our operations, is also higher while our team members log in to our network remotely.

The extent to which the COVID-19 pandemic will continue to negatively impact our business remains highly uncertain and, as a result, may continue to have a material adverse impact on our business and financial results.

-36-

Item 6. Exhibits
Incorporate by reference
Exhibit
no.
DescriptionFormFile No.ExhibitFiling Date
10.1+  
10.2+  
31.1+  
31.2+
32.1*#  
32.2*#  
101.INS  XBRL Instance document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH  Inline XBRL Taxonomy schema linkbase document
101.CAL  Inline XBRL Taxonomy calculation linkbase document
101.DEF  Inline XBRL Taxonomy definition linkbase document
101.LAB  Inline XBRL Taxonomy labels linkbase document
101.PRE  Inline XBRL Taxonomy presentation linkbase document
104  The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended April 30, 2020, formatted in Inline XBRL.

+Filed herewith.
*Furnished herewith.
#These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference in any filing the registrant makes under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.

-37-

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HEALTHEQUITY, INC.
Date: June 4, 2020By:/s/ Darcy Mott
Name:Darcy Mott
Title:Executive Vice President and Chief Financial Officer

-38-
EX-10.1 2 hqyadreiertransitionse.htm EX-10.1 Document

TRANSITION, SEPARATION AND RELEASE AGREEMENT
This Transition, Separation and Release Agreement (this “Agreement”), delivered February 13, 2020 (the “Offer Date”), confirms the following understandings and agreements between HealthEquity, Inc. (the “Company”) and Ashley Dreier (hereinafter referred to as “you” or “your”).
In consideration of the promises set forth herein, you and the Company agree as follows:
1.Opportunity for Review; Acceptance. You have twenty-one (21) calendar days from the Offer Date, until 5 P.M. Mountain Time on March 5, 2020 (the “Review Period”), to review and consider this Agreement. To accept this Agreement, and the terms and conditions contained herein, by the end of the Review Period, you must execute and date this Agreement where indicated below and return the executed copy of this Agreement to Del Ladd, Esq. (the “Company Representative”), the Company’s Executive Vice President, General Counsel and Corporate Secretary, by email (dladd@healthequity.com), or by a recognized national overnight courier service to 15 W. Scenic Pointe Drive, Ste. 100, Draper, Utah 84020. You acknowledge that, to the extent there are changes made to the terms of this Agreement, whether they are material or immaterial, the Review Period is not recommenced. In the event that you fail to execute and deliver this Agreement by the end of the expiration of the Review Period, this Agreement will be null and void and of no effect, and the Company will have no obligations hereunder.
2.Employment Status; Accrued Benefits; Transition Period; and Separation Benefits.
(a)Employment Status. You acknowledge and agree that your employment with the Company and its direct and indirect subsidiaries and affiliates (collectively, with the Company, the “Company Group”) will terminate as a result of your voluntary resignation, effective as of a date to be mutually agreed upon between you and the Company expected to be on or about June 1, 2020 (the “Transition Date”), or if earlier, on the date your employment is terminated by the Company or you for any lawful reason (the earlier to occur being the “Separation Date”). You acknowledge and agree that, after the Separation Date, you will not represent yourself as being an employee, officer, agent, or representative of the Company or any other member of the Company Group. During the period between the Offer Date and the Separation Date (the “Transition Period”), you will remain on the Company’s active payroll, be paid your current salary in accordance with the Company’s regular payroll practices, and continue to participate in all employee benefit plans and other programs or arrangements sponsored by or through the Company and any other member of the Company Group in which you are eligible to participate as of the Offer Date (the “Benefit Plans”), including, but not limited to, the Company’s Executive Bonus Plan for fiscal year 2020 and, subject to paragraph 2(e)(ii), the Company’s Executive Bonus Plan for fiscal year 2021. You hereby confirm your resignations from all offices, directorships, trusteeships, committee memberships and fiduciary and other capacities held with, or on behalf of, the Company Group effective as of the Separation Date (or such other date as may be mutually agreed upon), and your execution of this Agreement will be deemed the grant by you to the officers of the Company of a limited power of attorney to sign in your name and on your behalf any such documentation as may be required to be executed solely for the limited purposes of effectuating such resignations. You agree that within five (5) business days following the Separation Date, you will update your accounts or profiles on any social media platform (including, but not limited to, Facebook, Twitter or LinkedIn) to reflect that you are no longer actively employed by or affiliated with the Company.



(b)Accrued Benefits. The Separation Date shall be the termination date of your employment for purposes of participation in and coverage under all Benefit Plans, except as otherwise provided herein. You will be paid for (i) all of your earned but unpaid salary through the Separation Date on or prior to the Company’s next regularly scheduled payroll date on or following the Separation Date, or earlier to the extent otherwise required by applicable law, (ii) your accrued but unused paid time off as of the Separation Date to the extent required by the Company’s policies, and (iii) any business expenses incurred prior to the Separation Date and properly submitted in accordance with the Company’s policies and procedures within ten (10) days following the Separation Date. In addition, you will be entitled to continued medical and health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), and additional information concerning such benefits will be provided to you under separate cover following the Separation Date.
(c)Transition Period. During the Transition Period, you agree to perform your duties on a full-time basis from the Company’s offices in Draper, Utah, and to continue to comply with all Company policies and procedures. You shall also cooperate with members of management, your direct reports and other employees of the Company Group to facilitate an orderly transition to a new Chief Technology Officer and Chief Information Officer, provide information, answer questions and provide guidance as reasonably requested by your team members relating to any matter on which you will have worked prior to the Separation Date or of which you have knowledge.
(d)Modification of Non-Compete. Reference is hereby made to that certain Team Member Confidentiality and Non-Competition Agreement, dated April 5, 2018, by and between you and the Company (the “Restrictive Covenant Agreement”). You hereby acknowledge and agree that, notwithstanding anything set forth in the Restrictive Covenant Agreement to the Contrary, you shall be subject to the non-compete and non-solicit obligations set forth in such Restrictive Covenant Agreement through March 26, 2023.
(e)Separation Benefits. In consideration of (i) your agreement to cooperate after your Separation Date as set forth in paragraph 10 hereof, (ii) your release and waiver of claims set forth in paragraph 3 below and in the Supplemental Release of Claims in the form attached hereto as Exhibit A (the “Supplemental Release”), and (iii) your continued compliance with the Restrictive Covenants (as defined below) set forth in the Restrictive Covenant Agreement, as modified in paragraph 2(d) above, and subject to your (A) execution, delivery, and non-revocation of this Agreement, (B) execution, delivery and non-revocation of the Supplemental Release, and (C) continued compliance with this Agreement, including but not limited to paragraph 11 hereof, the Restrictive Covenants and the Supplemental Release, the Company will provide you with the following benefits (collectively, the “Consideration”):
(i)Restricted Stock Units. The Company will accelerate the vesting of each of the Restricted Stock Unit Awards and Restricted Stock Awards granted to you pursuant to the Company’s 2014 Equity Incentive Plan (the “Plan”) that are subject to solely service based vesting conditions (the “Award Vesting”) upon the expiration of the Cooperation Period (as defined below) and, with respect to each Restricted Stock Unit Award, shall effectuate the settlement of the corresponding shares of common stock subject to such award as soon as administratively possible following the expiration of the Cooperation Period, but in no event later than April 15, 2021; and
(ii)Pro-rated Annual Bonus. Subject to the achievement of the applicable performance conditions for fiscal year 2021, as determined by the Compensation Committee of the Board of Directors of the Company, payment of the annual bonus that you would otherwise have earned in
2


respect of fiscal year 2021, pro-rated to reflect the number of days you are employed during fiscal year 2021, such amount to be paid at the same time it would otherwise be paid to you had no termination occurred, but in no event later than April 15, 2021.
For the avoidance of doubt, the Award Vesting shall be limited to the Restricted Stock Unit Awards and Restricted Stock Awards, as applicable, granted to you on each of March 27, 2017, March 27, 2018, April 5, 2018, and March 26, 2019, of which awards in respect of 1,413, 2,295, 11,788 and 5,094 shares of common stock of the Company are expected to be unvested as of your Separation Date, respectively.
(f)Full Discharge. You acknowledge and agree that the payment(s) and other benefits provided pursuant to this paragraph 2 are in full satisfaction and discharge of any and all liabilities and obligations of the Company or any other member of the Company Group to you, monetarily or with respect to employee benefits or otherwise, including but not limited to any and all obligations arising under any alleged written or oral employment agreement, policy, plan or procedure of the Company or any other member of the Company Group and/or any alleged understanding or arrangement between you and the Company or any other member of the Company Group (other than claims for accrued and vested benefits under an employee benefit, insurance, or pension plan of the Company or any other member of the Company Group (excluding any severance or similar plan or policy), subject to the terms and conditions of such plan(s)).
(g)Taxes. The Consideration is subject to withholding for all applicable taxes, including but not limited to income, employment, and social insurance taxes, as shall be required by law.
3.Release and Waiver of Claims.
(a)As used in this Agreement, the term “claims” will include all claims, covenants, warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, accounts, attorneys’ fees, judgments, losses and liabilities, of whatsoever kind or nature, in law, equity or otherwise.
(b)For and in consideration of the payments and benefits described in paragraph 2 above and other good and valuable consideration, you, for and on behalf of yourself and your heirs, administrators, executors and assigns, as of the date hereof, do fully and forever release, remise and discharge each member of the Company Group and their successors and assigns, together with their respective current and former officers, directors, partners, members, stockholders, employees and agents (collectively, and with the Company, the “Company Parties”) from any and all claims whatsoever up to the date hereof that you had, may have had, or now have against the Company Parties, whether known or unknown, for or by reason of any matter, cause or thing whatsoever, including any claim arising out of or attributable to your employment or the termination of your employment with the Company or any member of the Company Group, whether for tort, breach of express or implied employment contract, infliction of emotional distress, retaliation, wrongful termination, unjust dismissal, defamation, libel or slander, or under any federal, state or local law dealing with discrimination based on age, race, sex, national origin, religion, disability, sexual orientation, or any other class protected under applicable law. This release of claims includes, but is not limited to, all claims arising under the Age Discrimination in Employment Act (the “ADEA”), Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family and Medical Leave Act, the Equal Pay Act, the Worker Adjustment and Retraining Notification Act, and the Employee Retirement Income Security Act (excluding claims for accrued, vested benefits under an employee pension benefit plan of the Company
3


Parties), each as may be amended from time to time, and all other federal, state and local laws, the common law, and any other purported restriction on an employer’s right to terminate the employment of employees. You intend the release contained herein to be a general release of any and all claims to the fullest extent permissible by law and for the provisions regarding the release of claims against the Company Parties to be construed as broadly as possible, and hereby incorporate in this release similar federal, state or other laws, all of which you also hereby expressly waive.
(c)You understand and agree that claims or facts in addition to or different from those which are now known or believed by you to exist may hereafter be discovered, but it is your intention to fully and forever release, remise and discharge all claims which you had, may have had, or now have against the Company Parties, whether known or unknown, suspected or unsuspected, asserted or unasserted, contingent or noncontingent, without regard to the subsequent discovery or existence of such additional or different facts. Without limiting the foregoing, by signing this Agreement, you expressly waive and release any provision of law that purports to limit the scope of a general release.
(d)You acknowledge and agree that as of the date you execute this Agreement, you have no knowledge of any facts or circumstances that give rise or could give rise to any claims under any of the laws listed in the preceding paragraphs.
(e)Notwithstanding any provision of this Agreement to the contrary, by executing this Agreement, you are not releasing any claims relating to: (i) your rights arising out of breach of this Agreement; (ii) your rights with respect to payment of amounts under this Agreement; (iii) your right to accrued, vested benefits due to terminated employees under any employee benefit plan of the Company or any other member of the Company Group in which you participated (excluding any severance or similar plan or policy), in accordance with the terms thereof (including your right to elect COBRA continuation coverage); (iv) any claims that cannot be waived by law; (v) your right to indemnification, advancement and reimbursement of legal fees and expenses, and directors and officers liability insurance, as provided by, and in accordance with the terms of, applicable law, the Company’s governing documents or that certain Indemnification Agreement, dated June 27, 2017, by and between you and the Company (the “Indemnification Agreement”); (vi) any rights or claims under the ADEA challenging the knowing and voluntary nature of the Agreement or that may arise after the date that you execute this Agreement; or (vii) your rights as a stockholder of the Company.
(f)Notwithstanding the foregoing or anything else in this Agreement, this Agreement will not prevent you from (i) filing a charge or complaint with, participating in an investigation or proceeding conducted by, or reporting possible violations of law or regulation to any federal, state or local government agency, (ii) truthfully responding to or complying with a subpoena, court order, or other legal process, or (iii) exercising any rights you may have under applicable labor laws to engage in protected concerted activity with other employees; provided, however, that you agree to forgo any monetary benefit from the filing of a charge or complaint with a government agency except pursuant to a whistleblower program or where your right to receive such a monetary benefit is otherwise not waivable by law.
(g)You acknowledge and agree that as of the date of this Agreement, you have reported all accidents, injuries or illnesses relating to or arising from your employment with the Company or the Company Group and that you have not suffered any on-the-job injury or illness for which you have not yet filed a claim.
4


4.Knowing and Voluntary Release/ADEA Claims. This paragraph of this Agreement addresses your release of claims arising under the ADEA. This paragraph is provided separately, in compliance with federal law, including but not limited to the ADEA and the Older Workers’ Benefit Protection Act of 1990, to ensure that you clearly understand your rights so that any release of age discrimination claims under federal law (the ADEA) is knowing and voluntary on your part. You expressly acknowledge and agree that you:
(a)are able to read the language, and understand the meaning and effect, of this Agreement;
(b)have no physical or mental impairment of any kind that has interfered with your ability to read and understand the meaning of this Agreement or its terms, and that you are not acting under the influence of any medication, drug, or chemical of any type in entering into this Agreement;
(c)are specifically agreeing to the terms of the release contained in this Agreement because the Company has agreed to provide you the Consideration and other consideration, which the Company has agreed to provide because of your agreement to accept such consideration in full settlement of all possible claims you might have or ever had against the Company Parties, and because of your execution of this Agreement;
(d)acknowledge that but for your execution of this Agreement, you would not be entitled to the Consideration;
(e)have been advised by the Company, in writing, to discuss this Agreement with an attorney, and to the extent, if any, that you have desired, you have done so; that the Company has given you twenty-one (21) calendar days from your receipt of this Agreement to review and consider this Agreement before signing it; and you understand that you may use as much of this twenty-one (21) day period as you wish prior to signing; that no promise, representation, warranty, or agreements not contained herein have been made by or with anyone to cause you to sign this Agreement; that you have read this Agreement in its entirety, and fully understand and are aware of its meaning, intent, content, and legal effect; and that you are executing this Agreement voluntarily and free of any duress or coercion;
(f)may revoke the Agreement for a period of seven (7) calendar days following the execution of this Agreement, by providing written notice to the Company Representative named in paragraph 1 hereof by email (dladd@healthequity.com), or by a recognized national overnight courier service to 15 W Scenic Pointe Drive, Ste 100, Draper, UT 84020) (which notice must be received within the seven-day revocation period at 5 p.m. MST) (“Revocation Period”);
(g)acknowledge that, provided you do not revoke this Agreement during the Revocation Period, the eighth (8th) day following the date on which this Agreement is executed shall be its effective date, and that, in the event that you revoke this Agreement during the Revocation Period, this Agreement will be null and void and of no effect, and neither the Company nor any other member of the Company Group will have any obligations to provide you the Consideration under this Agreement; and
(h)understand this Agreement and its release of ADEA claims do not waive rights or claims that may arise after the date the Agreement is executed.
5.No Suit. You represent and warrant that you have not previously filed, and to the maximum extent permitted by law agree that you will not file, a complaint, charge or lawsuit against any
5


of the Company Parties regarding any of the claims released herein. Except as otherwise provided in paragraph 3(f) above, if, notwithstanding this representation and warranty, you have filed or file such a complaint, charge or lawsuit, you agree that you shall cause such complaint, charge or lawsuit to be dismissed with prejudice and shall pay any and all costs required in obtaining dismissal of such complaint, charge or lawsuit, including without limitation the attorneys’ fees of any of the Company Parties against whom you have filed such a complaint, charge, or lawsuit.
6.Supplemental Release of Claims. You agree to execute the Supplemental Release after the Separation Date and to deliver the executed Supplemental Release to the Company Representative on or after the Separation Date, and no later than twenty-one (21) calendar days following the Separation Date. You agree that all Company covenants that relate to its obligations beyond the Separation Date are contingent on your execution, delivery, and non-revocation of the Supplemental Release.
7.Successors and Assigns. The provisions hereof shall inure to the benefit of your heirs, executors, administrators, legal personal representatives and assigns and shall be binding upon your heirs, executors, administrators, legal personal representatives and assigns.
8.Severability; Third-Party Beneficiaries. If any provision of this Agreement shall be held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect. The illegality or unenforceability of such provision, however, shall have no effect upon and shall not impair the enforceability of any other provision of this Agreement. You acknowledge and agree that each of the Company Parties shall be a third-party beneficiary to the releases set forth in paragraph 3 above, with full rights to enforce this Agreement and the matters documented herein.
9.Non-Disparagement. You agree that you will make no disparaging or defamatory comments regarding any member of the Company Group or their respective current or former directors, officers, employees, members, stockholders, or affiliates in any respect or make any comments concerning any aspect of your relationship with any member of the Company Group or the conduct or events which precipitated your termination of employment from any member of the Company Group. Your obligations under this paragraph 9 extend to, but are not limited to, text messages, e-mail communications, and comments or postings on blogs, comment boards or social media websites, including but not limited to Facebook, Twitter or LinkedIn. This paragraph 9 shall not prevent the truthful testimony by any individual or entity in a legal proceeding or pursuant to a governmental, administrative or regulatory investigation.
10.Cooperation.
(a)Following the Separation Date through January 31, 2021 (the “Cooperation Period”), you agree to consult, advise, and respond and provide information to the Company Group, as reasonably requested by the Company’s Chief Technology Officer and other members of the Company’s executive leadership team, with regard to matters in which you have knowledge as a result of your employment with, or serving as an officer of, any member of the Company Group. The Company Group will attempt to coordinate any such request for cooperation with your other business or professional commitments and responsibilities to minimize the degree to which such request interferes with such commitments and responsibilities. Your obligation to consult and advise may be accomplished remotely and via phone, text, and email, and will not exceed five (5) hours per week; provided, that, if you and the Company mutually agree for you to spend more than five (5) hours per week on such matters, the Company will compensate you at an hourly rate of $300.00 per hour.
6


(b)You agree that you will provide reasonable cooperation to the Company and/or any other member of the Company Group and its or their respective counsel in connection with any investigation, administrative proceeding or litigation relating to any matter that occurred during your employment in which you were involved or of which you have knowledge. The Company agrees to reimburse you for reasonable out-of-pocket expenses incurred at the request of the Company with respect to your compliance with this paragraph 10(b).
(c)You agree that, in the event you are subpoenaed by any person or entity (including, but not limited to, any government agency) to give testimony or provide documents (in a deposition, court proceeding or otherwise) which in any way relates to your employment by the Company and/or any other member of the Company Group, you will give prompt written notice of such request to the Company Representative, in writing, as specified above (or the Company Representative’s successor or designee) and will make no disclosure until the Company and/or the other member of the Company Group has had a reasonable opportunity to contest the right of the requesting person or entity to such disclosure. The Company agrees to reimburse you for reasonable out-of-pocket expenses incurred at the request of the Company with respect to your compliance with this paragraph 10(c).
11.Affirmation of Continuing Obligations. You hereby acknowledge and agree that the execution of this Agreement does not alter your obligations to any member of the Company Group under any confidentiality, non-compete, non-solicit, invention assignment, or similar agreement or arrangement to which you are a party with any member of the Company Group (including, without limitation, the obligations set forth in your Restrictive Covenant Agreement as modified by paragraph 2(d) (collectively, the “Restrictive Covenants”)), which obligations are hereby incorporated into this Agreement and shall survive the termination of your employment with the Company, and you hereby acknowledge, reaffirm and ratify your continuing obligations to the Company Group pursuant to such agreements or arrangements. You further hereby acknowledge that your continued compliance with these obligations is a condition of your receiving the Consideration described in paragraph 2 above and upon any breach of the Restrictive Covenants, the Company shall be entitled to a refund of any portion of your annual bonus for fiscal year 2021 already paid to you as of such date and to clawback any of the shares or proceeds in respect of shares delivered to or received by you in connection with the vesting of such Restricted Stock Unit Awards or Restricted Stock Awards, as applicable, or subsequent sale of the corresponding shares of common stock of the Company. You understand that the Defend Trade Secrets Act provides that you may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In the event that you file a lawsuit for retaliation by any member of the Company Group for reporting a suspected violation of law, you may disclose the trade secret to your attorney and use the trade secret information in the court proceeding, if you file any document containing the trade secret under seal and do not disclose the trade secret, except pursuant to court order.
12.Return of Property. You agree that, on or before the Separation Date, you will return to the Company, and you will retain no copies of, all property belonging to the Company and/or any other member of the Company Group, including but not limited to all proprietary and/or confidential information and documents (including any copies thereof) in any form belonging to the Company, cell phone, Blackberry, iPhone or other mobile device, keys, credit card, identification card or badge, access card, employee handbook, laptop, computer or other office equipment, computer user name and password, disks, data files, thumb drives, and/or voicemail code. If you discover after the Separation
7


Date that you have retained any proprietary and/or confidential information (including, without limitation, proprietary and/or confidential information contained in any electronic documents or email systems in your possession or control), you agree immediately upon discovery to send an email to the Company Representative to inform the Company of the nature and location of the proprietary and/or confidential information that you have retained so that the Company may arrange to remove, recover, and/or collect such information. You further acknowledge and agree that the Company shall have no obligation to provide you with the Consideration described in paragraph 2 above unless and until you have satisfied all your obligations pursuant to this paragraph 12.
13.Non-Admission. Nothing contained in this Agreement will be deemed or construed as an admission of wrongdoing or liability on the part of you or any member of the Company Group. Accordingly, this Agreement may not be admissible in any forum as an admission, but only in an action to enforce it.
14.Entire Agreement. This Agreement, the Supplemental Release, the Restrictive Covenants and the Indemnification Agreement constitute the entire understanding and agreement of the parties hereto regarding the termination of your employment. This Agreement, the Supplemental Release, the Restrictive Covenants and the Indemnification Agreement supersede all prior negotiations, discussions, correspondence, communications, understandings and agreements between the parties relating to the subject matter of this Agreement and the Restrictive Covenants.
15.Attorneys’ Fees and Costs. You hereby acknowledge and agree that the Company Parties are entitled to recover from you all reasonable attorneys’ fees and costs associated with their efforts to enforce this Agreement or the Restrictive Covenants and/or to recover damages for a breach of this Agreement or the Restrictive Covenants by you, and/or which are incurred by the Company Parties as a result of a breach of this Agreement or the Restrictive Covenants by you.
16.Governing Law; Jurisdiction; Arbitration. EXCEPT WHERE PREEMPTED BY FEDERAL LAW, THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF UTAH, APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE, WITHOUT REGARD TO CONFLICT OF LAWS RULES. BY EXECUTION OF THIS AGREEMENT, EACH PARTY TO THIS AGREEMENT HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF THE STATE OF UTAH AND FEDERAL COURTS LOCATED IN THE STATE OF UTAH AND HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY IN CONNECTION WITH ANY DISPUTE ARISING UNDER OR CONCERNING THIS AGREEMENT. ALL DISPUTES ARISING UNDER OR CONCERNING THIS AGREEMENT, AS WELL AS ALL CLAIMS ARISING OUT OF YOUR EMPLOYMENT OR TERMINATION THEREOF, INCLUDING WITHOUT LIMITATION ALL CLAIMS FOR PAYMENT OF WAGES, DISCRIMINATION, RETALIATION, AND ALL OTHER CLAIMS BASED ON ANY STATE, FEDERAL OR COMMON LAW WILL BE RESOLVED THROUGH BINDING ARBITRATION BEFORE A SINGLE ARBITRATOR. THE ARBITRATION SHALL BE ADMINISTERED BY JAMS, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. IF JAMS CANNOT SERVE AS THE ARBITRATION ADMINISTRATOR, THEN THE ARBITRATION WILL BE THROUGH THE AMERICAN ARBITRATION ASSOCIATION, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. THE EXCLUSIVE VENUE OF ANY SUCH ARBITRATION WILL BE SALT LAKE CITY, UTAH. THE NON-PREVAILING PARTY WILL PAY THE REASONABLE ATTORNEYS’ FEES AND COSTS OF THE PREVAILING PARTY. THE ARBITRATOR SHALL HAVE AUTHORITY TO ISSUE EQUITABLE AND LEGAL
8


RELIEF, INCLUDING WITHOUT LIMITATION INJUNCTIVE RELIEF AND MONETARY DAMAGES. ALL ARBITRATION PROCEEDINGS SHALL BE CONFIDENTIAL.
17.Construction. The section or paragraph headings or titles herein are for convenience of reference only and shall not be deemed a part of this Agreement. The parties hereto acknowledge and agree that each party has reviewed and negotiated the terms and provisions of this Agreement and has had the opportunity to contribute to its revision. Accordingly, the rule of construction to the effect that ambiguities are resolved against the drafting party, shall not be employed in the interpretation of this Agreement. Rather, the terms of this Agreement shall be construed in a reasonable manner to effect the intentions of both parties hereto and not in favor or against either party.
18.Section 409A. Payments and/or benefits under this Agreement are intended to be exempt from, or comply with, Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), and this Agreement will be interpreted to achieve this result. For purposes of this Agreement, each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A. In no event is the Company responsible for any tax or penalty owed by you (other than for withholding obligations or other obligations applicable to employers, if any, under Section 409A) with respect to payments under this Agreement.
19.Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument, and electronically delivered copies of executed counterparts shall be deemed to be originals for all purposes.
* * *

9


BY SIGNING BELOW, YOU ACKNOWLEDGE THAT YOU HAVE BEEN GIVEN TWENTY-ONE (21) DAYS TO CONSIDER THE TERMS OF THIS AGREEMENT AND THE RELEASE; THAT YOU HAVE CAREFULLY READ AND UNDERSTAND ALL OF ITS TERMS, WHICH INCLUDE THE WAIVER OF IMPORTANT RIGHTS; THAT YOU AGREE TO THE TERMS; THAT YOU HAVE BEEN ADVISED BY THIS WRITING TO CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING AND DID SO TO THE EXTENT THAT YOU DEEMED APPROPRIATE; AND THAT YOU SIGN THIS AGREEMENT AND THE RELEASE VOLUNTARILY AND OF YOUR OWN FREE WILL.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth below.
HEALTHEQUITY, INC.
By: ______________________________
Name: Darcy Mott 
Title: EVP, CFO
Dated: _______________________________

_____________________________________
Ashley Dreier
Dated:________________________________

[Signature Page to A. Dreier Transition, Separation and Release Agreement]


Exhibit A
SUPPLEMENTAL RELEASE OF CLAIMS
This Supplemental Release of Claims (this “Release”) is being executed and delivered as of the date written below next to my name, in accordance with paragraph 6 of the Transition, Separation and Release Agreement (the “Separation Agreement”) delivered to me on February 13, 2020, with HealthEquity, Inc. (the “Company”).
As used in this Release, the term “claims” includes all claims, covenants, warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, accounts, attorneys’ fees, judgments, losses and liabilities, of whatsoever kind or nature, in law, equity or otherwise.
For and in consideration of the Company’s agreement to provide me with the Consideration (as defined in the Separation Agreement), and other good and valuable consideration, I, Ashley Dreier, for and on behalf of myself and my heirs, administrators, executors and assigns, effective as of the date on which this Release becomes effective pursuant to its terms, do fully and forever release, remise and discharge each of the Company, its direct and indirect subsidiary companies and affiliates (collectively, the “Company Group”) and their successors and assigns, together with their respective current and former officers, directors, partners, members, stockholders, employees and agents (collectively, and with the Company, the “Company Parties”) from any and all claims whatsoever up to the date hereof that I had, may have had, or now have against the Company Parties, whether known or unknown, for or by reason of any matter, cause or thing whatsoever, including any claim arising out of or attributable to my employment or the termination of my employment with the Company or any member of the Company Group, whether for tort, breach of express or implied employment contract, infliction of emotional distress, retaliation, wrongful termination, unjust dismissal, defamation, libel or slander, or under any federal, state or local law dealing with discrimination based on age, race, sex, national origin, religion, disability, or sexual orientation, or any other class protected under applicable law. This release of claims includes, but is not limited to, all claims arising under the Age Discrimination in Employment Act (the “ADEA”), Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family and Medical Leave Act, the Equal Pay Act, the Worker Adjustment and Retraining Notification Act and the Employee Retirement Income Security Act (excluding claims for accrued, vested benefits under an employee pension benefit plan of the Company Parties), each as may be amended from time to time, and all other federal, state and local laws, the common law and any other purported restriction on an employer’s right to terminate the employment of employees. I intend the release contained herein to be a general release of any and all claims to the fullest extent permissible by law and for the provisions regarding the release of claims against the Company Parties to be construed as broadly as possible, and hereby incorporate in this release similar federal, state or other laws, all of which I also hereby expressly waive.
I understand and agree that claims or facts in addition to or different from those which are now known or believed by me to exist may hereafter be discovered, but it is my intention to fully and forever release, remise and discharge all claims which I had, may have had, or now have against the Company Parties, whether known or unknown, suspected or unsuspected, asserted or unasserted, contingent or noncontingent, without regard to the subsequent discovery or existence of such additional or different facts. Without limiting the foregoing, by signing this Release, I expressly waive and release any provision of law that purports to limit the scope of a general release.



I acknowledge and agree that as of the date I execute this Release, I have no knowledge of any facts or circumstances that give rise or could give rise to any claims under any of the laws listed in the preceding paragraphs.
Notwithstanding the foregoing, nothing in this Release shall be a waiver of: (i)  my rights arising out of breach of this Release; (ii) my rights with respect to payment of amounts under the Separation Agreement; (iii) my right to accrued, vested benefits due to terminated employees under any employee benefit plan of the Company or any other member of the Company Group in which I participated (excluding any severance or similar plan or policy), in accordance with the terms thereof (including my rights to elect continued medical and health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985); (iv) any claims that cannot be waived by law; (v) my right to indemnification, advancement and reimbursement of legal fees and expenses, and directors and officers liability insurance, as provided by, and in accordance with the terms of, applicable law, the Company’s governing documents or that certain Indemnification Agreement, dated June 27, 2017, by and between myself and the Company (the “Indemnification Agreement”); (vi) any rights or claims under the ADEA challenging the knowing and voluntary nature of this Release or that may arise after the date that I execute this Release; or (vi) my rights as a stockholder of the Company.
I acknowledge and agree that as of the date of this Release, I have reported all accidents, injuries or illnesses relating to or arising from my employment with the Company or the Company Group and that I have not suffered any on-the-job injury or illness for which I have not yet filed a claim.
I expressly acknowledge and agree that I –
Am able to read the language, and understand the meaning and effect, of this Release;
Have no physical or mental impairment of any kind that has interfered with my ability to read and understand the meaning of this Release or its terms, and that I am not acting under the influence of any medication, drug or chemical of any type in entering into this Release;
Am specifically agreeing to the terms of the release contained in this Release because the Company has agreed to provide me the Consideration, which the Company has agreed to provide because of my agreement to accept it in full settlement of all possible claims I might have or ever had against the Company Parties and because of my execution of this Release;
Acknowledge that, but for my execution of this Release, I would not be entitled to the Consideration;
Had or could have twenty-one (21) calendar days in which to review and consider this Release (the “Release Expiration Date”), and that if I execute this Release prior to the Release Expiration Date, I have voluntarily and knowingly waived the remainder of such twenty-one (21)-day period;
May revoke the Release for a period of seven (7) calendar days following the execution of this Agreement (the “Revocation Period”), by providing written notice to Del Ladd, Esq. (the “Company Representative”), the Company’s Executive Vice President, General Counsel and Corporate Secretary, by email (dladd@healthequity.com) (which notice must be received within the seven-day revocation period at 5 p.m. MST);
A-2


Understand that, by entering into this Release, I do not waive rights or claims under the ADEA that may arise after the date I execute this Release;
Have not relied upon any representation or statement not set forth in this Release made by the Company Group or any of its representatives;
Was advised to consult with my attorney regarding the terms and effect of this Release; and
Have signed this Release knowingly and voluntarily.
I represent and warrant that I have not previously filed, and to the maximum extent permitted by law agree that I will not file, a complaint, charge or lawsuit against any of the Company Parties regarding any of the claims released herein. Except as otherwise provided in the following sentence, if, notwithstanding this representation and warranty, I have filed or file such a complaint, charge, or lawsuit, I agree that I will cause such complaint, charge, or lawsuit to be dismissed with prejudice and shall pay any and all costs required in obtaining dismissal of such complaint, charge, or lawsuit, including without limitation the attorneys’ fees of any of the Company Parties against whom I have filed such a complaint, charge, or lawsuit. Notwithstanding the foregoing or anything else in this Release, this Release will not prevent me from (i) filing a charge or complaint with, participating in an investigation or proceeding conducted by, or reporting possible violations of law or regulation to any federal, state or local government agency, (ii) truthfully responding to or complying with a subpoena, court order, or other legal process, or (iii) exercising any rights I may have under applicable labor laws to engage in protected concerted activity with other employees; provided, however, that I agree to forgo any monetary benefit from the filing of a charge or complaint with a government agency except pursuant to a whistleblower program or where my right to receive such a monetary benefit is otherwise not waivable by law.
Notwithstanding anything contained herein to the contrary, this Release will not become effective or enforceable prior to the expiration of the Revocation Period provided that this Release is executed prior to the Release Expiration Date, and I do not revoke it during the Revocation Period, the eighth (8th) day following the date on which this Release is executed shall be its effective date. I acknowledge and agree that, in the event that I fail to execute and deliver this Release prior to the expiration of the Release Expiration Date or otherwise revoke this Release during the Revocation Period, this Release will be null and void and of no effect, and neither the Company nor any other member of the Company Group will have any obligations to provide me the benefit of the Consideration.
The provisions of this Release will be binding upon my heirs, executors, administrators, legal personal representatives, and assigns. If any provision of this Release is held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision will be of no force and effect. The illegality or unenforceability of such provision, however, will have no effect upon and will not impair the enforceability of any other provision of this Release.
This Release, the Separation Agreement, the Restrictive Covenants (as defined in the Separation Agreement) and the Indemnification Agreement constitute the entire understanding and agreement regarding the termination of my employment with the Company Group. This Release, the Separation Agreement, the Restrictive Covenants and the Indemnification Agreement supersede all prior negotiations, discussions, correspondence, communications, understandings and agreements between myself and the Company Group relating to the subject matter of this Release, the Separation Agreement, the Restrictive Covenants and the Indemnification Agreement.
A-3


EXCEPT WHERE PREEMPTED BY FEDERAL LAW, THIS RELEASE WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF UTAH, APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE, WITHOUT REGARD TO CONFLICT OF LAWS RULES. BY EXECUTION OF THIS RELEASE, I HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE STATE OF UTAH AND FEDERAL COURTS LOCATED IN THE STATE OF UTAH AND I HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY IN CONNECTION WITH ANY DISPUTE ARISING UNDER OR CONCERNING THIS RELEASE. ALL DISPUTES ARISING UNDER OR CONCERNING THIS RELEASE, AS WELL AS ALL CLAIMS ARISING OUT OF MY EMPLOYMENT OR TERMINATION THEREOF, INCLUDING WITHOUT LIMITATION ALL CLAIMS FOR PAYMENT OF WAGES, DISCRIMINATION, RETALIATION, AND ALL OTHER CLAIMS BASED ON ANY STATE, FEDERAL OR COMMON LAW WILL BE RESOLVED THROUGH BINDING ARBITRATION BEFORE A SINGLE ARBITRATOR. THE ARBITRATION SHALL BE ADMINISTERED BY JAMS, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. IF JAMS CANNOT SERVE AS THE ARBITRATION ADMINISTRATOR, THEN THE ARBITRATION WILL BE THROUGH THE AMERICAN ARBITRATION ASSOCIATION, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. THE EXCLUSIVE VENUE OF ANY SUCH ARBITRATION WILL BE SALT LAKE CITY, UTAH. THE NON-PREVAILING PARTY WILL PAY THE REASONABLE ATTORNEYS’ FEES AND COSTS OF THE PREVAILING PARTY. THE ARBITRATOR SHALL HAVE AUTHORITY TO ISSUE EQUITABLE AND LEGAL RELIEF, INCLUDING WITHOUT LIMITATION INJUNCTIVE RELIEF AND MONETARY DAMAGES. ALL ARBITRATION PROCEEDINGS SHALL BE CONFIDENTIAL.
* * * * *


A-4


BY SIGNING BELOW, I ACKNOWLEDGE THAT I HAVE BEEN GIVEN TWENTY-ONE (21) DAYS TO CONSIDER THE TERMS OF THIS RELEASE; THAT I HAVE CAREFULLY READ AND UNDERSTAND ALL OF ITS TERMS, WHICH INCLUDE THE WAIVER OF IMPORTANT RIGHTS; THAT I AGREE TO ITS TERMS; THAT I HAVE BEEN ADVISED BY THIS WRITING TO CONSULT WITH AN ATTORNEY OF MY CHOICE BEFORE SIGNING AND DID SO TO THE EXTENT THAT I DEEMED APPROPRIATE; AND THAT I SIGN THIS RELEASE VOLUNTARILY AND OF MY OWN FREE WILL.
Agreed and Accepted:
/s/ Ashley Dreier 
ASHLEY DREIER
Dated: 2/13/2020 
Please sign and date the above on or after the Separation Date, and no later than 21 days following the Separation Date, and return one signed Supplemental Release to the Company Representative.

[Signature Page to Supplemental Release of Claims]
EX-10.2 3 amendmentno1tokesslereea.htm EX-10.2 amendmentno1tokesslereea


 


 


 
EX-31.1 4 exhibit311-ceo302xfy21.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Jon Kessler, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: June 4, 2020
 
By:
/s/ Jon Kessler

Name:Jon Kessler
Title:
Chief Executive Officer
 (Principal Executive Officer)


EX-31.2 5 exhibit312-cfo302xfy21.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Darcy Mott, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 4, 2020
By:
/s/ Darcy Mott

Name:Darcy Mott
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


EX-32.1 6 exhibit321-ceo906xfy21.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jon Kessler, the Chief Executive Officer (Principal Executive Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended April 30, 2020 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: June 4, 2020
 
By:
/s/ Jon Kessler

Name:Jon Kessler
Title:
Chief Executive Officer
(Principal Executive Officer)


EX-32.2 7 exhibit322-cfo906xfy21.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Darcy Mott, Executive Vice President and Chief Financial Officer (Principal Financial Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended April 30, 2020 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: June 4, 2020
 
By:
/s/ Darcy Mott

Name:Darcy Mott
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 


EX-101.SCH 8 hqy-20200430.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed consolidated balance sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed consolidated balance sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed consolidated statements of cash flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of business and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of business and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Net income per share link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Net income per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Net income per share (Details) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Business combination link:presentationLink link:calculationLink link:definitionLink 2307302 - Disclosure - Business combination (Tables) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Business combination (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Supplemental financial statement information link:presentationLink link:calculationLink link:definitionLink 2311303 - Disclosure - Supplemental financial statement information (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Supplemental financial statement information (Contract balances) (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) link:presentationLink link:calculationLink link:definitionLink 2115105 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2316304 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Leases (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Leases (Lease Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Leases (Supplemental Cash Flow Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2121106 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 2322305 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Intangible assets and goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Commitments and contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Indebtedness Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Indebtedness (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Indebtedness Schedule of Maturities of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2132109 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2433417 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2134110 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 2335307 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2436418 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 2437419 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details) link:presentationLink link:calculationLink link:definitionLink 2438420 - Disclosure - Stock-based compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Stock-based compensation (Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2440422 - Disclosure - Stock-based compensation (Stock option activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2441423 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2142111 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 hqy-20200430_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 hqy-20200430_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 hqy-20200430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Software development costs incurred and expensed Research and Development Expense, Software (Excluding Acquired in Process Cost) Operating lease not yet commenced term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Amortization of acquired intangible assets Amortization Of Acquired Intangible Amortization of Acquired Intangible Other assets Other Assets [Member] Purchases of intangible assets Noncash or Part Noncash Acquisition, Intangible Assets Acquired Long-term line of credit Long-term Line of Credit Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition 2024 Long-term Debt, Maturities, Repayments of Principal in Year Four Revenue recognition Contract with Customer, Liability, Revenue Recognized Cash and cash equivalents, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents Total current liabilities Liabilities, Current Acquired in process software development costs Indefinite-lived Intangible Assets (Excluding Goodwill) Gross unrecognized tax benefits Unrecognized Tax Benefits Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Debt covenant, acquisition holiday provision Debt Covenant Period Four [Member] Debt Covenant Period Four Performance units awards (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Beginning balance, maximum (usd per share) Ending balance, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Recent adopted accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cost of revenue Cost of Goods and Services Sold Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Current Fiscal Year End Date Current Fiscal Year End Date Service revenue Service [Member] Debt covenant, beginning April 30, 2020 Debt Covenant Period One [Member] Debt Covenant Period One Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Address, Postal Zip Code Entity Address, Postal Zip Code Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent Property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Opening balance (shares) Ending balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Credit facility, amount Line of Credit Facility, Maximum Borrowing Capacity Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Client-held funds obligation Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation Variable rate borrowing spread Debt Instrument, Basis Spread on Variable Rate Total assets Assets Exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Entity Shell Company Entity Shell Company Total lease liabilities Operating Lease, Liability Cover page. Cover [Abstract] Exercisable as of year end, weighted-average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Document Type Document Type Variable Rate [Domain] Variable Rate [Domain] Principal payments on long-term debt Repayments of Long-term Debt Equity Interest Type [Axis] Equity Interest Type [Axis] Operating lease not yet commenced undiscounted amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] General and administrative General and Administrative Expense [Member] Restricted stock awards Restricted Stock [Member] Accounts receivable Increase (Decrease) in Accounts Receivable 2024 Lessee, Operating Lease, Liability, Payments, Due Year Four Current liabilities Liabilities, Current [Abstract] Exercised, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised ROU assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Client-held funds obligation, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Client Held Funds Obligation Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Client Held Funds Obligation Credit Facility [Axis] Credit Facility [Axis] Gain on equity securities Equity Securities, FV-NI, Gain (Loss) Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Beginning balance, minimum (usd per share) Ending balance, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Document Quarterly Report Document Quarterly Report Commitments and contingencies (see Note 7) Commitments and Contingencies Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Beginning cash and cash equivalents Ending cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Debt Instrument [Line Items] Debt Instrument [Line Items] Merger related costs, price per share Business Acquisition, Share Price Forfeited, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Percentage of capital stock Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Entity File Number Entity File Number Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Net income per share: Net income per share: Earnings Per Share, Basic and Diluted [Abstract] Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Document Fiscal Period Focus Document Fiscal Period Focus Issuance of common stock upon exercise of stock options, and for restricted stock Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Product and Service [Domain] Product and Service [Domain] Summary of assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Vested (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Secured Debt Secured Debt [Member] Income from operations Operating Income (Loss) Exercised, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Goodwill Goodwill Summary of restricted stock unit activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Statement [Line Items] Statement [Line Items] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Basic (in usd per share) Earnings Per Share, Basic Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Opening balance (usd per share) Ending balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Plan Name [Axis] Plan Name [Axis] Borrowing pursuant to term loan facility Business Combination, Consideration Transferred, Liabilities Incurred Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other long-term liabilities Increase (Decrease) in Other Deferred Liability Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Amendment Flag Amendment Flag Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Weighted- average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Operating lease liabilities, non-current Increase (Decrease) In Operating Lease Liability, Noncurrent Increase (Decrease) In Operating Lease Liability, Noncurrent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Denominator (diluted): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Interest expense Interest Expense Unrecognized stock compensation expense to be recognized in future Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total long-term liabilities Liabilities, Noncurrent Fraction of awards fully achieved Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fully Achieved, Ratio Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fully Achieved, Ratio Plan Name [Domain] Plan Name [Domain] Local Phone Number Local Phone Number Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Accrued liabilities and other current liabilities Increase (Decrease) in Accrued Liabilities Total lease payments Lessee, Operating Lease, Liability, Payments, Due Property and equipment Property, Plant and Equipment [Table Text Block] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts receivable, net of allowance for doubtful accounts of $1,681 and $1,216 as of April 30, 2020 and January 31, 2020, respectively Accounts Receivable, after Allowance for Credit Loss, Current Operating lease expense Operating Lease, Expense Total other income (expense) Nonoperating Income (Expense) Additional paid-in capital Additional Paid in Capital Summary of share based compensation recognized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Vested and expected to vest as of year end, aggregate intrinsic value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Lease renewal terms extension Lessee, Operating Lease, Renewal Term Total current assets Assets, Current Entity Current Reporting Status Entity Current Reporting Status Decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net income Net income Net Income (Loss) Attributable to Parent Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Common stock Common Stock [Member] Current assets Assets, Current [Abstract] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Leases [Abstract] Leases [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Product and Service [Axis] Product and Service [Axis] Numerator (basic and diluted): Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Entity Small Business Entity Small Business Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Purchases of marketable securities Payments to Acquire Investments Total consideration paid, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Entity Filer Category Entity Filer Category Number of team members modification affected Share-based Payment Arrangement, Plan Modification, Incremental Cost, Number Of Team Members Share-based Payment Arrangement, Plan Modification, Incremental Cost, Number Of Team Members Total stock-based compensation expense Share-based Payment Arrangement, Expense Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total liabilities and stockholders’ equity Liabilities and Equity Entity Address, City or Town Entity Address, City or Town Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Current portion of long-term debt Long-term Debt, Current Maturities Operating lease liabilities, non-current Non-current Operating Lease, Liability, Noncurrent Operating Expenses [Abstract] Operating Expenses [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Principles of consolidation Consolidation, Policy [Policy Text Block] Other income (expense) Other Nonoperating Income (Expense) [Abstract] Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Weighted average fair value at date of grant (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Revenues [Abstract] Revenues [Abstract] Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Vested and expected to vest as of year end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Other expense Other Nonoperating Expense Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Award Type [Axis] Award Type [Axis] Other income (expense), net Total other income (expense), net Other Nonoperating Income (Expense) Custodial revenue Financial Service, Other [Member] Operating cash flows from operating leases Operating Lease, Payments Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accumulated earnings Retained Earnings [Member] Amortization of debt issuance costs Amortization of Debt Issuance Costs Leases Lessee, Operating Leases [Text Block] Purchases of property and equipment included in accounts payable or accrued liabilities at period end Capital Expenditures Incurred but Not yet Paid Document Period End Date Document Period End Date Statement [Table] Statement [Table] Other current assets Other Assets, Current Entity Registrant Name Entity Registrant Name Equity Interest Issued or Issuable, Type [Domain] Equity Interest Issued or Issuable, Type [Domain] Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Forfeited, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Maximum Maximum [Member] 2023 Lessee, Operating Lease, Liability, Payments, Due Year Three Goodwill, adjustments Goodwill, Purchase Accounting Adjustments Outstanding stock options, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Deferred revenue interchange arrangement recognition term Contract With Customer, Recognition Term, Interchange Arrangement Contract With Customer, Recognition Term, Interchange Arrangement Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Sales and marketing Sales and Marketing [Member] Sales and Marketing [Member] Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accumulated earnings Retained Earnings (Accumulated Deficit) Entity Tax Identification Number Entity Tax Identification Number Diluted (in usd per share) Earnings Per Share, Diluted Sales and marketing Selling and Marketing Expense Trading Symbol Trading Symbol Minimum Minimum [Member] Preliminary Allocation of Consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Facility term Debt Instrument, Term Balance Sheet Location [Domain] Balance Sheet Location [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Remaining operating lease terms Lessee, Operating Lease, Remaining Lease Term Lessee, Operating Lease, Remaining Lease Term Acquired developed technology Developed Technology Rights [Member] Summary of stock option activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Supplemental financial statement information Additional Financial Information Disclosure [Text Block] Minimum interest coverage ratio Debt Instrument, Covenant Description, Interest Coverage Ratio Debt Instrument, Covenant Description, Interest Coverage Ratio Exercisable as of year end, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Income tax provision Income Tax Expense (Benefit) Stock-based compensation Share-based Payment Arrangement [Text Block] Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value 2022 Lessee, Operating Lease, Liability, Payments, Due Year Two Acquired customer relationships Customer Relationships [Member] Computer equipment Computer Equipment [Member] Other long-term liabilities Other Liabilities, Noncurrent City Area Code City Area Code Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Debt covenant, beginning July 31, 2020 Debt Covenant Period Two [Member] Debt Covenant Period Two Acquired trade names Trade Names [Member] Intangible assets, net Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) Title of 12(b) Security Title of 12(b) Security Exercisable as of year end, weighted-average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Number of common stock issuable (in shares) Common Stock, Capital Shares Reserved for Future Issuance Earnings Per Share [Abstract] Earnings Per Share [Abstract] Incentive Plan Incentive Plan [Member] Incentive Plan [Member] Other non-cash items Other Noncash Income (Expense) Deferred tax asset Deferred Income Tax Assets, Net Operating lease liability maturity schedule Lessee, Operating Lease, Liability, Maturity [Table Text Block] Weighted-average grant date fair value (usd per share) Granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Computer software intangible asset Computer Software, Intangible Asset [Member] Accrued compensation Increase (Decrease) in Employee Related Liabilities Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Term loan facility Total principal payments Long-term Debt, Gross Exercise of common stock options receivable Exercise of Stock Options Receivable Exercise of Stock Options Receivable Furniture and fixtures Furniture and Fixtures [Member] Assets Assets [Abstract] Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share WageWorks Incentive Plan WageWorks Incentive Plan [Member] WageWorks Incentive Plan Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Cash Flow, Operating Activities, Lessee [Abstract] Cash Flow, Operating Activities, Lessee [Abstract] Lease, cost, total Lease, Cost Summary of stock-based compensation expense by award type Share-based Payment Arrangement, Cost by Plan [Table Text Block] Unrecognized tax benefit Unrecognized Tax Benefit, Net Unrecognized Tax Benefit, Net Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Total operating expenses Operating Expenses Performance stock options Performance Shares [Member] Debt covenant, beginning July 31, 2021 Debt Covenant Period Three [Member] Debt Covenant Period Three Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total amortizable intangible assets, net Finite-Lived Intangible Assets, Net Deferred revenue recognition term Contract With Customer, Recognition Term Contract With Customer, Recognition Term Debt Disclosure [Abstract] Debt Disclosure [Abstract] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Income Statement Location [Domain] Income Statement Location [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Supplemental cash flow data: Supplemental Cash Flow Information [Abstract] Weighted average discount rate (percent) Operating Lease, Weighted Average Discount Rate, Percent Purchases of software and capitalized software development costs Payments for Software Beginning balance, outstanding stock options, aggregate intrinsic value Ending balance, outstanding stock options, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Incremental compensation cost Share-based Payment Arrangement, Plan Modification, Incremental Cost Accounts payable Increase (Decrease) in Accounts Payable Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] 2023 Long-term Debt, Maturities, Repayments of Principal in Year Three Income taxes paid in cash, net of refunds received Income Taxes Paid, Net Sublease income Sublease Income Expected stock price volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Performance restricted stock awards Performance Restricted Stock Awards [Member] Performance Restricted Stock Awards [Member] Exercisable as of year end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Indebtedness Debt Disclosure [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Common stock, authorized (in shares) Common Stock, Shares Authorized Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Central Index Key Entity Central Index Key Unvested, beginning balance (in shares) Unvested, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Entity Emerging Growth Company Entity Emerging Growth Company 2025 Long-term Debt, Maturities, Repayments of Principal in Year Five Merger integration Business Combination, Integration Related Costs Interest income Investment Income, Nonoperating Stock-based compensation Share-based Payment Arrangement, Noncash Expense Operating lease liabilities Current Operating Lease, Liability, Current Schedule of earnings (loss) per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Long-term debt, net of issuance costs Long-term Debt, Excluding Current Maturities Share-based payment arrangement, decrease in expense due to modification of terms Share-Based Payment Arrangement, Decrease In Expense Due To Modification Of Terms Share-Based Payment Arrangement, Decrease In Expense Due To Modification Of Terms Credit Facility [Domain] Credit Facility [Domain] Accrued compensation Employee-related Liabilities, Current Number of service-based common stock (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Customary Base Rate Base Rate [Member] Remaining 2021 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Income taxes Income Tax Disclosure [Text Block] Acquisition of intangible member assets Payments to Acquire Intangible Assets Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Fair value measurement Fair Value Measurement, Policy [Policy Text Block] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Other assets Other Assets, Noncurrent Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total Long-term Debt Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Vested and expected to vest as of year end, weighted average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment 2025 Lessee, Operating Lease, Liability, Payments, Due Year Five Weighted-average vesting period of non-vested awards expected to vest Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Additional paid-in capital Additional Paid-in Capital [Member] Maximum leverage ratio Debt Instrument, Covenant Description, Leverage Ratio Debt Instrument, Covenant Description, Leverage Ratio Deferred tax liability Deferred Income Tax Liabilities, Net Operating lease right-of-use assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets Technology and development Technology and Development [Member] Technology and Development [Member] Gains on marketable equity securities Gain (Loss) on Sale of Investments Stated interest rate percentage Debt Instrument, Interest Rate, Stated Percentage 2022 Long-term Debt, Maturities, Repayments of Principal in Year Two Entity Address, Address Line One Entity Address, Address Line One Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Entity Address, Address Line Two Entity Address, Address Line Two Property and equipment, gross Property, Plant and Equipment, Gross Business Combinations [Abstract] Business Combinations [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Gross profit Gross Profit Cash paid Payments to Acquire Businesses, Gross Entity Address, State or Province Entity Address, State or Province Income Statement Location [Axis] Income Statement Location [Axis] Business Acquisition [Axis] Business Acquisition [Axis] Other current liabilities, adjustments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Adjustment, Current Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Adjustment, Current Liabilities, Other Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Range of exercise prices (usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Aggregate fair value of WageWorks stock acquired Business Combination, Consideration Transferred Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Forfeited period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment Business Acquisition [Line Items] Business Acquisition [Line Items] General and administrative General and Administrative Expense Accounts payable Accounts Payable, Current Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Change in goodwill Goodwill, Period Increase (Decrease) Accrued liabilities Accrued Liabilities, Current Entity Interactive Data Current Entity Interactive Data Current Common stock, issued (in shares) Common Stock, Shares, Issued Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Acquired HSA portfolios Acquired HSA Intangible Assets [Member] Acquired HSA Intangible Assets [Member] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Unvested, beginning balance (usd per share) Unvested, ending balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Grant date fair value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Interchange revenue Credit and Debit Card [Member] Net income per share Earnings Per Share [Text Block] Fraction of awards modified Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Remaining Modified, Ratio Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Remaining Modified, Ratio Shares available for grant under incentive plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Award Type [Domain] Award Type [Domain] Other assets Increase (Decrease) in Other Operating Assets Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Secured Revolving Credit Facility Revolving Credit Facility [Member] Granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Leasehold improvements Leasehold Improvements [Member] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Software and software development costs Software and Software Development Costs [Member] Award vesting rights percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vested and expected to vest as of year end, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Cost of revenue Cost of Sales [Member] Restricted stock units Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Summary of business and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Cost of revenue Cost of Revenue [Abstract] Total liabilities Liabilities Business combination Business Combination Disclosure [Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Common stock, $0.0001 par value, 900,000 shares authorized, 71,398 and 71,051 shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively Common Stock, Value, Issued Deferred taxes Deferred Income Taxes and Tax Credits Technology and development Research and Development Expense Remaining 2021 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Acquisition threshold for maximum total net leverage ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Granted (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Granted Share-Based Compensation, Shares Authorized Under Stock Option Plans, Granted Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Denominator (basic): Weighted Average Number of Shares Outstanding, Basic [Abstract] Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Expected stock price volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted-average dilutive effect of stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Operating lease right-of-use assets Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Basic (in shares) Weighted-average common shares outstanding (in shares) Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Equity Components [Axis] Equity Components [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Acquisition costs Business Combination, Acquisition Related Costs Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Amortization expense Amortization of Intangible Assets Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Wage Works Inc. Wage Works Inc. [Member] Wage Works Inc. Fair value Fair Value Disclosures [Text Block] Schedule of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Other current assets, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets In Process Research and Development In Process Research and Development [Member] Lease cost Lease, Cost [Table Text Block] Total consideration paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Effective interest rate percentage Line of Credit Facility, Interest Rate at Period End Weighted-average number of shares used in computing net income per share: Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Amortizable intangible assets, gross Finite-Lived Intangible Assets, Gross Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively Preferred Stock, Value, Issued Variable Rate [Axis] Variable Rate [Axis] Security Exchange Name Security Exchange Name Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of derivative lawsuits Loss Contingency Number Of Lawsuits Loss Contingency Number Of Lawsuits Depreciation expense Depreciation Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Equity Component [Domain] Equity Component [Domain] Expected life of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Document Transition Report Document Transition Report Stock options Share-based Payment Arrangement, Option [Member] Less: unamortized loan issuance costs Unamortized loan issuance costs Debt Issuance Costs, Net Deferred tax liability, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes Settlement of client-held funds obligation Payments To Settle Client Held Funds Payments To Settle Client Held Funds Line of Credit Line of Credit [Member] Income Statement [Abstract] Income Statement [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] EX-101.PRE 12 hqy-20200430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 amendmentno1tokesslereea001.jpg GRAPHIC begin 644 amendmentno1tokesslereea001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# H'!P@'!@H(" @+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0,#G!Z'!I:KVO6;_ *Z& M@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[4?//[RG^ ME6*KVN=TW_70_P!* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 5!;?>F_ZZ'^E3U!;=9F_ZZ'^0J>H(/OS M?[_]!0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %06_WY MO]_^@J>H(/OS?[_]!0!/1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %0P?ZR;']_^@J:H8?]9-_O_P!!0!-1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9?B/6H MO#^@W>J2XQ!&2BD_??\ A7\3BM,\"N:UM)=:U;^S8[2.ZM[6%C<*\VQ2\BE5 M'0\A=Q_X$* -C2]135M(MM0MR-MS"LB]\$CI^!KE;#QS>#QBF@ZI;6\4<[2I M!<1D@2,CLN,$G'W3Q[BJ7POOIM.EU+PEJ$G^E6$S-'DYW*>N/;)S_P "JEXQ MTF2Z\*3:U9<7FCZK"?'*EE."2,>/KW1?%YTG5[6$:?Y@C%[$&4!BJL 02?[W/YUKV M*1^');M[B[DN/[1O(_($L@9R6"IM'L",_2J]QH=GXBF\1Z;>#*/] &HU[JA\0I9(UJ;62W:97*,7&"!C[V#][.:YS1O&&O:WK>KZ5;0Z>)M M,B"(6>HV)*SP2_.$()&>,9'! MJEX.\421(I /?V9?UK#^'=M)=:[XHUY8REEJVL6%SI<7A'Q7I<9DN!#!:RH#P^Y0%S^!8?B* .BUWQQJ M&G^+++1K.UMV@NIA 9I2V0^5W8 Z@;@/J#5C7?%&K:5XMTO0X4M)%U(?+(T; MYC(ZY ;G]*YOQ;9_V?XQ\&P%MTBS%I6!^\S2*6/XDFKOCB-9/B7X63S&CW;@ M60X(Y['M0!U5CJ&KS:H]K*;.6W:&0QW,". )$<*58$GU['L:P](\?73>*'T3 M7+2&U5V=;6YC)"RE7*]^F2I[]>*U]$:/08;/0YIC-<33SF/+[G*;F?.TF>V>%(%\MQ MNWDE9LOBG7(?&]OX886!DG@\[SQ$^!PQQC=S]WUH^'%YJ%]'JAU M:,QWMO.EM+NZML04:G#''/ M',R#R@=KJ.C#/J*Y7Q#XZU'PUXE2TO+.&73#Y9>YC5@T8NZ[5 MS5QIUIK/B'6M.O(UDAELK8,.X.Z7!^HZT 7'U*\?6[&"VEM9+&[@>;?M);"[ M>AS@YWCMVK*L_%UUX@\27NDZ''"L%@/W]Y."P+9(VJH(SR#SGM6+X.L=3T/Q M;_PC=\QEM[*VFDLYB,;HW9.!]".G:H_AC"^A^)-?T2]7R[H2*Z%C_K4!;D>H M^8'\: .ETOQ7(WBB?PUJT4<5[&HDAEB/R3H1G@'D'KQD]#73UYI+;/K7QK2Y MM,F#3($%Q*OW0VUOESZ_./R-=YI6N:=K/VC^S[@3?993#+A2-KCMR.?PH S/ M&OB:Y\*Z(^H06(N0"JY:3:JDG XZFMNQG:YL;>=P TL2N0.@)&:Y#XO?\B!= M>OFQ<#_?%=9I7_()L_\ K@G_ *"* +=%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5##_K9O]_\ MH*FJ&'_6S?[W]!0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 (>E5+?2K"UNI;JWLH(IYO]9(D M8#/]3WJY10!FCP[HPNC=KI5F+@G)E$*[B?KC-26VCZ;:02V]O8V\44V?,1(P M ^>N1WJ]10!0O=#TK4G5[_3;6Z9!A3-$K[1[9'%,N/#NC78C%SI5G.(QA/,A M5MH]!D<5I44 9<7AO1(+B.XATBRCFB.4D6!0RGV..*L6FDZ?8SR36EE!!)+_ M *QXXPI?ZD=:N44 0O:PO.9FA1I"AC+$<[3SCZ5GCPKX?5V<:)8!G.6/V=3^?*.626.-5>4@N MP'+$# S^%4F\/:,]V;M]*LVN"<^:85WY^N,UI44 )CC%4HM&TV"]:^AL+>.Z M?[TRQ@.?J>M7J* (C!&TZ3M&ID0%5?'(!QD#\A^50WFE6&H%3>64%P4^Z9(P MQ7Z9JW10!7M+&UL(?(L[:*WBSG9&@49_"DM+"TL?,^R6T4'FN9)/+0+O8]2< M=35FB@"I>Z5I^I;?MUE;W6WH)HP^/SJ6VM8+.%8;>)(HE^ZB* !^ J:B@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "H8?];-_O?T%35#%_K9O]X?R% $U%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T4E+0 44 M4E "T44E "T44E "T44E "T4F:* %HI,TM !2$XHI'1)$*.H96&"#T(H \Q^ M%Q \7>*L$D&X/&>_F25-JEO)HOQFL=6NABRU"+RDF;[J2;"NTGMT&/K7>VVC MZ793>=:Z=:P2=-\<*J?S JQ<6UO=PM#47;MW'T&3U]C7I%O&8;:*(G)1 I/K@57LM(TW3B396%O;EA@F M*,*3^(JW0 M%%)F@!:*3-% "T4E&: %HI*,B@!:*3-&: %HI,T4 +1249% " MT4E% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !4,/^NF_WA_(5-4,/^OF^H_E0!+FEHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** $-<5JGBK6+3X@V?AF#['Y5 MY%Y@F>%F9.'.,!P#]S]:[4G%>7>)HX+CXTZ7%/<-'&UEM8I*8V!Q+CD$$?\ MUZ .TTV^U>ZO9XI9+:2V:$/;W,5NRC=N*L&!8],>O>L+PAXZU#5_$$NCZO!; M0RM )K9H%8"1>#W)[']#6UH=U:Z:MEXVK1V[QJ3^\#$A(O'.I:=XKL=*L8K0VUU M<"W,LJLS;]R!B,,.!O ^H-3>+O%>K>'M=T;3[&&?O M]/:N<\9VIT_Q7X+B+*9%G+S,!U9I8RS?B2:M_%!E/B_P@OF%,W1#,IP5!DBY M]J -VU\6:@/&D_A2^CMS,8O,M[N!"%/RYPR$G!Z]Z/ GB?4_$YU%[X6L:V<_ MDJL*$%NO))8^E;6G^'-,TR]FU&*)I+R<8DN9Y#(Y'IDG@<#@8KB?A)-!"FNM M)-&N^])Y8#NW- '7^+O%-OX2T5M0GC,KLVR&)>"[GG'L,#-4;S5?$VG^&FUR M9+&1XXA/+9")E*IC)4/N^\![5S?Q&$OBCPS_ &GID9N(M+OG7,1W;U"X9QCK MALC\":Z+7?$-A<_#BZU))XV2ZLBJ -DEV7 7ZY.,4 ,U+Q;J$_@E/$OA^*"4 M*N^:"=6) !PW((Y7^56[3Q.]_P""8M9M6B>[G0+&@0X,Q.T)C/\ >XZ].:J? M#?1I].\$06]_$5>Y+2/%)SM5N@/X+?$.O^'=/MI[9;.YF,+R3HT3 ( 6*X;_:_2M2U\31WOA* M#6H C23QJ$C[>U4_"7C76?$FGWES/)IUF;:X6W7-O(P=FX'.\=R!5;X/LG]CZL0P)^V'G/ M;:*P/AOIL5[I]W,+ORY;34XYPAG*QLH.3N7H>,X/J!0!V^KZ]XDT_P *0ZC' M:6K:CYWDR6K1-AR7*C;\P/3D=(?"EW?6;0V^IV4;-/ ZEE!4$],@ MX./PJQJVK6VJ6%G<6TBO NK0Q)(&!$FUP"1[9R/PKEO'WAJ\T"^G\5:!N"31 MM'J%LHRK*PP7Q_/T//K0!V"WNOR1K*KVB0+8K.\K6[-OD.25 WC _.LCPK MXH\1^)?#B:Q&ECG[2(WMTA?)3(W$-OZX.>G:NHRD7AS!?Y%M/O$]MG6N2^#1 M'_"$!=RDBY?(';@&@#OA7,ZIXO@TWQKI>@-M/VQ7WMC[C?P#\>?S%;]]=P6% MG+=W,@CAA0N['L ,FO,?%^A:I>^%'UV2"".Y@F.H^:DS&0*2Z<,N/S(]>*V="UF*Z\!6\ME=Q6] MS:681T< F-T7!5E)R.10 S4_$6N:=X2U/5)[:WM[O3YBOE$,\;:^2R<%]G#[S[=JSI=?O_$WPCU?4M3>)#(#'&B) ML'!7GJK&WDW"%N'QW!'(S5B'5M&>QGDF2&::V%LZLL3D D'>>G/ M;M6)\0M0T_4?A:+G3GC-K(T/E@8 W#Y<=B/2I]#;3_#FFIKTEZ&CGTR!#$] MP78R+DA5!)QG=C H L>(?%&KZ7XUTK0[7[)Y&HC_ %DL3%H^3Z,,]*V-/N]6 MFU-HI)[6XLC%(%GA@9"LJ.%*D%B#W_(UQ?CD12_%#PT)I#&ACQ(5DV%YG#,>O<#ZF@#)TOQKJB^,X=&U9+46 MEWYJVLT2,I9D=EYR2.JD8]Q3O&OC74M"U.UMM-2U:-I5AF:968AV&<#!'12# M^(K*\8:7]O\ !']K::1?7$JM$V3L\]R1Q^!_"J7Q%1[;3O#;W;(+J>^^ MT7&6Z,0,_@.!] * .F\<>*M6\+W.DQ6K6THOY/*M)K M4-N;BVO+3S&BN62V:-X6\O>ISN((Z#\:X_XPF*2Y\.[G 47+%L-@[&'T-4/AS!JNGZEJND:L0TFGQPQ0OS\\ M67*G/<=Z+OY^[75:2VI_Z3'JA MB=DFQ#)$A0.FT$'!)YR2.O:N \67,47QE\.,957$0!R?4N*]/'(H 6BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AB_ MU\WU'\JFJ&+_ %\WU'\J )J*** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@!,9JG+HVESR-)-IMI([9Y6FVD?FKM?9 HWCT.!R*EM]/LK2+R;:T@ACSNV1QA1GUP.]6** *4^C MZ9=3>=<:=:S2D8WR0JS?F12R:1IDS[Y=.M78*%W-"I.!T'3I5RB@",P0M!Y! MB0Q8V["HVX],54&A:.!@:59 >@MT_P *OT4 0P6MO;0B&W@CAC'1(U"K^0J% M-'TR.?[0FG6JS9SY@A4-GUSBKE% #'C21"CH&5A@JPR"*K0Z1IMNX>#3[6)U MZ,D*J1^0JY10!6FTZQN9EFGLX)94^Z[QAF'T)J1[:"5762&-UD^^&4$-]?6I M:* *4>C:7$&$6FVB!EVL%@49'H>*C'A[1 ,#1[#'_7LG^%:-% %(Z-I30QPG M3;0Q1',:&!=J?08XJT88FB,31J8RNTH1QCTQ3Z* (9+6WF@^SRP1R0XQY;J" MN/H:9;:?96;,UK:00%N"8HPN?RJS10!%<6MO>0F&Y@CGC/5)%#*?P-1G3K%K M46K6RM+0,+:VB@#?>$:!<_E44VD:9<3>=/IUK++_ M 'WA5F_,BKE% %>6QLYXUBFM89$4Y56C! ^@HCL+.*)XH[2%(Y/OJL8 ;ZCO M5BB@"F='TPH$.G6I4'('DK@'UZ4T:+I2N'&FV@8'((@7(/Y5>HH J2Z7I\TC M22V-M([?>9HE)/U.*(M+T^ EH;&WB+*5)2)5R/3@5;HH KPV%G;(R06L,2/] MY4C"AOKBB:PL[A]\UI#*V,;GC!./QJQ10!5?3;"0@O96[%1M!:($@>G2B+3+ M"!P\5E;QL.A2)01^E6J* *\%C9VK,UO:PPLW4QQA2?RJ81H'+A '( +8Y(_R M:=10!6?3K&5VDDLX'=OO,T8)/UJP , 8 I:* "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@A/[^?_>'\JGJ"'_CX MG^H_E0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !14-S=V]F@>YN(H$)P&D<*"?QJO\ VUI7 M_02L_P#O^O\ C0!>HJK!J-GBDI: "BFNZQH78A549))P!21R++&LB,&1AE64Y!'J* ' MT444 %%%% !12$\56M=3LKV>>"UNHII+<@2JC E">@- %JBBB@ HHHH ***B MN+F"UB,UQ-'#&O5Y&"@?B: ):*BBN(9X!/%*DD3#(=&!4CV(J.UU"SO2XM;J M&"5)8G&5=#D$> MQH EHI*BBNH9VD6*17,3;'VG.T^E $U%4EU>PDU-M,2[B>\6/S&A5LLJY R1 MVY(J6]OK73K8W-Y.D$((!=S@ DX'ZF@"Q12 Y&:6@ HJ$W,(F>'S4\Q%W,NX M9 ]3^5/BD2:-9(W5T895E.010 ^BHXIXY@QCD5PK%25.<$<$?6I* "BBB@ H MHHH **IKJU@^J'3%NHFO%3S#"&RP7CD^G6KE !1110 444A- "T5GG7=*6VE MN3J-J(8)/*ED\T;4?IM)SP:M0W4-P[I%*CM&<. >5[C- $U%%)0 M%%% !15 M*_U:PTSR1>W,<)GD$<08\NQ. *N#I0 M%%-9@JEB<
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amendmentno1tokesslereea002.jpg GRAPHIC begin 644 amendmentno1tokesslereea002.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# H'!P@'!@H(" @+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V:BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2FQN)$#CH12M]T_2HK+BT MB_W: )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z'Z5#9 M?\>D7^[4S=#]*AL_^/6+_=% $]%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 AZ&H;/\ X]8_I4QZ&HK3_CVC_P!V@":BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH 0]*AM/^/6/Z5,>E0VG_ ![1_2@">BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2HK3_ (]D^E2U%:_\ M>Z?2@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AM?^/= M/I_6IJAM<_9USUY_G0!-1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %0VO\ Q[KGW_G4U0VO_'NOX_SH FHHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHI* %HI-U&: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHI,B@!:*3.:6@ HHHH **3-&: %HI < MTM !1129YH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,C%':@!:* M0'-+0 4444 %%%% !1110 4444 %%%% !129YI: "BBB@ HHHH **3-% "T4 MF:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;7_ %"_C_.I MJAM?]0OX_P Z )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ KD7\31WNJ72-J26&EVDWV8RC >>7C<-QX503CU)[UUU<'9V M\6F^%M:\/ZA$[W#2W)C0(6:Y$A9E*^I^;!]".: .YB $2@,6 '!)R3^-/K T M2X?1M/T30[[SI;R6VVF0(2H**-P9N@_KBM^@ HHHH **** *FJZA%I.EW.H3 MY\JVB:5P.I &:Q]&@U+5]+AU+4+^X@FNT$L<-N0B0*1E1T.XXZDYK2U_3!K. MA7VF%@OVJ!X@Q[$C@UD>'=;%EH]KIVK1RVM_:1+#(C0MB0J,90@88$#/'K0! M;L+NYT?3&_MVZ:6-[0!IHI8F1 MT!Z':1DCW%8?B![PZIH6O&UF-G:3R":)4+.J.FU9"HYX[CMF@Q"Y\87&O0^8 M+.'2_L[.$.)7+$C ZG 'ZT :MOXNT:ZDLTAN787O^HD\EPCG^[N(P&XZ9S5> MS\60W&JZK;2Q3Q1:>RKO-N_/RY8GCW&*YJ$./ OAB)K>X$MO?P&5/(<-&%8D MDC&0!6U93K9>(/$<<\4X-RR2QL('9601 ?> QU!&.M &G:^+M%O4WPWA\O[- M]J\QHG5/+]=Q&,^W6K%KKEE>W9L5:6*X,?F*DT31LR],KN S7'QV%[=?";3K M:UAE-S:) \MML*,^Q@S)@C.<#]*U[EUUWQ)H-]8"3R[+SI9W:-DVADVA#D=< MGI[4 9AENU\'>+)/[0NS+:75UY,OG'>H51@9[#V%;4%Y:A?#D-WJ%S'>21JT M<:%L3GRN=YP01U/)ZUAB0OX3\7Q>1/NGN;DQ+Y#[I ZX4J,U:Z5[B5VLV"SK%;O(4.,\A0>,=^E79M M9L(8+6;SPZWA MQ&"QER,\ =>.:YBPD6/6_&#LDH6H>1!D@<9- !K M-]J7A6_T^X-Y)>:7=W*V\\<^TM"7X5E8 '&>H.:V[S7["RDFCD>5VMU#3>5" M\GE ]V*@X]:P?$$864-TEQ=W,T31KA#D(N[!8D]QP*72[EM&U M37K/5(G NKMKFWD"%A.C(!M&!U&W&* .BFUFQAM8+CSO-2YQY'DJ7,N1GY0, MD\%K+PU>W=I<36]I%/ M'/'"AD>V$A!4[1R<#Y3BK_B"1M0T&:]LM*ECMHKZWN"1 5EG"N"[[,;N!ZC) MP?:@#I9=>L(+RXM)I7CFMH1/(&B; 0G&X'&#R#TJG'XTT.0VI%VZI=@&&5X' M6-B1D#>1@' Z9S66;\7GB>XODM;M;:71_+21[9UW$.QQ@C(Z]\9K-C+IX-\( MQ/!.);>\MFF3R'W1A<[B1C@#(H [+3M?T_5)[B&VE<2VX!D2:)XF /0X8#(X M//2HXO$NFS7$$*RRC[3D02-"RI*0,X5B,'@'ZUSVH6\M_P",-9@MUE0W6B^1 M%,48)ORW ;&,\@U#HMQ9W4&G6E ' M02>,]#BB\YKMS$)3"T@@D*HP.#N(&%Y[G%$GB0+XL31%MYB!;><\@B9@26 7 M! Z=/7% '84C#HK.8XIH_(G>%O-3;DKW'J/0U M;8A5)/0#- '(^'=4:!?$%WJ=_/)!I^H20*9"6"1JJGH!SU/-:]KXHTF[O+:T MBN',EVF^ F%PD@QNP&(P3CG&:/*;]W^X9?FXX^8@H>%KF*Q0RSJR2")>L@5PQ7\0* MIMKUOJUO-=V&AS3W4-I)O^TVIC*_+GRLL.26QP,CCZ4 ;%EXCT[4+B*W@ED# MSQ&6'S(F02H,9920 1R.GK1;^(M.NKF""*24FX+"%S"X20J"3M8C!X![UQ]A M<*^N^&[Q4O9D6UFBD)M71(W94PBKMPH&"/PY-3:0LD&HZ9'IDTTEC.SM)87< M),E@2AY5R 5 /&#Z\4 =2WB32TF6-[A@K3>0LIC;RS)G&W?C;G(QUZ\5I3W$ M-M \\\BQQ1J6=V. H'QN]2\(7MO8H9)\(XC'5PKABOX@$?C0!?M=>L+NZCMDDD269"\2RPO' MY@'4KN S^%<]-?KK_BG4='DFU"WBA@C2%K<2Q%9&W9@QGCBI=2D7Q'>: M!+IRNLEM=BXF\N&8(%3>PRTC=!P.I)["J\7B/3)DO&-P8C8X^TK,C(T>1D9!&> M>WK69XT2\@DT?5K:WDNHM.O/-N((AEBA1E+ =R,YQ69XBDDU_29[K1=-E/DR MP3R/);F-[L(^XH 0&8 ?AV% '4VVNV-SWL:YWRW;X8:I +>X\^34)62+R&WD&XW XQG[O.: .A\2:T$\2Z5I#&[6" M;S9+@P1R N%0%0&49(RV3CTJ+P[*^GZWXBLKG4;RYMK-8'C>X+_%!H6#(Q&5W+C('O7-6"7UKX,\+:@EE<3?V5<%KJV$9$@4AUSM(R2-V M<5H^(IH]<\*ZY-IFERJ)K952Z1Q(9&91C)PH)QR.?>L:^\9V4:Z6]EYEQ'J%SY6](68( &+ @#.[Y< M8ZUBW-M+H&I:7/JD5]<60TQ+22:T:0M#*ISDB,Y(;/7V%.N88;9-&OK32Y[. MR35S*P9':1@T;#S&7EAECW]L]: .J77[!KJZM0\OG6D8EF3R'RJGH>G/0]/2 MDA\1:;/I]K?Q2R/;W<@C@80OEV.<<8SC@\UC:]!?PZY8ZGI4;%K^)K&?(/R M_,DC#_9^;\\5%X8TBYT_5IM)>,G3]*E:6TD8YW^:,@?\!RX_X$* -VZ\2:99 M/()YG"Q.(Y91$QCC8XX9@,#J.M27FNV%B\B2R2.8HQ)((HFD\M3G!.T''0UQ M-DMK8+J6CZ[INHSW,EU,\2Q>>T5XKL67[IV#J ^ M$3VSV8F>, 1A3&?+/8CN* .L?Q/HZ26Z"]#MQ@AMKD"$(S"$,5V!FZ D M#IGUJ_X08B\\0*R2KOU1Y4+QLH9"B $9'(R#^5 &KJ&OZ?IL[P3R2-)'%YTB MQ1-(43GYFP#@<'\J9/XFTFW>U1[O+7D1E@"(S>8H&6%&*;6XAT4LNTA9&9@54#O@ G\: *_AZ0^(IIKZ2YU& M&>#4)2F-Z1F)'*",J?E/ Y'7-:5UXC6+Q7#H0BG^>V:1Y%A8\[E"X('3DY/3 MI5?P-+NT^]C:*:)SJ%S(%EC9"5:0E3R!P0:346:S^(-A=R0S&"2PD@$B1,X# M[U(!('''K0!0T'Q):Z/;ZJNJWMS(L6J3QB1E>;RT!4#<0"%'/? KJKO5K6R> M.-VDDDE4LD<,;2,5'4X4'CD<^]<2^9/!GBZ)8)_-N;JZ:)/)?,FX?*5&,G.. MU.N)%LM9T_4[VUOY--N-,CMC):B7=!(K$X94^;!SZ=10!V^FZG::M9B[LIA+ M$25R 001P00>01Z&LO3/$JW^MZI8M#+&EBZH'>)@,[=Q)/0#IBI_#4-M%I\K MV>GM8P2S-(BR;M\F<9=@W().>O/2N=EM9[C4?&&EI',EQJ2*;9_+;81Y 7._ M&!R,=: .BB\4:7-<0P":1&N0S0,\+JLP')VDC!XYJ"+QIHM8&AS65XFFQRZ#J"ZE9LOFB[$WEVQ489U9CM/L!R#STKBHT=/A_X5MVMY_,@O+8RQ MF!]R!6RQ(QD 5KWCA?'5],]I/<0MHNS C;;(=S,4SC&2* .@LM?LK^YCMXO/ M5YHS+%YD#H'08R02.>H_.I]0U2UTQ83011(B%F=L9P /8$_A7+>&X9[ M36;2WL;BYN]*:V-P' ^M %F7Q=H\&ESZE-%/%UC'8:AYEQ?K+"'A=F=3Y6#G M!R?E)]L ,N[&#W[]C79DA1DG '>O-!SNDO["[MDN(!; MN2NR098$#D$#.:[K7+:?4?#U_:VK%)KBUDCC8\88J0/IUH CA\2:9/=06Z7# M!KDD0,T3*DQ')VL1@\>AI)/$VEQ2E'N&""7R3-Y3>4'SC:7QMSGCKUXK!T76 MX=2T[3M/_L:==3LPD;QSVI5;4@;6<.1CIG&#DY K,AC<_#J[\,302C5EWP>4 M8SEW9R5D!QRIR&W=N] '97GB33+&\DM)YV-Q'%YK11Q.[;O:G?\)! MIATJ'5%N@UK/@1,JDLY)P %QDGVQFL6#-OX\B$I=A%I B>78=I<."1GIG'-< M_I\D]I8^']2DMYGM+"_NA=*(FS$)"P20KC.!GKZ&@#:T?63+XK\0^?J%P+*W MMX&59P4\@D-N^4@8[=JG;Q+;:-X;TJ6"\N-46[F2*.Z>-F+@O@L=H],X]>*K MZ;>P'QOKUV!*+>6RMRLQA8(=H;/.,=Q61;?N_AIX==DD"V=Y;M."AW1 2A% '81:C8W?B2*.+4IOM'V,L;+:0-I93O8$9#<@?C4K>)M*CF\MKE@OF^3 MYWEMY6_.-N_&W.>.O7BL:XN4N?']L8)&7S-)E17*$;6+J5SD<' )Q[5D0@R? M#&;PS/ XU9(FMOL^T[FE+':X]03AMW3K0!V-SXDTJTNYK26[S<0('DB1&=P# MP. "3^%7=/U"UU2RCO+.8302C*N._P#A7+6+I!\095G.: .EI,T'..*YZW\1?VCXCU'11#<1):QH/-\IP2[;B3G& , M8)QGF@#H0NI7LTL\TLD1F=7<;C*P4,^, ]!R?2MF.^L# MXENU6^G-S#:J9;=B1%&F3\_(QD^N>U &U25F6?B"RO;F&WB\Y7N(C+"9(642 M(,?,"1_M#WYK3H *,T5R2>(;H>.(X'8+I5TLEK N(\%C^.64?[AH ZZBL MZ^UW3]-N[>TNIRDUSN\I C'=@$GH/0527QCI#13.LLY:W.)81;2>9'QG)3&0 M,'.: -ZBLZ77+!+*VNUG\V.[Q]G$2EVFR,C:!R>.:J2^,-&AMIIYKEH_L\RP M3(T3;XW/0$8XSGKT]Z -2\M3=P&(3S09(.^%@K?G@U1.BON'_$YU(>WFKS_X M[3[37K*\U*73HVD6YB3S-LD3)N3.-RY'(SQD5SOB36XKU-*DL9[M8VU:WB65 M-R13@R889_B'!Z\>F: -\:(^,]&:&UN(YY7MKHJJ7"P/Y:E MC@!FQ@$GC!H M'0V[:MJ7_?\?X4?V&__ $%]2_[_ "__ !-/OM;MK&=H&66: M5(_-=(8RY1/[Q_(^YQP*K#Q9I#O;)#<-.UU 9X1%$S;T&.F!UYZ=: )O[$?/ M.KZD?^VJ_P#Q- T-Q_S%]2_[^K_\36?JGC&W@\,3ZO8QRS%)##L,3 Q29VX< M=1@FN@@F$\(D"N@.>'4J?R- &?\ V(_;5]2'_;9?_B:/[$? ']KZC]?-7_XF MM2LA_$^G)/LWR&(7'V5IPA\M9>FTGZD#/3/>@!_]B/\ ]!C4O^_J_P#Q-4;W MPI-/<)=VVO:C;W2(8Q(2KC:3DC!'J!5NX\3Z?;SW<'[^6:S"F6.*W=V&[..@ MY^Z>>E2OKU@--MK])6DBN]OV<(I+2DC( '7- %.U\--&THW-RB%/.9T M4X)!(P%XZ#\JM'1&/_,6U+_O\/\ XFL7PQ=/<>,O$2>;=M'&+;$=RS9B8JQ( M /3UXXY%=?0!E_V*P_YBVH_]_1_\333HC'IK&I#Z3+_\34&OZ^^DZAI=I';R MR&]G*,R1E@%"EB!COQ_.LFWU9-+\7:\UQ/>3Q+!;ND(5Y63(U &\ M-#?OJ^I'_MLO_P 32C1&'_,6U+_O\/\ XFE_M^P:QM+R.8S1WN!;"-2S2DC/ M ^F?IBGZ9K-KJIG2W9A+;2>7/%(I5XFQG!'T].* (_[$;_H+:E]?.'^%)_8K M?]!?4O\ O\O_ ,36K7'^)+E[7QEHMNVIS6=I>)/]H N-BG:HV]>G)[4 ;?\ M8K9_Y"VH\_\ 38?_ !-+_8C?]!74?^_P_P *HV4UI#J%QXIZ>--&>*TG\V9;>\XBG:%A&2C M$9(..U5(O'&ARO9[9Y1%>MMAF:!A&6)("EB, G'2@#H01TI:Y;2Y9(_'NOQ/ M<2M#':VSJLDA*IG?G /0<5HQ>)M/EDMQNE2*[?9;3O&1',WH#[X.,XSVS0!L M4E9]MK5I=ZG=:=$9/M%H%,JM&0 #TP3US[54_P"$MTGSK>#SI1):OW.L6EM';MN: M9KH9@2%2[2#&<@#MCOTH T*2L7_A+=&\B*4W142W'V8*T;!EE[JPQP?K2KXH ML9;6_E@6XDDL$#RPF!U?!!*D C)!P>: -FBLKPWJ[ZWH5G?O$\;SPH[!HV09 M*@\9ZCGJ*UJ $.**HZS?G3M+EN$4/+PD29^_(QVJ/Q)%9G@O5+J^T9[;49-^ MHZ?,]K='^\ZGAOH5(- '0T5EW7B&PLY;F.1W;[&H>Y:.,L(0>1NQ[/SH VZ*R!XEL7@CDC6XD:2'S_+2!BZ)ZL, M<=#QU..,T]?$6G2VUM/;2M="[4O D"%F=1U..V,\YQB@#4HK$_X2_1OL]O,; MH@7$_P!G0&)@1+T*D8X(P>M-3Q?IVF6VH1S&2&[P( B$M(3T 7KG@_3%5)/&.D6]K=7%S-);FS<)/%) M$V^,GID#/!['I0!NT5E0^(K&>_FL4\\7$49E"- R^:H."4R/FYXXJ+POKY\0 M:@S0 N10"#7!:IXCGUKP M7XAN8C=6,] >IK74Y&: "BHKNX%I M:R7!CDD$:EBD:[F;'8#UK#T3Q7#J'AVVU6Z22 S[0%,+#W% '0T M5B/XMTN&"\EN))8#8 &XBDA;S$!&0<#.01W'%,;QEHZ/LDFF3]['$K- X5V? M[N#C!'O0!I:K9W5]9-#9W\EA*2")XT#$8.<8/'/2G:;8)IMH($9G)8N\C_>= MBDR,XK*@\2:9<:.VK"Y@F=[6:UB$TL=PNPK&?X_3'!HM_$=E/>0VKK-;R7*E[<3Q%!, ,G; M^'.#@^U &O25@2^--'ACN9=\[QVDICG:.W=A&0 23QP!DN]9M(! BF2>6 MZ4M#' NYG7'+#L ,CDGO0!H;A2]J\_TG4[1/#'B*74KZ_6S74YXQ,#(9D7"X M /)&/RK>O?$C6.OZ5I,=K6%D^U+,6$<1VG&T'IP,G%36_B:PN)K>,F:);O\ X]I98RJ3]_E)]1R M<9[4 :]+6!-XST:!+MS-,RVCZ9NNEM[J21IS!')F15C)"AE' M/."<>E '4@@TM4=)L/[.M# +JYN%+ET-PVYD4GA(M,OGNH89W$EJH>57A=&"G.& (&1P>10!J]:6L+2]6TZV\/VD\6H7-[;S. M4@FE5GEF8EN, 9/0]N@K2L-1MM2CE>V9SY4ABD#QLA5@ 2"& /<4 6Z*** " MBBB@ HHHH **** "BBB@ HHHH **** "H;7_ (]U_'^=35#:_P"I'U/\Z )J M*** "BBB@ HHHH **** "BBB@ HHHH **** "N3N6ETKX@'4;J)S87=@L"3J MI98I%'3O%NH;72#42YMX]ARW[K;N _VCTKH/"\ MBOX9TY1N!CMHT=64@JP4 @@]ZU>** "N1LY#I_Q UQKF*98[NW@>*01L48*K M!OF P,5U])@4 >;*&3X56]MY9 M7A8&',++AACCYB!S183JGB7Q7,RR"-XXMC>686 MT%S:>'O".H2V-W=6VG0-!?6\:-YD6Y0-VWJ<$=NQJYK9M9_#][/INC36Z7$] MMM!Z487IQ0!QNK"2]\7[+8R)YVBS0)-L8*LC.I M4%L<' )_"LIKJ9_"6A::=-O5O=-O;7[3 ELYV"-QN8'&""!G@]Z]' '4"C ] M* .6TN<1^,O$%Q)',L,D-ML:].R*.* .'OV73O%UY>7^E75[I^I0P^3-!"TAC=004*CD YS^= M+:0^1XJT)DTMK"&*TN088XCLAWLI120,!B 2??-=OBC H \\N8)I_#'BN&*W MG+RZF;B-?)8%TS&E% :\W MU W5U97)FL[Y;B'5XW-O% RQ)&LP^<8&')')/)^E>D<&C H Y6QF*^+];N9( M9TBDM( C-"V&*A]P'')&16!IR7=EIGA'4FM+DP:<)8KR 0MOC+K@/MQDX/IZ MUZ3P* !VH Y709))O&FN70MKE;6ZBMC#))"R*VU6SUQZBNKI,#TI: .8\6HZ MZIX?O?)FDAM;XM+Y49!1B@#S#3[.[LO#?A>\ETNYNH=/\Z.[MEC;S$#GAPIY.,=O6NR\/):// M=7-GH[6$4VS]Y+%YE "UQWB-E_X3C0;AX)9+>U2 MX\YDMVD5-R@+G /6NQI,"@#GDOK%;J?[!93 30L]Q+]F>-1M&%ZJ,L<]!V%< MTD>E>F M7$;RV[QQN(W92 Q7./PJAX>T4:!H\6FK<-<1PYV.Z@-@DGG'N: .=EM)[WQ5 MXEMXDF07FEQ6\4QC8(7 D!^;&.-ZU T=QJ_A#2-%%I/;ZC;S6ZS*8R/(\MAN M;/3&%./7(KO,48]J .3\5VM[9ZOI^JZ25%U2_N=0N;H>87@@E(V6Y(P=N! MGIGKTR:U<#TH X:VDVV_C3=#,//G=HOW3?O 853Y>.?F!'%456:S7PSJUQ87 M%U8Q:;]CNDB1C);N=AW%1SC*X->CX'I1@>E '!:G]G,6GS6>E2VL+ZU#,?W+ M!Y% ^:5AU SQD]JLR>9)XWUP1)*5GTF.-#Y9VM(-_ .,9PP_.NTP/2C ]* , M+P7.)/"FF0&&:*2VM8H9%EB9,.J ,.0,X(Z]*WJ2EH YK4L:SXCM].\VX@CL M5^T&1$QNE/RJ 2"#@;C^59B^9X:\?@K]KN;35K5*IPK,5& "O'X" MNWP/2@C@X'- 'GE]=0VVO^)+5%O(H+Y8TGD2S>6QLTFA+F%\Q?($ ?CY3D=\5N1^&KJUN+A['7;VWAN)6E>'9&X5FZ ME2RDC\ZM.T/6K.O?9KWPMJT^E:#<6_VJ&)$D:W99KA@X.-O7: .I]Z]&P/2 MC ]* .6NIUD\>Z5<(DIB^PRH7$3;59BI4$XP"<'K5;0-770?#5R+NSO7DM+N M82)%;,3\TS$8X^;@@\9XKLL5!=VBWEN]O(6$;\.$."1W&: )+>>.ZMX[B([H MY4#J?4$9%/--BC6*)8T4*B !5'0 =J?0!YK(D\'@[Q=ICVMS]IDNKEXE$+$. M'(*;3C!S[5L7T_F:[X4=(Y2L0D:1A$V(\Q;1GCCGCFNQP*,#TH \XTE([.QN MM"U?P]<]*]%B&V-5P!@ 8'04[%% #)P6@=1U M*D"O.(+:\;P1H!&FW,[Z-<*;NT\IE=P RMMSC<1N!XKTJC ]* //]5^QWWAK M6[C2]"GMS('J>*T/$KK+X?T3RXIW5;VUD95B8LJHP+ M$@#(P*[# ]*,#TH Y:*95^(ES-LD$1TQ$$GEML+!V8C.,9P16)ID%O-X2L[. M_AO[5DO[AUN(4=9+5B\C(_3H0<>G/->B8HP/2@#"\)MJ!L;A=0?SBMTXAN#% MY9GCXPY'KVSWQ6]28'I2T >?^)1=7<_B.T:SN\M9@6J6\3!;CY#EF<=2"<;2 M?P-6["5CXKT:9K:Y2)-(:)G>%@$

  •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

    XML 55 R20.htm IDEA: XBRL DOCUMENT v3.20.1
    Business combination (Tables)
    3 Months Ended
    Apr. 30, 2020
    Business Combinations [Abstract]  
    Preliminary Allocation of Consideration
    The following table summarizes the Company's current allocation of the consideration paid in the Acquisition:
    (in millions)Initial AllocationAdjustmentsUpdated Allocation
    Cash and cash equivalents$406.8  $(14.5) $392.3  
    Other current assets56.5  1.0  57.5  
    Property, plant, and equipment26.6  —  26.6  
    Operating lease right-of-use assets42.5  —  42.5  
    Intangible assets715.3  —  715.3  
    Goodwill1,330.5  (2.5) 1,328.0  
    Other assets5.9  —  5.9  
    Client-held funds obligation(237.5) 17.8  (219.7) 
    Other current liabilities(69.1) (2.9) (72.0) 
    Other long-term liabilities(26.7) —  (26.7) 
    Deferred tax liability(128.7) 1.1  (127.6) 
    Total consideration paid$2,122.1  $—  $2,122.1  
    XML 56 R41.htm IDEA: XBRL DOCUMENT v3.20.1
    Indebtedness Schedule of Maturities of Long-term Debt (Details) - USD ($)
    $ in Millions
    Apr. 30, 2020
    Jan. 31, 2020
    Debt Disclosure [Abstract]    
    Remaining 2021   $ 31.3
    2022   62.5
    2023   70.3
    2024   101.6
    2025   968.7
    Total principal payments $ 1,234.4 $ 1,234.4
    XML 57 R45.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation (Narrative) (Details)
    $ / shares in Units, $ in Millions
    1 Months Ended 3 Months Ended
    Mar. 31, 2019
    shares
    Mar. 31, 2018
    shares
    Mar. 31, 2017
    shares
    Apr. 30, 2020
    USD ($)
    numberOfMember
    $ / shares
    shares
    Apr. 30, 2019
    USD ($)
    $ / shares
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Weighted average fair value at date of grant (usd per share) | $ / shares       $ 23.68 $ 25.97
    Expected dividend yield       0.00% 0.00%
    Restricted stock units          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Aggregate intrinsic value | $       $ 2.1 $ 9.2
    Weighted-average vesting period of non-vested awards expected to vest       3 years 1 month 6 days  
    Award vesting period       4 years  
    Weighted-average grant date fair value (usd per share) | $ / shares       $ 56.27 $ 73.02
    Performance units awards (in shares) | shares       1,085,000  
    Aggregate intrinsic value | $       $ 16.4 $ 7.7
    Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future | $       $ 109.1  
    Stock options          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Expiration period       10 years  
    Forfeited period       90 days  
    Weighted-average vesting period of non-vested awards expected to vest       1 year 3 months 18 days  
    Unrecognized stock compensation expense to be recognized in future | $       $ 6.1  
    Performance restricted stock units          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Performance units awards (in shares) | shares 129,963   146,964 257,680  
    Award vesting rights percentage     118.10% 100.00%  
    Fraction of awards fully achieved       33.33%  
    Fraction of awards modified       66.67%  
    Number of team members modification affected | numberOfMember       12  
    Incremental compensation cost | $       $ 6.6  
    Share-based payment arrangement, decrease in expense due to modification of terms | $       2.9  
    Grant date fair value | $       $ 19.0  
    Performance restricted stock units | Minimum          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Award vesting rights percentage     0.00%    
    Performance restricted stock units | Maximum          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Award vesting rights percentage     150.00%    
    Performance restricted stock awards          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Performance units awards (in shares) | shares   227,760      
    Award vesting rights percentage       100.00%  
    Fraction of awards fully achieved       66.67%  
    Fraction of awards modified       33.33%  
    Number of team members modification affected | numberOfMember       10  
    Performance restricted stock awards | Minimum          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Award vesting rights percentage 0.00% 0.00%   0.00%  
    Performance restricted stock awards | Maximum          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Award vesting rights percentage 200.00% 200.00%   200.00%  
    Restricted stock awards          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Weighted-average vesting period of non-vested awards expected to vest       10 months 24 days  
    Award vesting period       4 years  
    Weighted-average grant date fair value (usd per share) | $ / shares       $ 74.81  
    Performance units awards (in shares) | shares       14,000  
    Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future | $       $ 2.4  
    Restricted stock units | Wage Works Inc.          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Number of service-based common stock (in shares) | shares       523,318  
    Incentive Plan          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Number of shares authorized (in shares) | shares       2,600,000  
    Percentage of capital stock       3.00%  
    Shares available for grant under incentive plan | shares       6,500,000  
    WageWorks Incentive Plan          
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
    Number of common stock issuable (in shares) | shares       5,255,027  
    XML 58 R25.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation (Tables)
    3 Months Ended
    Apr. 30, 2020
    Share-based Payment Arrangement [Abstract]  
    Summary of share based compensation recognized
    The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:
    Three months ended April 30,
    (in thousands)20202019
    Cost of revenue$1,463  $860  
    Sales and marketing958  1,007  
    Technology and development2,917  1,499  
    General and administrative2,058  2,662  
    Total stock-based compensation expense$7,396  $6,028  
    Summary of stock-based compensation expense by award type
    The following table shows stock-based compensation by award type:
    Three months ended April 30,
    (in thousands)20202019
    Stock options$1,449  $1,783  
    Performance stock options—  —  
    Restricted stock units6,509  2,926  
    Performance restricted stock units(1,979) 651  
    Restricted stock awards872  163  
    Performance restricted stock awards545  505  
    Total stock-based compensation expense$7,396  $6,028  
    Summary of assumptions The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented are as follows:
    Three months ended April 30,
    20202019
    Expected dividend yield—%—%
    Expected stock price volatility37.97%
    35.98% - 36.53%
    Risk-free interest rate1.39%
    2.21% - 2.43%
    Expected life of options5.18 years
    4.95 - 5.09 years
    Summary of stock option activity
    A summary of stock option activity is as follows:
    Outstanding stock options
    (in thousands, except for exercise prices and term)Number of
    options
    Range of
    exercise
    prices
    Weighted-
    average
    exercise
    price
    Weighted-
    average
    contractual
    term
    (in years)
    Aggregate
    intrinsic
    value
    Outstanding as of January 31, 20202,040  
    $0.10 - 82.39
    $30.35  5.90$74,009  
    Granted16  $66.06  $66.06  
    Exercised(51) 
    $0.10 - 44.53
    $22.07  
    Forfeited(4) 
    $25.45 - 44.53
    $32.61  
    Outstanding as of April 30, 20202,001  
    $0.10 - 82.39
    $30.85  5.72$54,009  
    Vested and expected to vest as of April 30, 20202,001  $30.85  5.72$54,009  
    Exercisable as of April 30, 20201,632  $25.71  5.29$50,730  
    Summary of restricted stock unit activity
    A summary of the RSU and RSA activity is as follows:
    RSUs and PRSUsRSAs and PRSAs
    (in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
    Outstanding as of January 31, 20201,380  $63.33  235  $61.91  
    Granted1,085  56.27  14  74.81  
    Vested(296) 51.38  (10) 62.80  
    Forfeited(167) 71.72  (14) 63.31  
    Outstanding as of April 30, 20202,002  $60.57  225  $62.58  
    XML 59 R21.htm IDEA: XBRL DOCUMENT v3.20.1
    Supplemental financial statement information (Tables)
    3 Months Ended
    Apr. 30, 2020
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Property and equipment
    Property and equipment consisted of the following as of April 30, 2020 and January 31, 2020:
    (in thousands)April 30, 2020January 31, 2020
    Leasehold improvements$22,084  $19,240  
    Furniture and fixtures9,097  7,929  
    Computer equipment24,123  22,074  
    Property and equipment, gross55,304  49,243  
    Accumulated depreciation(19,483) (15,757) 
    Property and equipment, net$35,821  $33,486  
    Other income (expense), net
    Other income (expense), net, consisted of the following:
    Three months ended April 30,
    (in thousands)20202019
    Interest income$600  $1,343  
    Gain on equity securities—  23,511  
    Acquisition costs(94) (1,184) 
    Other expense(1,270) (7) 
    Total other income (expense), net$(764) $23,663  
    XML 60 R29.htm IDEA: XBRL DOCUMENT v3.20.1
    Supplemental financial statement information (Property and equipment) (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Jan. 31, 2020
    Property, Plant and Equipment [Line Items]      
    Property and equipment, gross $ 55,304   $ 49,243
    Accumulated depreciation (19,483)   (15,757)
    Property and equipment, net 35,821   33,486
    Depreciation expense 3,900 $ 900  
    Leasehold improvements      
    Property, Plant and Equipment [Line Items]      
    Property and equipment, gross 22,084   19,240
    Furniture and fixtures      
    Property, Plant and Equipment [Line Items]      
    Property and equipment, gross 9,097   7,929
    Computer equipment      
    Property, Plant and Equipment [Line Items]      
    Property and equipment, gross $ 24,123   $ 22,074
    XML 61 R48.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation (Restricted stock unity activity) (Details) - $ / shares
    shares in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Restricted stock units    
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
    Unvested, beginning balance (in shares) 1,380  
    Granted (in shares) 1,085  
    Vested (in shares) (296)  
    Forfeited (in shares) (167)  
    Unvested, ending balance (in shares) 2,002  
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
    Unvested, beginning balance (usd per share) $ 63.33  
    Granted (usd per share) 56.27 $ 73.02
    Vested (usd per share) 51.38  
    Forfeited (usd per share) 71.72  
    Unvested, ending balance (usd per share) $ 60.57  
    Restricted stock awards    
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
    Unvested, beginning balance (in shares) 235  
    Granted (in shares) 14  
    Vested (in shares) (10)  
    Forfeited (in shares) (14)  
    Unvested, ending balance (in shares) 225  
    Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
    Unvested, beginning balance (usd per share) $ 61.91  
    Granted (usd per share) 74.81  
    Vested (usd per share) 62.80  
    Forfeited (usd per share) 63.31  
    Unvested, ending balance (usd per share) $ 62.58  
    XML 62 R40.htm IDEA: XBRL DOCUMENT v3.20.1
    Indebtedness (Narrative) (Details) - USD ($)
    3 Months Ended
    Aug. 30, 2019
    Apr. 30, 2020
    Debt Instrument [Line Items]    
    Unamortized loan issuance costs   $ 20,300,000
    Stated interest rate percentage   2.15%
    Effective interest rate percentage   2.59%
    Acquisition threshold for maximum total net leverage ratio   $ 100,000,000
    Minimum interest coverage ratio   300.00%
    Debt covenant, beginning April 30, 2020    
    Debt Instrument [Line Items]    
    Maximum leverage ratio   525.00%
    Debt covenant, beginning July 31, 2020    
    Debt Instrument [Line Items]    
    Maximum leverage ratio   500.00%
    Debt covenant, beginning July 31, 2021    
    Debt Instrument [Line Items]    
    Maximum leverage ratio   450.00%
    Debt covenant, acquisition holiday provision    
    Debt Instrument [Line Items]    
    Maximum leverage ratio   500.00%
    London Interbank Offered Rate (LIBOR) | Minimum    
    Debt Instrument [Line Items]    
    Variable rate borrowing spread   1.25%
    London Interbank Offered Rate (LIBOR) | Maximum    
    Debt Instrument [Line Items]    
    Variable rate borrowing spread   2.25%
    Customary Base Rate | Minimum    
    Debt Instrument [Line Items]    
    Variable rate borrowing spread   0.25%
    Customary Base Rate | Maximum    
    Debt Instrument [Line Items]    
    Variable rate borrowing spread   1.25%
    Secured Revolving Credit Facility | Minimum    
    Debt Instrument [Line Items]    
    Commitment fee percentage   0.20%
    Secured Revolving Credit Facility | Maximum    
    Debt Instrument [Line Items]    
    Commitment fee percentage   0.40%
    Credit Agreement | Secured Debt | Term Loan Facility    
    Debt Instrument [Line Items]    
    Credit facility, amount $ 1,250,000,000  
    Credit Agreement | Secured Debt | Line of Credit    
    Debt Instrument [Line Items]    
    Facility term 5 years  
    Credit Agreement | Line of Credit | Secured Revolving Credit Facility    
    Debt Instrument [Line Items]    
    Facility term 5 years  
    Credit facility, amount $ 350,000,000  
    Long-term line of credit $ 0  
    Other assets    
    Debt Instrument [Line Items]    
    Unamortized loan issuance costs   $ 6,000,000.0
    XML 63 R44.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation (Stock-based compensation expense by award type) (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense $ 7,396 $ 6,028
    Stock options    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 1,449 1,783
    Performance stock options    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 0 0
    Restricted stock units    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 6,509 2,926
    Performance restricted stock units    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense (1,979) 651
    Restricted stock awards    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 872 163
    Performance restricted stock awards    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense $ 545 $ 505
    XML 64 hqy-20200430_htm.xml IDEA: XBRL DOCUMENT 0001428336 2020-02-01 2020-04-30 0001428336 2020-05-28 0001428336 2020-04-30 0001428336 2020-01-31 0001428336 us-gaap:ServiceMember 2020-02-01 2020-04-30 0001428336 us-gaap:ServiceMember 2019-02-01 2019-04-30 0001428336 us-gaap:FinancialServiceOtherMember 2020-02-01 2020-04-30 0001428336 us-gaap:FinancialServiceOtherMember 2019-02-01 2019-04-30 0001428336 us-gaap:CreditAndDebitCardMember 2020-02-01 2020-04-30 0001428336 us-gaap:CreditAndDebitCardMember 2019-02-01 2019-04-30 0001428336 2019-02-01 2019-04-30 0001428336 2019-01-31 0001428336 us-gaap:CommonStockMember 2020-01-31 0001428336 us-gaap:CommonStockMember 2019-01-31 0001428336 us-gaap:CommonStockMember 2020-04-30 0001428336 us-gaap:CommonStockMember 2019-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2020-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2019-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0001428336 us-gaap:RetainedEarningsMember 2020-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2020-02-01 2020-04-30 0001428336 us-gaap:RetainedEarningsMember 2019-02-01 2019-04-30 0001428336 us-gaap:RetainedEarningsMember 2020-04-30 0001428336 us-gaap:RetainedEarningsMember 2019-04-30 0001428336 2019-04-30 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-02-01 2020-04-30 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-02-01 2019-04-30 0001428336 hqy:WageWorksIncMember 2019-08-30 0001428336 hqy:WageWorksIncMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksIncMember hqy:TermLoanFacilityMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksIncMember 2019-08-30 2020-04-30 0001428336 hqy:WageWorksIncMember 2020-04-30 0001428336 us-gaap:LeaseholdImprovementsMember 2020-04-30 0001428336 us-gaap:LeaseholdImprovementsMember 2020-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2020-04-30 0001428336 us-gaap:FurnitureAndFixturesMember 2020-01-31 0001428336 us-gaap:ComputerEquipmentMember 2020-04-30 0001428336 us-gaap:ComputerEquipmentMember 2020-01-31 0001428336 srt:MinimumMember 2020-02-01 2020-04-30 0001428336 srt:MaximumMember 2020-02-01 2020-04-30 0001428336 srt:MinimumMember 2020-04-30 0001428336 srt:MaximumMember 2020-04-30 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-04-30 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2020-04-30 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2020-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2020-04-30 0001428336 us-gaap:CustomerRelationshipsMember 2020-01-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2020-04-30 0001428336 us-gaap:DevelopedTechnologyRightsMember 2020-01-31 0001428336 us-gaap:TradeNamesMember 2020-04-30 0001428336 us-gaap:TradeNamesMember 2020-01-31 0001428336 us-gaap:InProcessResearchAndDevelopmentMember 2020-04-30 0001428336 us-gaap:InProcessResearchAndDevelopmentMember 2020-01-31 0001428336 2018-09-06 2018-09-06 0001428336 2018-06-22 2018-06-22 0001428336 us-gaap:OtherAssetsMember 2020-04-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2019-08-30 2019-08-30 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-01 2020-04-30 0001428336 srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-01 2020-04-30 0001428336 srt:MinimumMember us-gaap:BaseRateMember 2020-02-01 2020-04-30 0001428336 srt:MaximumMember us-gaap:BaseRateMember 2020-02-01 2020-04-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2020-02-01 2020-04-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2020-02-01 2020-04-30 0001428336 hqy:DebtCovenantPeriodOneMember 2020-04-30 0001428336 hqy:DebtCovenantPeriodTwoMember 2020-04-30 0001428336 hqy:DebtCovenantPeriodThreeMember 2020-04-30 0001428336 hqy:DebtCovenantPeriodFourMember 2020-04-30 0001428336 us-gaap:CostOfSalesMember 2020-02-01 2020-04-30 0001428336 us-gaap:CostOfSalesMember 2019-02-01 2019-04-30 0001428336 hqy:SalesandMarketingMember 2020-02-01 2020-04-30 0001428336 hqy:SalesandMarketingMember 2019-02-01 2019-04-30 0001428336 hqy:TechnologyandDevelopmentMember 2020-02-01 2020-04-30 0001428336 hqy:TechnologyandDevelopmentMember 2019-02-01 2019-04-30 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2020-02-01 2020-04-30 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-02-01 2019-04-30 0001428336 us-gaap:EmployeeStockOptionMember 2020-02-01 2020-04-30 0001428336 us-gaap:EmployeeStockOptionMember 2019-02-01 2019-04-30 0001428336 us-gaap:PerformanceSharesMember 2020-02-01 2020-04-30 0001428336 us-gaap:PerformanceSharesMember 2019-02-01 2019-04-30 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2020-04-30 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-02-01 2019-04-30 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2020-02-01 2020-04-30 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-02-01 2019-04-30 0001428336 us-gaap:RestrictedStockMember 2020-02-01 2020-04-30 0001428336 us-gaap:RestrictedStockMember 2019-02-01 2019-04-30 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2020-02-01 2020-04-30 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-02-01 2019-04-30 0001428336 hqy:IncentivePlanMember 2020-04-30 0001428336 hqy:WageWorksIncMember us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2020-04-30 0001428336 hqy:WageWorksIncentivePlanMember 2020-04-30 0001428336 srt:MinimumMember 2019-02-01 2019-04-30 0001428336 srt:MaximumMember 2019-02-01 2019-04-30 0001428336 2019-02-01 2020-01-31 0001428336 us-gaap:EmployeeStockOptionMember 2020-04-30 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockAwardsMember 2019-03-01 2019-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockAwardsMember 2019-03-01 2019-03-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2020-04-30 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockAwardsMember 2020-02-01 2020-04-30 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockAwardsMember 2020-02-01 2020-04-30 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2020-01-31 0001428336 us-gaap:RestrictedStockMember 2020-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2020-04-30 0001428336 us-gaap:RestrictedStockMember 2020-04-30 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-04-30 shares iso4217:USD iso4217:USD shares pure hqy:lawsuit utr:Rate hqy:numberOfMember 0001428336 --01-31 2021 Q1 false P5Y P5Y P4Y P4Y 0.6667 0.3333 0.3333 0.3333 0.6667 0.6667 10-Q true 2020-04-30 false 001-36568 HEALTHEQUITY, INC. DE 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper, UT 84020 801 727-1000 Common stock, par value $0.0001 per share HQY NASDAQ Yes Yes Large Accelerated Filer false false false 71399355 171093000 191726000 1681000 1216000 69789000 70863000 42901000 34711000 283783000 297300000 35821000 33486000 97554000 83178000 777483000 783279000 1332631000 1332631000 38000 18000 35169000 35089000 2562479000 2564981000 7338000 3980000 27197000 50121000 39985000 46372000 46875000 39063000 13210000 12401000 134605000 151937000 1167192000 1181615000 81982000 68017000 3783000 2625000 134267000 130492000 1387224000 1382749000 1521829000 1534686000 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 0.0001 0.0001 900000000 900000000 71398000 71398000 71051000 71051000 7000 7000 827303000 818774000 213340000 211514000 1040650000 1030295000 2562479000 2564981000 111271000 26808000 46899000 41952000 31841000 18292000 190011000 87052000 71013000 20649000 5045000 4123000 5879000 4527000 81937000 29299000 108074000 57753000 11455000 8970000 31078000 10905000 18998000 8709000 18702000 1491000 12770000 0 93003000 30075000 15071000 27678000 12263000 63000 -764000 23663000 -13027000 23600000 2044000 51278000 218000 9456000 1826000 1826000 41822000 41822000 0.03 0.67 0.03 0.65 70980000 62326000 72292000 63901000 1030295000 477079000 7000 6000 7000 6000 818774000 305223000 1133000 4370000 7396000 6028000 827303000 315621000 211514000 171850000 1826000 41822000 213340000 213672000 1040650000 529299000 1826000 41822000 27507000 4773000 7396000 6028000 1201000 15000 0 23511000 -1494000 -12000 3786000 7542000 -552000 1354000 8360000 1694000 -3104000 -635000 3632000 -1577000 -22924000 -8480000 -2270000 1769000 -3045000 -627000 1127000 -17000 15026000 25336000 0 53845000 7511000 1126000 11775000 5497000 6008000 1262000 -25294000 -61730000 7812000 0 3776000 0 1223000 4229000 -10365000 4229000 -20633000 -32165000 191726000 361475000 171093000 329310000 10749000 50000 733000 -51000 0 141000 968000 21000 1537000 158000 Summary of business and significant accounting policies <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Business</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. HealthEquity, Inc. is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Principles of consolidation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the accounts of HealthEquity, Inc., and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of presentation </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements as of April 30, 2020 and for the three months ended April 30, 2020 and 2019 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2020. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Significant accounting policies </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2020.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recently adopted accounting pronouncements</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020 using the modified retrospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Principles of consolidation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the accounts of HealthEquity, Inc., and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div> Basis of presentation The accompanying condensed consolidated financial statements as of April 30, 2020 and for the three months ended April 30, 2020 and 2019 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2020. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. Certain reclassifications have been made to prior year amounts to conform to the current year presentation. <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recently adopted accounting pronouncements</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020 using the modified retrospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div> Net income per share<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted net income per share: </span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator (basic and diluted):</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,826 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,822 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,326 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator (diluted):</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,326 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,312 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,575 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,292 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,901 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income per share:</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.67 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended April 30, 2020 and 2019, approximately 0.5 million and 0.2 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.</span></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted net income per share: </span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator (basic and diluted):</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,826 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,822 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,326 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator (diluted):</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,980 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62,326 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,312 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,575 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,292 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63,901 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income per share:</span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.67 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.03 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.65 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1826000 41822000 70980000 62326000 70980000 62326000 1312000 1575000 72292000 63901000 0.03 0.67 0.03 0.65 500000 200000 Business combination<div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Acquisition of WageWorks</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 30, 2019, the Company closed the acquisition (the "Acquisition") of WageWorks, Inc. ("WageWorks") for $51.35 per share in cash, or approximately $2.0 billion to WageWorks stockholders. The Company financed the transaction through a combination of $816.9 million cash on hand plus net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.5 million, under a term loan facility (see Note 8—Indebtedness).</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the Acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to potential adjustment during the measurement period (up to one year from the Acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company's current allocation of the consideration paid in the Acquisition:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.198%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.548%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Initial Allocation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Updated Allocation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">406.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">392.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant, and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">715.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">715.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,330.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,328.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Client-held funds obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(237.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(219.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(128.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(127.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1pt solid #000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,122.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,122.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div>Adjustments to the initial allocation are based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters. 51.35 2000000000.0 816900000 1220000000 30500000 <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company's current allocation of the consideration paid in the Acquisition:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.198%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.548%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Initial Allocation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Updated Allocation</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">406.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">392.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant, and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">715.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">715.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,330.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,328.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Client-held funds obligation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(237.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(219.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(69.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(72.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(128.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(127.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1pt solid #000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,122.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,122.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 406800000 -14500000 392300000 56500000 1000000.0 57500000 26600000 26600000 42500000 42500000 715300000 715300000 1330500000 -2500000 1328000000.0 5900000 5900000 237500000 -17800000 219700000 69100000 2900000 72000000.0 26700000 26700000 128700000 -1100000 127600000 2122100000 0 2122100000 Supplemental financial statement information<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income components consist of the following:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Property and equipment</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment consisted of the following as of April 30, 2020 and January 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,240 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,097 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,929 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,123 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,074 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,304 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,243 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,483)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,757)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,821 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,486 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense for the three months ended April 30, 2020 and 2019 was $3.9 million and $0.9 million, respectively.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contract balances</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. The Company's deferred revenue increased from $3.7 million as of January 31, 2020 to $4.1 million as of April 30, 2020. The balances are related to cash received in advance for an interchange revenue arrangement, other up-front fees and other commuter deferred revenue, and are generally recognized within twelve months, with the exception of the interchange arrangement, which is recognized over a term of approximately ten years. Revenue recognized during the three months ended April 30, 2020 that was included in the beginning balance of deferred revenue was $0.2 million. The Company expects to satisfy its remaining obligations for these arrangements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other income (expense), net</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense), net, consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">600 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,343 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,511 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(94)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,184)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,270)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(764)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment consisted of the following as of April 30, 2020 and January 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,240 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,097 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,929 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,123 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,074 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,304 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,243 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,483)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,757)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,821 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,486 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 22084000 19240000 9097000 7929000 24123000 22074000 55304000 49243000 19483000 15757000 35821000 33486000 3900000 900000 3700000 4100000 P12M P10Y 200000 <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense), net, consisted of the following:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">600 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,343 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,511 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(94)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,184)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,270)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(764)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,663 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 600000 1343000 0 23511000 94000 1184000 1270000 7000 -764000 23663000 LeasesThe Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of less than 1 year to approximately 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.<div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization and interest expense related to finance leases were not material during the three months ended April 30, 2020 and 2019.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of operating lease costs are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except for term and percentages)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,308 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,074 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sublease income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(450)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,858 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,074 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average lease term and discount rate are as follows:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of April 30, 2020</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average remaining lease term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.47 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of operating lease liabilities as of April 30, 2020 were as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiscal year ending January 31, (in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining 2021</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,177 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,517 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,348 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,318 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,429 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,068 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,876)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,192 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,210 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,982 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,192 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April 30, 2020, the Company had an additional operating lease for office space that had not yet commenced with aggregate undiscounted lease payments of $63.1 million. This operating lease will commence in fiscal year 2021 with a lease term of approximately 11 years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information related to the Company's operating leases was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except for term and percentages)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,297 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">977 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ROU assets obtained in exchange for new operating lease obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,480 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> P1Y P11Y P3Y P10Y <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of operating lease costs are as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except for term and percentages)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,308 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,074 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sublease income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(450)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,858 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,074 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted average lease term and discount rate are as follows:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of April 30, 2020</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average remaining lease term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.47 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average discount rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information related to the Company's operating leases was as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except for term and percentages)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,297 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">977 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ROU assets obtained in exchange for new operating lease obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,480 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 4308000 1074000 450000 0 3858000 1074000 P9Y5M19D 0.0435 <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of operating lease liabilities as of April 30, 2020 were as follows:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiscal year ending January 31, (in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining 2021</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,177 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,517 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,348 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,318 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,429 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,068 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,876)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,192 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,210 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,982 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,192 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 9177000 14517000 12348000 10318000 10279000 60429000 117068000 21876000 95192000 13210000 81982000 95192000 63100000 P11Y 3297000 977000 17480000 199000 Intangible assets and goodwill<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intangible assets</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of April 30, 2020 and January 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software and software development costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,949 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,221 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired HSA portfolios</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,778 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,770 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired developed technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,925 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,925 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired trade names</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortizable intangible assets, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">899,333 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">879,597 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,442)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(98,851)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total amortizable intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">776,891 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">780,746 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in process software development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">592 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,533 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangible assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">777,483 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">783,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended April 30, 2020 and 2019, the Company expensed a total of $10.3 million and $3.9 million, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization expense for the three months ended April 30, 2020 and 2019 was $23.6 million and $3.9 million, respectively.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no changes to the goodwill carrying value during the three months ended April 30, 2020 and 2019.</span></div> <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of April 30, 2020 and January 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software and software development costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,949 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,221 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired HSA portfolios</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,778 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,770 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired developed technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,925 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,925 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired trade names</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortizable intangible assets, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">899,333 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">879,597 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,442)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(98,851)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total amortizable intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">776,891 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">780,746 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in process software development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">592 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,533 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangible assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">777,483 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">783,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of April 30, 2020 and January 31, 2020:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Software and software development costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,949 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,221 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired HSA portfolios</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,778 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,770 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired customer relationships</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">601,381 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired developed technology</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,925 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,925 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired trade names</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,300 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortizable intangible assets, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">899,333 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">879,597 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(122,442)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(98,851)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total amortizable intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">776,891 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">780,746 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in process software development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">592 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,533 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangible assets, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">777,483 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">783,279 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 89949000 76221000 98778000 92770000 601381000 601381000 96925000 96925000 12300000 12300000 899333000 879597000 122442000 98851000 776891000 780746000 592000 2533000 777483000 783279000 10300000 3900000 23600000 3900000 0 0 Commitments and contingencies<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commitments</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the indebtedness described in Note 8 below, the Company’s principal commitments consist of operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments. These commitments as of January 31, 2020 are disclosed in the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the fiscal year ended January 31, 2020, and did not change materially during the three months ended April 30, 2020.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contingencies</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Legal matters</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">WageWorks is pursuing affirmative claims against the Office of Personnel Management ("OPM") to obtain payment for services provided by WageWorks between March 1, 2016 and August 31, 2016 pursuant to its contract with OPM. In connection with WageWorks' claims against OPM, OPM has also claimed that an erroneous statement in a certificate signed by a former executive officer constituted a violation of the False Claims Act and moved to dismiss part of WageWorks' claim against OPM as a result. As with all legal proceedings, no assurance can be provided as to the outcome of these matters or if WageWorks or OPM will be successful.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs </span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks, its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleges claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages and fees and costs. </span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">WageWorks voluntarily contacted the San Francisco office of the SEC Division of Enforcement regarding the restatement of WageWorks' financial statements and related independent investigation. WageWorks is providing information and documents to the SEC and continues to cooperate with the SEC’s investigation into these matters. The U.S. Attorney’s Office for the Northern District of California also opened an investigation. WageWorks has provided documents and information to the U.S. Attorney’s Office and continues to cooperate with any inquiries by the U.S. Attorney’s Office regarding the matter.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Beginning on July 30, 2019, putative class action suits were filed in the U.S. District Court Courts for the Southern District of New York, the District of Delaware, and the Northern District of California asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks and the former members of its board of directors. The complaints generally allege disclosure violations in the proxy statement issued by WageWorks in connection with the stockholder vote on the proposed merger with the Company. After WageWorks issued certain supplemental disclosures, these actions were voluntarily dismissed, but WageWorks may still be required to pay attorneys fees to the plaintiffs' lawyers.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense of its former directors and officers in the legal proceedings described above. </span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. While it is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, the Company believes, based on current knowledge, that such litigation, proceedings and claims will not have a material impact on the Company’s financial position, results of operations and cash flows for the period. </span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains liability insurance coverage that is intended to cover the legal matters described above; however, it is possible that claims may be denied by our insurance carriers or could exceed the amount of our applicable insurance coverage, we may be required by our insurance carriers to contribute to the payment of claims, and our insurance coverage may not continue to be available to us on acceptable terms or in sufficient amounts.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.</span></div> 2 2 Indebtedness<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April 30, 2020, long-term debt consisted of the following:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term loan facility</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized loan issuance costs (1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of issuance costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,214.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1) In addition to the $20.3 million of unamortized issuance costs related to the term loan facility, $6.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the April 30, 2020 condensed consolidated balance sheet. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the closing of the Acquisition, on August 30, 2019, the Company entered into a credit facility (the "Credit Agreement”) that provided for:</span></div><div style="text-indent:-27pt;padding-left:45pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i)       a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwZDNhY2JkZWZmOTQ2MjA4OTIxMGQ1ZDNmMzNjZjNhL3NlYzo5MGQzYWNiZGVmZjk0NjIwODkyMTBkNWQzZjMzY2YzYV81OC9mcmFnOmY1MzFiOWJlNTg5MjQzNzc4M2YwMDU2MmMyODhmNGI0L3RleHRyZWdpb246ZjUzMWI5YmU1ODkyNDM3NzgzZjAwNTYyYzI4OGY0YjRfNDM5ODA0NjUyNDk3OQ_8ca6da05-b97d-4d11-ba2c-72061de937d4">five</span>-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion, the proceeds of which were used to finance the Acquisition, to refinance substantially all outstanding indebtedness of HealthEquity and WageWorks and to pay related fees and expenses; and</span></div><div style="text-indent:-27pt;padding-left:45pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii)      a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwZDNhY2JkZWZmOTQ2MjA4OTIxMGQ1ZDNmMzNjZjNhL3NlYzo5MGQzYWNiZGVmZjk0NjIwODkyMTBkNWQzZjMzY2YzYV81OC9mcmFnOmY1MzFiOWJlNTg5MjQzNzc4M2YwMDU2MmMyODhmNGI0L3RleHRyZWdpb246ZjUzMWI5YmU1ODkyNDM3NzgzZjAwNTYyYzI4OGY0YjRfNDM5ODA0NjUyNDk4MA_d34815a5-b601-44f0-8555-8a56dc407412">five</span>-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of April 30, 2020. </span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of April 30, 2020, the stated interest rate was 2.15% and the effective interest rate was 2.59%. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loans made under the Term Loan Facility are required to be repaid as described in the following table:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiscal year ending January 31, (in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal payments</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining 2021</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">968.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1pt solid #000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total principal payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.25 to 1.00, which steps down to (x) 5.00 to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) 4.50 to 1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of April 30, 2020, and for the period then ended.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of HealthEquity and the guarantors, in each case, subject to certain customary exceptions.</span></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April 30, 2020, long-term debt consisted of the following:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term loan facility</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized loan issuance costs (1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of issuance costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,214.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1234400000 20300000 1214100000 20300000 6000000.0 1250000000 350000000 0 0.0125 0.0225 0.0025 0.0125 0.0215 0.0259 0.0020 0.0040 <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loans made under the Term Loan Facility are required to be repaid as described in the following table:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:80.456%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.544%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fiscal year ending January 31, (in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal payments</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining 2021</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">968.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1pt solid #000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total principal payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 31300000 62500000 70300000 101600000 968700000 1234400000 5.25 5.00 4.50 5.00 100000000 3.00 Income taxes<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows FASB Accounting Standards Codification 740-270, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes - Interim Reporting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three months ended April 30, 2020, the Company recorded income tax expense of $0.2 million. This resulted in an effective income tax expense rate of 10.7% for the three months ended April 30, 2020, compared with an effective income tax expense rate of 18.4% for the three months ended April 30, 2019. For the three months ended April 30, 2020 and 2019, the net impact of discrete tax items caused a 16.8 and 4.5 percentage point benefit, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes relative to pre-tax book income. Due to significantly lower pre-tax book income during the three months ended April 30, 2020, such excess tax benefit had a greater impact on the effective income tax rate.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April 30, 2020 and January 31, 2020, the Company’s total gross unrecognized tax benefit was $9.6 million and $9.4 million, respectively. As of April 30, 2020 and January 31, 2020, a net unrecognized tax benefit of $0.5 million was recorded in the condensed consolidated balance sheets. If recognized, $8.8 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of April 30, 2020.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2000.</span></div> 200000 0.107 0.184 -0.168 -0.045 9600000 9400000 500000 500000 8800000 Stock-based compensation<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,463 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">958 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,007 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technology and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,917 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,499 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,058 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,662 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,396 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,028 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows stock-based compensation by award type: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,449 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,783 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,926 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,979)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">651 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">872 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance restricted stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">545 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">505 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,396 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,028 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock award plans</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Incentive Plan. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of April 30, 2020, 6.5 million shares were available for grant under the Incentive Plan.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">WageWorks Incentive Plan. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the closing of the Acquisition, and in accordance with the merger agreement related to the Acquisition, certain RSUs with respect to WageWorks common stock, granted under WageWorks, Inc. 2010 Equity Incentive Plan (the "WageWorks Incentive Plan"), were replaced by the Company and converted into RSUs with respect to 523,318 shares of common stock of the Company. No additional shares were issued under the WageWorks Incentive Plan, and the period during which the remaining 5,255,027 shares were available to be utilized expired on May 26, 2020.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock options</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation assumptions.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average fair value of options granted during the three months ended April 30, 2020 and 2019 was $23.68 and $25.97 per share, respectively. The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented are as follows:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">—%</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">—%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.97%</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">35.98% - 36.53%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.39%</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">2.21% - 2.43%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.18 years</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">4.95 - 5.09 years</span></div></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company estimates the expected life of an option using historical option exercise and termination data. Expected volatility is determined using the weighted average volatility of the Company's historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term of the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of stock option activity is as follows:</span></div><div style="margin-top:3pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:36.450%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.846%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding stock options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of January 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,040 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$0.10 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.90</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,009 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$66.06 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.06 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$0.10 - 44.53</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.07 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$25.45 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$0.10 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.85 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.72</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,009 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.85 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.72</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,009 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,632 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.71 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.29</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,730 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options. The total intrinsic value of options exercised during the three months ended April 30, 2020 and 2019 was $2.1 million and $9.2 million, respectively.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April 30, 2020, the weighted-average vesting period of non-vested options expected to vest was approximately 1.3 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately $6.1 million.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Restricted stock units and restricted stock awards</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company grants RSUs and RSAs to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwZDNhY2JkZWZmOTQ2MjA4OTIxMGQ1ZDNmMzNjZjNhL3NlYzo5MGQzYWNiZGVmZjk0NjIwODkyMTBkNWQzZjMzY2YzYV82Ny9mcmFnOmI1NzYzZGMwNmE1OTRhMGZhZGJmODc5ODY5ZTY4ZDQ3L3RleHRyZWdpb246YjU3NjNkYzA2YTU5NGEwZmFkYmY4Nzk4NjllNjhkNDdfNDM5ODA0NjU1NjM4Mw_2a3b019f-ae3d-405e-95e5-86223064309d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwZDNhY2JkZWZmOTQ2MjA4OTIxMGQ1ZDNmMzNjZjNhL3NlYzo5MGQzYWNiZGVmZjk0NjIwODkyMTBkNWQzZjMzY2YzYV82Ny9mcmFnOmI1NzYzZGMwNmE1OTRhMGZhZGJmODc5ODY5ZTY4ZDQ3L3RleHRyZWdpb246YjU3NjNkYzA2YTU5NGEwZmFkYmY4Nzk4NjllNjhkNDdfNDM5ODA0NjU1NjM4Mw_f683317b-f196-4878-a2e5-8cd653dcf979">four</span></span>-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate. The weighted-average fair value of RSUs granted during the three months ended April 30, 2020 and 2019 was $56.27 and $73.02 per share, respectively.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Performance restricted stock units and awards.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In March 2017, the Company awarded 146,964 performance-based RSUs ("PRSUs"). The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred during the three months ended April 30, 2020 following approval by the Compensation Committee of the board of directors, based on the level of achievement of the performance goal as measured on January 31, 2020. The performance conditions allowed for a range of vesting from 0% to 150%. The PRSUs vested at 118.1%.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2018, the Company awarded 227,760 performance-based RSAs ("PRSAs"). The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. The underlying shares were issued at 200% of the target level of achievement at the grant date. During the three months ended April 30, 2020, the Compensation Committee modified the awards by deeming the performance condition related to two-thirds of the awards to be achieved at 100% and creating a new performance condition related to the remaining one-third of the awards to reflect the state of the Company after the Acquisition of WageWorks. The new performance condition is based on the achievement of certain financial criteria measured on January 31, 2021. The modification affected 10 team members and did not result in an adjustment to stock-based compensation expense. The PRSAs cliff vest upon approval by the Compensation Committee. The modified performance condition for the one-third tranche allows for a range of vesting from 0% to 200% based on the level of achievement of the performance condition, and the Company believes it is probable that the PRSAs will vest at least in part. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company awarded 129,963 PRSUs. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. During the three months ended April 30, 2020, the Compensation Committee modified the awards by deeming the performance condition related to one-third of the awards to be achieved at 100% and creating new performance conditions related to the remaining two-thirds of the awards to reflect the state of the Company after the Acquisition of WageWorks. The new performance conditions are based on the achievement of certain financial criteria measured on January 31, 2021 and 2022. The modification affected 12 team members and will result in incremental stock-based compensation expense of $6.6 million, which will be recognized over the remaining service period, adjusted for the level of achievement of the performance conditions and any forfeitures. Prior to the modification, the Company did not believe the PRSUs were likely to vest, and as a result, $2.9 million of previously recorded stock-based compensation expense was reversed during the three months ended April 30, 2020. The PRSUs cliff vest upon approval by the Compensation Committee. The modified performance conditions for the two-thirds tranche allow for a range of vesting from 0% to 200% based on the level of achievement of the new performance conditions, and the Company believes it is probable that the PRSUs will vest at least in part.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended April 30, 2020, the Company awarded 257,680 PRSUs subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2023. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was approximately $19.0 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the RSU and RSA activity is as follows: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.163%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.525%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs and PRSUs</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSAs and PRSAs</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of January 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.91 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,085 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.27 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.81 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(296)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62.80 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.72 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.31 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.57 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62.58 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended April 30, 2020 and 2019, the aggregate intrinsic value of RSUs and RSAs vested was $16.4 million and $7.7 million, respectively.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total unrecorded stock-based compensation expense as of April 30, 2020 associated with RSUs and PRSUs was $109.1 million, which is expected to be recognized over a weighted-average period of 3.1 years. Total unrecorded stock-based compensation expense as of April 30, 2020 associated with RSAs and PRSAs was $2.4 million, which is expected to be recognized over a weighted-average period of 0.9 years.</span></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,463 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">958 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,007 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Technology and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,917 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,499 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,058 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,662 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,396 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,028 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1463000 860000 958000 1007000 2917000 1499000 2058000 2662000 7396000 6028000 <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows stock-based compensation by award type: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,449 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,783 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,509 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,926 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,979)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">651 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">872 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">163 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance restricted stock awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">545 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">505 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,396 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,028 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1449000 1783000 0 0 6509000 2926000 -1979000 651000 872000 163000 545000 505000 7396000 6028000 2600000 0.03 6500000 523318 5255027 P10Y P90D 23.68 25.97 The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented are as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.327%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.546%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended April 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">—%</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">—%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.97%</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">35.98% - 36.53%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.39%</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">2.21% - 2.43%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life of options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.18 years</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">4.95 - 5.09 years</span></div></td></tr></table> 0 0 0.3797 0.3598 0.3653 0.0139 0.0221 0.0243 P5Y2M4D P4Y11M12D P5Y1M2D 0 <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of stock option activity is as follows:</span></div><div style="margin-top:3pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:36.450%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.842%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.846%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding stock options</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of January 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,040 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$0.10 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.90</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74,009 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$66.06 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.06 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$0.10 - 44.53</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.07 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$25.45 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.61 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">$0.10 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.85 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.72</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,009 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,001 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.85 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.72</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,009 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,632 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.71 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.29</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,730 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 2040000 0.10 82.39 30.35 P5Y10M24D 74009000 16000 66.06 66.06 51000 0.10 44.53 22.07 4000 25.45 44.53 32.61 2001000 0.10 82.39 30.85 P5Y8M19D 54009000 2001000 30.85 P5Y8M19D 54009000 1632000 25.71 P5Y3M14D 50730000 2100000 9200000 P1Y3M18D 6100000 56.27 73.02 146964 0 1.50 1.181 227760 2 1 10 0 2 129963 1 12 6600000 2900000 0 2 257680 19000000.0 0 2 <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the RSU and RSA activity is as follows: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:30.163%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.525%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs and PRSUs</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:2pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSAs and PRSAs</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of January 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,380 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.33 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61.91 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,085 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.27 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.81 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(296)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62.80 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.72 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63.31 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding as of April 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.57 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">225 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62.58 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1380000 63.33 235000 61.91 1085000 56.27 14000 74.81 296000 51.38 10000 62.80 167000 71.72 14000 63.31 2002000 60.57 225000 62.58 16400000 7700000 109100000 P3Y1M6D 2400000 P0Y10M24D <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Fair value</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </span><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of April 30, 2020 due to the short-term nature of these instruments. </span></div><div style="margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.</span></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div><div style="margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of April 30, 2020 due to the short-term nature of these instruments. </span></div><div style="margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.</span></div> XML 65 R2.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed consolidated balance sheets - USD ($)
    $ in Thousands
    Apr. 30, 2020
    Jan. 31, 2020
    Current assets    
    Cash and cash equivalents $ 171,093 $ 191,726
    Accounts receivable, net of allowance for doubtful accounts of $1,681 and $1,216 as of April 30, 2020 and January 31, 2020, respectively 69,789 70,863
    Other current assets 42,901 34,711
    Total current assets 283,783 297,300
    Property and equipment, net 35,821 33,486
    Operating lease right-of-use assets 97,554 83,178
    Intangible assets, net 777,483 783,279
    Goodwill 1,332,631 1,332,631
    Deferred tax asset 38 18
    Other assets 35,169 35,089
    Total assets 2,562,479 2,564,981
    Current liabilities    
    Accounts payable 7,338 3,980
    Accrued compensation 27,197 50,121
    Accrued liabilities 39,985 46,372
    Current portion of long-term debt 46,875 39,063
    Operating lease liabilities 13,210 12,401
    Total current liabilities 134,605 151,937
    Long-term debt, net of issuance costs 1,167,192 1,181,615
    Operating lease liabilities, non-current 81,982 68,017
    Other long-term liabilities 3,783 2,625
    Deferred tax liability 134,267 130,492
    Total long-term liabilities 1,387,224 1,382,749
    Total liabilities 1,521,829 1,534,686
    Commitments and contingencies (see Note 7)
    Stockholders’ equity    
    Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively 0 0
    Common stock, $0.0001 par value, 900,000 shares authorized, 71,398 and 71,051 shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively 7 7
    Additional paid-in capital 827,303 818,774
    Accumulated earnings 213,340 211,514
    Total stockholders’ equity 1,040,650 1,030,295
    Total liabilities and stockholders’ equity $ 2,562,479 $ 2,564,981
    XML 66 R6.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed consolidated statements of cash flows (unaudited) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Cash flows from operating activities:    
    Net income $ 1,826 $ 41,822
    Adjustments to reconcile net income to net cash provided by operating activities:    
    Depreciation and amortization 27,507 4,773
    Stock-based compensation 7,396 6,028
    Amortization of debt issuance costs 1,201 15
    Gains on marketable equity securities 0 (23,511)
    Other non-cash items 1,494 12
    Deferred taxes 3,786 7,542
    Changes in operating assets and liabilities:    
    Accounts receivable 552 (1,354)
    Other assets (8,360) (1,694)
    Operating lease right-of-use assets 3,104 635
    Accounts payable 3,632 (1,577)
    Accrued compensation (22,924) (8,480)
    Accrued liabilities and other current liabilities (2,270) 1,769
    Operating lease liabilities, non-current (3,045) (627)
    Other long-term liabilities 1,127 (17)
    Net cash provided by operating activities 15,026 25,336
    Cash flows from investing activities:    
    Purchases of marketable securities 0 (53,845)
    Purchases of property and equipment (7,511) (1,126)
    Purchases of software and capitalized software development costs (11,775) (5,497)
    Acquisition of intangible member assets (6,008) (1,262)
    Net cash used in investing activities (25,294) (61,730)
    Cash flows from financing activities:    
    Principal payments on long-term debt (7,812) 0
    Settlement of client-held funds obligation (3,776) 0
    Proceeds from exercise of common stock options 1,223 4,229
    Net cash provided by (used in) financing activities (10,365) 4,229
    Decrease in cash and cash equivalents (20,633) (32,165)
    Beginning cash and cash equivalents 191,726 361,475
    Ending cash and cash equivalents 171,093 329,310
    Supplemental cash flow data:    
    Interest expense paid in cash 10,749 50
    Income taxes paid in cash, net of refunds received 733 (51)
    Supplemental disclosures of non-cash investing and financing activities:    
    Exercise of common stock options receivable 0 141
    Purchases of property and equipment included in accounts payable or accrued liabilities at period end 968 21
    Computer software intangible asset    
    Supplemental disclosures of non-cash investing and financing activities:    
    Purchases of intangible assets $ 1,537 $ 158
    XML 67 R38.htm IDEA: XBRL DOCUMENT v3.20.1
    Commitments and contingencies (Details) - lawsuit
    Sep. 06, 2018
    Jun. 22, 2018
    Commitments and Contingencies Disclosure [Abstract]    
    Number of derivative lawsuits 2 2
    XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 119 368 1 false 45 0 false 7 false false R1.htm 0001001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed consolidated balance sheets Sheet http://healthequity.com/role/Condensedconsolidatedbalancesheets Condensed consolidated balance sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed consolidated balance sheets (Parenthetical) Sheet http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical Condensed consolidated balance sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited Condensed consolidated statements of operations and comprehensive income (unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited Condensed consolidated statements of stockholders' equity (unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed consolidated statements of cash flows (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited Condensed consolidated statements of cash flows (unaudited) Statements 6 false false R7.htm 2101101 - Disclosure - Summary of business and significant accounting policies Sheet http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies Summary of business and significant accounting policies Notes 7 false false R8.htm 2103102 - Disclosure - Net income per share Sheet http://healthequity.com/role/Netincomepershare Net income per share Notes 8 false false R9.htm 2106103 - Disclosure - Business combination Sheet http://healthequity.com/role/Businesscombination Business combination Notes 9 false false R10.htm 2110104 - Disclosure - Supplemental financial statement information Sheet http://healthequity.com/role/Supplementalfinancialstatementinformation Supplemental financial statement information Notes 10 false false R11.htm 2115105 - Disclosure - Leases Sheet http://healthequity.com/role/Leases Leases Notes 11 false false R12.htm 2121106 - Disclosure - Intangible assets and goodwill Sheet http://healthequity.com/role/Intangibleassetsandgoodwill Intangible assets and goodwill Notes 12 false false R13.htm 2125107 - Disclosure - Commitments and contingencies Sheet http://healthequity.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 13 false false R14.htm 2127108 - Disclosure - Indebtedness Sheet http://healthequity.com/role/Indebtedness Indebtedness Notes 14 false false R15.htm 2132109 - Disclosure - Income taxes Sheet http://healthequity.com/role/Incometaxes Income taxes Notes 15 false false R16.htm 2134110 - Disclosure - Stock-based compensation Sheet http://healthequity.com/role/Stockbasedcompensation Stock-based compensation Notes 16 false false R17.htm 2142111 - Disclosure - Fair value Sheet http://healthequity.com/role/Fairvalue Fair value Notes 17 false false R18.htm 2202201 - Disclosure - Summary of business and significant accounting policies (Policies) Sheet http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies Summary of business and significant accounting policies (Policies) Policies 18 false false R19.htm 2304301 - Disclosure - Net income per share (Tables) Sheet http://healthequity.com/role/NetincomepershareTables Net income per share (Tables) Tables http://healthequity.com/role/Netincomepershare 19 false false R20.htm 2307302 - Disclosure - Business combination (Tables) Sheet http://healthequity.com/role/BusinesscombinationTables Business combination (Tables) Tables http://healthequity.com/role/Businesscombination 20 false false R21.htm 2311303 - Disclosure - Supplemental financial statement information (Tables) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationTables Supplemental financial statement information (Tables) Tables http://healthequity.com/role/Supplementalfinancialstatementinformation 21 false false R22.htm 2316304 - Disclosure - Leases (Tables) Sheet http://healthequity.com/role/LeasesTables Leases (Tables) Tables http://healthequity.com/role/Leases 22 false false R23.htm 2322305 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillTables Intangible assets and goodwill (Tables) Tables http://healthequity.com/role/Intangibleassetsandgoodwill 23 false false R24.htm 2328306 - Disclosure - Indebtedness (Tables) Sheet http://healthequity.com/role/IndebtednessTables Indebtedness (Tables) Tables http://healthequity.com/role/Indebtedness 24 false false R25.htm 2335307 - Disclosure - Stock-based compensation (Tables) Sheet http://healthequity.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://healthequity.com/role/Stockbasedcompensation 25 false false R26.htm 2405401 - Disclosure - Net income per share (Details) Sheet http://healthequity.com/role/NetincomepershareDetails Net income per share (Details) Details http://healthequity.com/role/NetincomepershareTables 26 false false R27.htm 2408402 - Disclosure - Business combination (Narrative) (Details) Sheet http://healthequity.com/role/BusinesscombinationNarrativeDetails Business combination (Narrative) (Details) Details http://healthequity.com/role/BusinesscombinationTables 27 false false R28.htm 2409403 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) Sheet http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails Business combination (Preliminary Allocation of Consideration) (Details) Details http://healthequity.com/role/BusinesscombinationTables 28 false false R29.htm 2412404 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails Supplemental financial statement information (Property and equipment) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 29 false false R30.htm 2413405 - Disclosure - Supplemental financial statement information (Contract balances) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationContractbalancesDetails Supplemental financial statement information (Contract balances) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 30 false false R31.htm 2414406 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails Supplemental financial statement information (Other income (expense), net) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 31 false false R32.htm 2417407 - Disclosure - Leases (Narrative) (Details) Sheet http://healthequity.com/role/LeasesNarrativeDetails Leases (Narrative) (Details) Details http://healthequity.com/role/LeasesTables 32 false false R33.htm 2418408 - Disclosure - Leases (Lease Cost) (Details) Sheet http://healthequity.com/role/LeasesLeaseCostDetails Leases (Lease Cost) (Details) Details http://healthequity.com/role/LeasesTables 33 false false R34.htm 2419409 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) Sheet http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails Leases (Maturities of Operating Lease Liabilities) (Details) Details http://healthequity.com/role/LeasesTables 34 false false R35.htm 2420410 - Disclosure - Leases (Supplemental Cash Flow Information) (Details) Sheet http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails Leases (Supplemental Cash Flow Information) (Details) Details http://healthequity.com/role/LeasesTables 35 false false R36.htm 2423411 - Disclosure - Intangible assets and goodwill (Narrative) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails Intangible assets and goodwill (Narrative) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 36 false false R37.htm 2424412 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails Intangible assets and goodwill (Schedule of intangible assets) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 37 false false R38.htm 2426413 - Disclosure - Commitments and contingencies (Details) Sheet http://healthequity.com/role/CommitmentsandcontingenciesDetails Commitments and contingencies (Details) Details http://healthequity.com/role/Commitmentsandcontingencies 38 false false R39.htm 2429414 - Disclosure - Indebtedness Schedule of Long-term Debt (Details) Sheet http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails Indebtedness Schedule of Long-term Debt (Details) Details 39 false false R40.htm 2430415 - Disclosure - Indebtedness (Narrative) (Details) Sheet http://healthequity.com/role/IndebtednessNarrativeDetails Indebtedness (Narrative) (Details) Details http://healthequity.com/role/IndebtednessTables 40 false false R41.htm 2431416 - Disclosure - Indebtedness Schedule of Maturities of Long-term Debt (Details) Sheet http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails Indebtedness Schedule of Maturities of Long-term Debt (Details) Details 41 false false R42.htm 2433417 - Disclosure - Income taxes (Details) Sheet http://healthequity.com/role/IncometaxesDetails Income taxes (Details) Details http://healthequity.com/role/Incometaxes 42 false false R43.htm 2436418 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) Sheet http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails Stock-based compensation (Summary of share based compensation recognized) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 43 false false R44.htm 2437419 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details) Sheet http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails Stock-based compensation (Stock-based compensation expense by award type) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 44 false false R45.htm 2438420 - Disclosure - Stock-based compensation (Narrative) (Details) Sheet http://healthequity.com/role/StockbasedcompensationNarrativeDetails Stock-based compensation (Narrative) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 45 false false R46.htm 2439421 - Disclosure - Stock-based compensation (Assumptions) (Details) Sheet http://healthequity.com/role/StockbasedcompensationAssumptionsDetails Stock-based compensation (Assumptions) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 46 false false R47.htm 2440422 - Disclosure - Stock-based compensation (Stock option activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails Stock-based compensation (Stock option activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 47 false false R48.htm 2441423 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails Stock-based compensation (Restricted stock unity activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 48 false false All Reports Book All Reports hqy-20200430.htm amendmentno1tokesslereea.htm exhibit311-ceo302xfy21.htm exhibit312-cfo302xfy21.htm exhibit321-ceo906xfy21.htm exhibit322-cfo906xfy21.htm hqy-20200430.xsd hqy-20200430_cal.xml hqy-20200430_def.xml hqy-20200430_lab.xml hqy-20200430_pre.xml hqyadreiertransitionse.htm http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 69 R30.htm IDEA: XBRL DOCUMENT v3.20.1
    Supplemental financial statement information (Contract balances) (Details) - USD ($)
    $ in Millions
    3 Months Ended
    Apr. 30, 2020
    Jan. 31, 2020
    Organization, Consolidation and Presentation of Financial Statements [Abstract]    
    Remaining performance obligation $ 4.1 $ 3.7
    Deferred revenue recognition term 12 months  
    Deferred revenue interchange arrangement recognition term 10 years  
    Revenue recognition $ 0.2  
    XML 70 R34.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases (Maturities of Operating Lease Liabilities) (Details) - USD ($)
    $ in Thousands
    Apr. 30, 2020
    Jan. 31, 2020
    Leases [Abstract]    
    Remaining 2021 $ 9,177  
    2022 14,517  
    2023 12,348  
    2024 10,318  
    2025 10,279  
    Thereafter 60,429  
    Total lease payments 117,068  
    Less imputed interest (21,876)  
    Current 13,210 $ 12,401
    Non-current 81,982 $ 68,017
    Total lease liabilities $ 95,192  
    XML 71 R17.htm IDEA: XBRL DOCUMENT v3.20.1
    Fair value
    3 Months Ended
    Apr. 30, 2020
    Fair Value Disclosures [Abstract]  
    Fair value Fair value
    Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
    Level 1—quoted prices in active markets for identical assets or liabilities;
    Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
    Level 3—unobservable inputs based on the Company’s own assumptions.
    Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of April 30, 2020 due to the short-term nature of these instruments. 
    Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.
    XML 72 R13.htm IDEA: XBRL DOCUMENT v3.20.1
    Commitments and contingencies
    3 Months Ended
    Apr. 30, 2020
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and contingencies Commitments and contingencies
    Commitments
    In addition to the indebtedness described in Note 8 below, the Company’s principal commitments consist of operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments. These commitments as of January 31, 2020 are disclosed in the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the fiscal year ended January 31, 2020, and did not change materially during the three months ended April 30, 2020.
    Contingencies
    In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
    Legal matters
    WageWorks is pursuing affirmative claims against the Office of Personnel Management ("OPM") to obtain payment for services provided by WageWorks between March 1, 2016 and August 31, 2016 pursuant to its contract with OPM. In connection with WageWorks' claims against OPM, OPM has also claimed that an erroneous statement in a certificate signed by a former executive officer constituted a violation of the False Claims Act and moved to dismiss part of WageWorks' claim against OPM as a result. As with all legal proceedings, no assurance can be provided as to the outcome of these matters or if WageWorks or OPM will be successful.
    On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs
    asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks, its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleges claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering.
    On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages and fees and costs.
    Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint.
    WageWorks voluntarily contacted the San Francisco office of the SEC Division of Enforcement regarding the restatement of WageWorks' financial statements and related independent investigation. WageWorks is providing information and documents to the SEC and continues to cooperate with the SEC’s investigation into these matters. The U.S. Attorney’s Office for the Northern District of California also opened an investigation. WageWorks has provided documents and information to the U.S. Attorney’s Office and continues to cooperate with any inquiries by the U.S. Attorney’s Office regarding the matter.
    Beginning on July 30, 2019, putative class action suits were filed in the U.S. District Court Courts for the Southern District of New York, the District of Delaware, and the Northern District of California asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks and the former members of its board of directors. The complaints generally allege disclosure violations in the proxy statement issued by WageWorks in connection with the stockholder vote on the proposed merger with the Company. After WageWorks issued certain supplemental disclosures, these actions were voluntarily dismissed, but WageWorks may still be required to pay attorneys fees to the plaintiffs' lawyers.
    WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense of its former directors and officers in the legal proceedings described above.
    The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. While it is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, the Company believes, based on current knowledge, that such litigation, proceedings and claims will not have a material impact on the Company’s financial position, results of operations and cash flows for the period.
    The Company maintains liability insurance coverage that is intended to cover the legal matters described above; however, it is possible that claims may be denied by our insurance carriers or could exceed the amount of our applicable insurance coverage, we may be required by our insurance carriers to contribute to the payment of claims, and our insurance coverage may not continue to be available to us on acceptable terms or in sufficient amounts.
    As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.

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htm IDEA: XBRL DOCUMENT v3.20.1
    Indebtedness (Tables)
    3 Months Ended
    Apr. 30, 2020
    Debt Disclosure [Abstract]  
    Schedule of Long-term Debt
    As of April 30, 2020, long-term debt consisted of the following:
    (in millions)April 30, 2020
    Term loan facility$1,234.4  
    Less: unamortized loan issuance costs (1)20.3  
    Long-term debt, net of issuance costs$1,214.1  
    Schedule of Maturities of Long-term Debt
    The loans made under the Term Loan Facility are required to be repaid as described in the following table:
    Fiscal year ending January 31, (in millions)Principal payments
    Remaining 2021$31.3  
    202262.5  
    202370.3  
    2024101.6  
    2025968.7  
    Total principal payments$1,234.4  

  • .]%]\1+"_M;2[>U;3983,ULZ*K%U(SN M ]#798HQ0 5S_C6UOI]%AFT^%KB:RO(;KR%/,RHV2O\ 7\*Z"B@#B-;DN?%O MA^_32])G@D>V&9+J$PO(RL&$0SR1P<]NE3:B3XFET#[)'/!)9W:W-P7B9# J MJ5 SSC'3M7H&!Z48'I0!YT\5W)X2\7V_P#9 M]XKW=[/);J8&S(&"XVCKV-:VH-)%XE\-ZG]FN9+<6TT+%(6)1F"XR,9'0]:Z M_%&!0!P,VFW>J7OC:UMXYHFU"&-+>1XV57(C*G#$8Z\58N!)X@TC0K&.UGMK MNUNX)+A7C*FV\O[W/3G&!CKFNVP*,#TH X++&S\<#RIO])D;R?W+?O!Y*H-O M'/S CBDEBBN(=+E2ZO-)U"WTV,17B1L48]&BD4C!P0#@\\\5WV*,#TH S/#D MEW+X>L7OK=;>Y:$&2)%VA3].WTK4I*6@#@;6*6R\,:]H%Y!)+?3S7)A C)%R M)22C ].^#Z8JQ>J^F:QX.@N/,D-G'(D\JHS!28@H)('&6KM<#T%&!Z4 .1D M4V49B<#J5-.I: /,8YMWP\T&R>"X6XM+VV69&@<%=DF6[= !G/2NB-W$GQ$E MG.[RO[*5#)L.W<)"V,XQG!S75X'I10!YYIL-K<> ](M;[[;:.ER^VXA5EDM9 M 7*N>.!CCD8^:NB\(2ZB]O?)J$B7/EW&V*\6+RSH^[D<<5T.!Z48H M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&U_U _WC_.IJAM?]3_P) MOYT 34444 %%%% !1110 4444 %%%% !1110 4444 %5M0O8M.T^>\F.(X$+ MM[X'2K-M+.XE@ M(FFD@C\V988B_EKV)Q]#QUKB#'0>,C(H Z)O%^C![9$N6F:[A, MT BB9_,4=<8')]NM2Q>)=-FTB34Q(Z01R&)E>-E<2 [=FTC.[) Q[USUM#]E M\3>'O+TJ6RMX;:X!BCA9DAWD;58@8!/?WS67-::AY5[>V]E=.+7Q']N: P.# M-",#*@@;O48]* -VQU$'QSJ$CF\CACTZ.1H90YV$NV2%YZ@#I5U?'&B&WM;G MSI1:W3!8[@P.(@2< ,V,*?K6?!>--XVN]12SO?LCZ4J"1K5U!8.QQ@C.<'TK M&,,X^%FF6!L;S[2EQ!O@^RR%UVS!F)&,XQSF@#M;'Q'8:AJ#V$1F2=8_-"S0 MM'O3.-R[@,C/<5&_BK3(W3>\BPR3_9UN#&?*,F<;=WU&,],\5E:B7G^(6ES1 MPW7D_P!G3QM*+=]B,Y4J"<8!X/Y5CZ%;+:Z9#H.H^'KFYU*UE"AGCI]_2B\\1-#XJLM)2 MVF:.:V>9I%C)!P5 P?09.?PKGI4F;PYXSA6TNS)=7,K0)]EDS*&C505XYY!J M_P"9)%XD\/7IM;HP_P!GR0,5MW)1SLP&&,KT/7TH ZC4+^#3+-[NY8B-"!P, MDDG '=R6B89!P00>?NG\JV?%20RZ%+#'/$=C')?:I:R6(CLI9;5O/+D,#' M]T%@.#DCO0!U.D^([!Y+'3-T_G30 PR/$P2;:HSM8\-ZU(OBK3I9TC'G&*2Y M-JEQY?[MIXTO4A=6^LI+/%';,(HD$C?<4<-D8)89.2,O$MJ\]PT7EVQ4 M-.YV;E?.WG*\CM3_ (>22R^$+=Y99)7\Z<;Y'+,0)6 R3[5'I,SQ^-=?N9+6 M[CAFAMO+=K9]KE%;< <5)IBR31-&0&D9AP0.Q M% &K?:U;V-Q]G,V&IV\48>UB,C0O'NX8#L=V.SGLGMFB@C,AMCOW*2JYZCKC@&@#9D\6:5%I-QJ;R2+#:2&.X4Q-OB<<8 M9<<=1[5+!XCL;C4VTY5G6X\HRH'B*B5 <$H3PW6N/UK3+LZ/XKOH+.Y)U:2, M6UND+L[[ H+%0,C//7'05M7TK3^-= NX[6[,*V\X=_LT@6,N%VACCCH>M !I MGC6%M N=8U.&>VMXKB1<^22%4.5 )&>>.3TK27Q18/Y@"W 99A"BM RF9B,C M8#]X8YSTX-E+10 FT48%+10 FT>E&*6B@!" :,"EHH 3 HP*6B@!-HHP*6B@!,"C I: M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AM M?]3_ ,";^=35!:_ZD_[S?SH GHHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBN>NO'/A^SN9;>6[D,D+E'V6TK@,.HRJD<4 M =#15>QO8=1LH;RV8M#.@>-BI7*GH<'FK% !1110 4444 %%%4[G5+2TO[6Q MGF5)[S<(4/\ %M&3^E %RBD!S4-Y=+9VDEPZ2.L:EBL:[F./04 3T53TG4HM M7TJVU&!66*YC$B!Q@X/3-7* "BBB@ HHK,U?7+;1A;?:(YF^TSI AC0D!F.! MD]!UH TZ*0'-(S;5)Y./09H =16;I&MV^LBZ-NDR?99S!()4V'< #T].:TJ M"BBB@ HHHH **C>6-)$C9U#OG:I/)QUQ4E !116/=>)K"SU8:5*MRUXT1E6* M.W=]R9QD;0>,T ;%%4++5[:_N);>)9TEA56=)H'C.&S@CE7Z "BBB@ MHHIDDB11L[L%51DDG % #Z*ISZBL&H6UDT,S-<*["1(\HFT _,W;.>*MT +1 M110 4444 %%9FI:[:Z5>6-K<),7OIA#$5C)7<03R>@Z&M(=* %HHHH ***2@ M!:*RH-?M;CQ#-HBQSK<0P^87%O',H($BA@#[C- $E%%% !114-U * M)J*SAK"?:+*$VMT#>!BC&(X0 9^<_P .>V:GL[^"],JQDB2!]DB,,,A]Q[CD M'O0!:HIDLB0Q-)(ZHB#+,QP /4UFW.OVMKK-EI3QS&:^W>4XC/E_*I8_-TZ# MM0!JT44E "T4R*1)4#HRNIZ%3D&LW4/$-CIE_;V5SY_GW.[R5CMW??@9.-H/ M04 :M%9UIK5K>7GV1$N(Y]GF!)[=X\J#@D;@,\D?G6C0 4444 %%%1S31P1M M+*ZQQH,LS' ]: )**I7.HK;7MI:F">0W3,%DC3*)@9^8]L]JN#I0 M%%(3B M@!:*RXM>MYO$,FB"*87$<'GLS)A"N<<$]>:U* "BBB@ HHHH **** "BBB@ MHK,U/7;;2KNRMKA)B]],(8BD9*[CZGH.AJ^)D,IB#KYB@,5SR +?1ETRS41R:C,+9 G& Y)=OJ%W'ZUOUGS:9]HUFUOY) M-[8&[/L 1^)H MP11V]O'!$NV.-0B@=@.!4M4;JSNIM2L[B*_>&"#=YMNJ B M?(P,D\C'7BKU !1110 4444 )7G'B:?X17<:U-+#IDIA>9)&&U7A@,S*3QD(.M9%A?Q:=HT6FK:ZC(8H?+60 MZ9* W'4KZ^O- $FK^)5M_#5GJ=B5)U&2"*!F&50RD ,1[ Y_"GM9ZO9W<^_4 M5NM.>T?*S >:LO\ L[5 VX[&NG MV<1G4* \Q897 93\O'4=?PJQ)>:W)"FKF%M+E8Q>7 G($0<*J5 MIIRV/]F26C:O#<:;$T(F_LER9HCC"..X&*L1JR)K*XU8G6"3(?[(DQ&2NP[> M?[H[T 7++Q!::+^=XP"V#M 5200.2>W:H)-3UN2Q\1:?;71 M.H:.P>"81J3,A7> PQC/4<8[5#!:Q6<&E-;+JR7>E0_9XY_[+D(EBP/E=>XX M'((Y%:>F7UKI[W4S66K37-Y)YD\ITZ0;B !C@ # % %/\ X2=G\0:*\5]( M^F7UL#)\J[5D924R<9&0K\>H%,UB6XN/#.FW=U,TIN=6MY8\J!LC,P*#@?W< M5"=(T9/#\FCK8:P8I+K[0'^P2EE(?( XX V_2K^O3)K%I:V\46JVB03I,-N MER-RARHZ#C(H DN=5U#4?$.I:98M<1KIT48)@$>YI'!()W]@ .![U%9:IK-] MJ=AH=](MG>+9M:<-;M;VU1XVN#ILDGG*[;FW@J,DMSQTH ;I5U?Z M3H'BVZMQ]KO;>_F9"4Y.N*NPZCJ,GB#2[2QU0W-M=V33SN8U?R MR-NT\8P&R1CVK,NF_LW1M7C@_MV:35)2TDCV#((=^%9QA1T'..^*JZ7JTT,B M-HFJZC?JCJLT+:-@%7 MSW'!'0]JW8;W4-.\4_8+R_-Y!/8O<@&)5,;(P! QV(/?)XZUA/IB-X7&A,^K MF(W/GF3^R7W9W^9CT^]^E:4DYE\16VL.FJ$PV[6YA&E2A65B"QSZY H CT_4 MO$.JZ98:S9;V6Y=9'B=HA"(6/(&/FW =\]14(O\ 7[G3_$TXU81-I-S(L)2W M7#!8E8*0<\9/U]ZAL=,ATZ5X(+CQ!_9)D\Q=._LY]JG.=H;;G;GM4T4)BM-: MMMVJD:O(SR'^R)/W990IV_@!UH E\V?4_%WAVZ%Y/"+K3)9_*7:54_N\@94] M<\]_3%=L#VKB+>W5)M':-]6CGTV(VPD&EN!+&=HP<@@?='-=5I]EH2V-_? 3:4SI=! G^DDL=C 8X4 =N^1VK7_L346:::;6Y M9)VA,4+B%5$.2,L%'4G Y/2HE\*K#>Z;=VET;:6PA,+%(QBX4X)#_B,_4DT M93:CK^KKJ<^DF97M;J2WMD!B$68R =^?F.3GIC Q5N"_U/7;S4[2"Z^P3:?' M&H6,JP,S)NRQ(.5!(''7!I\O@PKJEU=Z?K%[807SE[NVBVE)&/5@2,J3W(I; MGP:@U4:CI.I7&DR-"L$RVZJRRHHPO# X('&: $M[S5H_$NGZ??7B,;C3Y))T MA4;!*K(,H2,X^8]:P=5O=0OO">H>=J,Y:UUH6P954%T$J@!OEYZY[5TMSX5# M3Z?/8:A/8RV*/%O55+](TW[;YEK=03EPT:ARR $$D<=^@ JK'K%[IFI:Y9 M:C>O.\$2SV*E%4O&PP ,#E@_R_B*T9- N9M8TW4I-29Y;!'3YH1^\W_>S@C' M08Q^M3ZCX?M=2UC3]3ER)K$M@#HX/8^P(!'N* ,674M5&KP:$);B6:&Q%QV>GX[?AU]7;3,:VB"[21EW)CYTS\I(' .,9QWJIK?AEZ?\ V=:F(SR7$CL7EFE(W2,>I../ M3@= * .9\3ZOJ-E-JLEO?%#9V@FMX+= Y! 8LTN1@+P !D9YJZNJW.IZ]%I, M,YM=M@EY-)&H+,6.%4;@1C@D\>E%_P"$#>7>JR)JD\-OJL>VXMU12"P7:"&( MR!C''M27/A":5K*ZMM9N+74K2/R?M:Q*?,C_ +K+TQZ4 8WB26_L;7P]-KW0G686L&Q2C"(D8?(R=Q!Z$8X_&[)X6G=-$0:EC^QF#1GR. M9,*4YY_ND].]*GA3[.M_;V5]);V6HLSS0; 2C-]\QMGY<^X/MB@"BFN7LU_X M>U W#P:;K$)1X2J_NYBFY,'&>?F_'%5M+U[4[VTO[-KV4WQU!(K:0PJO[AOF M5\8P1L#GWQVKH-7\-VFK:''I# PP1-&8S'P4V$$8].!C\:YQ(:@L-2\2:E9:?J]DLCK< MNLDL3M$L'DL>@_BW =SWK<_X1Z3_ (2J37#>AA+;"V:W,7&P'/7/7-9^G^!O M[.;[-%K%X=)63S$TXA=JG.=N[&=N>U &-K5_=^(O .O:NEZ\5NOG1PP*B[3& MAVG=D9R<$]>.*VKK4KJ&]\/6 F-M:7L#>9.,9+*@*H">F>3^%-G\#DVNI6%M MJT]MIVI,[R6JQ(=C-][:Q' /7%9_B.&.#4=+T^[U2[L;>RMBR7KP+(DSG"[6 M^7:" #UQU&* $A\1ZO#IMQ)+=_:&GU7^S[*41HH*;L>8#T8XR/3(J\\_BFT3 M43%#+/#]D,EMYYC,RR@\J G!!'(SWXJ&VT6;Q%8W6FZAJ,U[8*4>UO%MQ;O% M("?N8&"!QSC')K3C\,79MY#=Z[=W-V4"17!15\H!@W"@8R2HSGK0 SPOJZ:I MLB8*NH]RI./<"@!NIW^H6WC'1+*.X46=XL_F1>7R2B9!W53U"Z;3_B M=I,P SWYH 9\0HY6\%:@T5S+"40$^7CYA MD#!R#QSVJEKL$\?B'PG$MV[S-+<;9I54ELZ;PY=W%[I-Y/JIDETPNP+0#]XS+M.<$8&.@'ZT 9UMJNK11>)+)[^ M*2?3&4P75RH10'0-\V!C@YJ*WU6_N-6U#3%OKHVYTL7,,\L2I(&W%25&WH>. MHJ[<^##>_P!M"XU%MNK["X2+:8F3&T@YYZ#(/6IH/"TR:T-5N=6GN)FM?LTH M,2*LBY)[#@9/_P!>@!? 4"M*=[B2;S+6-@) OR?*.!@#]7?]I)#"0BK;R6YW;00=V"PZ MY XQC@5@Z%JFLWGB"?0KW41YVFRM)-(BH/M,;8V #'&.=WH?KQN#1]0>Z^TW M&L/*\<;+ H@55C9AC>1_$0.F?4U5D\)'.F36U^;>[T_=FX6$%IMWWMV3T)Y/ MOZ4 49=5UC5[[6(=+:>/[!+]GA\ORMID"AB7W?>@"."[UFUU[0[#4+V* M62YM[C[4L*C8S)MVD9&0?FY%87B.\O[SPEXFBFOYL6.H+"A4(I:,^7\IXY'S MFNGNO"HD6P>RU">TNK)W87&U7:3?]_=D8R< ^U0/X)BDTS5[%]2NG75)!*[/ MM)C<;<,..?NC/;Z4 )JMWJ>G>)_#MBFH-):WDDJ3*\2[WVQE@2P [XX '2F# M6+K1_$>J6FK7CRVPM?M=G\J@[!PZ\ 98''X$58S#!SCH,< #]:M:KX?M=7O=/NK@L'L)C*FTXW@C!4^V<'\* ,274=8BNM M*T62:9[NXM9+JY>,1A\ J-BY&!RW7&>*V/#C:QY%Q'K"C=',1 Y92[Q]BX7@ M-]*C\0>&EUJ:UNX+V>PO[,GR+F$ D ]5(/!!]*NZ3I?]FQ2>9=37=Q,VZ6>; M&YSC X ["@#GKR"XN?B3+#;W1M6;2%S*BAF \T],Y'Y@U'9ZWJ=SX6AFG MOXX9TU![2>XV?.Z)(RG8H!RY"CC'"#N/TH JV^L:VUCXB@M5FN+C3Y M4%MYJJ)2K(K$$#@D G&?;-:7A?5H]4NKOR-4DNHHT0&WN8PD]O)\VX,-HX/& M/H:;'X/EBN]0N8];O ]\T;L=J95TQANG^R!CI6A8:(UMJ]QJUS,D]W/"D):. M+RP$4DCC)).3Z^E $&MZA<+K.EZ/;S?9S?&1WF4 L%102%R,9)(Y] :S+Z^U MK1!%I\][%*VHZBEO9SXS)%$P))<8P6&"!]1FMCQ%XW$* MA)%:8H3G&0<8QCTKJ(M#E^VG4;F\^T7RP&"*7R0JQ \DA<]2<9Y[=JS5\%.O MABWT'^U7,5O.LRR>2-QP^\ \X^]0!6U'7+RV\075C=7\FFLTD8T]I(U^SSKA M=RERI^;.X=1VJ]:7VH2ZWXAL'O&\JSCA>W;8FY-R,3VYY'<5)J'AF?4H;NTN M=1\RRO)%DDA:'+)C;D(V?E!V]P<9.*=<>&I6UJ?4+34Y;1+N)([F%(U;S-F0 MN&/3@X/]* ,&6_N-5T#P9?W;B2>?4(FD;: "2C]JLVDDUIXW\374M[<216EK M!*8R%P5VR';]W.!SC'KSFK,?@N6'2]'T^/57,>DSK.AD@#%RH( X(P.3ZGWK M0/AUO^$AN=56]=8[N%(KFV\M2)-H(!R>0,,>* ,73=5\1WEKI>JI%))!<[9; MJ-S$L2Q,,Y3!W97CKUYK+\07M[KOP[DUPWI6"YN(F2U5%VB+SU"C.-V[@'.? MPKH-+\%-IA2U&L79#8NJ[4(.0"_4J#R!4,O@21M&N-$@UB6'3)91+' M#Y*LT7SA]H8_PY' QWH ZXC(P#BN#NM=URVTSQ#;F_+:IIUTHM L"'S8W *# M;CG/(SZBNZ@1XXE1Y&D91@NP +>YP *RYO#UM-XGBUTEO-CMS#Y?\+'.0Q]2 M 6'_ *@"EI^HW6M3V\NG:@/L_V!97+Q!@TC_=SC'0 D@$=JYN[U'4]:^'6D M:A=7SI<3:C$LIB10''G[1P0>F ?PYKL=#T"+0-.FM+)R/,F>52XR%W'@8ST MP/PK,A\&/%X2CT$ZB6\B<3P7 A *L)-XR,X//TH J7EM>-\2+>""],IZ1,;YUDN+:[FMGD5=H?8Y ..W&*1- NQXB@UI] M1$LL5F;4JT&-P+;BV01SD>G3\ZG\.Z)+H4-U$]VMPMQ^+6T*VN M6M(X+07,LD84NY9BJJ-P( X)/'I0!T=%4$$2X^Z,=1[GF@!NM:Q!H6ES: MC/\ CP)K/_7JU5$NM3TO7]%MY;\S MV^IQNK0-$JK"R(&!4CGV.2: .MHKA;G7=4M;I)SJ!G(U9;:2*% ;=(F;:%+% M0=^""<$X-2W^MWUMXBFLKJ_GT\OQNQYFW<5'[LY M /&?K0!UXY%+7&6NK:M%I/B&W?48I+G3+@QQ7ETJH I56RVT8R-Q[Y::>5W5D0*K&!S\N #CDCDFNW% $;W$ M<;I&SJ'?)1,\MCK@51T?7(-:-YY$,T7V.X-O()5VG< ">/3FL'4(+B7XFZ>@ MU"XC3^SY9%C385&'3(Y'?OW^E9*'4K?3?&%_8:DUFUGJ,\RK'$K>85C0X;<# MQQVP?>@#T>BN/DUZ_P!3U*PLK47$:R::E]+]F,8&GUC^ MSWCUO8;F.5E5U9263JI8+P&P><4 ;%%8GB[6)=#T"6\MPIF+I%&6Y56=@H)^ MF<_A6?J5YJ>@:MHX-_->VU_/]EF694RK%25==H'<'(H ZNBN!^T^)+W2M>NH M-<:&;2KR80J+=")%1%8*V1TZ],'FIH-4UK6=WU,V=M?Z.MV0L2EHV++] MW(///?/6@#N**\]M/%.KPI+H=S<>;?IJZZ>M\8U&49=P?;TW;01CIDBMAKW4 M=/\ %2:*][-/#>V;S032(A>&1",C@ $$$=1UH Z>218D+N0%4$L3T HCD2:) M)8V#(ZAE8'((/>O.+A]:Y-EM,E+PQ1(@=LG#;L9' P0*VA-J&FW M_ABW74;AXKP,DT4BQX($6X=%!&#[T =A2'BN(EU;5X6\91)J#M_9<<&! SG(]<<]* .FMM0% MUX]ZLP2Q7$*30NKQNH964Y# ]"*XV:[U&[TKQC M!/J$O^@EU@>-51D40A\=/4GGK4#?VMIOP^T?4[#4KD+;06\US%LC.Z#:N]1\ MO89(_&@#O:6L73KN74==N)H+MFT^"%$5 !M>1AN+9QGA2G?O6NZEE(#%21C( MZB@!(YHY2WEL&V,5;!Z$=14E>YU22UC,VUE1VG*^8< M $GG/7'%;ES?7^A>*-'LI+Z:]M=4,D3>>(=:A\-ZHHOMM[IFI):?:/*7]\C,N"1T!P M_./2@#T&BN6BNM3L?&HTR347O(;JQ>X1)$11$ZN!@;0#CGN3TJCH>JWM[J%O M8WNJ7EIJ*Q2&ZLKB-%W''#Q';@J#[G@\T =L3@5FP:Y#/KUQHWD3)/!"LQ=U M 1E)(&#G)Y![5RL>M:N_P\LM7;4)!>"ZC21]B?O%-P$((VX^Z>V*TVC:3XAZ M@B2-&6T:(;UZK^]DY&>* .FBFCG7?$ZNN2,J7'V2SFN3 M%)*(D+[(UW,V!G '3G=@J>>30(+^77_%ALM0>R:+R'$D<:LS,(P'>JGAK49-7\-:;J,V/-N;:.1\=-Q49_6JGC: M]O=-\)ZA?Z?<_9Y[:$R*VP-T]C0!N1OYD:OM*[@#AA@CZTZN3OK[53K/A^TM M]1\F+4+>4S?N58DJ@.1GW;Z<50'B34M-TS5K6>]^TW5OJJ6%MW.!0!U#Z]!'XAAT1H)Q/-"TROM^0JI /.?<5IUQ+PW%C\2])6>^FNU? M3;C!E505(*$_= ZX%166I^)=8TBVUG3S-OFE\SRI'A%OY6X@K_?!V]_7VH [ MRBN&63Q)J_2@#O:*X.YU#Q38V^G07EVL$LVK+;AML;M) P)&[ M' ;C''6I9M=U'P]<^((;R]?44L;*.[@:5%5@6+#:=H QE1[\T ='?Z[#I^IV M%A)!.S7\ACCD51L4A2W)SZ"M(C=7$:G:WD.M>$Y[K5);DR7AWJRH%W&%SE< M$=QC)ZTG]J>(-;CU.XTAYUDM[N2WMT5H1$/+('SAOF.[GIC (Q0!W(&*9)-' M" 9'5 S!1N.,D\ 5Q]O.-C&[[L@,001QW%9%W> M:AK6B^$+NYOI8YYM56&4Q!0KLID&_!!Y^3..G/2@#TH4'FFQ*4C"EBQ QN/4 M^]8.MZI,FOZ5H<$[6S7XED>90"P6, X7((R21VZ T =!C% &*Y"^O]9T<0Z= M/J$63SPSLJ>9 M"Z$!AD#!!!!Y% '645P$>NZO)X(T+53J$OVF>^AAG8(F)%:7:M:2MN4,.XS7GGB@ZRO@?Q'#JNX MPA8VM&E:,R[2RY#;..#T/I7H,7^J3_=% #Z0\5@^)-5GM+S2M-MI3#+J=R8O M. !,:JI9L \9.,#/K52&]O[?Q;-X9$0VUATP>H(R/SH MOKXFADNEC@L;N> W)M3-4O-F\MNW;N,= MJTO%$VI:9HMOJFGW)# M>?;'F3SH%;;LB#MA5R ,A=PR3Z&E-QXATR[BO)'N)]/CAD:[%R\.6(74HF0J*" ?EP?RH [A[B))T@:11+("RH3RP&,D?F/SJ"RO MS>374?V2X@^S2^7NF3:)>,[E]1[UR0CN+GXC:9(]_< OHYE*KMV@[TR "O0] M^_TJSI,^L:H/$EE_:KK<6MV8;698T'EC8".,8/)YS0!V%%<9I&LWNLZ1I%NE M_-%J#2LM\VU"R^5Q("-N!EBH''\0J :EXAURVU&YTF2>.6&ZD@ME#Q"(>6V/ MG!^8YP<^@(Q0!U#Z[9QZ['HSB5;F6+S4)C.QASQNZ9X)Q6C5"*S6XFMM0N.9 MXXL!5;*(6'S$>_;/I7+P:S?)XA6RU*_N["Y:^(BCDC7[-?/X@UF7PS M=7WVR2*;1=0,%XT<:XGA5AN;!!P=ISQZ&K8\2O:>+[V"XOYI=.-FTL!VH%$B M@,Z@@9)VLI'XT =M17&2W.OVE[X7ZRBY+0H3N$9;C&!P>.G;G-:/A M:^OI;O5]-OKIKMM/NA&D[JJLRLBL 0H R,^E '14C-M4M@G SP*AOKD6=A<7 M3*6$$32$#J0!G^E10(Q$XSB,@9W#CJ>: -G1 MM:M]!A*FT[EZ\5HUYQ'/J=AX>\1ZK87_ -G^PZE=R^4(E82X M8$AB>V..,5OIJ]QK6O'3+2ZDLXX;*.ZD>-5+LTGW5&X$8 !)X[B@#>U&_73K M1KAX)I@I4;($WLZ3J(M)91$#YR[D ('120 MX_&MVYO[F^\3G1(+IK1(;07$LD84NY9BH W @ 8)/'<4 =#17&S:IKMG+I>B M74HFO[DS/)/9A-S1IC& ^%#$,N?QQ6OX=?6M][%JR-Y22 VLDA3S&0CD.$)& M0>_>@#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AM?]6?]]OYU-4%K M_JV_WV_G0!/1110 4444 %%%% !1110 4444 %%%% !1110 5CW^@"XUF#6+ M2Y-K>PQF%FV;UEC)SM9!3_9_V"/6KI+:.[^U0 M((T/EMOWX)(RPSGKZ]ZNW'AAKI)+>XU&66UEN%G:-XP6#*0<*W8$KGIZUT-% M "#I6/>:";OQ+9:W]L9'LHGB2'RP5(?&[)Z]A6S5.]U 63VR&VN)OM$HB!AC MW"//\3>B\=: ,*Z\%I>0:K%+J,P&IS).Q1 #'(NW:1ZCY1P:7VI MW%U]JLS:7$3(BK(N3CH.,9/3\ZZ8'(I: .7A\(2HVD^9K5U(NDN6M\QIDC:5 MPQQSP<9KIQTI:* ,74= -[KMEJ\-[+:S6L;1,$16$B,02#GIR.M5D\)XT[6+ M)M1E*:O(\DS>6H*E@%;;^ J[K7B&UT32+C4I(Y;B*V)$@@ 8J1USSQ6G&XDB M60# 8 XH YNY\&K,FG2V^IW5I?:=#Y$5W"%W-'_=92"I''I6UI>FQZ9;&)99 M)I'8O+-*H(/8@X-4HM!Q/9W%_?2WGV $P^8JJ V,;VQU;&?S M-;59^KZU9:);17%])Y<([1-3:*"YU&4O'&J MDO&5494GH#@C/-278B3XE64%I>+9B#3&A7: R@[QA"#WQSCK7<@#'%&* .?E M\(V4^ER6CRR^<]U]K^UC D$^%X(/";^&Y+F6:U>%H-[!0X5L^@QWJ*Y\*OPH YS_ (0U"FK# M^U;PG5XQ'<,P0GA-I8<<'&?8>E3GPP3'I"?VC,!I&#"?+7Y\+M&[C^Z<<8K1 MT/5HM=T>WU."-XX[A2RJ^-P&2.&E@?5C+>2SQZL29XV50!E=GR MX&>@%57EM_"FC6NE73WFI&6,P0*+?<6"J $.P8''<^]=/10!D>&-(&A^'[2P MQAD3+C.?F/)&?;I] *UZ2F0SQ7"LT,BN$/>S6B,D!= H7=@%L#JQ QGW- M:]% !7.7WA%9M;EU;3]4N],GN%"7(MPA68#H2&!Y XR*Z.B@##;PQ;Q7MK?6 M,\EI'?M6L1ZG)?2^9' M:M:E B@,K8+'IG.126?AP07.GSW5]+>-IT;);F1%!^9=I+$#GBK-]KL5CK-A MI;VT[/?LRI* -B[5+')SZ#TK4H Y,^!8#ITFG?VM?"R,XFB@!4"$^8'P#MR> M1WSUK5AT,Q:_+K!O97>6W6W:(JNW:I)';.A:*-"LS:1W2>M:9Z4CML4MM+8&<#J:SM#UR+7;:>>*WF@$%P\#+, &W*<' MH30!6_X173OM.K3LA)U9-LZGD ;=IP/?J?<"GMX>B_X18^'XYWBA-O\ 9VE M!8@C!//<\G\:V:* ,"?PSYL6DE=0FCGTK(BF5%RRE-A!&,=*?#X>,-YJMR+Z M4MJ@42 HN$PNT8_"MRB@#.T/2AHFCVVF).\T=L@CC=P =HZ9Q2:_I"Z]HUSI MDD[P1W*;'= "<=\9K2HH P9/#ADU'2KUM0FWZ6C)&HC7$@88.>/0#I5:;P5; M74.K0W5Y-*FJ3+.V %,,B@!60XXQM%=%<3?9X'E\MY-@SM098_2JNAZO#KNC MV^IP1R1Q7 )59,;A@DW_ZJ MK6W@>"QFE2WU6^CTR67S7T[Q% '%Z'$VI^(O%,5MJA@2XN5&U%4[T\I5+*3[Y&>1Q6S? M^#+.=-.;3[F?3+G34\NWGM\;@G&5(((8''>NCP*6@#FI_!R7$5H'U.Z::WNU MO'G<*7FD48&[C '& !4UQX6AO-3O[RZN9)4U"U%K- 54+L&<8/7/S&K;Z[$ MGB.'0S;3B6:!YEE(&S:I /?.?F':M2@#F(_![^7IL<^MWLHTR426Y*QAL!2H M#';\W!Q2R>#(UU2[O+#5;ZPCOFWW=O 5V2MW(R"5)[D8KHEGB:X>!9%,J*&9 M,\@'.#^A_*I* ,.T\-K8ZQ<:C;7DB&:W2W$.Q=B*F=N._&3WJD/!42Z+9ZLGQ!X< M@UU;:3[1-:7=G)YEO,8Y/K5ZTT4)J!U&\N M&NKKR?(5R@0(FKW"K M9"14W1H0ZN02&&.<$<$8IMSX)L;C2XK47-Q#<0W+W45W"0KI*Q)8@=,GW>J7<\E M[M$]TZIO95.0H &%&?0=S710(T<*1N^\J "V,9J2B@#+US0[?6X(4E=X9K>5 M9K>>+&^)QT(SQ^!ZTEMH_E7TNH37#37TD(A$Q0 (@.< ?4Y/X5H27$44D<% MYI75(T!9F8X ZDFL=/%-K-;_:X;*^EL\9%TD.4(]0,[B/<+0!!:>#[6WL=0 MTV:XEN=/OW=VM750L98Y(3 ! SSBC2?":Z;Y*7&JWNHP6PQ;Q7)7;$,8[ %N M"1SFMC3K^#5-.@O[8L8;B,21EA@E3TXJU0!R^G>"8-.801ZG?/IJ2>9'8.ZF M-#G(&<;BN><9Q1=^"8;EM40:G>0VFJ%FFM4V[-[+M+ XS[XSC-=110!@/X84 MZC87\6HW4<]E ;=(KJH"M@# MC Z8%:]% &5IV@6>G:OJ&I0!O-OW5I 3PN!C@>YY-9TG@N%=2N[JSU6_LH;Y M]]U:P,NR1CU/()4GN017344 1I$D,2QQJ%1 %4#L!6&OA<,L$%QJ$]Q:P77V ME(G5TNGM+ORO)D*J&65,Y 8'N#T- M;%% &99Z%9VNDS:?M,D=P9&G9^LK/G<3]'[$7ES!/+&75/W2@[2Q & .Y)X H GD19(V1U#*PP0>XKF=,\"EO'JUY)IL,GF06+; M=D9SD#,?*Q!X;GI4/]N1);75S/:7 M<$5K.T3M)%C('_+0>J>] &:/"+G1-6TI]29DU26221_) *%_O8Y_*I1X:EAN M[2_M;\Q7MO;"UDD,(9)XQR RY'(/0@^M;Z2+(@=&#*PR"#D$4I( )/ % '.W MGA..ZT.?3$NWB:ZN/M%Q.$!:1]P;.#P.0!]!3M6\+'4;^UU.VU.XT_4K>(P_ M:($4^8AY*LK @C/-6[WQ#:V5]IUJ8II?[2?9#+& 8\[2W)SZ ]*UJ .9OO!< M%W:6Y34+J'4+:4SQZ@,&0N1AB1C!!&!C&, 5J:/I&19%!*Y4Y&0<$?@010!)1110 4444 %%%% !111 M0 4444 %%%% !1110 5!:_ZMO]]OYU/4-M]QO]]OYT 34444 %%%% !1110 M4444 %%%% !1110 4444 )7/7>HW-YXM_L*&Y>UCBL_M,KQXWR9;: "0< 8. M>_(KHJP]9\,0ZKJ%OJ<%Y<6&H6ZE$N8,9*'JI!!!% &7)J.LV5]I6@7M^C7. MH7$^+J)!N$$:[@#D8WD$#IZU#?ZUJVFW&OZ8+TR-9Z<+ZTN712ZCY@488 /* M]<=ZUYO"=O+;P?Z9<_;;>?[0EZQ!D\S&#GC&".-N,8IUQX82ZMM166\$Q*J@^27#+@9!RO<] MZEMKC6/$.EWFH:9J?V6Y6YDBMHF53$H1]OSC!)) )]L\5>D\,-*-(SJ,@.DM MNB/EK\YVE/F_X"2.,5#_ ,(7#%?7 "&!&0.A MJ:V\+QV>KVNH6]Y*HMK9K<1,H(=68,Q)ZEBP!S0!C03ZY>:AXBL6UN6(::L/ ME21PQ@DF+<>"#P21^5(VOZK)IOA.^%UY?]I311W4:Q@A]R$GGMR.U;D/ASR+ MW5KM+Z3?J@7S 47"%5VC'X>M53X._P")?I%DNIS*FDR+)"WEKEBH( ;VP30! M6:75[WQ=JFE+K$EO;Q6D,T?EPIN0L7! )!_NCK^E4X?$FJ3>"=&OI9]CW-VD M%Y=*HRB;RI;'09P!GMFNABT"2+7;O5UU!_-NH%A*&-=JAT6,L 0H/!8]2,#'TH U_#UWJ-QXAU:"2ZDGTVU9%M MG8*0Q*@L-V,G:?YUT(-4N[_3O*)9KFU$05N-N MPA5SGG/&*ZJ@#S#R'C^%7B&1KRXFR]TI67:>1*?FR #D_6NC6YU&P\4Z3:-J M$DUOJ-O+OA=%"QE%4KMP,]R.2:EE\%1R:1J&E#5+E;2^D=S'M3]V';=[N]M-1>"' M"JK>6I7(7C&<9Q[UH^$]5CU.XO1!?W,L<0C!M;Q=L]N_S;@P(!P>,'GH:EM_ M"26\%]&FI7(-Y=B\9U"ADDR#QQTX'!S5_3]'6SO[C4)9VN+JX1(WD*A1M7.! M@?4\T :-<3XC@@\2WU_8SP7$EO:VY@B>&%G"W#@$MP.JC;_WT:[216>-E1RC M$8# 9Q[U1T;21H]D;87,EQND>0R2 ;BS$L'4;E1JQ8W";4V@D8RHQP<4LGA*.2UTBW_M"X"Z0RO 0J9)4;5W<< M\<4 93Z]?:#-XFBGNI;^/3+6.ZA:8+NRRME3M XROI4UB/$;RZ9>+>_Z/.G^ MEF:965]R_*T:[?E(;''<5K#PU;MJFH7T]Q),-1A6&>!PNPHH( '&>Y[]ZJZ7 MX,ATLQHNJ7]Q;VQS:6\\@9(#C (XRV,G&2<4 <_%JFM_\(=%X@?69GFM[THT M6Q DJ?:-A#<=<'MC&.E;L%U=ZYKNKVRWLMK#II2&-(L EV0.7;CD<@ =.#3E M\&1)X=.B#4KG[.9_.+%4W9W[\=,8W'A'XAGUM;Z433VXMRFU=H4!;!O# MR:+-=W,D<4QG@G!"RPODG*D#U)IT_@N*[TRXM+O5;VXEN56.6YD*E]BG(4#& M%&?09K5GJKWTQFM(6A5=J[65L;L\=3@=/2LNY\,OI M6A7=GIVHZD!+(7@CMRH:)F;=@''0D\D]!0!U=8?B>ZFMTL4BO#;K-=!)$B!, MLR[2=D>!US@Y[ 'D5JV*3QV,"73B2=8U$KCHS8Y/YU1UK0(M8GLKG[5-:W-C M*9(98L$C(PP(((((H Y)]=UD>'=4:.]F@FL-76V0RJCR&-F3Y6/() ?J#GCK M6F^I7^B^,FLY[^:\M9]-ENV215'ENC ?+@# (/3GI4[>!+4VU];KJ5Z$OKI; MJ3)5B'7:<@D=RH)_I6A+X=2?78M7EO)7DBMVMO+*KL9&(+9XSDD"@#D]6:\U M'P9IFLW5_*TEW=VLKP@#RPK2J0H&.,<<]3WZUZ)7+KX$MUTU=+&JWPT^.998 M;<%/W15MP ;;G&>Q-=.B;%"Y)P,9/4T E;^I:&-2U2QOVNY8C8. M7B154@L05.KJBSWER5U1D>4#:-C)C:5.,\;1US0!FV&I:F- M=U+3;:2Y*_V8MS;+>E2XE)9<^H4X'!Z>@J7PMJKW>I"VN+N^BO(K;_2K&]'S M;\C]XAQ@KUZ''(Z5=_X0Z![^6^FU*^EN)[0VDK%U&]>3G & 023Q5VVT)8]2 MBU"ZNY+N>"(PPM(JJ54D$YP!DG H U#VKS>VAU6+P]KVHZ;JSVLEGJ%W*D2Q MJ4D*MDA\C)S[8KTBL#_A$H!%?6B7MPMC?RM+/;_+R6^\ V,@'N/Y4 9D6N:C MKFHVUK;B2)/[-BNY$BE6-V:3IR0>!@].N:A.K>(+>YTO0+Z57O;IYV>:"159 MXD *C)&%8[AG [<=:VM6\)6VH7=M?6MY6T7DI-:D F/^Z00013+SP78W M5E;Q+=W<-W:RF:*^23]]O/WB21@Y[C&.!Z4 8VH7?B;2;-4FOU0-JMM% Q*R M2&&1P"K\#ISR.HK3TZZO[/QK<:1<:A+>P2V2W2&55!C;?M(&T#@\<>U2W/@Z M*ZM$AEU.[>47$=S)?P);S6-S8C4[Q+::Z^U)$NS$4F_?D'&2,]B2* %CN[O7-=U>V6\EM+?3"D M2+#C<\A7<6;(.1R !TZUS^G7&H:;\+M(U.SNI42S.^[1%'[V'S#OQQP<<\5U M3>%E357U*SU*[M9IXUCNMNQA.%& 2&! ;W%6-(\.VND:$-&626YMMK*1,020 MV&R5'UVYQSBNGTS0X=(T*+2;*5XTBCV+(<,V?4YZFJ5GX M5&GZ;86=KJ=RAT_<(9-J$E2,%6&,$4 8R>(9I;#3[?3M4>\_M"_>)9VPLD:* MI;8Q>60220&0[7+<#(')&?I6Q<^"].O M-/DMYI9A-)=?:_M41"2)-C&Y<# XXQ22>"[.[TNXL]2O+N_EN-NZYF<>8NTY M7;@ #!)/3O0!G_8Y+/XE:4K7<]PK:;<8\Y@Q!W1Y.??CCH.U=G6#;^%RFJV> MIW6KWMU<6D3Q(6V(K*V,Y"J,]!6]0!PMO(^F^+/%FHFZN91:6\4WE%@58>6Q MV],X':DOM5U32_"-CXI^W2W$K&&2Z@X,;I(P!55[8W#!Z\ M@^E &\*YW4+ZXO?%T.@Q73VT*69NYFB(#R?/M50>PZDD<]*Z+%8^J^'(M1U. MUU2&[FLK^U4HD\04[D/56# @B@#D;+4[K0]/UM(KC-Q/KXM5N)%'R;]@W'C! MP/UK?FN[W1?%FEV/VJ6YL]321668[FCD0;@0?0C((J5?!5@UGJ-K73"6 M:W*J1GCA3C(!P/\ ZU %.VNKW7]1UI([^:S33YOL]NL) ^?8&+MD?-R>G3 J M[X-UF?7_ Q:W]TJBX;W%M$T<+.H78#C)P/XC@#- '.0ZIJ5E#KFBW5[--J<-'N8FB9G8]-IZA0#SZM74T "WES$KQ7'RQL, A1S@@\G-4 M%BO6N_&,]IJ,MDUO<"13$JDLP@0\Y!XXZ#%=3JV@1ZI?V-\+J>VN+(ML>+'* ML,,#D'KZU73PP(QJP74)O^)JE;.F:9%I<#QI++,\CF26:9M MSR-TR3] !QZ4 <]\4'E7P-=!"1&TL2SD=HRXW?I740"%;9%AV^4% 0+TVXX_ M#%%W:07UI+:W42RPS*4=&&0P/:LJT\.R6-NMG;ZS?"S0;4B;8S*OH'*[L?CG MWH SWG \2VGA>QE>TM([)KIS"V&;Y]H0-V .2<<]*R+_ %S6;33/%5@FH2"; M1D$MO=%%+LC)N"MQC(Y&<9KJ;OPS:S7%G=6LLEG=60*Q2Q8/R'[RL#]X'K]> M:CN?"EK=:9J%F]S,&U,YNYU"[W& ,#C &!CI0!D74VL6_B/1K5-:GV:K#*)5 M:-"(RJA@4XX/7KFJ=UJFLV/A[Q7#%JLS3:/(3!&?$MRES//-JL3$Q%0W=% C;9N5DP,CH);, MZW'?%1AN[BWDTNX4 M6[2A'D561&*L>0?O=>M=EK>A1:U]D=KB:VGLIO.@FAQE6P0>"""""167-X$M M)H-4A.I7VS52IN 64Y( !(XZG:/;T% $+W]_I'BRS@N-0FN[6_LYY7C=% C: M/:05P.F"1@DU@Z]->ZM\/(=;GOY&-W/!(;-?"^G,V(&DGN77^\T:#;^1;-=3&GEQ*FYGV@#/PK2U"RBU'3KBQF)$=Q$T;$=<$8H XBYAF33 M?!*)>.\CW,96215.S-N_ '';-7[74]5MCXFL'U1)9=.1)+>YNU50F]"?FV MC& 1Z5=3PE*MMI,+ZO/(=*E$D3-$GS84H < <;2?>DO/!L5]-K#3W\VS5XU2 M5$11LV?=*GV_6@#/T_5K^;Q'_91O+MK:YTLW"RS(JNKA@NY..AST8=JM?#59 M/^$+LY9+F6;S QQ(%^4[VSC !.3ZDU;M_"S1:S;:K-JUU//#;FW?2SVZL3"DBJ/*!). 0,GKWH UZ*** "BBB@ HHHH * M*** "BBB@ HHHH **** "H;;[K_[YJ:H;;[K_P"^W\Z )J*** "BBB@ HHHH M **** "BBB@ HHHH **** "L?5_$EMHUY:6MQ:W4CWK^7 8E4AVQG;RPP<5L M5Q?CH.==\*"(J)/[2.TN"1GRSUQ0!T-OK:S7T=G+87EL\JLR--&H5L=1D$\\ M_P ZTLBLBVCU4ZM/]O>$VQ@40M"I&'RV[J2=W4= !TZTW3=1U>[U*QT+4[I(;J.P:XNY+5@?-8/L !QQTR<#KQ0!V&12,Z MJI9C@#DD]JX^]DUG21I<=QJWVAY-72 E !N@QW&*@UNXNY7\6V)O9 MQ#;ZKN:XF M66]TS1?"K6NHS!+FZMHI4<*=R,F<9QD#C]:NW%Y=Z1XWA6\OI3I=_;OY*MC; M%,O)!.,X*Y(SZ&@#JK:E;66G*)YQ-K=\1'N9C75A!+;32?;KA;=)$ MQM1CZ\Y[>E:P-@^\ M%.3U ZCBFZ)K%VVL6-AJEU>66IEW,L%P/W-TN#_JF QQP<9!QGK0!W!.*,BJ MNI^8--N#%,T+K&S*Z@$J0/<$5PZ:MJUGX)LM??59II[Z""#;($$<3NP'F=.H M!/7(_E0!Z%D49%]JX*W=P'990,AQ@#C Y%9^F:E?QZUX M?1KJ\GBOXIA/+-@1SLL>X.BGE1D'' R* .F\0:TN@:3+J#VLUPD6-RQE00"< M9.2..>V:TU.5SC%>;:I>7'B#X=:EKYP,D]%;?B.VPN2)">&)/89.#VK0DGU"^\6 MPV"ZG/!;3Z7]H98E4%6WJ/E)''7OG_ ZS-9=OK8G\17&CM:31/! LWF.5VN MI8@8P3Z'KBN4M/$&HMI%EI\EXYN+G69-/^UD#?Y:%CGTW$+CIWK2TNU:U^(U M\AN)9U.F0E#*VYE'F/QGOSS0!UN:,BLKQ3+-;^&=2N;>>2&:"VDEC>,@$,JD MBL1]2OMOA"87)[@ M:U=I)I4\QMR@09V1A@&^7D>W'6M"UU>XUS7;+33/);1C2H[Z;R6VF1G( &>N M!R>/:@#;T'6TUVUGN$MY+?R+F2W9)""=R'!Z$CK6GD5YOIFHW>E>&I+>WE)G MN_$4UJ9V(!P93DYQ@$@8Z=35_5#XBTVRUB18XUQEF.!R<#]37'W$>NVVA6^I07E]J+3K \]M&45P MFWY_*. -:P7]U)Y5@SK# P$BMD_O78\;>, =^>#6>-7UB^'@XC4Y( M/[4A;[3Y:+AB(LY&1US^'M0!WV:J]2 ,@$YJS=6,EGX\\-YO;BY#0W M0;SFW9.PV-X]XWEE_FM;N/+;50@8!P1P M<'CO79W4?FVTB;V3. M.,UK9^6O,H86C^#UM*)I'=[B CS&W!2+H<@5T]LUY;>,I]+.I7,T,^GFX'F; M28G$@7Y>, 8/0^E &[IUY)>V@GEM9K5BS#RIAAA@D9_'&?QJUFN&L]0UN?P+ M:7D;7%_/]K?[1Y3*)I(ED<';T&< <#TK8\(ZA%J,-[+!?SW,8N<+%<*5EMOD M7*," M=H]S/'"55!Y@C;(\SY>B)IZW3+%*(V=G; M'4@\#'0>M4'N/$EH^@VE[JH6>>^DMYC$$<,FQF7=P/GQCV]J .\S63?Z]'I^ MN:;IG>N7N/$5_X=7Q5'+=RWPTR.&2V><*64RC& M#@#(!P:DU2QEM?%_A!I=0GN6>2?1DG@8ZU;^W:E;7_AF^;4II5U8A)X"%$0W1%P5 M&,@@CU/>@#M<@49%<,MWK_B"#5;C3+AH)X+N2"W/GA8XMA ^=<'.>2<^O%6( M?[4U+Q'J%A)K$\,:V,$P%OL^1VW9VMCIQ^/K0!ULMQ%"%,L@0,P1:-=7>M^'_"%]>730 VZE:"U MEF6)Y6C0L(T'S/@=![FF6=PUS90SO!) TJ!C%)]Y"1G!]Q57Q$\\?AZ_EMKE M[>6*W>1)$"D@A2>X(KG+O4-3CT+0;[;?7-JUN&OC9G]]DH-K8ZD9SD#UH [3 M.:H:KJT6F"W1D:6:[F$,$:D NQ!/4] "3]*B\-7<=]H<-Q%?F^1RY6=A@D; MS@$8&"!@'Z5A^+K7S?%'A@_:9H]]Y(OR-C;^YPK!>]N-0\(>#;V]F:6XEU:V+NV,L!9S(^-KJ3CC!)[=ZU8 \D9P>] '?9%&17*:C>3Z5 MXL9;S4)TTV]LI&B&X 12IRV#CNO(^AJCX>U/4]3L;'3;FZN$U*"\<7Q8C?Y: M#(S@8 (>,<>IH [G(HR*X+5=6U"U%S=PW\\[1:I'$'B $$:%U7RB#]YL$Y(S M@]ZOE=3U#Q9JFFIK5W;P0PP31^6J94DMD?=Z@OYK>X@EN#;1*1L41 M$@*R]\[><^O&*BU1SK-WX,U%Y9X3>2;RB/@(3 S<>_- '7:7?S7]N\EQ936< MD7 $J@ [UYZ5:6/9$%#,2!C<>3 M]:X.[EO;KPGXRANM0N)C:3S)%(6"L%$2D+\H QR>U '>0SQ7$*31.'CD4,K# MN#T-/S7&73ZAIVA:)-;K?7=D(@UXML_[X*4&TJ.I4'.0.>E;?A>[COM&2XBO MVOHWED*RN"' W'"L,#E1P?I0 [4=?33M:TW3'M)F.H.R),"NQ2JECGG/0>E: MV17*^*%8^+O"97H+J?/_ 'Z-4/M6O>(#K#Z9,T$MM=/;VQ%P$6(ICETVG=DY M//8\4 =SD49%<;<:K<_V\+75;_[' =+66%X9-J239^: .F\0:TN@Z//J3VLMQ'",LL14$#U MY(K0A?S8$DQC>H;![9%>?WE[>7?@'Q3!>R2.;2>6&/S6!=4PI )'7&>M=]:? M\>!AL M8S0!T(\37"W0L9])FAOI)FBBC,@*2@+N+A_[N,#IG)K4TJ_EU"S\Z>RFLI [ M(T4W4$'&01U![&N8UK3L>./#L8O+OYX[@;O-.1A%Z'W[TS[3K6NW&M1Z?.\4 MEE<-;6^VX"",JH(9UVG=DD]>,4 =OFHWN(HY8XGD >4D(I/+8&3C\*Y>QN[_ M %O4KO3YK\VTUC:P[OLK##RNI)?..5& /K5">TO6\8>&XK_ %222Z^QW*RR M6Y"HS+MR0,<$]_I0!W=% Z5C>*;F:UTD-#>K9LTT:-)M+,5+#*H #ER,@<4 M;.11D5P%SJ^K0Z7XJ6*[NK=].C26W,^QI$S'D@GD=?Q%:$=WJ-AXAT<3:C-= M0:C:RO+%(J[49%5@4P,CJ1R30!M^(==A\.Z5)J-Q;S311D;A" 2N2!DY(XR: MU/X:\UURYNM>^%UYKLUY*/M.)%MUQY:QB4 +C'7 ZYZUZ4.E &78:Y%?ZU?Z M6MO-%+8A"[2 ,&S@C!]JU,UQ+VMQ<^,O$:V]_-8E;:V;S( N_(5^[ C'X9] MZ6TUR^U'P]X=NI;TQO>*3/% O[ZX8*>$[ 9Y)X '>@#MG8L..G49K?\*W\>HVMU/!J,E[#Y^$$R[9(?E&4<8!! M!S^= &[1110 4444 %%%% !1110 4444 %%%% !1110 5#;?=;_?;^=35#;? M<;_?;^= $U%%% !1110 4444 %%%% !1110 4444 %%%% !6)K?AF/7+VQNY M+^ZMWT^3S81#LP&QC)W*<\5MTF10!E'1)I+J&>XU:[G\@EHT=8PH8@@,0JC) M&3C/%4YO!]O+:6$8KK5EU6VU.]L+PQB*>6V91YZCIN!4C/N!3;WP58W"V3VMU=6%U8AA# M=0./,PW+!MP(;)Y.>];\-Q#<0)/#(LD4BAD=>0P/0BGY% &#<>$K:XTO[(;R M[$_GK<_;-X,OFKT?D8Z #&,8I(_"%JLU[-->WEP]];"WN/,<$. ",X Z_,>G M%;^102,4 XLHPH/RXP!^>>:T-:T&TUZSBMKS M<5BF2967@Y4]/H1D'V)IEKKBW'B&ZT8VLT7 6 )QN.3T'4T 5]<\/V>OZ>+.Z,D81Q)%+"VQXG'1E/8 MTFD:&-++R2WUU?W#J$,]TP+!1T48 '/ISWK3!XY/-,N+J"UB\V>58TR%W,> M,DX _,B@#.UG0(]:DLGEO)X/L4XN(Q%MP7'3.0?4U6NO"-K>7VHW,]YR/6B@#G(?!R1WMA>RZOJ$\UBC1HSLGS(0!M("CTZ M]?>I[7PO'"^G_:-0NKR/33NMDF"?*VTJ"2%!. 36BE[(=5>S-G,(UA$@N2!Y M9).-@[Y[U8AN(KA2T,@=59D)'8@X(_ B@".]M3>V/&X ^F016 M7#X3L$\+CP[<2375FL8C4RE0Z@=,%0.1V-6]4U9=/DM($C\ZYO)?*ACW;02 M6))[ 'UI=)OY[^W:2YL)K*5)&1HY2#G'=2.JGL: ,ZT\'VL%O+!=W]]J*O" MUNINY0WEQL,$+@#MW.34<7@FWC;3G;5M2DDTW(@=I5SM(VE3A>F._7WKI,CU MHS0!S,_@6QE@O;5+Z]@LKUS)):QNOEAR025RI(R1TSBNCAB\F)8][/M &YSD MGZFLRYUW[-XELM%:TE_TR.21+@LNSY ,C'7/(]*ULB@#G+SP597CZH&OKV.# M5,F>WCD 3?@#<.,YX'&<<=*GM/"R6FJ0:@NIWKRP6QM@'*%2A(//RYSD ]?T MK9FD,<3,B-(RC(1<9;V&:H>']:37=*6_6![<&1T,Q. MFRV+WEX^^[-Y',6020S$YW*0H[GOFKMAX=CLM7;57U"\NKEX! QF9<%021PJ M@=S6OD4;AZT 175M%>6LMM,NZ*9"CJ>X(P:Y^W\$6T*Z>LFJ:C/_ &=(&MM\ MJC8 I4+@*,C!^OO72[AZTA8=C0!@IX1A6UU6V_M*\9-69VGSY>06&T[?EXXX MI#X0MPUC-#J%Y!=6,/D):0UG+"UI$DGF.R MXD#$@8 )_N]\?2M;- '-KX%THZ-=Z5-)U0S^#[*YTZ]M9KBX,E],D\UR"HD\Q=NTCC QM'&* MTM7U(:1ID]^]O+/' A=UBV[@H&2>2*RE\5L^EQZFNBZ@UI)&)?,'E'"$ [L! M\]* 'R>$K>2_^V'4+[S'M_L\^)!_I"9)^;C.>3]W%0V_@FUMO[)\O4K[_B4[ MOL^YD/!&,'*],<5T88$9S2Y'K0!@R>$+.XDU4W=S<7,>K!1/%)M"@J,*5PH( M( '>D@\(Q1WMA>3:KJ%S-IX80M+(HX8 $':HSP*W]P]:,B@##B\*P*+:*:]N MKBWM9_/AAEV85@21R%!P"?7M6V5!!![TN14/VJ)Y9HHW#RP %T'49&0/QH P M/^$'M!HIT==2OUL_-$J)N0[,/O"C*]-W/K[U>?P^'UH:M_:-VMP+]1>(?#L'B.P6RN+JX@C6190T!4-N4Y!R0<<^E:V11D4 8J^&E M_MJVU>34[R2YMH&@7<(]K*Q!.0%ZY _*JP\&6XT?4=+.IWIAU*5Y9F_=[@7^ M]@[. :Z/(HS0!S]]X/MKUK.<7UY;7MG'Y4=Y RK(4_NMQM(_"E?PA;-)8.E_ M>(UC,9U(96,LA!!9R5))()':M_* .?7PA"MKJUO\ VE>%=7=GN"?+R"0%.WY>. !W MI9/",4B:2AU.]']DD& CR_F(7:-WR<\$CM6_D5DZ=KGV[6]0TQK26!K%8VWN MP/F!\X( )XX[_E0!1G\#V,FJ7%];WU_9K=G-U;VTVV*<]RPQD$^H(JU#X:CM M]5N-1@U"ZC>>!8/+ CV(BYV[1MSQD]2:VLBC(H YF'P-:0:);:5'J-\$L[@7 M%O-N3S(WR3P=N"/F/4'K5BWTV[A\5O=K>7S6IMA')'/(#$6&-I1>H/!)/O6] MD4F5- %?4K%=2TVXL7EDA2XC,;/'C< 1@XR".GM6;#X9%M;V$5OJM[$UA"88 MY!Y9+H<<,"N#C:.U;>1ZU%<7<%J(S/*$\R18TSW8\ 4 0:5I<&D68M8"S+O9 MV9L9=F.23C Y)[54UCPZFL7UC=O?W5N]A(981#LQN((R=RG/!(K8HH Q+GPQ M#<:P=36_O()9(EBG2%PJSJI)&[C(ZGH150>![-=+TW3H]0ODATV=;B'YD8[U MZ9W*>!D\5TU% &-_84=OKTVO_;+MYC;^4T("%"@R0 -N7P%92VMU:#4=02VGN/M M*PK(H6&3?ORORYZ]CD5U-% &7J&@6>J0V4=YOE^Q3K.C,02S*".?KGFGV^B6 MEKK-WJT:D7-XB)(>,87./Y_H*T:* .8E\"V4MO<'(K0M?#\=IK4VJK?73RSQK&Z.4*D+G'\.>Y[]ZUZ* .QD97=WP14FH^&H=0NM/G%Y_$MFC1I*2A+(=ORD%<8^4=JT-*TJ#2+9H(&=_,E:61WQN=V.23@ ?D*O M44 9.J>'XM4U.POY+NXB?3W+PI'MVEB,'.5)/''6J5UX*LI]5GU"&]OK-KO' MVJ&VFV1S\8RPQG..X(-='10!P.I6\:>*9VN)MTDT^-GBE0#/.%;G M)(Q@=*OZ?X=N=36*YOM1U))+.=FL9Y/+6X\ME 8.-N,$Y[ @8Z&NNHH YQ_! M5DUEJ=F+Z^6+4W+S#S QR0 <9!ZX%;MG;FTM([6H7S),;FQZX 'Z5/1 M0!@ZOX2L]6U*+4EN[RPO8T\OS[.7RV=,YVMP011>>$K.[M;*V6ZNH$LIQ<(8 MW!9I02=S%@23DFMZB@#&O/#B7NJ66I/J%VD]DK"+9LV_,,-D%>>#+.Y MU:;4K>^OK":Y %R+2;8L^!@;A@\X[C!KHJ* .>O/!MG/>6]Y97EWID\$(@#V M;A=\8Z*P8$$"GS^$[1I=.FM[JYM9-/WB-XV!+A_O!BP.<]<]:WJ2@##T>RO; M?7-3GDN[R6TF93'']6M=T.'7K2*"6>:W:"99XI82 R.O0C( M(_,5I8I: .9F\$V\XU(/JE^?[3A6*X.]"3@8R,KP<<>GM5M_#2R7VFW;:C=% M].C:.,$1X<, #N^7N !QBMNB@#E)/ -LVFWFDQZG>0Z;=L6^RILQ&2VX[25R M!GM73PQ&&!(C(\A10-[G+-[GWJ2B@#%7PX$U6_U%-0N!+?1K&Z[4*H%SMQ\O M49/7-4(? MO;6^EQV^J7L4FEAT@F&S=L;JI^7!Z=<9KJ:* .-=JV5;:S @CD<@Y[UI:5HZ:8]U.96FN+R023R%0NXA0HP!T&!6C10 4 M444 %%%% !1110 4444 %%%% !1110 4444 %06WW7_WV_G4]0VWW7_WS0!- M1110 4444 %%%% !1110 4444 %%%% !1110 5RFJZA?7?BY-$M6*)%9_:71 M9_):4EMH&X*3@8[8ZUU=86N^%+77+JWO3VP*QW5K)LD"GJI]10!SUU+ MXET]-,M;O5@)9=6$&8BLC-"P)4.2H^88_'O3-0EO4@\7Z-+J5U/':V*7,4KL M!(N]'RN0!QE>GO6_+X0@DAM$6_NU>UN1=>.,<5,WA>WEU'4 MKR6YF?\ M. 03QD+MV $#'&1]X]^] &$+N[L[/PUH]G<2$W\)D9I9@C%4C4^ M6K;3CJ.V< U4\03>)M$T+5)7U41!)H6M LHEE1'<*RN2H)&Z?5KAY-TTBQF-$3)C1@IQD^V<9^M0 MW-WKFDRQZ;=WJ(NIZA%#:R";S9;>-E)8%BHR24(4G/7VKH=9\-6VNZ?#;7DT MPE@820W43;)8W'\0(Z56?P993:6]GI=?T"+Q!9QVL M]S- DAP: ,:]>_N/B"-*75+F&TDTTS[(@HVMY@'!QZ>N>M M8.HS7=[X4MUN[^XEDL_$*6GFA@K2*MP%!;U(&/QKL_\ A'%_X2!-;:_N#F.N>:J_\(7:G2KC3VO;IEGO!>"0E0TWNFOJ$[6KZ6LR1C:!$QD*DK@>@[YJ+X<6QB\ M+12FXGE,DTPVR2;@,2N./<]ZUUT%%\1/K?VN*;$3>+O#A^U7*>=-,N$E*[<1 M'E?0U!8V^HWWBO7+%]>U!(-/DM9(@A7)!4L5/'(/?UKH=3T!-3U*SOWO+B*2 MR):%8RNT$C!)R#GCBEL= BL-8O=4CNIWEOMOG(Y7:=HPN!CC ]Z .3L;GQ#X M@\.KK=A>0V\[S-(LDEXXBC17(,;1["N HP3USSFKJ76J>(-5UB"WEV"R98(Q M'?/#Y;% V_"J=V2>,\8'2M!? NFQWDLD5S>Q6L\ADEL4G(@=BTG,?G*.@;U^M &0AO?^$I\)+J,\,]XEK>I-+ HV7@.ZUS3]4G@ET^YN M)5MQM\J11,VX,,<^E>G'D5@KX1M%B:U^TW#6#S&9K-B"A8MN.3C<1NYQ MG]* ,C7;ZYG:_>"ZNV>+3EEC@M7\O[*^&.]VR MV3V&AW]^GFWNH.@F@EWR1P!"X0L M5'S'IG'3GK6K>^"-+NK*QMXGN+233P1;7-O*5ECSUY[Y[U)/X.T^?3DM'EN3 M+',+A+LRDSB4='W'VXQTQVH H:-;?9/B+K$8FEE0V%NR^:Y?6 MKFNZA*WB31M"2:2".]$LLLD;%681J#L!'(R3DXYP/>K5AX<@LM7?56O+NXNY M8EBD>67A@"2/E [GM5C5]%M]7^SO(\D-Q:2>9;SQ$!XVZ'&>""."#UH Y+4 M-1U.Q_X2G2XKZ<"PM$N[2X+!I$#!LH2P.>5."><'K5J26^TWQ)X@##\87=WH]_:ZC9ZE*;6\1H9HC*Q2$, !< M#H%R,]N15S7;RZTI-"T:TNI96U"&W8-;RO)^]A(^Z58 'B@# M$U"[USP[#?-/>0I!:7O<:B+I DLMW*7I7=]#=W4+WB@21HXV;@NW=@CKCUXH Y=)= M5N_A?IVL)?W;7MLBW,Q20@SH&RZG'JN:T-0UIFMM1\06$TDEI8:?F)=[!)9" MN_)'0X4K^9]*WM'T2WT72(]+@DDEMX@543$$A3VX ]:-/T'3]-T0:/# #9A6 M4QOSD,22#^= V^NIPP.:VM3LYK?1 M]2?2<)?SQLR2.W)DQA6-H;F\EA@)-O;SSEXX#_LCZ$]>E M:^H6,>I:?+9RNZ+*N"T9PP[Y!]: .<\+ZFESJLUN\FH6UW';KYVGWS,S*=V/ M,5CG(/3(..G2K.KWTTOBS3-"6=X(9X);B5HV*M)LP @(Y'7)QZ5H6>B+;7_V M^>YEN[D0^2LDNT%4SDCY0.IQ^5+JNAP:I-;7)DDM[JT8M!<1$;DR,$<@@@CJ M#0!S9.KW,OB3P_!J%P)K)(Y["YW_ +Q=ZDA&/?!4CGG!JE_PDC/?^'M4CNKI M=/DC6+4$,IVQR.-L>[WW*P/X9KM=.TJ+3FGE5WFGN7#S328W.0,#H , < "J M#>#]);1K[2O*/V>_G:>;IGQU"'4+F W^K1X0ON A=\ M*O/0;0#@>M7](DN[+QW?Z1)?W%W;&QCND%PVXHY=E... <#BM;5]!@U>WMH' MFEMTMIDF00[1\R_=Z@\#TI(] BC\0OK?VFIS0!1\;7% MW9:7:W%I=RVY%];QN$Q\ZM(H(.1GH>U-M9)Y/'.JV#7,YM180R+'YAPCLS@E M>XX4=*C\4R/K!CT:WM+L317MO*TC0,(BBN&)#]. /SJ_J'AFWU#6(M5%U=VT MZQ>3(+>78)4!R%;V!)H Y?2M:OKK3?#VF27LWF:E'@32TTN&QBDN8_LTYN M+><3'S(7)))4G@#D\8Q3;WP^VEV^IZM9&[U'4Y[7RMDDV!(0"!\HP,\G^F* M,6QN]1OXO#ILM4OC<7)/]I@-NVC:5@Q%QM4 M#C!'6J\,^N^)(-6N=/N5MYH+V6WMV:\9%A\LX^:,(0V<9.<\'M70R>%X95TL M/>W7_$J(,!!7D@;?F^7GYA^"KJ\O)S.^H M^5)(LA7=@2#=Q_%\HY]Z[:'PW!;ZK=:E#=W,4./,C?)/!Q[GJ.] '0HNQ0N2<#&24L@V_P 0'J>YK0H 6BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;;[K_[ MYJ:H;?H_^^: )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I *6B@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** $P**6B@ HHHH 3 I:** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "H;?\ Y:?[YJ:H;?\ Y:?[YH FHHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "DR*6N$N-=GDN-=@NK^YL]2M'(LK6, M#]XF/W;*,?/N/7^E '=4M5[!KA]/MVNU"W!B4RJ.@?'(_/-6* "BBB@ HHHH M *3(JMJ=_%I>FW-_/GRK:)I7QUPHR:P=!BU#7M'BU?4;^YMY+Q?-B@MV"+ A M^Z.GS'&"2<_2@#IP76BZ=*=>NC-)]J=(I F6E4GY %4=<<8 [&K,' MB+3[@W*(TPFM5#2P- XD53T.PC)'N!0!JT5C?\)3I/V&QO?/,(;2_T M6&V22XAU-BWFQPLX,81F&W'4\#\,UH7WB33M/>5)Y)/W"AYV2%W6%3R"Y ^7 M\?K0!K45A77C'1+.5XI+LLZ6XN"(XG?,9( 88'/7M4E '0T5ER^(=-CCM'6!D5 _B_1 M([&UO6O0(+N40Q,8VY?=MP1C@@\'- &W17*R>.;.35-/M;.&YECN9)5DD^R2 M@KL4\ ;K6]U=V/D6=RUM(TB;I5^\J;@6QP>2,C\:Y>-;U_B!<:,=5O_L<>F+< M "49$ADV]<>E ':9%&:XA[JYT+Q9I\6H:E[F.(X8R[?0#-,-$1K=1>>8;J$S0 MB.)W,B#N,#GZ=: -RD!!Z5E6_B72KG2)=52YVVL+,DC2(R,C X*E2,@Y[8K# MAUCS?B%&L=S>+;'2Y)9+>='15(= &"$#MGGZT =E17/KXX\/O';RK>GRKB0Q MI,87$8;<5PS8PO(/4BKFG^(M.U.^ELK:5_/B7>4DA>/U02^-="AAFE:[=D@E,,S)!(PC88 MSNPO Y')XH WZ*YW4?%4=GXBTW2DBDD6[1Y&E2%G&T+QM('/)&?05T.?ER: M%HK F\:Z'!'/\ M*))0DA560Y)# =>E '545D:9XFTO5Y+ MB*UN#YMKS-'+$T3(.QVL <>])!XHTNXN[6W661&O,_9FDA=%FP,G:Q&#QS[T M ;%%(:Q[CQ5I5M*5EGD6,3>29_)O'7K0!LT5B2^+=(@N;RVEFE M26QB\V=6MY 0F<9'R_-SZ9JW/K5I;P02R-(#$>2^V0*NXX;&.!VK/T/Q7#JEO M?W$\3R' M".2"0-Q& >#QG-;E !165>^(].L9IXY7E;[, 9VB@>18@1GYBH(''/TI+KQ+ MI=E-;0S7.7NHVDA"1L_F*%W$C .>.W6@#6HK*M?$>F7FF3:C%<%;>W9DF,D; M(T;#J"I (/(XQW%.LM?L;Z_:P1I8KI8_-\F>%HV*9QN 8#(H TZ*9+(D,;22 M,%102S$X [UDP>*=+GGMXA++']K.+=Y8'1)CC/RL1@^WKVH V:*PF\8Z*MY M)9BYD>>&9(9$2!R49_NYXX'OTK:D<1H78X"C)H ?17.-X[T!8/M NI3"LQA> M46TFV-@0#N.WY1D]35VU\2Z9>:H=-BF?[1M+H'B=%D ZE&( 8#/8F@#6HK&N M/%6E6IE,LTGDPR>7+<+"[11MTP7 P,9Y].])?^*](TVZ^RW%PYF\DSA(X71$B6:0Q0.WE(PR"V!QQSCK[5J6US#>6L5U M;R+)#,@='4\,#R#0!+15"_U:VL)8X'\R2>4%DAAC:1R!U.!T'N?6J\?B?2I] M/AOH;DR1SR&*-4C9G9QG*[0,Y&#GCC% &O16,?%.EKI]U?--((K-BMR/(??" M0,_,N,@8YSCI4\NO6$-[9V M4WQ:..4PR.D+LL;#'WB!\HY')XI+_P 4QV?B>QT<0RLMQ"\KR+ [CC:%"D#W MY/;B@#H:*R+KQ/I=G*Z3SNJQR"*241.8T8] S@;0>1U/>H+CQIH-KYP*O7W MB#3M.?9/,S/Y1F*PQ-(1'_>.T' ]Z -.BL6Y\6:):+;--?QXNHS+#M!;>@&[ M(P/053M?&EG?^(8=/M4F>"6U699?LTGS%FPO;@8SDGB@#IJ*RH/$>G7%U%;Q M22$SNR1.87"2,N<@,1@]#W[5JT %%%% !1110 4444 %%%% !1110 4444 % M%%% !4%MG]YG^^:GJ&W_ .6G_70T 34444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 44E% "T444 %>>:G:VM^-5DU=I;;6X)W.GR1@^8J*, MQ^5C[P/<#J2SU=[:#1[+4XY?[0OH0',<9*+(J ON(ZVS7=N8EN)K:)K8M)_L=E=L98@I+B-D*B0KUX)Z=0#3ELWU3QVVL69; M[+#IC6SN5($KLV0!GK@#]:V3H4A'_(:U/_OZG_Q-']AMWU?4O^_P']* .$BN M)F\'Z#IG]FWYN=.U&$W*?97P@60Y(./FXY^7-;NGW"+K'BUWBF592AC+0OB0 M"(*<<<\\<5O#0\?\Q;4?^_X_PH_L,GIJVI?]_P ?X4 <58&2VT?P'.;-39-:11:(+< M1HC-'$_F[M@;&"0/>G6&I6=IXE\71W:2.'FB^18B_F#R5&T8')]JZ'^Q''/] MK:E_W^7_ .)K-TWPC^T51C)_X1:QMFMKM7A\1^;(CP.2$\]F M))QSA2"37?\ ]B/G/]L:E_W]7_XFC^PY/^@QJ7_?U?\ XF@#)\13?9_%/AW4 M6CF>UC^T*[Q1,^TN@VY"@GFLB_#QZC/>:.US% O%<8=1YBY'RG& M&W XXKKO[$?_ *"^HG_MJO\ \31_8C?]!743_P!MA_\ $T 6+34HKN\N[5(I MT>T8*S21E5?(SE3W%7::HP *=0 A.*XZ&7'Q9N)]DPA;2E@$GE-L,@DSC=C& M<5V-&!0!RM_(%^)&FR&.0QII\\;2"-BJL60@9QC) -<[.S-X*\4PI;W!DN-2 MD>&,0/EU+J00,\MUM[AH$,D2C 4XZ =OI6C@4#':@#G/$K+J-Y9:& M7FBCGD\V>6.,\*F"J[L$ EMO7L#6-K%K+X;\8Z5K$4NH7_VD-:7F4WE8CRK? M(HX5O7UKO,"C H Y*RF">/\ 6K@I*(9;"W"2&)MK%3)N ..2 1^=<_ TB_#G M28&MKE9X]3C9X_(?:]-P*,#TH X&ZV:1XPU*?5;+4)[+4UB>W MN+196"E5VE&"'/N,CO2V<,=GXK\.I#ILEC;QVERODK&Q6'>RE QZ!B!TSUS7 M>X%&!Z4 >97"73VFIW-K:33BU\0I?- (F!FA7;DJ".>>?PK;&HP7?Q LM0@C MN&MO[+EC,IMI JMO5L$D<< UV6!Z4 #M0!Y5Y#;_P#C MYWYQC.-O.:Z&^(N?B!;O#Y@6329(EF$;;0[,"!G&,XYKL,"CB@#S30%M5T>T MT+4]#OY=6LY$0QR"8P$JW$H;.P #G^0JW!,I\.>,XC%-OGNKEHE,+9D5HU52 MO'.2,<5Z!@48% '!K*;?4O!]])%.8(K*2%V6%B5 P*OR\<_,".*6XGW:=X*!AGW03Q--B%_W8$+* M=W'') YKO<"C:,]* /+]?EFO-+UV)[&[BN([]66W@M7$;('7]Z2!^\) SU_" MNC\6"2*+3O$]A$YNK%P/+8;6EBDPK(0>^2I /I76D"LB?1);K61>7&HSR6B% M'2QVJ$61>C9ZGGG'K0!8T73SIVF102-OF.9)G_O2,=S'\R:R/&\4CP:3.L4D MD=MJ<,TVQ"Q5!G+$#L,BNF'3FCB@#AM2TN77]>U6^TU61&T=[,3%2HFD8D@# M/4 =_>H?#\MCJ$6EV[^'KY-3LW3S!=+*(['7=$T>Z^S6^HQ7$R,C^?=*%*L^UN>-PQW M.#5W6YE\2>'-:;2=+E4SV)4SRP&*29QR$ 8!CCGGID\9KM\"D^7VH X9=434 M=?\ "MU;V=]Y%O'.DKM:NH1C&HP01GKWQCWJE+:7E]X3\2Z+;6\_V[^T9YU1 MHV59$\T. &/!W#(X->CX HP* . !L_$=MC2]*OXM2^S3*9;SSE^R,T9& 7." M2<#Y>W-5S?&YT+PK;+87B7.GWUN+J$6LG[K8"#_#C'TKT? ]*,#- #FN1BG M5/&7B&0I*$:RB57\IMK,H?(!QR1D=*ZZC H \WB=E\!^%8?(G6:VO;5I8_)? M=&%;YB1C@ &O1PP< CH>:7 HX% '%:5(VBR^(=/U.WE9[FZEN8'6)F%PCKPH M(&,C&W%5=,LKC1[OP;9W:RO):V\ZS,$9A$60;5) P/[OX5W_ :,#TH \VO+ M2\OK+Q5'96TLLO\ :D5U'"49//1/+)"DXZ[2./2MS09M-U+5H+VPT:[BDCB8 M2W%['(C19_@&_J2>N..*ZW HP* ,GQ7I]SJWA;4K"S;;/<6[(ASC)QT_'I^- MM=I@48' MI0!Y_IZR6?@?4_#5[9S-J"BXB1!$Q%P9"Q5U;&#G<,^G>K%C;2:;XJ\/VMSY MLKVFD-;R3"-BOF93C=C'.#7<8'I1@4 >>SK#I7BC5XM:T>]N[?4)1-;3V\3R M*PV!2C!>G3OZUVFBP_9]&M8A9)9!8QBV0Y$0_N_A5[ HXZ4 (1X=!(HQ* MR#ID@Y[@$9[UW'&*,#- '!W^EW&HR^+[^RBD,-]IRV\2E2//D"-E@#]0,U"^ MK1:CJ7A&>WMKTQVK.LQ:TD7RV\K;@Y'KW''O7H6!Z4 #M0!YPI_XH[QE#Y4C M27%WOI7:8' MI1@4 >;6T=M:C5-$UO2=0NKF2[EEMT3SC#=J[EESM.P8)YSC&*V_#;*GC#Q MK1LA*Z[ ]*1@=IVX!QQF@#S:RN;*3P?XDTN1-]S<7UY M'';A"6E8L=N/7G'/;%6&,EA>PZ/>K+!-'HT<8E@A+27;@$&,, 7!Z48% 'GVBNU MIJFF1Z7<2SV4\S-+IMU&3)8DJQ+*V,J >,'^]Q78:+KUCKT<[V1E_P!'E,4B MRQE&!'L>U:! P:JV%A'9&9@\DLD[[Y)9""S'&!TP, #% %RBBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ J&W_P"6O_70U-4-O_RT_P!\T 34444 %%%% M !1110 4444 %%%% !1110 4444 %4;[5K:PEBAEWO-,"8XHD+NP'4X Z#(Y M]ZO5POB96TWQG;ZM?6-S=:5-9_9GDMP[- X?<"0O.#0!T:>)]*ELTNHIV=9) MC;JBQMYAE'5-N,Y&*DB\0:=-82WHGVPPR&*7>I#)(#C:5QG=DCCOGBN3NIX+ M6*RFLM)FL+"YU L]T+=GG7]V?WFT@E2Q^7)&SUU+[R M94;=-$ G0MU/!..O% '0^)=<@O?#VLV]G=7-G?V=HTQ0!HI%&#M/(Z<=JMZ% MXCL9(-,TZ6:7[7/:HRL\;!96" MAR,$]^M9.MZM!K7AS5KBQTR=1+I\D1GEM MFCD=S]V-01EN_L*9=2JLW@F0))BW8^<1&?W8\AE^;CCYL"@#MYIHX(FEE=4C M0%F9C@ #J:S[7Q#87=S#;JTD;W"EX/-C*"8#NI/7CG'7'-5_&5A=:KX0U*RL M>;B: B-?[QZX_'I^-9%S+_PD=QX;>TBF@EL[D7%R&C*F!1&P*-D=R0,>F30! M$MV/$OB;6=.FEU*W2W$$=J\"21F%BI8N>, YQ][@@5TNHZO9Z!8QS:A-+Y0* MQF7RVL1K,>D%I1>21F54,3 %!U.<8]JY_7M7CDN]' MO;:[N8H$U0VTZ?,J/M#;AC^+D8_"L@1:_)VM)!J=C(MHMMN/SQG]W(Q MX[L=WT45L:W:KIJ^&+4;Y/LU\CRN$+<;&#.V!QEF_6@#5?Q%I5]I.HN;J>VC MM08[AC&\'["X^US3P31(())07EGR..,9+$<]*Y MN:4)K7C,LDH2XM(UA/EMB1A$5(7CDY('%546]LO#?@S58K2XGCTB,+>VR1DR M*#%L+;>I*G^= %[QKKD5YX/U273KVYM;O3Y(EF0%HG0LZC##T*M]*Z2R\06% MWJ;:9&95N%0R 21,@D4'!*DC# $CIZUR?BR]75O">J26.ES1I< (;=EEN' M$BD_+C. HZFM>[G63Q[HTT:R-%]CF5I!&VT%BFT$XXS@]: .@U"_@TVU-Q<$ MA-P4!5)+,3@ =220*Y?QCJJW7A+4I;:6\L[BR,9<07$T+RH&-OGS(_F&'&.?E.#7'WZ:BWA;7;%IY]4A/DK9W36Y\Z7D$JV M!\VW'WL=S0!VEEX@L;K43IB-*MRL?F 21,@D4'!*DCY@#CD>M11>*M-GFA5& ME\JXF,$5P8R(WD&05!^H(]#BLF^D+^/M#NHXI7B2PG1G$3;0S[-H)QQG:>M< M^SW-QIVESS6&H"YM]71[B".W=8K90[<*H&&Z@YP3SUH Z2PCE;Q7XGMFN[DQ M""W9,S,3&65R=O\ =_"K/P]FEN/ ^FS3RO+(Z-N=V+,WSGJ356PE*>+_ !#< M203I#-;6_EN86PQ56W '&"1D=*M?#Z.6#P786\\,L$L097CE0HRG<3T/L10! MG2ZLFD?$>_6XN+N6%M+CE2!=\N&,C [4&<<*.@K?@\2Z7X_XEOQ'FU2[CE2TFTM+>.81LREQ(S%> <'!'7K6#+H6I M66E1ZJEA-/&-A]P?44[4-6MK!X8)/,>>X)6&&)=SOCDD#T'J>*R_#QL;N_FOM/T:2TC:) M5:YGA,?2_'-CJ\UO-+I[V+VKR11M(8'+A@2%!.#@#\* M (O"FJI"GB.ZNKNFS/2M!N+2[:SFB:XNX6C:!F0C8I;J22,XXP* .EC\5::\]O&QFB6[S]FDDB*I M-@9^4_3D9Z]JK'QSH@MENO,G^S&8P-/]G?9&P;;\QQ\O/'-8>A36UW!I]M-X M8N8M2LV3SCRM/O4@ M8SC;S0!VMGXBL;[49-/C,R3HGF 2PL@D3.-RDCYAGN*B?Q5ID3H7>18))O(2 MY\L^4TF<;=WUXSTSWK*OR;GQ_ITT44WD_P!G31F7R6VJSE2H)QP< UBZ%%%! MH\&@ZCX8N)]4MB(_WD+&"3#<2;_NX[^N10!N^,-<@_L#5[>VDNA+:P-OGM@P M$+[<@%A]1T]>:W=$=FT&P=R2QMHR23DD[17%%[JQ\/>)]#N[*Z>[FDN9;>2. M!W6Y63)!# 8!'3GTKM-!+?V!8!XI(G6WC5DD7:RD* #3Y=@DEC*@ (&)8]!UR/:KD/B2QENK:W830-> FV::(JLV!GY3ZXYP<&N5 MU#3;V^3QGI,$,Z7&H.LEL_ED(ZB%!C?TY*E>M7[\MXD@T&&VMYXI[:^BN)P\ M17[.(P=P)(QDGC'?/I0!N^)59O#6HO'-+"Z6TCJ\3E6!"DC!'TK)\/>*].%C MHVG7$TPN;BTB"2R1-LE?8,@.1@FMK78)+GP_J%O A>66VD1%'4DJ0!7*2VKZ MUH7AG2X+>=;FQGM9;AI(63R/* W9)'4D8'KF@#I;[Q+86#7'FB9TM<&YECB+ M)#D9^8CV()QG K3BF2:%9HV#1NH96!X(/>O/X4CTO5]6T_6-!O+W[7=23VLT M,+2).KC[A(X!'3GC%=O8QM!I,$?V>.!TA4>1&?E0@#Y1[#I0!2A\5Z9<36Z1 MM+Y=U*T,$YC/ERNN<@'\#ST.*AN/&ND6Z73DW,BV4ICN#';N?*P 23QP,$>36DZS2Z=XUC^RW(:Z= MC #;OF7,*H-O'/S CB@#NHY4EB61&#(X#*1W!Z5E77B?3K1K@OYSQ6C;;F>. M(M'">N&(] 1G&<=\5-X?W?\ ".Z>KHZ.EM&K*ZE2"% ((/O7+6"S:9HNNZ'? M6LSW4LUP\&V,L+I9,E<$#'?!STQ0!T5]XKTG3[J.VFG=II86FC6.)GWJ #Q@ M71N&L@_V9E98PA;AB"/O=JPK"QFT?7/"EI<":3[%I MTL,THC9E5V"8!8#'8_E6INS\3"^R7RQI8BW^6VS?YA;&[&,XH NS^+M(MTDF MDED^S1S_ &=KA8F9!+G&W@9)SQTQGBHX=2TR;Q1*([Z[-S'9AGMF#B)4W<-@ MC[W.*XR&6R;2[G2+Q-0BTK^TY)<+8R2':)2V!(O&TL"<]0#CWKH;:[BE^(IO MXA(]I+I"K'.(V*,=V[ .,9V\T :<7C319DMY(Y9FAN)O)2;R'V!]Q4!FQ@9( MP,U8O_$MAI\UQ%+YSFTC$MR8HRPA4]"WY$\9Z5P[QS?\*O%LMK<_:1J2R>5Y M#[\?:0^<8SC;S5[6[B>^OO$%N;2\ >R M%M86 N-I(^AH U=8N M&;Q?X6EMKN4V]VTQ*)(?+D B)4D=^M;7B!&;P_J!266)UMY&5XF*L"%)&"*Y M-9FDN_!$WV6Y1+='$Q:!QY>8=@W<< MQS78ZM$]SHM[#$NYY+>154=R5( H MYSPUXNTQ-,T;3[FYE^TW-M&J2RQMLEDV@E0Y&"WXUM)XCLI/[0").7TU@+B/ MRSN7(W @=^.>*Y0VSZOX4\/:-#;3"\M9;=I]\+)]F\O!8DD=>"!CKFI]\^G^ M)?%,$MA=2'4DB>V:*(LK@1;#EN@P1WH T[SQ?&+[1([.WGF@U,-+YBPL?D"$ M@#WS@_2NC>58XFEQNT6TC>*9/(8NC&+ RH&<$ MBNVU66>/1KN6UMQ<3K YCA8<2-M.%/U/% %.T\3:=J%Q;6T9FC-]$TEJ[QE1 M,H )*GZ$'G%6)R2=HJ"\\0V=G-/&4GF^RKNN&AC+B$=?FQWQS@9.. MU/T%BWA_3]RNK"VC#*ZE2"%&00:Y_26ET#4M?M=2BG=;V[>[MI5B9Q,K*!LR M!U&,8]* )?&'B 1:-8M8O,\6H7,">?;J2#&S#.&'0D(]2T<1.-(UA!=7$@/"LHVL@] MV.P_@:M>&(K^/1+B^UI"MS'";1?E+,4CRN[&,_,V3^5 $?@_Q-:Q^&]$MKR6 MYDGNHP@G>-V1I#GY2_3G3>)=36&\N7N88HA/"^X11#YL%01C)YR1 MZ5R<231^ O#$+6MRLMK?V[S1B!]R*CDL2,9P!6F;>:]\6>)H84EC%[IL4,$Q MC8(7"N#AL8XW"@#:'B;3)Y;>W,DT27S&.VG9"J3-C.%;Z=#W[9K!\.^([71= M-U%=2N+N9(-4GB,S*\OE('PI=N<#ZU+H&L7$VEZ?I=SH%RFH6/EQR^=;D11; M1@R*YXZ XQSS6:\EV?VEY6E,%I((KB=(RR1/QP<<]QT!QFLO4% M;Q'JOAZXLXIX397!N;AI(RAB7804.>Y) QZ FL"Y>V*^(-)FCU"+3;N_9I&B ML7FSRN_:Z\ %@>Q(YH [F;Q%9Q.D<<=Q/*\1F\J*%BZITW$$#'X\GM67<>-+ M=]2TB&QBGN;:_620S10LWRJIX QUW8SZ8K&GG@M?%#ZO-IUUJ.D:G:PK!<6T M+2&%DR-K*.1G/YU/Y/\ 9^J>';U-&EL;.-[H>1!"6,>\?(650<%NI]": )=- MUF'0]7\2?;9[VXBM[F-A\KS&)#$K$G&=JCFNEN-:M($MBF^=[M=\$<*[FD7 M)(]L$E+ M9744<+&2VD 4[MO4C((./2@#K/\ A,]%^SV\QN' N)S;JIB;DS66BS6D!UE+EHTMVWE N&D M=0"02?7G&*[X8*\=* ,,>+M.-GJ%V8[D1Z;(8[K,)S&0,GCJ< @\>M6/[?LR M+#"3$:@I:'$9/R@9)/H,G=U(6IO! MNFWEEYL>H(X72]]E:LYSOBW;@_XC8O\ P"@"IJMQ:7'@#Q%=Z5J-^QA-Q)YK M2NC)(HR5'0A0>U374DRZGX.=;B<"<%9$\PA7_.: .R=UBC9W M8*J@DDG K(A\4:=-=VMOF6/[=G[+))&0D^!D[3].><9[5+XCT^?5O#>HV%L M^R:YMGC1B<8)! K#TG5[G4[&RT^30KFWU"!529Y[?;';D+AF5SP?;'K0!K3> M*],@1IG:7[(DOE-=B,F)7SC!;Z\9Z9[TZ[\3Z=9Z@VGOYTET(?.$44+.67(' M&!SU[5R5I!=1_#J[\*W5G<-J:1R6Z+Y3%9=S';(&Z8YR3GBM2U@DL_&UBKQW M$D=OH_V=[CR6*%PP.-V,9(!- &S#XGTZYTVVOKA&T MYSZ5FZUXP6TT^*:TM+DR/?):.'A_U1+#.1]#QZUA6-I%+X>^QZC8:C&#JT\R MS0PR)); L[)(,#.#T_'FENK75Y_#+?:1/?+:ZQ#+%227'Q!T2^2SNA;K9S))(UNV$9MNT$XP"<&J"V=U/H M7C#15M+@75U-=/%F(A'#J-N&Z'/H* .K;Q!8I=6=NQE#WT9DMSY9PX"[B,^N M.U9V@>+8M4M]2NKF.2UAM+B10TL3(%1,#))XW9SQ6-%?OJ&J>%)X=-OQ':K) M',SVS+L)B"]QTSWZ53^Q7MSX8\2Z-;VTYO?[1EN%C,;*LJ;U8 ,>#N [&@#M MK7Q#876H)8 RPW$D9DB2>)HS*@ZLN1S_ #JU?ZA;:;;^?=2;%+!5&"2S$X"@ M#DDGM7+Z%=:7JVIV4]IH-U%0_;AFW=H6".<;MH8C&[':LF\"WWB*XUJV#FT@TF2!I/+8"5V M.0H&,G&/UK)1A%X2\%0R0RI):W-N9T,39CVJ0Q88X )ZT =G>^)M-T]IA/)+ MMM\>?(D+.D.1GYF P.HK2CF2:%)HF#QNH96!R"#T->>1&UT[5M8T_7M*OKC[ M7=R3VLD"2NEQ&X^Y\IP".G-=WIT7V?2+:$6RVVR%5$"MD1X'W<^W2@"G#XHT MN>ZB@25R)I6ABE\IO+DD7.5#8P3P?RJ"?QIH<"73&YD<6;[)_+@=O+(&23@< M ]>E<;#E8?@ M*\FO#KIDNY[F./4G2(SD[E4*O&#TQZ5CZ7/)I.KZ#JEW%.U@^BI9M(L+-]GE M!!(8 9&<8SCM6QX'9A>>("UO<1+-J;S1M+"R!E*K@C(]J .NHHHH **** "B MBB@ HHHH **** "BBB@ HHHH *@M_P#EI_OFIZAM_P#EI_OF@":BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ I,"EKG-5\3&Q\3Z?I M;AUN(Y)'=(2V0 MH& N/O-=5 M-K=G$ML4,D[7:;X4@0N77&=WL.1R?44 :&!FC%4]+U:SUBU^TV4A= Q1@5*L MC X*D'D$5)?7T&G6DEU$3O')"V[RSD!@ "2.#].] &O@4 M8KGU\<:(3:%I+B..\4&"9[=Q&Y*[@ V,9QVJ[IGB&QU62YBA$\4MKM,L=Q"T M3*#R#A@#@X/- &GM%! -8R^*]++VP9IDBNY/*MYWB81RL>@#>_;U[5LT &!1 MM%8:7NG#Q3> 7%V;N"T4RP%7\M4W'#*N.23D9&>E1IXWT22&VG62X-O.-'E3?"+N1/WF76U?: MICSN!..#P>#S5U_$6GHNG.QEV:F5%L_EG#%EW 'TX!- &I@4;17/R>-M(2"[ MF5+R5+*0QW'EVKDQ$ $EAC@ &IT\5Z:]]:VH%P!=G;!.86$4C8SM#]"<4 ;& MT4H&*R-0\36.G-<^9'<2): &YDBCW+"",\_@<\9P*C?Q;IJW4MK&EU<31PK. M$AMV8NC="O'(XZ]* -L@=Z,"N7U/QC"-*TN\TR&:>/4KJ.%7$?W 6^8$'G=@ M$8]:Z:)_,B5]K+N&=K#!'UH < !TH*@TM(>E "!0*7 KE?$MC=66B:_J_P#: M-V)8[>26U2*X=%A"Q\< X)W GGUIFGZ5/>>'M+U!M3OMSVBR72FZDQ+NBSD< M\'=@\8[T =9M%*0#UKB_!WB:TM_#.B6UVUTTER@C%P\;-&9"3A2Y[FMZ^\1V M=@]PK17,PM%#7#0Q;A",9Y_#G R<4 :VT4;13()XKJWCN(7#Q2J'1AT8$9!J MOJ&J6^FB$3;VDG?9%'&NYG;!/ ^@)S0!;(!HQQBL*7QCI<%C=WDBW*K8OLND M\DEX#C.64=L=QQ5VSURTO[M[:W$K&.-)&?9\@##(&[IG'.* -# HV@5BCQ9I MOF6P83I!=2^3!QHN_%FF6:RRR^=]FAE\F6Y6/,:/G&" M?J0"0"!0!M8HP*S(=?M)[F^MHTF,U@J-,FSG# E2/7@&LB_\9*3H3Z=;SS0: MI-_K!%_ %8D8/.[B@#J<"EP*P+2]TV?Q==1QS7@OH[13+#)O6)4W<$ \9SW' MI4H\6::?)40Q71C_=.Y. >O)& 2,'UH V=HI=HK$N/%FGP7EY9K%= MS7%DJM+'%;.3@YP1QR/E//2M/3M0MM5TZ"_LY/,M[A \;8QD&@"P!BC JO?W M]MIEG)=WQ^G M6@#3P*;)&)(V0D@,,'!P:XFPQXHU76HKL7\+07:Q6TD>8S;A41NO8DDY]X+_=W[R:9864M&5V*."P/)SDXKHM-\1637%I MIC"X6>6'=$\D+!)MJ@MM8\$@4 ;>T4N!7/Z=JVDP1:O?1W%VT<5T1<"M*RUB"]NYK013PSP(KNDT>T[6S@CL?NGIZ4 7MHHXZ4M#] 6_EN'FO8]L;>6\A M=N3RV.N!]:TX_&NFR_:8TM[]KBU(\VV^RMYJ@C(;;Z8[_AUH Z#:*6LL^(M/ M.G6=]$[S1WV/LRQKEI21G 'T!Z],54D\::/!;W$UP\\)M9EAGC>%MT3-C;NQ MG .1STH WB 3FC K(M_$UC!D,J XRF>O/'XU!X/UV7Q# MHRWTT#Q,[R8RN%VB1@ #W( &?>@#>P*-HJ&[NXK*VDN)@^R,;FV(7./H 2:Q M!XXT8I9R,;E(+W'DSO;L(V)&0N[IDXZ4 =#M%&!658>([&_GNH%6>"6T4/(E MQ$8SL.<, >HX/Y5'9^*M.O;BTA19T-]&TMJTD>T3J "2OX$'!Q0!LXHVC.:R MM/\ $EAJ45]) )A]@=H[A9(RA5@,D<^WX5?L[J._LH;N)76.9 ZAUVG!Z9% M$NU2*YZT\*W%@K6]GX@U"*T+%A#MC8IDDD!RN>I/7)JIXIN!IWBGP].>VN)XS)"L\>SS5'7'N/0\UJ. M-RXYY]#0 N!1M'I7 Z#XELM!36EU":]ECAU28&39),(4^7&YN=HKJI?$5A%J M%A8DRF345+6SJA*2 #9:[?,)7Y?F&0 ?I M4UQ<16EM+W,T>T2H,9 M(Y]QP<'FF3^+-,MP))#*+4S_ &?[5L_=>9G;C/UXSC&>] &U@48%5+$G![\8J\?%.G"STV\'G&WU1TCMY!&<%G^Z#W&: - MC'&*,"L6[\5Z;:27*R"8!D*3@<>E '5;11M%':LB^\2VEC-%+1]V&SC M@@>AJ;_A*--;3K"]A:29=1.VVC1/GD."2,'I@ YSZ4 :VT TNT5RVL>,HH-! M_M#3X)I7^U+:LICYB?>%8,/49_'BM:/Q!9OJ:::8[B.ZD@:=$>(C* @$_F10 M!IX%!&:PG\9:-%I\U_)+,D,%P;:4F!LI("!@\<E &OM%+M%4=,UBTU83BW+K);R>7-%(I5HVZX(^E6;FY MAL[>2XN)%CBB4L[L(]/DNH+9_.@DNE+0":(IYH R=N>^.< M=:KP>,]%N;L6T$TTDGVG[,0+=_EDP#SQP.>IH W=HI-HI>H-<'HWB.UT"Z\1 M#4KF]GB@U%@&V/.8H]B'+$9VKR>M '>8%&!65/XETZ"YL("TCG4(#):>-= U#[-<2VZ0W,3M#"TFUF";CR@OR\<_-QQ6?&D]A_P (_J=UI-]=V/\ M926=PD,4GFV\@P<8I/%26\F@3Q75E->02%$DB@#%\%@-R[1G*]>/2MC%!&: //%.K6> MGZU';?:-9LXK2/[*]Y9YER6.Y#E09=H^;D=\4[)76KRXCM-5FBN-%,2S36TA M+N&;(QCY>HP,#V%>@[:,4 >? R+X9\&PFSO/,MKJ!IU^R29B"HRL6&WCDBK% MQ:S7WC+Q%#%#&=H'$9?#Y&[&.-PKN<48H \]T QSV-AIEWX7NUU. MT:-'\^)_(0I@>8KD[>@R,2#4%VC 92NWN5[$8YK3@>6Q\=7%Q=6=QMO-/@59(H6>-6 M4N6!8# QD=>M=;BC% '&>&[>>Y\$ZE9"VGAN)9+O:D\+1D[WXX]Z]#Q1M% ' 6AF6P\:*UC>@W4 M\K6X-K)^]!C"C;\O/(I;MY7T+P>HLKTR6D]NTZ?99-T02,JV1CC!/XUWQ&:, M4 >?+ =+UO5K74_#MSJD5]<--)GFL9H(ET MF&',5N_DJZLQ9%.,' (Q788'K2X% 'F-C:WL?@G2V;3[WS++6A<31?9G\P1^ M8QR%QD\,.E>@0ZEYNHBS^R7* VXF\UX\(,G&W/\ >[X]*O8!HVT +1110!A^ M- \G@[5H(HI999[26*-(HV=F9E( P >],T28Q^"K02PSH\-DD;QM"X<,$ (V MXR>?2M[K1B@#S:.*YC^'_AJU:RO?M%M?6[RQBUD+(J298D8XXJT8O[+\0ZI' MJ6@76IV^HR_:+2>&V\P".W9(E!BB^['Q M]T>PZ5S/C2UNH]5TC6(].DU&TM#)'=6\2EG"N!\ZKW(VUU]&,T <(LFY RL"W1>H/)K(L[:_MO#_A":;3;L'3KH_:(Q"6=048 M[1DXR1]*](QFC;0!Q+6\][X^U-E@NH8KG1EMDG:!@@DW,<;L8R 151[*\U'X M?VWA:6QGBU&/R;=R8F$:"-U_>!\;2,+G@YS7H.!1@4 :WFB5@\4T91E.\GH1Z$5T>*,4 M <[XXTZ]U#1(GL$,LUG=17/DC_EJ$;)4>^.GTJ":,Z[XGT;4+>&XBAT]99)7 MFA:,Y=0H0!@,GJ3CCBNIHP* .3\)RLNL^(5DMKJ(7-^9HFEMW173RT7()&.J MFNL/(HVT4 >YN'AVVSL) X&W:0.?PZ=ZT[]VFUKPE, MEM=E(/,,Q%K)B/,6T;N..>*[/:*,4 <+!LFL_$Z76EWEQ!9 MMG0SXM7_ '0\HH=W''S$5WF*,4 >?ZAI]WK%[XSL;:"YB>_MX5MI9(72.0HA MR Q&.N!^-6='N;>Z:UD/A.XM+JU&ZXFN+4CRL*0?+/5B3C&WM7;XHQ0!YA## M=CX56MC_ &?>_:X[Q"83:2;\"??G&.FWFMNUGN=*\1:V+FRO);?5"D]K/%;N MX^X%*-@?*1@=<5VF*-HH \WT^*[M_#_@Z&;3;U)+.[#3J;=B8U"N-QP#@?,. MM:NGL\7CGQ)=/:78@FMH!'(;9]KE%(8*<*3 H \O@LKZ+PSX7OFTBY MNDTI9(KVQ:!A+M<8W*I W$>U7-=C2X\-W&".174XHQ0!6U-Q'IMRQ5VQ$V B%F/'8#D MUY^R7!\#>%+DXHQ0!QDTMTOC?5KBUL9Y2V MDK' SP.(I)5+MLW8QW%9-I]I?5_"U^-.U5S#YR732VS((W:+ 4)P$4'C( 'O M7I.T4FV@#B];TFXC\6I'9;1;:]%Y5\N[&WR\$N!W+(2GXBNT4!5 P , "LO M2M 33;B2YDOKN^G;(WUM##;+,I0S&,EB2#R ?N\^]=[ MBC&* ./T*:#4+^UE@\+36-Q#DW$]W;[/*XP0A_B)..G&,UV!HQ2T <';I<6- MCXHTV;3KI[B^NYGMU6!F242* IW ;0,]&7/\ M<2C(^A (_&NO(K*U#08]3U".XGO;H0(FUK17Q%)@Y!88YH =X>MIX=,$]TNV MZNV-Q.N<[6;G;G_9&%_"I-<:ZCT2^>RMUN+@0.8XF&0[8X&._P!*OTM 'G=B MDS>(-!O5T_5F#6LT,TT\#*4D8+QM. @&#V ]*L>';G4]'T9?#4^AW,][:EDA MG:+-O*NXE79^@Z\CK7=XHQ0!QVFP7%OXN\2V\MK<_P#$R\IX9A$?*($6TY;I MG/;KTK'A-\_AOPWIQT;4?.TO4+?[2#!@#9D$J3]X=\CCWKTG HP* /-?$B:C MJ%AK\$FEZ@]PMPIMXX(6$31 J=^1P[$ YZGMBMR-YIOB'9W?V.Z2$Z4T9D>! M@JL7#!2<8!P*Z[%&!0 'I7!^(K-I=7U"]TV/4;'5HU5(I(87D@O1M!"N,%>I M*Y.,>M=Y1@4 FRQ)-&T,G*NI!&>H/6L.T\(I:6JV4> MLZF;%%"K;&5I8X&>,UMZG= M/;^+](US[!>R6DEE- ?+MG9TM=E@48H \NGBO1X5UN!]+OQ+- MK@G2,6S,73S$8D;0>RFN@\612MJ6BZY%I]Q?V5MYJ7$$4;>:%D <+P3@CD= M:['%&* ,/PV()#MHS_VA87<- MN#;:E9H[\#I/)'8 &[EBCW+#D9YYR>.> <5SN=1<>$6U&TE%S#,TER8K<[4! MC=06 &%))'';-4M4G":KXCLUM-2-I>LB7#VUF9P6\L!BK C:<$#!!Z9]J .L M/B[2Q<1VZK=O--"9XT%JX+J"!P".3R*=#XLTN716U7?+'$DOD/&\9$BR[MNP MKZY(K$L[F"Y\4Z+=6%O=?88]/E@WM X\MMR@*V1P?D(.?2LR!]0L])U[R;"Z MS-K;3@_96+"!F7,B C!88..N.M '53^*;=+34F6SNOM6G1"22U9!O(()4@@D M$<'G/.C^*TGT_1OM]O<1SZDJJCF(!&?9O/?(& ><=JP[6VF?7->2#3]1$ M=]IB+#+,7$7D$2 >44)"GD@$T M =)/XNTRU34WN5N8O[**_:1Y)8@,-P(VYR,#K2P>+M+GBFFQ;) R MK('^Z$/\1SQ@=ZY34(M0N(O&S_V5>HNI6D26JF+)=O**XP,\Y(^G>M+7]+O= M5\!ZUO&B\Y(ITP9 M$Z9!!(X[CJ/2K.I:G;:5:_:+DM@N$147K--#&,LR;2I('U M%'1KU3\0=;9S=01QV,+R1W+DB-BSDDH$K:S2 M1[4F.,X!Z@DU<_=V5WKVNZ[]EM+J&"_T=+>&XFB:-=X,G!#8/\ $.U) MH7ESI8VD_@PVVHVS)YTTMJOE1;>KJ_25(PJC@C)&!WKH5\06.FQ:/:>3>.FH(B6LA ;/RY 9B>#CGGK7-6<-U_P MC?C*+['=^9>7MS);J8'!E5U 4CCG)%;%_I4^I^ ;:*W62*_M+>*6W+H59)HP M,<=>2"/QH V)]>L[6YNXIQ(B6<(FFF(!10*;-;P6ES;7=K,\ M!N(DEBR94'7;M)Y&1D=?:L;4M$U'5? ]XR0JNJ7Y6[:%^FX%2L9SZ*H7ZYI= M,DAN76XA\)2:=)#$_GS2VJJRDKC;'MY;)/4<8% &E9^--*O(1<(EU':FV-S] MID@*QA0<$;O[WM5B+Q+:-J-O87$%S:374;2V_GH )%49.""<$#G!P:YF/1K_ M %/X41Z1#;R0W\,*#RKA"FYU8-MY'(.,>G-2VUL-;MC!;^%3I%T89$ENI[9$ M,+,A7]V1R3D]?04 1>*]9@U*+1;JU2\2%]6@2.XR5BF&_GY0W(XX)&..*[BY MC$UO)&Q8!U()5BI'T(Y%>?.NIR>%-#TIM$O1>:9>6PFC$7RE8V +*Q."".>O MUKT/YGC/RD$CH: ."\)^+;#1?">GIJ'VPHTCI)=F%GC1C(P 9_\ ]?O76'Q! M;#Q"NB-!<"Y>$S*Y50C(, D'//)Z8S7'PZ=>S?#M_"CZ?HRKKNC::;.XFMYIW>54"[9@L9(7DC/."0?0=: MZ#2;'^SM-AM2Y=T7,CGJ[DY8_B236'XC$Q\4:!,EIYKB/$T.J:C:>)K-]+OI967%DL"%8738/F)!&YLY&#D M\ 5?FDU/3/$EMKJZ3>W5E>6"VTL42 RP.K$J=N>AS0!N6WBW3KZVM)K))[E M[LR".%%"OE.'SN( P>.OTJI?:UI&H?V0]RE_$\M]MMU567$JEEPY!QC@\$U1 MU>V&IK9G4]+O;(%I9;>XL0QFLS\N-VS/+9)/4=JJ/%K']F^'Q?V]S=36VJF5 MY%MCN,(+A7< <$@@D=: .@E\9:?',]*GEL1$MTT%^RK!=>01$689"[CW-9EB+B'Q;XGN9+*[$%Q%#Y+^0^)"J%6 M XY.?SK)-I?CP)X7M/[/O/M%G>6[3Q"!LQA#\Q(QT_G0!T\$^EWOBG4K:,W@ MOEM$6<,71 FYL%.G.<\C\ZSO!FH1:9X(2XNY)7 NYD7DN[DS,JJ,\DG@58M# M,OQ U&[-KC"N?CTC59_ ]NL>FR/=:=JCW?V.="OG MIYC':,]^,5'XFL[V'Q!HNN6UN]S#8M)'Z6,PI,LTD)6-PW96[D=ZY^^L9 MKW4M:UN&UN!%)I?V.%?)8/._S'(7&<#('(]:Z#PN'3PUIT4D,D,D-M'$Z2(4 M*LJ@'@^XH PO$\PL/'7ARZW7#*RW6^*,L^_$?&$'&(=;UR6%X8]1,4<<:,&,$X!8,& /L<8_&@!]O MXCM9=2@T^>"XM)[J,R6ZSJ!YH'7&"<$>AP:MZIJEMH^G37]T)/)@4L_EQER M/85S&D1+JM%S_ &I#?>+[BPTZ:2:>*$VHD@.R4JFUL9&#C/3O0!T5KXFLKJZ> MT:&Y@G6V%RLW:GZ;%/%XVL]273M3:VDTMHGGN$8MO#ACD$Y7CM@>PJG]DOS\+KS3O[ M.N_M;74A6#[.VX@SEP>G3;S0!Z2OW1]*P[KQ;I]H;EGCN&M[2=;>XN40&..0 MXX/.3]X9(!'-;$,GFP(X5@& .&4@CZ@UYQXBAU+4=,UR&72]1DNX[L- D2$0 MF)74AQ@@.Q .4OFJG0-CD#VS0!EOXMT])&_=W!MUNQ:-!DUYMJ<6J7ME<-/I.HR74&JK(4C3$2Q+*""BY 8E<'/)SFO1XW M:2%79&0L,E6ZCV- '-O\0=%2T-X8[[[,DS12S?96VPD-MR_IS^/M6M/KEO'< MBUMX9KR;RA,4MPIVH>A)) Y[#.37#Z=(][X.U[1H;*XFN;J]O(8@(6*,66\2[=I"Y(SG/3% &K-XST> M'2[;4O,F>WN9A I6(DHY;;AO[I!]:I3^,I'U?3+6UTF_"7$TR2>;"$9@B$_* M&(SR0<^@K$O-&O[3P^%^QW$LEYKZWQABC+F*+S0QSCO@9_'%;_B!)U\0^'M3 MBL[FX@MWF$@BC)9=\>%)'89_*@"W>>++"SDN@\4[Q64B1W4Z!=D+-C /.3U& M< XS6+-J":-\1-2D,5[=*^F12"&$-*<^8^< G & /05F^);?5=3L?$%K+I6H M2W'F VBQ+B$Q#;\W!&Y^O7)X&*W!)/:>,9=8GL+Q+6ZTV*)"L)=@ZNY*L%R0 M<,* *GBK5+37O"-EJVFW$OEF^@ PS(?]:JLK+^F#737>M0VMV;..WN+NY6+S M7C@4$JO0$DD#G!P,Y.*XRZT:^LO!SQ_89S/>ZNMZ;:*,N84,H;!QTPH_.K&J M6LFG^,+C5KK09=7T[48(@IBMQ));NN1@J><$&@#L=*U6SUK3HM0L9?,@E!VD MC!!!P01V(-9NM:O;217VGQQ7=P\$.ZX:U.WR01D9.X'..<#)QVJWX?MQ;:6J MC3HM.5W9UMHD"[ 3QG'&[')KG+&.^T37/$-M=65W<1:G-]HM9X8RX;*!2A(^ MZ1@=>,4 6?">L16?@G01-YMQ4X))Y/8#))-;-IX@L;F.\+LUL] M@?\ 2HYP%:(8SDX)&".00<5QVDV&J:;:>%=3ETZY5-/MY+:Z@V[G0.!B0*,D M@%>1UYZ5:O\ P[=:]/XDO[<2VXO[*.VMA(I3S&3+%B#R!G"\^] '0IXHMGNK M>V:TNXY;N-Y+5711YX49./FX..<-BH_^$PT[^P8-:$-RUI-*(LA!N0E]@R,_ MWN.,U6T?5]2U-+2WDT&YLIX1BYDN4 1 !@A#GYB3TQQCK7+K;:K'X%E\/_V- M?-=VEXK%P@V2*+@."ASSD<^U ':3^*[*'4;K3DMKVXNK2-9'CBMR20Q(&,XS MT//2H(_'&DRQ6H MQD#WYZ=N^*P+FU?3?%=_=WOAR75;+5!')#-%;B1X6"A2C*V" <9JS;6UQ;^* M=$=M):TAALIXV2W@)B@+NI5<@8Z YQQF@"?5_&B+X7?5=-M;AY/M M61T :! M]X4[AGW_ !XKJ;>D7UA=O:1V M2JJX7",SD&7[W' &#U'-:UKXETVQTZV_X^VT]76UCOY<,CL#M!)SNY(QN(QG MO5'R9Y?'^IL;:[CM[K3DMDN1 VP.&8GG'HPYZ5G1V%_/X!7PE-83K?QA;;>8 MCY>T.,2A_NXVC/7.>* .CNO&.GVVH7-@+:_GN+4(9$AM68[7) 8>H&.H_6H9 M?'6F16ES=BUU"2"SG:"X=;8_NBN,ELX('/UZ\5#IJ30^/=4E>UN1!+9V\4<[ M0ML9DW[AG'^T/K6.+:];PMXOM_[/O/.O;RXDMT-NP,BN%"D<>H/TH ZJ#Q18 MSZM%IWDW437"L;>66$K'/@9.TGKQS45SXNT^V:Y+17#6]K<+;3W"JNR.0XX/ M.>-PR0".:R-06XFUCPC/%8W9BM3(;@_9W_=9BV#=QQS65X@M]3U'3]8AFTG4 M9KI;Q7A6)<0>2LBD,HR [%1SP3GT% '41:_-)]&%G-Y$%LCF3Y<$LQ^;K MG&!C^E7O$FLIX?\ #UYJKJ&^S1EE7^\W0#\216/;_:X?'+7KZ==>3>Z?%&KA M,B-E=B0YS@<$&I?B+83ZCX&U&&V0O*BK*$'\6Q@Q'Y T :^CV\T&G1-6*6U]<7-FJM)%#;,6(;.",XR/E//2K$VL&W MT>SO;:SGOEN/+ 6W ) ;'S<]AWK BOTL?B5K'F17#J]A;',,328(+\$*": - MF'Q=I-UH]OJ5O))+'=2>3#$J?O&DZ;-O8C!SGI6+H5RX\=^(G^S7@*6ELQMY M7#-N)D)V_,5P>.AQ67;>'M5T=--UF.QDEV:M<7!S-9>&WB MO;:>UDAFFD83Q%/E+LP.3QT-)\.;::#PC%-,I4WD\MRJ^BNY*_IS^- $?B_4 M)AK>A:;]CN)K:XN6,R)MQ.%C9@O+#(!P2#@<4_0;/1(-<_=X]#2^)A/_ ,)-X=N([.ZFBM)Y7F>*%G"*T94'@>I[4MGY MR>/M3NFL[I;>2RA1)C VUF4L2 <>C"@"+PAJ<&F^"89KJ263_2IHD!R[R,9F M55&>2>U;MAKMK?WT]ALEM[RW56>"90&VMT88)!'T-<0-)U&3P59&/2I9IM.U M1[N2QFCVF:,O)P PP3M<$5T?AX6UU>F^L_#?]EQ^5L:6>V6*9VS]T <[1SU] ML4 ;.H:K;::L7G;WDG?RXHHUW/(V,X ^G.>@JFGBC3VBOFD6XBET\ W-NT1, MB C(.%SD$=QD5G>*+2\BU[0]<@AEN+?3Y)5N(HE+,%D7;O"]\8[<\U6GLY;C M6=:UZ."?[/+I@M(D\I@TS_,8XG;& 3G/\0Z XR*LWFN6]I? MI8)#/(1J%[;Z_ ^G:@TZ72/;I!"PB:(%# MYA(X=C@\')X&!Q6AJ^H2VGBZVU"SLK\RMINR8Q6OG?*7RH9,@J1ACF@#H;?Q M9I5WIR7UN\\D4L@BB'D.&E?GY5! ST.>PPQ:/=N]]8W4)6:02 [F"'@GYB1BNJ\.+:3W M4U[8Z!_9L+1JGFS6XBEE.>F.NT#UH Z.EI!TI: "BBB@ HHHH **** "BBB@ M HHHH **** "H8/O2_[YJ:H8/O2_[YH FHHHH **** "BBB@ HHHH **** " MBBB@ HHHH *0G%+7)>.-2N+9M*LHX+AHKJ_B25H\ 2+R2G4=<#(Z8H ZO<&' M%847A?[/-.UIK6I6T,\K2O CH5#,36QE M,$C.L4:$@':,[0$K^+2]#U::[FD:*'5KF-"S&1V_>;549R2>@% ' M565E#86R6\ (C3/WB222>.M2:GK,.FW-M:F.6>YNRPAAB RVT98Y) ]Z -*BN1UCQF$\.QZAID M$[O+=K:L"JYA?>%8,">O4#&>HJU_PD-XWBV'2_[.N4A:S\YLA,@EP 3\W0V AN%M[NX-O!C#:2"/?/'>IX?$]K-JL.G&VNXW MN8VDMWDC 68*,D*<]>>^* -RBN=\*:]=ZX+Y[FRFMUBNY(DW[2%"X7;D$Y.< MD]O>NAH 6BBB@ HHHH 2LJ7P_#/K0U.:]O) I5EM&FS KKT8+Z_C[UK44 %% M%% !1110 4444 %%%% !1110 4444 %%%% !534K'^TK&2T^U7-KY@QYMM)L MD7G/![5;HH IZ;IL.EV@MX6=QN+.\C;G=CU9CW)JY110 4444 %%%% !1110 M 4444 %%%% !374LA 8J2.H[4ZB@#*T/08]"AGBANYYTGF>>YC6)XVV;-JYV@87/&3WK7HH 0<"EHHH K7]C%J-L;:GZ;'IZ/MEEFDD.Z2:9LNYQ@9[=.P % M7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&#[TO^^:FJ&#[TO^ M_0!-1110 4444 %%%% !1110 4444 %%%% !1110 5R?C43276A>39W5P+?4 M4GE,$#.$0 @DX'N..M=910!RCO(WQ"M[U;2Z^SC36B,WV=PH8N& SCTS_+K6 M VE:E>^%=2CM;";[5%K%VTA M%B(DDN(%CD+$CY5QR1UR>G3%)XG>^&O:7&+*[FTYA)Y[V:$R!\#:I(Y53SD@ MCWKJ:* /,H].U(>%;^U_LB[C>#6A=+$4W%X_-5OEQG<<>E=$TET?&UIJ(TV[ M^SW.FF$'R_\ 5MY@/S\_+P<\UU=% 'F?DZG+!I-SHZG8W&B7M_;WMT]S;36R!E._&4MH%S NFWYE?Q"+I5 M^RN"8O.#[^G3 /O7I=% '*Q-(OQ NKLVEV+9M-2)9?L[[2P=F(SCK@_TKE[7 M1=5/@RP9=*EEN--U62ZDLIXRAGC9GX&X8)PV:]2HH \_U)&U'PWJ_P#9WA:> MP^T630QA[4)/+(W; SA1ZGN?:KU\MS+XA\+7,=G=-%;)+Y[>0W[O<@4;N..1 M7944 5IK:*5HVB9T#&-^J MDCH?<5)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %0P'YYO\ ?_I4U0P??F_W_P"@H FH MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H8/]9-_O\ ]*FJ M&'_62_[_ /2@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH *Q;CQ18P-=,$N)H;)MMS/%'N2(]P3U..^ <=ZVJX.T:[\+Z1 MKUGJ=A-+ TUQ"=)MKP$3);KN!/*YY _ $5OT %%%% !1110!'/(T43.L3RE1G8F,GZ9 M('ZUF:/X@AUS2SJ-E:W1A)(3>JJTA!(.!GU!'.*UC7#> AK/_"'V?V,V A\R M;'FARW^M?TXH Z30-?MO$=B;VSAN$@WL@:90N2#@X )Z$5J[A7FGA[5[C1_A M8EQ;E1.]_) K?PH7N"N>?3.:Z%(]>L=3$K72Q:!QPTX7LUM--%O5&,>WY=S!03DCC)% MV<[S22X"3.BJV^->JCD]AD$5F:]=7.K_ Q'B":[D9[J>&3R,CRU0SJ%3'MQ MSUR* /1&O674H[/[-,5>(R&<#]VI! VD^IS^E6LBNG'&* /1LBC M<*Y?6-1FC\66=C=W;6.F2V4DJRK($WS!@-I;MA3G'?\ "LJWU#Q$/#-I?S_; M;U#=OYZPHJ3-;@L%9 #S\I/<]NM '>TM87A*^CO],FGAU%[Z$W#B-I01)&O M'R." 00<]:W: *FIZE:Z382WMY)Y<,0R3C).> .Y)XQ5*'Q#$]]:V4]E>VL MUWN\D31C#84L>5) X'0\T>*-,L]8T66PO9VMTF=%CE4X9)-PV$>^[%85EJ&K MZ7K&GZ;XIMXKO?*5L=3@X#.5(PZ]F*D\]* .TR*,BN'CO-?U^SU&[TR9H9H; MN2&WS,HCC$;;<.N#G."3GU&*N6MY>>(=0U>T6^>T?3UCBC$+<>8R;BY/\0R0 M .G!]: .H>YA2:.%I%$DN2B]VQU_G5>TOI+F[NX7M)H%MW"+)( %FR M:H 3'/$VH?VY=++I-S<&WVJ@#!%!"L-O(Z],=: /0R>"1S67HFN1 MZR;P);S0-9W!MW6;&2P .>"?6KFG7!N]-MKENLT*N<>X!K@BE['IGC"_L]2G MLY+*]GF00A<.RQJ<-D'(X[8H ]%R*-PKCVUN]U/5M.T^%742Z8M[*LYMWFD2XDUS^SH)9<,\*-M.2 M1D$@$X_"M&&R>V^(PB6[G?S-'?:TC;V0^:O()'Z&@#I=.O7O;8RRVDUJV]E\ MN8#=P<9X['K5K(KSY]8U?_A6]YJ*ZG*+RWO)(_.V+EE$VS!&,#@]L=*UUGO] M/\M&17G3ZUK,^C-/#?31ZX- M3,!LEVG">9MVA"#QLPVXCWJ[KNIWNEZA<0ZA>7UK;.D:V5_& 85?'/F[1QEN MY&,=,4 =QGBC(]:8&S!O##&W.X]/K7#V6JZB+[1&^W3W(O+J2*XFX$$HVL1Y M:GG P,$#!]30!W>11D5QNGMJUWJ.L-+K5QY6F7P*(D:#S$$:L4;CISVYJ#3K MOQ'J^C:=K=E,JO.R33"6=?),1/S)MQP0.^( A''!)'7:#QFM>>(S0/&)'B+ C>A 9?<9KS;2;VXT+PE/F9% (-7%[HWBC2[&.\GFM=426)A*0[12*NX M.#[C.0>*K>##JVJP_P!HWFM3RBWO+F'R0BA9%#E1NXZC'&,4 =ED49%87B'4 M9K:]TK3X93"=0N3&\HZJJJ6('N< ?B:R]9O=4\.0S@ZDLL5]=V]O9>8-TEMO M.UV8G[P'49H ['(HW"N7O)[W1O$^E6D=W-<6>IB2)TE(9HY%7<'4_@UFM_(F:(&48\P#'S+[&K> M17!_\)%J>G^'O$%Q)=-<7%KJ9M8))%4; 2B@X QQNS6@8O$-K?!UNC'8O;2" M3SYUED\T#*LGR^QR.GM0!UF11FO/[+4=671/#&LR:M<2O?7$,,\+*HC=7#9. M,9SD=(I-(21G%I8Q2R-;3"+S)'R"P.#E1MZ>_-;?AL:JNCI'K4D,MY&[*SQ-D, M >"< MT\0:MJFG^&Y?MK6\MS?26=WY<:XD*+)\PR..4!]* .UU2_73--GOGBEE6!"[ M)$!N(')QDBC2]035-+M;]$9$N8EE56Z@$9YKE%N+S['XOTJXO9;N.R@S#)-C M> \))!P!GD>G>H'DOK+X=Z%JUI MN=9O?#FIZ['->S7\-KIBWL8GV[E?+ @%0/EX'TH Z+4M:73M0T^S>VE@/:M0=.:X:^MIX[OPCXOX)XM-D$^GWX.\/VD4XP1U'!QR*J:9- MJ.E^&?"-]!JC9%9+ZZD?B2+0VMIQ));O<+, M=H1@I4$#G.?F%?\ F+2_^@K2^))]0BU[0K>TU![:*[FDCE544YQ&Q!Y'7(^GM0!TN11D M5P,_B&_\/)XJMWNI;W^S1 ]M)<8+#S5Z' &0#S6AJES>^';K1)H[VXNXKVY6 MUNDE(;=O!PZ_W2".W&* .JBN89GE2.16:%ML@!^Z< X/X$?G6=J6N)INKZ;8 M/;3/_:,IB25<;%(4MSSGMZ5D^#++R-0\0/\ :KB7;JZ_,#B@#KLBC<*Y+4KJ^\/:AHLGV^>\@U"X%K<1R8/S,I*NN!\ MN".G3%9EU>:R=!\27HUJX672;J7R-D: ,%56"MQTZ],=: /0-PJK+?>7J4%F M+:=Q,C-YRKF-,8X8]B<\5R^NZS=6DEK>737L&F3608W%FF[R9CSEP 3MQ[8Z MYJ:'4+]?$>AQ'4AHR,UYYJUY=^(_AQK>M&]DC1EF$-N@78L2L5VL,9 M)(!.>V>*V)-1O;G5;71;,RI&FFI3(J.VX[1@L#P,$\>HH Z_(HR*X.6Y\ M46TNAV5[J2137%[+;R&)48NFQF5CQPV,<#CO5E+G56UM_#XO;BZ-C:+)+.K) M%)*SLV">.@ '3OUH [,GBLS2-)["58I/-4#)*[N!GT(KGK/4M M;EU33O#FIW*17;133W$]L06=%8! #C )WM "T5%+<0PM&LDBH97V("?O-C.!^ -24 +65=:&NH MW"OJ-R]Q#&X>.V "QY!R"PZL1[G'M6ID5C7WB![>]N+*SL)KZ>UA$TR1L%VJ M2< 9ZL<' ]J +EUITES?6=RM]/ MJS,T,9 2;(QAAZ#J*O556_B&G)>SYMXV MC5R)1M*9['T/.*I_VXH\2+HCVLR2-;M.LQV[&4$# P<]^X% &M15+4[Z6PM/ M/BLI[QMZKY4 !;D@9Y(X'4U;!XYZT .HI,U0U?6K+1(89KZ7RTFG2%3_ +3' M H ?JL\EO82/%'<._0"V17<>X#M+Q0!P=GI=E;^'9M ET77KJQF8MMFBBW*Q;<2"&'G2RB46J)#MC.\/A23G&1TS7H M6145Q*T,+R)&TK*N0B8RWL,X% ')DN=;AU46&O\ G0P&!4,,)4J2"Q\0M;7DK32GR8-V6;:ZKP[K!)&=?+< M@L-K%><<=JU,CUH \WUB_D_MJ"XO+7Q-:"&U$4$UG;*[2Y.7+@!E'W5["K=D M=5E=9)E\0RK _F6<[P0B3#+A@X. 1Z< UWO%)\M ',6&CK=6D\<;:KILK7BW M4\S;(WG;C(^4D;2 174TG%1P7,-R',,BN(W*-M/1AU% %76-)AUFQ^R3R2Q MIYB2!HFVL"K!A@]N0*KKH.^\M[F]U"XO/LK%X$E"!5;&-QVJ,G!/7UK7HH Y MM_!5I_:=U=P7]]:Q7K;[JU@EVQ3-W)&,@GO@C-.OO!MK:>V:Q1XU\MAEU;!8,2"3DC.>M- MB\)V2OJIGFFNH]7.;F*7;M)VA>,*". !UK=HH Q;3PW%;M:&:\N+I; '[*LV MW]WQMSP!N(!(R:@_X0^W_LS5-/:_NVBU5W>X)V9RXPV/EXR*Z&B@"O8V@L;& M&T65Y%A0(K/C) &!G K''A& 66JVG]H79CU9F:X)\O.6&UMOR\9'%=!10!S MEUX+M+F&PVWUY!=:>GEP7D+JLH3&-IP,$8'I3Y/"%LR6C1WMY%JQZI+J5[/=QVYMP[LH!4G/("@'D5N44 IP/2MJDH \UTM76RV MQZIXEM-0D=Y&LUM"R+(S%BH9HR,9/4MBNG7PU<7UC*E_J$RF_B47\"A"C-L5 M6VG&5SCL?I71XHQ0!&;=#:FVQ^[*;,>V,5SD'@>"X3JNH.NFR[[;+J-BX M(V_=YX.,GFNHHH RM.T*/3;N^N%NIIC?R>;*DH7:&P!Q@ ] !UK,LO MI82L MD&H7PT\R>8-/,H,(;.?3.,]LXKJ** &R*60A6VDC@XZ5S\'@RQ31;K2)[BXN M;:YE:8^85#(Y;<64@#!SR*Z*B@#)M]"\NYANKJ]EN[BWC:.&255'E@XR< 8+ M''6ET'08O#]K);07,\TO:!:>(;);:[,B>6XE MBEB;:\3CHRGL:IMX0LKC39[/4+BYOWN%427$\F9!M.5VD !<'G@?G7044 9% MOH.R[AN[J^GN[BWC:.%Y%4>6#C+ MOZ>+.[WH$<2121-M>)QT93V(K4HH YN;P9;W6DW-A=ZE?7#7<8BEN)'4R% < M[1\N ,^V?>K0.:6Y\'6TVK3ZC;ZA?63 MW0 NH[:4*L^!@$\<''<8-=%10!SVH>#[.\NK:\M;JYTVZMHA"DMHX!,8_@(( M((K6T[3X=,LQ;0L[C<69Y&W,[$Y+$]R35NB@#&?PY&NKW&IV=W-9SW2!+@1A M2LN.APP.&'K4;^$[/9I<<%Q/;QZ7)YD*1E3N;!!+9!SD,?SK=HH P6\*1-."14$\T'A?2;314M;_40\30P 0[QP,!7( !S MC)]ZZ6DV@]J ,WPYI*:'X?L]-0 >1& V.[=6/YYIFIZ!'J.I6>H+>7%K$CYD;&Y3D'T%:M+0!S"^!;-+'[&NHWPA%[]M4;U)60,7'53QN.>>M79?#- MM<:M<:C/<32FZMOLLT+A/+:/GC&W/4D]:VJ* .;A\%V\4>GPMJ5_+%ILHDM4 M>1?DP" ,A02,'N>U;.H6":EI\UE*[QI,A4M&<,ON#ZU;HH Q#X:$LTEQ<5T5 M% '-7?@>RNQJB/>WJ0ZI\UQ"D@"%]H&X<9SP.,XXJTGAF--6LM2.H7CSV<#0 M)O9"&5B"V[Y>IP.F.G%;=% &7I&A1Z/)>/%=3S&\G,\@EVX#GKC"CT%)J6A) MJ6HV-Z]Y<0O8N7B6/;M)(P6'( + 8ST [T_5M$@U >@]:J:1X.M-'DAV7]_XFWI#QC@8SP"0,DXKH:* ,W6]#L_$&F2:??!C$Y#!D;:R,.0RGL0:HQ^$ M;62SGM]3N[G5//A,#/8 D9XZFJ_\ PB"'3]5LI-2N'CU5V><[4!!88.WCC@ 5T5% &$?# MDJ*/)U6X0FW6VDW(C!T&<$@CAOF/(_*FP^%(;:^TNXMKR6*/2X#;PP[5*E" M#DXSDX%;]% '*R>!HOLVHV-OJEU;Z?J)=I+1%0JK-]XJ2,@'KBIKWP9#V,7D1W<14NT?]U@1@C\*Z2B@#G7\(1&6PE2_N!)93M<;V"LTTC J2 MY(]#C QBGZQX3BU/4X-5@OKK3[^%/*\^V89=,YVL""#6_10!SL_@ZV;[%-:W MEQ;7UD[,EX"&D??]_?D8;-6M)\/+I6H7U]]NN+B6^96E$FW;E5"Y 'I6Q10 M 4444 %%%% !1110 4444 %%%% !1110 4444 %00?ZV;_>_I4]0P_ZR;_>_ MI0!-1110 4444 %%%% !1110 4444 %%%% !1110 E%H;B_15F8-LW$L0..F2>N37/6- ML][XW\1F&_NK19A JM&@VR 1X;&Y2,@]Q0!%I6MZAJ^B:'+=7T& MV6X=#M# ]%48))R.H^E0G6-9D\(6=VFHRQ7*ZL+1RRHV]//*8;CT]"*Z.3PC M:!].>RNKJP.GQ&%/L[+\T9QE6W ]P#D8-5?^$$M1I_V%-3OTA%Y]K4;T8JV[ M?0UT?BS6)- M\+W=_#@RQ*%C+\@,Q"@GV&R16_B% '.:C/J&@ZOH+1WTUU;7\_V6YCF(;+%.E;-IX;C@FM9+F\N+[[$"+83[ M?W9(QGY0,G'&3FBS\._8M?N]874;IY;Q46:)]FPA1A<87(QD]Z ,GXE0EO#, M;+-+'B]MP0C;0P,JCFDOK*23QY96J7D\0.E2@S*1YG^L7N1U]\5OZYHL&O:7 M)87+R1HS*XDC(#(RL&4C((X(':JJ^&RNKP:H=3O'G@@, WE"&4G))^7J2 : M.7GU75T\#+>)JDPN+;5/LK284F5!<^7\W'7;Z8K2\3ZC?:;JTCW1OXM*-L!' M=6?S"WER!H'T>72SJM]Y$MU]J)S'N$F_?UV=-W-7KCPX\ M]S/.NJWD1NH5AG51&5< $9P5.#R>E %_2I#)I5I(TZW!:%"9EZ2<#YA]>MW MDJ ,#K4&C:.-&M7MUNY[D/(TA>?;N+,37)N);74K. M&2*X9=I=)HP%=076KL2ZD\4$Z,%*$/$26"X^\"N03GK M^%;<'@J"U?5&@U2^0:LS-$8FL=+M/[2O FE.KVY!3.5 M!"Y^7G )% &2-4O= D\6(;J>^CTRVCN8/M#;F#,C$C./NY44^UMO$#?V5J$> MI1I"^W[4TMX76=6&!M4H%5LGC'TYK;B\.0+JE_?2W$TQU&-8KB%]OELH! & M,]">]4]-\#V&ERKY-[J$EO$=UO:RW!>*!NQ53Z9XSG% '-/=ZLGA'4-7.LWK M3Z?JGM701SRZ[XHU:Q>\GM[?3$B1(X)"A9V4L7)'4= M !TX-2?\(3:G1;K26O[PV]W.9Y263<6+;FYV\9/-3S^%(9-474X;^[M;LQ+% M/) RC[2HZ;P5(S[C!H XW2[F^LO GAYK74);*Q MW@Y'53QDG@5H#P^!KLNL"_N1/+;BW*_)L" DCC;UR2: .7M_$&IOX9\/0_:" MUSJ%[):R7#-L+*AD_B .&;8!G'K4?B%_$.AZ!K4W]J^2B)'+:HMP9IH_F"L" MS*"5.?J/6M\>!].;0!HL\]S/ DIFA=W DA";.YT>?3KF^ MO[C[2JK/<33!I753D+G& ,\\ 4 56-Y8>--+M#J=U/#J=K.94D8;590I!4 ? M+U(IWP]MO)TJ\83SR8U"Y3$C[NDK<_6M.7PXDVJ:?J,E]=&?3T9(^4PP8 -N M^7O@5'#X5@MK/4;2WOKV**_:1R$E ,+.6 M@7>YRS8&,D]S4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 5##_K)?][^E35##_K)?][^E $U%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 E&T4M% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %0P_ZV7_>_I4U0P_ZR7_>_I0!-1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4F12UQ'BK7-0M]:6SM7WQQ202[8@ZN#N^ZS8(8-Z#YO8T M=M2UGZ#>2:AHMM=RR1R22KEFC1D4G/8-R/QK0H **** "BBB@!*,BD;I7GC^ M)]4&M-+]HB"*6MP^R7R-OF@;]F-Q8?=W?=YZ]J /1*6D7I2T %%%% !1110 ME&16=X@O9=.T.ZO(9(XY(DW*TB,Z@Y[A>3^%>>@H [:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&'_6S?[W] M*FJ&'_6S?[W]* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUY8VU\L:W,2R"* M194W?PNIR#^%6:* $ P*6BB@ HHHH **** "JQL;8Z@M^85^TK&8A)W"$@D? MF!5FB@ HHHH **** "BBB@!",U7M+&WLA*+>)8_-E:5\?Q.QR3^-6:* "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ J&+_6R_P"\/Y5-447^ME^H_E0!+1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %0Q?ZZ7ZC^535#%_K9?J/ MY4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44?\ K9?J M/Y5+44?^NE^H_E0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %11?ZV7ZC^52U%%_KI?J/Y4 2T444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !44?\ KI?J/Y5+4,?^NE^H_E0!-1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %11_ZZ7\/Y5+44?\ KI?J/Y4 2T444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !44?^NE^H_E4M11_ZZ3\* M ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*/_72_4?RJ M6HH_]=+]1_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M*BC_ -=+]1_*I:BC_P!=+^'\J ):*** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ J*/_72_A4M1)_KY/PH EHHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "HD_UTGX5+42?Z^3\* ):*** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ J)/\ 7R<]A4M1)_KY/H* ):*** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)/]?)]!4M1)_KY/H* ):*** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)/\ 7R?05+42?Z^3 MZ"@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *B3_7R?05 M+42?\?$GT% $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5 M"G_'S)]!4U01J!=2$ 9('- $]%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 5"G_'S)]!4U1)C[0_T% $M%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 5$G_'S)]!4M0H?])D^@H FHHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "H4Q]ID_W14U0I_Q\O_NB@":BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *A3_CYD_P!T?UJ:H4_X^I/] MT4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4*#_2I/\ M=%35"G_'S)_NB@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *B7_CY?_=%2U$N/M+^NT4 2T444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !4*_\?3_[HJ:HE_X^7_W10!+1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %0K_P ?3_[HJ:H5_P"/I_\ =% $U%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 5"I_TIQ_L#^M35"O_ !]-_N"@ M":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *A7_ (^V_P!P M5-4*_P#'VW^X* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ J%?^/IO]P5-4*_\?;_ .X* )J*** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ J%?^/MO]P5-4*_\?;_[@_K0!-1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %0C_ (^V_P!P?SJ:H1_Q]M_N#^= $U%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 5"/^/MO]P?S-35"/^/QO M]P?SH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBDH 6BFJH1< D_6G4 %%%% !1110 4444 %%%% !1110 4444 %%% M% !4(_X_&_W!_.IJ@'_'X?\ KG_6@">BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH *A'_'V?]P?SJ:H1_P ?9_W/ZT 34444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !4(_X^C_N?UJ:H1_Q]GG^ ?SH FHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H1_Q^'_KG_6IJB_Y M>L_[']: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J'_E M\_[9_P!:FJ'_ )?/^V?]: )J*** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ J$?\??_;/^M35#_P OG_;/^M $U%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 5#_R]_P# /ZU-4/\ R]_\ _K0!-1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %1?\O?\ P#^M2U#C_2\_[']: M )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J'C[5[[/ZU- M47_+T/\ <_K0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%1?\O0_W/ZU+47_+R/\ <_K0!+1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %0\_:_\ @']:FJ'_ )>O^ ?UH FHHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "H?^7H?[A_G4U0_\O7_ #^M $U%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M"4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !4./\ 2P?^F9_G4U0_\O8_ MZY_UH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9*KM& MPC8*Y!VDC(![<4 .KG];\07^D+->+IBRZ?:D">0RE9,$C)5<<@9]>>:OZ5;Z MQ!YG]JW]K=9QL\BV,6/7.6;-8VOZYITM\=,O$O?(A97F\JRFD$Q'(0%5(QG! M//MZT =2#D9IU5+@7=Q8-]BE2VN&4%&FCWA3[J",_G1I\5]%;!=0N(;B;/+P MQ&-?MB^GEG^8H MFHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H?\ E\7_ *YG M^8J:H/\ E]4_],S_ #% $]%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 5 3_ *:O_7,_S%3U ?\ C\3_ '#_ #% $]%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 5 W_ !^+_N'^8J>H#_Q^)_US/\Q0!/11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1%?](#^BD?RHHH "_]D! end GRAPHIC 15 amendmentno1tokesslereea003.jpg GRAPHIC begin 644 amendmentno1tokesslereea003.jpg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end XML 16 R27.htm IDEA: XBRL DOCUMENT v3.20.1
    Business combination (Narrative) (Details) - Wage Works Inc.
    $ / shares in Units, $ in Millions
    Aug. 30, 2019
    USD ($)
    $ / shares
    Business Acquisition [Line Items]  
    Merger related costs, price per share | $ / shares $ 51.35
    Aggregate fair value of WageWorks stock acquired $ 2,000.0
    Cash paid 816.9
    Borrowing pursuant to term loan facility 1,220.0
    Line of Credit | Term Loan Facility  
    Business Acquisition [Line Items]  
    Cash paid $ 30.5
    XML 17 R23.htm IDEA: XBRL DOCUMENT v3.20.1
    Intangible assets and goodwill (Tables)
    3 Months Ended
    Apr. 30, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of finite-lived intangible assets
    The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of April 30, 2020 and January 31, 2020:
    (in thousands)April 30, 2020January 31, 2020
    Amortizable intangible assets:
    Software and software development costs$89,949  $76,221  
    Acquired HSA portfolios98,778  92,770  
    Acquired customer relationships601,381  601,381  
    Acquired developed technology96,925  96,925  
    Acquired trade names12,300  12,300  
    Amortizable intangible assets, gross899,333  879,597  
    Accumulated amortization(122,442) (98,851) 
    Total amortizable intangible assets, net776,891  780,746  
    Acquired in process software development costs592  2,533  
    Total intangible assets, net$777,483  $783,279  
    Schedule of indefinite-lived intangible assets
    The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of April 30, 2020 and January 31, 2020:
    (in thousands)April 30, 2020January 31, 2020
    Amortizable intangible assets:
    Software and software development costs$89,949  $76,221  
    Acquired HSA portfolios98,778  92,770  
    Acquired customer relationships601,381  601,381  
    Acquired developed technology96,925  96,925  
    Acquired trade names12,300  12,300  
    Amortizable intangible assets, gross899,333  879,597  
    Accumulated amortization(122,442) (98,851) 
    Total amortizable intangible assets, net776,891  780,746  
    Acquired in process software development costs592  2,533  
    Total intangible assets, net$777,483  $783,279  
    XML 18 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 19 R42.htm IDEA: XBRL DOCUMENT v3.20.1
    Income taxes (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Jan. 31, 2020
    Income Tax Disclosure [Abstract]      
    Income tax provision $ 218 $ 9,456  
    Effective tax rate 10.70% 18.40%  
    Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense 16.80% 4.50%  
    Gross unrecognized tax benefits $ 9,600   $ 9,400
    Unrecognized tax benefit 500   $ 500
    Unrecognized tax benefits that would impact the effective tax rate $ 8,800    
    XML 20 R46.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation (Assumptions) (Details)
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Expected dividend yield 0.00% 0.00%
    Expected stock price volatility 37.97%  
    Expected stock price volatility, minimum   35.98%
    Expected stock price volatility, maximum   36.53%
    Risk-free interest rate 1.39%  
    Risk-free interest rate, minimum   2.21%
    Risk-free interest rate, maximum   2.43%
    Expected life of options 5 years 2 months 4 days  
    Minimum    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Expected life of options   4 years 11 months 12 days
    Maximum    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Expected life of options   5 years 1 month 2 days
    JSON 22 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20200430.htm": { "axisCustom": 1, "axisStandard": 16, "contextCount": 119, "dts": { "calculationLink": { "local": [ "hqy-20200430_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20200430_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "hqy-20200430.htm" ] }, "labelLink": { "local": [ "hqy-20200430_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hqy-20200430_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hqy-20200430.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 440, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 4, "http://healthequity.com/20200430": 6, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 15 }, "keyCustom": 35, "keyStandard": 333, "memberCustom": 14, "memberStandard": 29, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20200430", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Supplemental financial statement information", "role": "http://healthequity.com/role/Supplementalfinancialstatementinformation", "shortName": "Supplemental financial statement information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115105 - Disclosure - Leases", "role": "http://healthequity.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Intangible assets and goodwill", "role": "http://healthequity.com/role/Intangibleassetsandgoodwill", "shortName": "Intangible assets and goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Commitments and contingencies", "role": "http://healthequity.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Indebtedness", "role": "http://healthequity.com/role/Indebtedness", "shortName": "Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132109 - Disclosure - Income taxes", "role": "http://healthequity.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134110 - Disclosure - Stock-based compensation", "role": "http://healthequity.com/role/Stockbasedcompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142111 - Disclosure - Fair value", "role": "http://healthequity.com/role/Fairvalue", "shortName": "Fair value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of business and significant accounting policies (Policies)", "role": "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies", "shortName": "Summary of business and significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Net income per share (Tables)", "role": "http://healthequity.com/role/NetincomepershareTables", "shortName": "Net income per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed consolidated balance sheets", "role": "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "shortName": "Condensed consolidated balance sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307302 - Disclosure - Business combination (Tables)", "role": "http://healthequity.com/role/BusinesscombinationTables", "shortName": "Business combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311303 - Disclosure - Supplemental financial statement information (Tables)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationTables", "shortName": "Supplemental financial statement information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316304 - Disclosure - Leases (Tables)", "role": "http://healthequity.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - Intangible assets and goodwill (Tables)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillTables", "shortName": "Intangible assets and goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Indebtedness (Tables)", "role": "http://healthequity.com/role/IndebtednessTables", "shortName": "Indebtedness (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335307 - Disclosure - Stock-based compensation (Tables)", "role": "http://healthequity.com/role/StockbasedcompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Net income per share (Details)", "role": "http://healthequity.com/role/NetincomepershareDetails", "shortName": "Net income per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i26a817bcc51f45c2a5485e8729e27515_I20190830", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Business combination (Narrative) (Details)", "role": "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "shortName": "Business combination (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i26a817bcc51f45c2a5485e8729e27515_I20190830", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details)", "role": "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "shortName": "Business combination (Preliminary Allocation of Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ibf30d5a73634429f82cf108bee8dc7ac_I20200430", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Supplemental financial statement information (Property and equipment) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails", "shortName": "Supplemental financial statement information (Property and equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed consolidated balance sheets (Parenthetical)", "role": "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical", "shortName": "Condensed consolidated balance sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Supplemental financial statement information (Contract balances) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationContractbalancesDetails", "shortName": "Supplemental financial statement information (Contract balances) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails", "shortName": "Supplemental financial statement information (Other income (expense), net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Leases (Narrative) (Details)", "role": "http://healthequity.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Leases (Lease Cost) (Details)", "role": "http://healthequity.com/role/LeasesLeaseCostDetails", "shortName": "Leases (Lease Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)", "role": "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails", "shortName": "Leases (Maturities of Operating Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Leases (Supplemental Cash Flow Information) (Details)", "role": "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases (Supplemental Cash Flow Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Intangible assets and goodwill (Narrative) (Details)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "shortName": "Intangible assets and goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails", "shortName": "Intangible assets and goodwill (Schedule of intangible assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i7ccd057eecb645ecbf7126744e32f11f_D20180906-20180906", "decimals": "INF", "first": true, "lang": "en-US", "name": "hqy:LossContingencyNumberOfLawsuits", "reportCount": 1, "unique": true, "unitRef": "lawsuit", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Commitments and contingencies (Details)", "role": "http://healthequity.com/role/CommitmentsandcontingenciesDetails", "shortName": "Commitments and contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i7ccd057eecb645ecbf7126744e32f11f_D20180906-20180906", "decimals": "INF", "first": true, "lang": "en-US", "name": "hqy:LossContingencyNumberOfLawsuits", "reportCount": 1, "unique": true, "unitRef": "lawsuit", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Indebtedness Schedule of Long-term Debt (Details)", "role": "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails", "shortName": "Indebtedness Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "shortName": "Condensed consolidated statements of operations and comprehensive income (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Indebtedness (Narrative) (Details)", "role": "http://healthequity.com/role/IndebtednessNarrativeDetails", "shortName": "Indebtedness (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ie1082fcae13f4194ab4eec7f41ae48f1_I20200430", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ifd82a8fc1d2c434baaf956394f5b68c6_I20200131", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - Indebtedness Schedule of Maturities of Long-term Debt (Details)", "role": "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails", "shortName": "Indebtedness Schedule of Maturities of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ifd82a8fc1d2c434baaf956394f5b68c6_I20200131", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433417 - Disclosure - Income taxes (Details)", "role": "http://healthequity.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436418 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails", "shortName": "Stock-based compensation (Summary of share based compensation recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i4463b7202bce48cd93f22afc7fa71117_D20200201-20200430", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437419 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails", "shortName": "Stock-based compensation (Stock-based compensation expense by award type) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ib5fdd9a4b2454df7bbd0253ec10a4013_D20200201-20200430", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438420 - Disclosure - Stock-based compensation (Narrative) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "shortName": "Stock-based compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Stock-based compensation (Assumptions) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "shortName": "Stock-based compensation (Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "4", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ifd82a8fc1d2c434baaf956394f5b68c6_I20200131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440422 - Disclosure - Stock-based compensation (Stock option activity) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails", "shortName": "Stock-based compensation (Stock option activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i7b557b367efb485f96337d0f03c8631f_I20200131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441423 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "shortName": "Stock-based compensation (Restricted stock unity activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i7b557b367efb485f96337d0f03c8631f_I20200131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i8255248a21474c1f9bc39e43f320150b_I20190131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "shortName": "Condensed consolidated statements of stockholders' equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "i8255248a21474c1f9bc39e43f320150b_I20190131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed consolidated statements of cash flows (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "shortName": "Condensed consolidated statements of cash flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of business and significant accounting policies", "role": "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies", "shortName": "Summary of business and significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Net income per share", "role": "http://healthequity.com/role/Netincomepershare", "shortName": "Net income per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Business combination", "role": "http://healthequity.com/role/Businesscombination", "shortName": "Business combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200430.htm", "contextRef": "ida91e7ec0be443daa7186d8a880667dc_D20200201-20200430", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 45, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hqy_AcquiredHSAIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired HSA Intangible Assets [Member]", "label": "Acquired HSA Intangible Assets [Member]", "terseLabel": "Acquired HSA portfolios" } } }, "localname": "AcquiredHSAIntangibleAssetsMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "hqy_AmortizationOfAcquiredIntangible": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Acquired Intangible", "label": "Amortization Of Acquired Intangible", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangible", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCashAndCashEquivalents": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents", "terseLabel": "Cash and cash equivalents, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCashAndCashEquivalents", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentClientHeldFundsObligation": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Client Held Funds Obligation", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Client Held Funds Obligation", "negatedLabel": "Client-held funds obligation, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentClientHeldFundsObligation", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxes": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Taxes", "negatedLabel": "Deferred tax liability, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxes", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Current Assets", "terseLabel": "Other current assets, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherCurrentAssets", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdjustmentCurrentLiabilitiesOther": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Adjustment, Current Liabilities, Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Adjustment, Current Liabilities, Other", "negatedLabel": "Other current liabilities, adjustments" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdjustmentCurrentLiabilitiesOther", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedClientHeldFundsObligation": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation", "negatedTerseLabel": "Client-held funds obligation" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedClientHeldFundsObligation", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseRightofuseAssets": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseRightofuseAssets", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContractWithCustomerRecognitionTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Recognition Term", "label": "Contract With Customer, Recognition Term", "terseLabel": "Deferred revenue recognition term" } } }, "localname": "ContractWithCustomerRecognitionTerm", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationContractbalancesDetails" ], "xbrltype": "durationItemType" }, "hqy_ContractWithCustomerRecognitionTermInterchangeArrangement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Recognition Term, Interchange Arrangement", "label": "Contract With Customer, Recognition Term, Interchange Arrangement", "terseLabel": "Deferred revenue interchange arrangement recognition term" } } }, "localname": "ContractWithCustomerRecognitionTermInterchangeArrangement", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationContractbalancesDetails" ], "xbrltype": "durationItemType" }, "hqy_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Four", "label": "Debt Covenant Period Four [Member]", "terseLabel": "Debt covenant, acquisition holiday provision" } } }, "localname": "DebtCovenantPeriodFourMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period One", "label": "Debt Covenant Period One [Member]", "terseLabel": "Debt covenant, beginning April 30, 2020" } } }, "localname": "DebtCovenantPeriodOneMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Three", "label": "Debt Covenant Period Three [Member]", "terseLabel": "Debt covenant, beginning July 31, 2021" } } }, "localname": "DebtCovenantPeriodThreeMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Two", "label": "Debt Covenant Period Two [Member]", "terseLabel": "Debt covenant, beginning July 31, 2020" } } }, "localname": "DebtCovenantPeriodTwoMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "label": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "terseLabel": "Acquisition threshold for maximum total net leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_DebtInstrumentCovenantDescriptionInterestCoverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "label": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "terseLabel": "Minimum interest coverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionInterestCoverageRatio", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCovenantDescriptionLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Leverage Ratio", "label": "Debt Instrument, Covenant Description, Leverage Ratio", "terseLabel": "Maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionLeverageRatio", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_ExerciseofStockOptionsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exercise of Stock Options Receivable", "label": "Exercise of Stock Options Receivable", "terseLabel": "Exercise of common stock options receivable" } } }, "localname": "ExerciseofStockOptionsReceivable", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Plan [Member]", "label": "Incentive Plan [Member]", "terseLabel": "Incentive Plan" } } }, "localname": "IncentivePlanMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "label": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "terseLabel": "Operating lease not yet commenced undiscounted amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Remaining Lease Term", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining operating lease terms" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_LossContingencyNumberOfLawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency Number Of Lawsuits", "label": "Loss Contingency Number Of Lawsuits", "terseLabel": "Number of derivative lawsuits" } } }, "localname": "LossContingencyNumberOfLawsuits", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "integerItemType" }, "hqy_PaymentsToSettleClientHeldFunds": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments To Settle Client Held Funds", "label": "Payments To Settle Client Held Funds", "negatedTerseLabel": "Settlement of client-held funds obligation" } } }, "localname": "PaymentsToSettleClientHeldFunds", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_PerformanceRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Awards [Member]", "label": "Performance Restricted Stock Awards [Member]", "terseLabel": "Performance restricted stock awards" } } }, "localname": "PerformanceRestrictedStockAwardsMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "domainItemType" }, "hqy_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Units [Member]", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance restricted stock units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "domainItemType" }, "hqy_SalesandMarketingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales and Marketing [Member]", "label": "Sales and Marketing [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SalesandMarketingMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "terseLabel": "Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFullyAchievedRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fully Achieved, Ratio", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fully Achieved, Ratio", "terseLabel": "Fraction of awards fully achieved" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFullyAchievedRatio", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingModifiedRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Remaining Modified, Ratio", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Remaining Modified, Ratio", "terseLabel": "Fraction of awards modified" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingModifiedRatio", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "terseLabel": "Exercised, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "terseLabel": "Forfeited, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "periodEndLabel": "Ending balance, minimum (usd per share)", "periodStartLabel": "Beginning balance, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "terseLabel": "Exercised, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "terseLabel": "Forfeited, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "periodEndLabel": "Ending balance, maximum (usd per share)", "periodStartLabel": "Beginning balance, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Granted", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Granted", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGranted", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedPaymentArrangementDecreaseInExpenseDueToModificationOfTerms": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-Based Payment Arrangement, Decrease In Expense Due To Modification Of Terms", "label": "Share-Based Payment Arrangement, Decrease In Expense Due To Modification Of Terms", "verboseLabel": "Share-based payment arrangement, decrease in expense due to modification of terms" } } }, "localname": "ShareBasedPaymentArrangementDecreaseInExpenseDueToModificationOfTerms", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ShareBasedPaymentArrangementPlanModificationIncrementalCostNumberOfTeamMembers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Payment Arrangement, Plan Modification, Incremental Cost, Number Of Team Members", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost, Number Of Team Members", "terseLabel": "Number of team members modification affected" } } }, "localname": "ShareBasedPaymentArrangementPlanModificationIncrementalCostNumberOfTeamMembers", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "hqy_SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "terseLabel": "Percentage of capital stock" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_SharebasedCompensationArrangementbySharebasedPaymentAwardExpirationPeriodfromTerminationofEmployment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period from Termination of Employment", "terseLabel": "Forfeited period" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardExpirationPeriodfromTerminationofEmployment", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_TechnologyandDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Technology and Development [Member]", "label": "Technology and Development [Member]", "terseLabel": "Technology and development" } } }, "localname": "TechnologyandDevelopmentMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Facility [Member]", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_UnrecognizedTaxBenefitNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefit, Net", "label": "Unrecognized Tax Benefit, Net", "terseLabel": "Unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefitNet", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "hqy_WageWorksIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Wage Works Inc.", "label": "Wage Works Inc. [Member]", "terseLabel": "Wage Works Inc." } } }, "localname": "WageWorksIncMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WageWorksIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "WageWorks Incentive Plan", "label": "WageWorks Incentive Plan [Member]", "terseLabel": "WageWorks Incentive Plan" } } }, "localname": "WageWorksIncentivePlanMember", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "label": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net income per share:" } } }, "localname": "WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://healthequity.com/20200430", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r99", "r144", "r147", "r275", "r276" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r17", "r100", "r101", "r145" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $1,681 and $1,216 as of April 30, 2020 and January 31, 2020, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r26", "r125" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental financial statement information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Supplementalfinancialstatementinformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r148", "r150", "r188", "r189" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r150", "r181", "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r23", "r102", "r105" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r52", "r68", "r235" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r68", "r111", "r118" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r255", "r266" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r41" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r152", "r184" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r227", "r228" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Customary Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r205", "r206" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Number of service-based common stock (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "verboseLabel": "Merger related costs, price per share" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r204" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r216", "r217", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Aggregate fair value of WageWorks stock acquired" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r215", "r216", "r217", "r220" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Borrowing pursuant to term loan facility" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Businesscombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Merger integration" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "auth_ref": [ "r210" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "totalLabel": "Total consideration paid, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedTerseLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r194", "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r207", "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total consideration paid" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedTerseLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r207", "r208" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r72", "r73", "r74" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable or accrued liabilities at period end" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r24", "r70" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r64", "r70", "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending cash and cash equivalents", "periodStartLabel": "Beginning cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r64", "r231" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r37", "r129", "r259", "r271" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r128", "r130" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of common stock issuable (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r136" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 900,000 shares authorized, 71,398 and 71,051 shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r43", "r45", "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r112", "r116", "r213" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer software intangible asset" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r76", "r223", "r224", "r225" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognition" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationContractbalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r54" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditAndDebitCardMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Card issued to user to facilitate payment for purchase of product and service paid directly to merchant by issuer, or from user's checking account.", "label": "Credit and Debit Card [Member]", "terseLabel": "Interchange revenue" } } }, "localname": "CreditAndDebitCardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Acquired customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Indebtedness" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Indebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r256", "r257", "r265" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate borrowing spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r13", "r133", "r257", "r265" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Term loan facility", "totalLabel": "Total principal payments" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails", "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r35", "r78", "r137", "r138", "r139", "r140", "r233", "r234", "r236", "r264" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Facility term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r27", "r235" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Less: unamortized loan issuance costs", "verboseLabel": "Unamortized loan issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r200" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r195", "r200" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r69" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r68", "r123" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r68", "r96" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Stockbasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r50", "r82", "r85", "r87", "r88", "r89", "r92", "r262", "r273" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income per share:", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r50", "r82", "r85", "r87", "r88", "r89", "r92", "r262", "r273" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net income per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Netincomepershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r79", "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r190", "r196" ], "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "negatedTerseLabel": "Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average vesting period of non-vested awards expected to vest" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r183" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r183" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock compensation expense to be recognized in future" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of equity interests that are issued or issuable in a business combination.", "label": "Equity Interest Type [Axis]", "terseLabel": "Equity Interest Type [Axis]" } } }, "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.", "label": "Equity Interest Issued or Issuable, Type [Domain]", "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]" } } }, "localname": "EquityInterestIssuedOrIssuableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r104" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "Gain on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Fairvalue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialServiceOtherMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.", "label": "Financial Service, Other [Member]", "terseLabel": "Custodial revenue" } } }, "localname": "FinancialServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r117" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r112", "r114", "r117", "r120", "r253" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r117", "r253" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Amortizable intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r112", "r116" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r117" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total amortizable intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r68" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "negatedLabel": "Gains on marketable equity securities" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r106", "r107" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Intangibleassetsandgoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Change in goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r108", "r203" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill, adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r53" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r48", "r82", "r254", "r260", "r274" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r77", "r97", "r201" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid in cash, net of refunds received" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r86", "r91" ], "calculation": { "http://healthequity.com/role/NetincomepershareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted-average dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r113", "r119" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "verboseLabel": "Acquired in process software development costs" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r113", "r119" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r110", "r115" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "verboseLabel": "Total intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r47", "r95", "r232", "r235", "r263" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r63", "r65", "r71" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r56" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r249", "r251" ], "calculation": { "http://healthequity.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Lease, cost, total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease not yet commenced term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating lease liability maturity schedule" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remaining 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal terms extension" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r258", "r269" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r6", "r7", "r8", "r13", "r14" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r13", "r257", "r265" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Effective interest rate percentage" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r134", "r257", "r267" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r80", "r131" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r80", "r131" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r80", "r131" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r80", "r131" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r80" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year", "terseLabel": "Remaining 2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofMaturitiesofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of issuance costs" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r35", "r132" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r66", "r69" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r42", "r44", "r49", "r69", "r91", "r261", "r272" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator (basic and diluted):" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent adopted accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r72", "r73", "r74" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Purchases of intangible assets" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses [Abstract]" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r239" ], "calculation": { "http://healthequity.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r238" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r238" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r238" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r240", "r245" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r237" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r248", "r251" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r247", "r251" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r81", "r94", "r226" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of business and significant accounting policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r227", "r229" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r57" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r59" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Purchases of software and capitalized software development costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r58", "r219" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r59" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Acquisition of intangible member assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r60" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r152", "r184" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of April 30, 2020 and January 31, 2020, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r185" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r26", "r126" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r25", "r124" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r126", "r270" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r126" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r124" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r62" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Principal payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r192", "r278" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Technology and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "Software development costs incurred and expensed" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "netLabel": "Restricted stock units", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r141", "r268" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r143", "r144" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "verboseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationContractbalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues [Abstract]" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Secured Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r246", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r205", "r206" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense by award type" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r35", "r78", "r137", "r138", "r139", "r140", "r233", "r234", "r236", "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings (loss) per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetincomepershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r150", "r180", "r187" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of share based compensation recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r112", "r116" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r112", "r116" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r119", "r121" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r119", "r121" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of indefinite-lived intangible assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r26", "r126" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Preliminary Allocation of Consideration" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r152", "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of restricted stock unit activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r157", "r168", "r171" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Performance units awards (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value (usd per share)", "verboseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, ending balance (in shares)", "periodStartLabel": "Unvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, ending balance (usd per share)", "periodStartLabel": "Unvested, beginning balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant under incentive plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable as of year end, weighted-average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value at date of grant (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Ending balance, outstanding stock options, aggregate intrinsic value", "periodStartLabel": "Beginning balance, outstanding stock options, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r159", "r184" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Opening balance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number\u00a0of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (usd per share)", "periodStartLabel": "Opening balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r173" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest as of year end, aggregate intrinsic value (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable as of year end (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest as of year end (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest as of year end, weighted average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental compensation cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r149", "r156" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationStockbasedcompensationexpensebyawardtypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]", "terseLabel": "Range of exercise prices (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r175", "r186" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable as of year end, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable as of year end, weighted-average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding stock options, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest as of year end, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r39", "r136" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r136", "r141", "r161" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r15", "r16", "r141", "r151", "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock upon exercise of stock options, and for restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r103" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r244", "r251" ], "calculation": { "http://healthequity.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow data:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Acquired trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r193", "r198" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Gross unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r199" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r84", "r89" ], "calculation": { "http://healthequity.com/role/NetincomepershareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator (diluted):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r83", "r89" ], "calculation": { "http://healthequity.com/role/NetincomepershareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Weighted-average common shares outstanding (in shares)", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomeunaudited", "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator (basic):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetincomepershareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=SL65897772-128472" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r279": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r281": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r282": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r283": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r284": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" } }, "version": "2.1" } XML 23 R8.htm IDEA: XBRL DOCUMENT v3.20.1
    Net income per share
    3 Months Ended
    Apr. 30, 2020
    Earnings Per Share [Abstract]  
    Net income per share Net income per share
    The following table sets forth the computation of basic and diluted net income per share:
    Three months ended April 30,
    (in thousands, except per share data)20202019
    Numerator (basic and diluted):
    Net income $1,826  $41,822  
    Denominator (basic):
    Weighted-average common shares outstanding70,980  62,326  
    Denominator (diluted):
    Weighted-average common shares outstanding70,980  62,326  
    Weighted-average dilutive effect of stock options and restricted stock units1,312  1,575  
    Diluted weighted-average common shares outstanding72,292  63,901  
    Net income per share:
    Basic $0.03  $0.67  
    Diluted$0.03  $0.65  

    For the three months ended April 30, 2020 and 2019, approximately 0.5 million and 0.2 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
    XML 25 R4.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed consolidated statements of operations and comprehensive income (unaudited) - USD ($)
    shares in Thousands, $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Revenues [Abstract]    
    Revenue $ 190,011 $ 87,052
    Cost of revenue    
    Cost of revenue 81,937 29,299
    Gross profit 108,074 57,753
    Operating Expenses [Abstract]    
    Sales and marketing 11,455 8,970
    Technology and development 31,078 10,905
    General and administrative 18,998 8,709
    Amortization of acquired intangible assets 18,702 1,491
    Merger integration 12,770 0
    Total operating expenses 93,003 30,075
    Income from operations 15,071 27,678
    Other income (expense)    
    Interest expense (12,263) (63)
    Other income (expense), net (764) 23,663
    Total other income (expense) (13,027) 23,600
    Income before income taxes 2,044 51,278
    Income tax provision 218 9,456
    Net income 1,826 41,822
    Comprehensive income $ 1,826 $ 41,822
    Net income per share:    
    Basic (in usd per share) $ 0.03 $ 0.67
    Diluted (in usd per share) $ 0.03 $ 0.65
    Weighted-average number of shares used in computing net income per share:    
    Basic (in shares) 70,980 62,326
    Diluted (in shares) 72,292 63,901
    Service revenue    
    Revenues [Abstract]    
    Revenue $ 111,271 $ 26,808
    Cost of revenue    
    Cost of revenue 71,013 20,649
    Custodial revenue    
    Revenues [Abstract]    
    Revenue 46,899 41,952
    Cost of revenue    
    Cost of revenue 5,045 4,123
    Interchange revenue    
    Revenues [Abstract]    
    Revenue 31,841 18,292
    Cost of revenue    
    Cost of revenue $ 5,879 $ 4,527
    XML 26 R19.htm IDEA: XBRL DOCUMENT v3.20.1
    Net income per share (Tables)
    3 Months Ended
    Apr. 30, 2020
    Earnings Per Share [Abstract]  
    Schedule of earnings (loss) per share, basic and diluted
    The following table sets forth the computation of basic and diluted net income per share:
    Three months ended April 30,
    (in thousands, except per share data)20202019
    Numerator (basic and diluted):
    Net income $1,826  $41,822  
    Denominator (basic):
    Weighted-average common shares outstanding70,980  62,326  
    Denominator (diluted):
    Weighted-average common shares outstanding70,980  62,326  
    Weighted-average dilutive effect of stock options and restricted stock units1,312  1,575  
    Diluted weighted-average common shares outstanding72,292  63,901  
    Net income per share:
    Basic $0.03  $0.67  
    Diluted$0.03  $0.65  
    XML 27 R15.htm IDEA: XBRL DOCUMENT v3.20.1
    Income taxes
    3 Months Ended
    Apr. 30, 2020
    Income Tax Disclosure [Abstract]  
    Income taxes Income taxes
    The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three months ended April 30, 2020, the Company recorded income tax expense of $0.2 million. This resulted in an effective income tax expense rate of 10.7% for the three months ended April 30, 2020, compared with an effective income tax expense rate of 18.4% for the three months ended April 30, 2019. For the three months ended April 30, 2020 and 2019, the net impact of discrete tax items caused a 16.8 and 4.5 percentage point benefit, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes relative to pre-tax book income. Due to significantly lower pre-tax book income during the three months ended April 30, 2020, such excess tax benefit had a greater impact on the effective income tax rate.
    As of April 30, 2020 and January 31, 2020, the Company’s total gross unrecognized tax benefit was $9.6 million and $9.4 million, respectively. As of April 30, 2020 and January 31, 2020, a net unrecognized tax benefit of $0.5 million was recorded in the condensed consolidated balance sheets. If recognized, $8.8 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of April 30, 2020.
    The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2000.
    XML 28 R11.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases
    3 Months Ended
    Apr. 30, 2020
    Leases [Abstract]  
    Leases LeasesThe Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of less than 1 year to approximately 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.
    Amortization and interest expense related to finance leases were not material during the three months ended April 30, 2020 and 2019.
    The components of operating lease costs are as follows:
    Three months ended April 30,
    (in thousands, except for term and percentages)20202019
    Operating lease expense$4,308  1,074  
    Sublease income(450) —  
    Net operating lease cost$3,858  $1,074  
    Weighted average lease term and discount rate are as follows:
    As of April 30, 2020
    Weighted average remaining lease term9.47 years
    Weighted average discount rate4.35 %
    Maturities of operating lease liabilities as of April 30, 2020 were as follows:
    Fiscal year ending January 31, (in thousands)Operating leases
    Remaining 2021$9,177  
    202214,517  
    202312,348  
    202410,318  
    202510,279  
    Thereafter60,429  
    Total lease payments117,068  
    Less imputed interest(21,876) 
    Present value of lease liabilities$95,192  
    Current$13,210  
    Non-current81,982  
    Total lease liabilities$95,192  
    As of April 30, 2020, the Company had an additional operating lease for office space that had not yet commenced with aggregate undiscounted lease payments of $63.1 million. This operating lease will commence in fiscal year 2021 with a lease term of approximately 11 years.
    Supplemental cash flow information related to the Company's operating leases was as follows:
    Three months ended April 30,
    (in thousands, except for term and percentages)20202019
    Cash paid for amounts included in the measurement of lease liabilities:
    Operating cash flows from operating leases$3,297  $977  
    ROU assets obtained in exchange for new operating lease obligations$17,480  $199  
    XML 29 R32.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases (Narrative) (Details)
    $ in Millions
    3 Months Ended
    Apr. 30, 2020
    USD ($)
    Lessee, Lease, Description [Line Items]  
    Operating lease not yet commenced undiscounted amount $ 63.1
    Operating lease not yet commenced term of contract 11 years
    Minimum  
    Lessee, Lease, Description [Line Items]  
    Remaining operating lease terms 1 year
    Lease renewal terms extension 3 years
    Maximum  
    Lessee, Lease, Description [Line Items]  
    Remaining operating lease terms 11 years
    Lease renewal terms extension 10 years
    XML 30 R36.htm IDEA: XBRL DOCUMENT v3.20.1
    Intangible assets and goodwill (Narrative) (Details) - USD ($)
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Finite-Lived Intangible Assets [Line Items]    
    Software development costs incurred and expensed $ 10,300,000 $ 3,900,000
    Amortization expense 23,600,000 3,900,000
    Change in goodwill $ 0 $ 0
    XML 31 R1.htm IDEA: XBRL DOCUMENT v3.20.1
    Cover Page - shares
    3 Months Ended
    Apr. 30, 2020
    May 28, 2020
    Cover [Abstract]    
    Document Type 10-Q  
    Document Quarterly Report true  
    Document Period End Date Apr. 30, 2020  
    Document Transition Report false  
    Entity File Number 001-36568  
    Entity Registrant Name HEALTHEQUITY, INC.  
    Entity Incorporation, State or Country Code DE  
    Entity Tax Identification Number 52-2383166  
    Entity Address, Address Line One 15 West Scenic Pointe Drive  
    Entity Address, Address Line Two Suite 100  
    Entity Address, City or Town Draper,  
    Entity Address, State or Province UT  
    Entity Address, Postal Zip Code 84020  
    City Area Code 801  
    Local Phone Number 727-1000  
    Title of 12(b) Security Common stock, par value $0.0001 per share  
    Trading Symbol HQY  
    Security Exchange Name NASDAQ  
    Entity Current Reporting Status Yes  
    Entity Interactive Data Current Yes  
    Entity Filer Category Large Accelerated Filer  
    Entity Small Business false  
    Entity Emerging Growth Company false  
    Entity Shell Company false  
    Entity Common Stock, Shares Outstanding   71,399,355
    Entity Central Index Key 0001428336  
    Current Fiscal Year End Date --01-31  
    Document Fiscal Year Focus 2021  
    Document Fiscal Period Focus Q1  
    Amendment Flag false  
    XML 32 R5.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed consolidated statements of stockholders' equity (unaudited) - USD ($)
    $ in Thousands
    Total
    Common stock
    Additional paid-in capital
    Accumulated earnings
    Beginning balance at Jan. 31, 2019 $ 477,079 $ 6 $ 305,223 $ 171,850
    Stockholders' Equity        
    Issuance of common stock upon exercise of stock options, and for restricted stock     4,370  
    Stock-based compensation     6,028  
    Net income 41,822     41,822
    Ending balance at Apr. 30, 2019 529,299 6 315,621 213,672
    Beginning balance at Jan. 31, 2020 1,030,295 7 818,774 211,514
    Stockholders' Equity        
    Issuance of common stock upon exercise of stock options, and for restricted stock     1,133  
    Stock-based compensation     7,396  
    Net income 1,826     1,826
    Ending balance at Apr. 30, 2020 $ 1,040,650 $ 7 $ 827,303 $ 213,340
    XML 33 R9.htm IDEA: XBRL DOCUMENT v3.20.1
    Business combination
    3 Months Ended
    Apr. 30, 2020
    Business Combinations [Abstract]  
    Business combination Business combination
    Acquisition of WageWorks
    On August 30, 2019, the Company closed the acquisition (the "Acquisition") of WageWorks, Inc. ("WageWorks") for $51.35 per share in cash, or approximately $2.0 billion to WageWorks stockholders. The Company financed the transaction through a combination of $816.9 million cash on hand plus net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.5 million, under a term loan facility (see Note 8—Indebtedness).
    The Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the Acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to potential adjustment during the measurement period (up to one year from the Acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
    The following table summarizes the Company's current allocation of the consideration paid in the Acquisition:
    (in millions)Initial AllocationAdjustmentsUpdated Allocation
    Cash and cash equivalents$406.8  $(14.5) $392.3  
    Other current assets56.5  1.0  57.5  
    Property, plant, and equipment26.6  —  26.6  
    Operating lease right-of-use assets42.5  —  42.5  
    Intangible assets715.3  —  715.3  
    Goodwill1,330.5  (2.5) 1,328.0  
    Other assets5.9  —  5.9  
    Client-held funds obligation(237.5) 17.8  (219.7) 
    Other current liabilities(69.1) (2.9) (72.0) 
    Other long-term liabilities(26.7) —  (26.7) 
    Deferred tax liability(128.7) 1.1  (127.6) 
    Total consideration paid$2,122.1  $—  $2,122.1  
    Adjustments to the initial allocation are based on more detailed information obtained about the specific assets acquired, liabilities assumed, and tax-related matters.
    XML 34 R14.htm IDEA: XBRL DOCUMENT v3.20.1
    Indebtedness
    3 Months Ended
    Apr. 30, 2020
    Debt Disclosure [Abstract]  
    Indebtedness Indebtedness
    As of April 30, 2020, long-term debt consisted of the following:
    (in millions)April 30, 2020
    Term loan facility$1,234.4  
    Less: unamortized loan issuance costs (1)20.3  
    Long-term debt, net of issuance costs$1,214.1  
    (1) In addition to the $20.3 million of unamortized issuance costs related to the term loan facility, $6.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the April 30, 2020 condensed consolidated balance sheet.
    In connection with the closing of the Acquisition, on August 30, 2019, the Company entered into a credit facility (the "Credit Agreement”) that provided for:
    (i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion, the proceeds of which were used to finance the Acquisition, to refinance substantially all outstanding indebtedness of HealthEquity and WageWorks and to pay related fees and expenses; and
    (ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of April 30, 2020.
    Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of April 30, 2020, the stated interest rate was 2.15% and the effective interest rate was 2.59%. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
    The loans made under the Term Loan Facility are required to be repaid as described in the following table:
    Fiscal year ending January 31, (in millions)Principal payments
    Remaining 2021$31.3  
    202262.5  
    202370.3  
    2024101.6  
    2025968.7  
    Total principal payments$1,234.4  
    The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.25 to 1.00, which steps down to (x) 5.00 to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) 4.50 to 1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of April 30, 2020, and for the period then ended.
    The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of HealthEquity and the guarantors, in each case, subject to certain customary exceptions.
    XML 35 R10.htm IDEA: XBRL DOCUMENT v3.20.1
    Supplemental financial statement information
    3 Months Ended
    Apr. 30, 2020
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Supplemental financial statement information Supplemental financial statement information
    Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income components consist of the following:
    Property and equipment
    Property and equipment consisted of the following as of April 30, 2020 and January 31, 2020:
    (in thousands)April 30, 2020January 31, 2020
    Leasehold improvements$22,084  $19,240  
    Furniture and fixtures9,097  7,929  
    Computer equipment24,123  22,074  
    Property and equipment, gross55,304  49,243  
    Accumulated depreciation(19,483) (15,757) 
    Property and equipment, net$35,821  $33,486  
    Depreciation expense for the three months ended April 30, 2020 and 2019 was $3.9 million and $0.9 million, respectively.
    Contract balances
    The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. The Company's deferred revenue increased from $3.7 million as of January 31, 2020 to $4.1 million as of April 30, 2020. The balances are related to cash received in advance for an interchange revenue arrangement, other up-front fees and other commuter deferred revenue, and are generally recognized within twelve months, with the exception of the interchange arrangement, which is recognized over a term of approximately ten years. Revenue recognized during the three months ended April 30, 2020 that was included in the beginning balance of deferred revenue was $0.2 million. The Company expects to satisfy its remaining obligations for these arrangements.
    Other income (expense), net
    Other income (expense), net, consisted of the following:
    Three months ended April 30,
    (in thousands)20202019
    Interest income$600  $1,343  
    Gain on equity securities—  23,511  
    Acquisition costs(94) (1,184) 
    Other expense(1,270) (7) 
    Total other income (expense), net$(764) $23,663  
    XML 36 R18.htm IDEA: XBRL DOCUMENT v3.20.1
    Summary of business and significant accounting policies (Policies)
    3 Months Ended
    Apr. 30, 2020
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Principles of consolidation
    Principles of consolidation
    The condensed consolidated financial statements include the accounts of HealthEquity, Inc., and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
    Basis of presentation Basis of presentation The accompanying condensed consolidated financial statements as of April 30, 2020 and for the three months ended April 30, 2020 and 2019 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2020. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
    Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
    Recent adopted accounting pronouncements
    Recently adopted accounting pronouncements
    In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020 using the modified retrospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
    In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
    In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
    Fair value measurement
    Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
    Level 1—quoted prices in active markets for identical assets or liabilities;
    Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
    Level 3—unobservable inputs based on the Company’s own assumptions.
    Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of April 30, 2020 due to the short-term nature of these instruments. 
    Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.
    EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 R33.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases (Lease Cost) (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Leases [Abstract]    
    Operating lease expense $ 4,308 $ 1,074
    Sublease income (450) 0
    Lease, cost, total $ 3,858 $ 1,074
    Weighted average remaining lease term (in years) 9 years 5 months 19 days  
    Weighted average discount rate (percent) 4.35%  

    XML 39 R37.htm IDEA: XBRL DOCUMENT v3.20.1
    Intangible assets and goodwill (Schedule of intangible assets) (Details) - USD ($)
    $ in Thousands
    Apr. 30, 2020
    Jan. 31, 2020
    Finite-Lived Intangible Assets [Line Items]    
    Amortizable intangible assets, gross $ 899,333 $ 879,597
    Accumulated amortization (122,442) (98,851)
    Total amortizable intangible assets, net 776,891 780,746
    Intangible Assets, Net (Excluding Goodwill) [Abstract]    
    Total intangible assets, net 777,483 783,279
    In Process Research and Development    
    Indefinite-lived Intangible Assets [Line Items]    
    Acquired in process software development costs 592 2,533
    Software and software development costs    
    Finite-Lived Intangible Assets [Line Items]    
    Amortizable intangible assets, gross 89,949 76,221
    Acquired HSA portfolios    
    Finite-Lived Intangible Assets [Line Items]    
    Amortizable intangible assets, gross 98,778 92,770
    Acquired customer relationships    
    Finite-Lived Intangible Assets [Line Items]    
    Amortizable intangible assets, gross 601,381 601,381
    Acquired developed technology    
    Finite-Lived Intangible Assets [Line Items]    
    Amortizable intangible assets, gross 96,925 96,925
    Acquired trade names    
    Finite-Lived Intangible Assets [Line Items]    
    Amortizable intangible assets, gross $ 12,300 $ 12,300
    XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.1
    Net income per share (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Numerator (basic and diluted):    
    Net income $ 1,826 $ 41,822
    Denominator (basic):    
    Weighted-average common shares outstanding (in shares) 70,980 62,326
    Denominator (diluted):    
    Weighted-average common shares outstanding (in shares) 70,980 62,326
    Weighted-average dilutive effect of stock options and restricted stock units (in shares) 1,312 1,575
    Diluted weighted-average common shares outstanding (in shares) 72,292 63,901
    Net income per share:    
    Basic (in usd per share) $ 0.03 $ 0.67
    Diluted (in usd per share) $ 0.03 $ 0.65
    Antidilutive securities excluded from computation of earnings per share (in shares) 500 200
    XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 R22.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases (Tables)
    3 Months Ended
    Apr. 30, 2020
    Leases [Abstract]  
    Lease cost
    The components of operating lease costs are as follows:
    Three months ended April 30,
    (in thousands, except for term and percentages)20202019
    Operating lease expense$4,308  1,074  
    Sublease income(450) —  
    Net operating lease cost$3,858  $1,074  
    Weighted average lease term and discount rate are as follows:
    As of April 30, 2020
    Weighted average remaining lease term9.47 years
    Weighted average discount rate4.35 %
    Supplemental cash flow information related to the Company's operating leases was as follows:
    Three months ended April 30,
    (in thousands, except for term and percentages)20202019
    Cash paid for amounts included in the measurement of lease liabilities:
    Operating cash flows from operating leases$3,297  $977  
    ROU assets obtained in exchange for new operating lease obligations$17,480  $199  
    Operating lease liability maturity schedule
    Maturities of operating lease liabilities as of April 30, 2020 were as follows:
    Fiscal year ending January 31, (in thousands)Operating leases
    Remaining 2021$9,177  
    202214,517  
    202312,348  
    202410,318  
    202510,279  
    Thereafter60,429  
    Total lease payments117,068  
    Less imputed interest(21,876) 
    Present value of lease liabilities$95,192  
    Current$13,210  
    Non-current81,982  
    Total lease liabilities$95,192  
    XML 43 R43.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation (Summary of share based compensation recognized) (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense $ 7,396 $ 6,028
    Cost of revenue    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 1,463 860
    Sales and marketing    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 958 1,007
    Technology and development    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 2,917 1,499
    General and administrative    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense $ 2,058 $ 2,662
    XML 44 R47.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation (Stock option activity) (Details) - USD ($)
    $ / shares in Units, shares in Thousands, $ in Thousands
    3 Months Ended 12 Months Ended
    Apr. 30, 2020
    Jan. 31, 2020
    Number of options (shares)    
    Opening balance (shares) 2,040  
    Granted (shares) 16  
    Exercised (shares) (51)  
    Forfeited (shares) (4)  
    Ending balance (shares) 2,001 2,040
    Vested and expected to vest as of year end (in shares) 2,001  
    Exercisable as of year end (in shares) 1,632  
    Range of exercise prices (usd per share)    
    Beginning balance, minimum (usd per share) $ 0.10  
    Beginning balance, maximum (usd per share) 82.39  
    Granted (usd per share) 66.06  
    Exercised, minimum (usd per share) 0.10  
    Exercised, maximum (usd per share) 44.53  
    Forfeited, minimum (usd per share) 25.45  
    Forfeited, maximum (usd per share) 44.53  
    Ending balance, minimum (usd per share) 0.10 $ 0.10
    Ending balance, maximum (usd per share) 82.39 82.39
    Weighted- average exercise price (usd per share)    
    Opening balance (usd per share) 30.35  
    Granted (usd per share) 66.06  
    Exercised (usd per share) 22.07  
    Forfeited (usd per share) 32.61  
    Ending balance (usd per share) 30.85 $ 30.35
    Vested and expected to vest as of year end, weighted average exercise price (usd per share) 30.85  
    Exercisable as of year end, weighted-average exercise price (usd per share) $ 25.71  
    Outstanding stock options, weighted average contractual term (in years) 5 years 8 months 19 days 5 years 10 months 24 days
    Vested and expected to vest as of year end, weighted average contractual term (in years) 5 years 8 months 19 days  
    Exercisable as of year end, weighted-average contractual term (in years) 5 years 3 months 14 days  
    Beginning balance, outstanding stock options, aggregate intrinsic value $ 74,009  
    Ending balance, outstanding stock options, aggregate intrinsic value 54,009 $ 74,009
    Vested and expected to vest as of year end, aggregate intrinsic value (usd per share) 54,009  
    Exercisable as of year end, aggregate intrinsic value $ 50,730  
    XML 45 R3.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed consolidated balance sheets (Parenthetical) - USD ($)
    $ in Thousands
    Apr. 30, 2020
    Jan. 31, 2020
    Statement of Financial Position [Abstract]    
    Allowance for doubtful accounts $ 1,681 $ 1,216
    Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001
    Preferred stock, authorized (in shares) 100,000,000 100,000,000
    Preferred stock, issued (in shares) 0 0
    Preferred stock, outstanding (in shares) 0 0
    Common stock, par value (usd per share) $ 0.0001 $ 0.0001
    Common stock, authorized (in shares) 900,000,000 900,000,000
    Common stock, issued (in shares) 71,398,000 71,051,000
    Common stock, outstanding (in shares) 71,398,000 71,051,000
    XML 46 R7.htm IDEA: XBRL DOCUMENT v3.20.1
    Summary of business and significant accounting policies
    3 Months Ended
    Apr. 30, 2020
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Summary of business and significant accounting policies Summary of business and significant accounting policies
    Business
    HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. HealthEquity, Inc. is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
    Principles of consolidation
    The condensed consolidated financial statements include the accounts of HealthEquity, Inc., and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
    Basis of presentation
    The accompanying condensed consolidated financial statements as of April 30, 2020 and for the three months ended April 30, 2020 and 2019 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2020. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
    Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
    Significant accounting policies
    There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2020.
    Recently adopted accounting pronouncements
    In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020 using the modified retrospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
    In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
    In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. The Company adopted the new standard as of February 1, 2020. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
    XML 47 R31.htm IDEA: XBRL DOCUMENT v3.20.1
    Supplemental financial statement information (Other income (expense), net) (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Organization, Consolidation and Presentation of Financial Statements [Abstract]    
    Interest income $ 600 $ 1,343
    Gain on equity securities 0 23,511
    Acquisition costs (94) (1,184)
    Other expense (1,270) (7)
    Total other income (expense), net $ (764) $ 23,663
    XML 48 R35.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases (Supplemental Cash Flow Information) (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Apr. 30, 2020
    Apr. 30, 2019
    Cash Flow, Operating Activities, Lessee [Abstract]    
    Operating cash flows from operating leases $ 3,297 $ 977
    ROU assets obtained in exchange for new operating lease obligations $ 17,480 $ 199
    XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.1
    Indebtedness Schedule of Long-term Debt (Details) - USD ($)
    $ in Millions
    Apr. 30, 2020
    Jan. 31, 2020
    Debt Disclosure [Abstract]    
    Term loan facility $ 1,234.4 $ 1,234.4
    Less: unamortized loan issuance costs 20.3  
    Total $ 1,214.1  
    XML 50 R16.htm IDEA: XBRL DOCUMENT v3.20.1
    Stock-based compensation
    3 Months Ended
    Apr. 30, 2020
    Share-based Payment Arrangement [Abstract]  
    Stock-based compensation Stock-based compensation
    The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income during the periods presented:
    Three months ended April 30,
    (in thousands)20202019
    Cost of revenue$1,463  $860  
    Sales and marketing958  1,007  
    Technology and development2,917  1,499  
    General and administrative2,058  2,662  
    Total stock-based compensation expense$7,396  $6,028  
    The following table shows stock-based compensation by award type:
    Three months ended April 30,
    (in thousands)20202019
    Stock options$1,449  $1,783  
    Performance stock options—  —  
    Restricted stock units6,509  2,926  
    Performance restricted stock units(1,979) 651  
    Restricted stock awards872  163  
    Performance restricted stock awards545  505  
    Total stock-based compensation expense$7,396  $6,028  
    Stock award plans
    Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
    In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of April 30, 2020, 6.5 million shares were available for grant under the Incentive Plan.
    WageWorks Incentive Plan. At the closing of the Acquisition, and in accordance with the merger agreement related to the Acquisition, certain RSUs with respect to WageWorks common stock, granted under WageWorks, Inc. 2010 Equity Incentive Plan (the "WageWorks Incentive Plan"), were replaced by the Company and converted into RSUs with respect to 523,318 shares of common stock of the Company. No additional shares were issued under the WageWorks Incentive Plan, and the period during which the remaining 5,255,027 shares were available to be utilized expired on May 26, 2020.
    Stock options
    Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.
    Valuation assumptions. The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.
    Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.
    The weighted-average fair value of options granted during the three months ended April 30, 2020 and 2019 was $23.68 and $25.97 per share, respectively. The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented are as follows:
    Three months ended April 30,
    20202019
    Expected dividend yield—%—%
    Expected stock price volatility37.97%
    35.98% - 36.53%
    Risk-free interest rate1.39%
    2.21% - 2.43%
    Expected life of options5.18 years
    4.95 - 5.09 years
    The Company estimates the expected life of an option using historical option exercise and termination data. Expected volatility is determined using the weighted average volatility of the Company's historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term of the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations.
    A summary of stock option activity is as follows:
    Outstanding stock options
    (in thousands, except for exercise prices and term)Number of
    options
    Range of
    exercise
    prices
    Weighted-
    average
    exercise
    price
    Weighted-
    average
    contractual
    term
    (in years)
    Aggregate
    intrinsic
    value
    Outstanding as of January 31, 20202,040  
    $0.10 - 82.39
    $30.35  5.90$74,009  
    Granted16  $66.06  $66.06  
    Exercised(51) 
    $0.10 - 44.53
    $22.07  
    Forfeited(4) 
    $25.45 - 44.53
    $32.61  
    Outstanding as of April 30, 20202,001  
    $0.10 - 82.39
    $30.85  5.72$54,009  
    Vested and expected to vest as of April 30, 20202,001  $30.85  5.72$54,009  
    Exercisable as of April 30, 20201,632  $25.71  5.29$50,730  
    The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options. The total intrinsic value of options exercised during the three months ended April 30, 2020 and 2019 was $2.1 million and $9.2 million, respectively.
    As of April 30, 2020, the weighted-average vesting period of non-vested options expected to vest was approximately 1.3 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately $6.1 million.
    Restricted stock units and restricted stock awards
    The Company grants RSUs and RSAs to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate. The weighted-average fair value of RSUs granted during the three months ended April 30, 2020 and 2019 was $56.27 and $73.02 per share, respectively.
    Performance restricted stock units and awards. In March 2017, the Company awarded 146,964 performance-based RSUs ("PRSUs"). The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred during the three months ended April 30, 2020 following approval by the Compensation Committee of the board of directors, based on the level of achievement of the performance goal as measured on January 31, 2020. The performance conditions allowed for a range of vesting from 0% to 150%. The PRSUs vested at 118.1%.
    In March 2018, the Company awarded 227,760 performance-based RSAs ("PRSAs"). The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. The underlying shares were issued at 200% of the target level of achievement at the grant date. During the three months ended April 30, 2020, the Compensation Committee modified the awards by deeming the performance condition related to two-thirds of the awards to be achieved at 100% and creating a new performance condition related to the remaining one-third of the awards to reflect the state of the Company after the Acquisition of WageWorks. The new performance condition is based on the achievement of certain financial criteria measured on January 31, 2021. The modification affected 10 team members and did not result in an adjustment to stock-based compensation expense. The PRSAs cliff vest upon approval by the Compensation Committee. The modified performance condition for the one-third tranche allows for a range of vesting from 0% to 200% based on the level of achievement of the performance condition, and the Company believes it is probable that the PRSAs will vest at least in part. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance.
    In March 2019, the Company awarded 129,963 PRSUs. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. During the three months ended April 30, 2020, the Compensation Committee modified the awards by deeming the performance condition related to one-third of the awards to be achieved at 100% and creating new performance conditions related to the remaining two-thirds of the awards to reflect the state of the Company after the Acquisition of WageWorks. The new performance conditions are based on the achievement of certain financial criteria measured on January 31, 2021 and 2022. The modification affected 12 team members and will result in incremental stock-based compensation expense of $6.6 million, which will be recognized over the remaining service period, adjusted for the level of achievement of the performance conditions and any forfeitures. Prior to the modification, the Company did not believe the PRSUs were likely to vest, and as a result, $2.9 million of previously recorded stock-based compensation expense was reversed during the three months ended April 30, 2020. The PRSUs cliff vest upon approval by the Compensation Committee. The modified performance conditions for the two-thirds tranche allow for a range of vesting from 0% to 200% based on the level of achievement of the new performance conditions, and the Company believes it is probable that the PRSUs will vest at least in part.
    During the three months ended April 30, 2020, the Company awarded 257,680 PRSUs subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2023. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was approximately $19.0 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee.
    A summary of the RSU and RSA activity is as follows:
    RSUs and PRSUsRSAs and PRSAs
    (in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
    Outstanding as of January 31, 20201,380  $63.33  235  $61.91  
    Granted1,085  56.27  14  74.81  
    Vested(296) 51.38  (10) 62.80  
    Forfeited(167) 71.72  (14) 63.31  
    Outstanding as of April 30, 20202,002  $60.57  225  $62.58  
    For the three months ended April 30, 2020 and 2019, the aggregate intrinsic value of RSUs and RSAs vested was $16.4 million and $7.7 million, respectively.
    Total unrecorded stock-based compensation expense as of April 30, 2020 associated with RSUs and PRSUs was $109.1 million, which is expected to be recognized over a weighted-average period of 3.1 years. Total unrecorded stock-based compensation expense as of April 30, 2020 associated with RSAs and PRSAs was $2.4 million, which is expected to be recognized over a weighted-average period of 0.9 years.
    XML 51 R12.htm IDEA: XBRL DOCUMENT v3.20.1
    Intangible assets and goodwill
    3 Months Ended
    Apr. 30, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Intangible assets and goodwill Intangible assets and goodwill
    Intangible assets
    The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of April 30, 2020 and January 31, 2020:
    (in thousands)April 30, 2020January 31, 2020
    Amortizable intangible assets:
    Software and software development costs$89,949  $76,221  
    Acquired HSA portfolios98,778  92,770  
    Acquired customer relationships601,381  601,381  
    Acquired developed technology96,925  96,925  
    Acquired trade names12,300  12,300  
    Amortizable intangible assets, gross899,333  879,597  
    Accumulated amortization(122,442) (98,851) 
    Total amortizable intangible assets, net776,891  780,746  
    Acquired in process software development costs592  2,533  
    Total intangible assets, net$777,483  $783,279  
    During the three months ended April 30, 2020 and 2019, the Company expensed a total of $10.3 million and $3.9 million, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software.
    Amortization expense for the three months ended April 30, 2020 and 2019 was $23.6 million and $3.9 million, respectively.
    Goodwill
    There were no changes to the goodwill carrying value during the three months ended April 30, 2020 and 2019.
    XML 52 R28.htm IDEA: XBRL DOCUMENT v3.20.1
    Business combination (Preliminary Allocation of Consideration) (Details) - USD ($)
    $ in Thousands
    8 Months Ended
    Apr. 30, 2020
    Jan. 31, 2020
    Aug. 30, 2019
    Business Acquisition [Line Items]      
    Goodwill $ 1,332,631 $ 1,332,631  
    Wage Works Inc.      
    Business Acquisition [Line Items]      
    Cash and cash equivalents 392,300   $ 406,800
    Cash and cash equivalents, adjustments (14,500)    
    Other current assets 57,500   56,500
    Other current assets, adjustments 1,000    
    Property, plant, and equipment 26,600   26,600
    Operating lease right-of-use assets 42,500   42,500
    Intangible assets 715,300   715,300
    Goodwill 1,328,000   1,330,500
    Goodwill, adjustments (2,500)    
    Other assets 5,900   5,900
    Client-held funds obligation (219,700)   (237,500)
    Client-held funds obligation, adjustments 17,800    
    Other current liabilities (72,000)   (69,100)
    Other current liabilities, adjustments (2,900)    
    Other long-term liabilities (26,700)   (26,700)
    Deferred tax liability (127,600)   (128,700)
    Deferred tax liability, adjustments 1,100    
    Total consideration paid 2,122,100   $ 2,122,100
    Total consideration paid, adjustments $ 0    
    ZIP 53 0001428336-20-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-20-000019-xbrl.zip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

    B,"Q$E!,PJF@2>B#'<7^:ZY M0N -<$3JA??*!"XM8+^T@!?: B;?7H , ;8>DR+)=BY""B-AK 6OK@A4>_P M6.M J*2Z\LE(,,4_BA!NB1<8-\DCV"/\BW8GPA2/1T:*L4A8/2TNC>=RY0$? M6,H20 %<+XKOX2D\C!EZ &"=68Z?[#DWJ>&GQ!O*&!2H^("_^*;;&(\;?],8 MXW*LKQ*O O"R#HWZ>(SR'M]G,.7:S&KY[PON'8>R?DBC)<$Q;E8.G,I M(CZ-J;PO/S:7^.G4"$8HOP8L[5>,4,&NC6"A\UG2V^#[>:1-@[F43 RN+JU*BK[09KD"X6!?">%EJ9QXC&^KMP!>)*PL<(+AQ,L42U! MF( X@/L627P7^-)<'.SA _QKW85FQDQEDHD@TC""M_BY1U[493WD72?-O1EN M:RW<6DBQN8B6JU#'72*RD!R=(>H9YES)&?01,*ZFI=C5M_2S@!^F MDF+"&(\DU, @80DWA*_\"D9R #;L,X;Y7/PI\T0^PV^G ?!-@30[E5%J>*,( M$W6<&J"A970=>-F]#@HPXB,LBU^QSO"8XNM?6K!9#G4"*0-+AEOR2!\8;L7$ M+80&T[N#T5=D_/KTBA='U7?C*]97WQUUX6J# SM.B117Z\CT?ILHA!&C#,*#GC5;=5Q%D6\,G81YGC@P0#"G[]T E7CU1]K'('99&)/(LU%G Z M%/VB,J@ (*%8I/*U_F,M29C^C6'\*'N-8-#3X(.( $#?+_QM95\,;YX/NA=7XPW7]_Z\/:+@][%^/*1#_=[@VT71]?GCWS6+KD)2[[L M[_KP Y7!.S(@.\B[*5,;XMB!X_VTP6'BC/KN#KGQ6HA$,7M%#W.KI<&6 MT: ].GMT]NCLT=FCVW)T1VA)\RW'W(Z3?$F^VSB'-_FIZ\BOG@2<++/?TA_M M>.]'S[;L#_O?F[FT S*G7X =7?^MN#T8'P6WVP^:TR_ (O2=/\,5&+#_M=(4.S$O5%8@8Q$KMV.>3=*?I^-CGJX';']BQS\WM3]T! M-G;Z!1R^Q9?EH*=G!WGZ)OZ6@UH.:CFHY:!MY* 7?7=T>?)I"9:# M6@[:WKZ(W^] F\$SAN>68;1Z]DH[V$;9UJ76!WJ^I8W$ MJ6^8>]I!/-EY[FD'3MZRCYU!=>X.AD=P2W< B;Y;0_1V2.C3+Z!)#<];0=OC MX8]VII MV]*VI>T30VS4MX3=\)AW-T:,;'FSY-O_$5->W_J0.S(S;,8:CTJ;%3I@X\ M>O6BWSNOC%X;GJ_.7DW- SC5U-6;E4EL:F!H'F8!SDN"?E[,)ST*-YPL9I32@D09)1:ETZ<'*(SR/ M1UT_",/%O*#=M_+\NC=Z MU./#/L_(*K9$G+9VXC0/PM-[K4[^6PA0D>#3N&&1TCBD]2V7LY]IR_W>;[#Q#6DM>MBSIT-/H5S2B47_+,'K%E/9#;IK9F/ TP$A+8MN,>F1UQ7#<^H'U]7/?#7ZBOO0$9N36 MIC)8:CTWCZ9"FG3DXP ]P-DYO@-?;"K_ MJXJ_J\=CLB:OIF_VG+=U7UD=X&N,[17&I%8_@ L)FAY3X65Q4AG5BXL0H 0$ MV9+6YHFP,H049\H&0&Y+=W6MI4DC"DM*$21.$ 7Z)'-GFD<>34/=+$YIP"Z. MF:?!IO"UZ)\4D!7LMDV\4:??-5U2?,7PZ./-!)J?B M =L1\FQX=5:%F/G?65*ZMV[E&8U6/1-3V,UK$=Z+9?KL5673*U!< \ZW0F Z M/30$Z)A L0)H==K'@:+M^&215N6ZH XGO[MV5^"<=\?"6_BR^ET?'XY[%^/ MAX.^?^&/IJ.1-QV)_[T"+D^S.G$0.GP2NX6[9G8580WDEAWF.\:K^WX&T:\;M5G[,37S1=;.8O4+ME.?+7#T^S$UV8> MKYWXVH)#.OT"[.Q)>W3VZ.S1V:-[_-'9B:^/ *2=^&HGOEK^87%[?]RV$U\M M0 MN(=]=W!EQSM;XK;$W3WB'AS#J]%V-]EA UTN >&/P^B(,T2:F71 M#(=:2\C1'8]/[C=K)'[9>;"/,L0[T/OT"FA1L M:P5M#_KN\-H2MR5N2]P=).Z!U?IM0/P0$+N9Q[#R_Q.ZP:S ?K/8'#>(,A'= M!M@8C5M-6S?9/G;Y5?\(P]@[X"FS 7(;(+?\XR'^X9Z/!Y9]V!#:4U?=NTC; M5^YP8(G;$KT;2/D!X#8/V1RBS,CHDS>OA*7L MW2C[M %R56^OWM;6/A0\\')]5MEQ_3^/::RS/\ ; -Z#=MW9SX_V[8!L$EL< MC]Q^_^1U>8>":4.P\[M%++K!*T^_@,,W/;.\N=1W^U#MWQ,?K,'1-R#<$TRTT[P4U/D[OSC6?:#.8Q/$:I[!/@ M'#69/Z]H\#W\KQ_<_?17^(]>WUPDMT%$(+R$!:I_JOU>KN]GQT545_[ -DL8 M#?H:2/2YUT$&I^&M@2T,(GDVXW\/AH2L-;->>@[^GX;%*3:Q?3V>:Q',G@]=D&^9;,_F L>/@ MI#@GBW>^>]AW[D7JP,_P6=BRX^<2G]=+0R(4TRFLIEQNBNN-X0M)X9-U:>4S MV#;\F&:Q]^5L0D][\1SOX"HHO9]$IGE(.RQV=H/546F M_4*M&X+$F\__\^2 M-NYE3IPGV\XY-0'O3 %+$#+POS*5$NG:F>99GF#9F',O ;01/%T]+GH"5X<5 M9YL^%R>W(M*5:7@)OH__$T3PIDC>JUO3GO,!K\/_BW(1.G"@ 1ST_5[;2>1< M('9G4OA+7+@PQIWJ16;DZ4_DG83M])S?XGOX,W$?_L!<+)UIF'M9+C*YT]L9 MX^"F(/9Q?>HOA?4$/8!C' $_RI;U;\"U$'D%L<.K!]<4*J\XV[K 9'!MP&C XDN%9(D,@#%\O:X6%+Y)X*M,T M0&QWIA*YN,GVMS/QE7<)L]J5H;)(I!?0#RP=6&*43VV7 L!H9H$W W8##&\A MX.4B#)$BIZG,G,FR^GE/+ A#_T^N8%SKR&T?6?(P(GZ32+F3:4;X#H^8[\9O MI=++$X-% BX!1LI,)$MG 4@'GYCO)$#VW<-.3'Z1)VDNX!7P)%Z%@[O/9O 2 M0"UJA89+V_'CS90Q.ZR\^Z)FO@27,1(;<'=8!+UF7*,B%Z?V3/(4MIX@$>%,8XO^R>N#% M:99B7XP8=0= AOL &/=$$A<$OCX!UD +$]%R%_&R(^CV-U.<&$P4@F,D!?+C M9+ZSV-EE4#&*(X T/H2KJD$NUD%V!?%&+K*(^?;7]"80D6_N S^; 2T MJBNT/Q_VKBZ8H=0]*29I'.:9?*-X3]]\1?49(]"%2H),FJG8G@VOSZH0,_\[ M2\J8WZT\FX H^G(FIK";UR*\%\OTV:O*IE>@N :<;X7 ='IH"- Q^=*+&==> M.[ :F>!MN&31EJ4ZP&^G?WOVEV#<]T?"F_AR.AV?7P[[U^/AH.]?^*/I:.1- M1^)_KX"IDP$"1/,6/@FXF?[UE?BI#@G:+(*OZO']/9(B^M$4RVV=SK&;O!Z9 MPB)8V?.^4AID"UARF>EX .0IW@J"-)R8;>PN@698PNQ1%\>2B&ETJ[: MEK V,-]!* -(R=7=.LS:EY0^Z/A!/)?.2W50/[I@?V?M4^5WB42=]\X+LO)F M8.O(,O!>"P:7[3!U#5#U^7#4NRK>X>>)ULEV-],T0>#;^H9>ON?+-KD2!:VQ MU,]N!3$0Y &1--1K1'DDA6RI A/DZH8;"T5L_^WU'(0SNWZ(E;""JD!MV JB MY 4F>S/@W"_![*[<+@S%D35+?�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͚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